Nothing Special   »   [go: up one dir, main page]

US20060046987A1 - Substituted quinazoline derivatives and their use as inhibitors - Google Patents

Substituted quinazoline derivatives and their use as inhibitors Download PDF

Info

Publication number
US20060046987A1
US20060046987A1 US11/070,057 US7005705A US2006046987A1 US 20060046987 A1 US20060046987 A1 US 20060046987A1 US 7005705 A US7005705 A US 7005705A US 2006046987 A1 US2006046987 A1 US 2006046987A1
Authority
US
United States
Prior art keywords
alkyl
optionally substituted
compound
mmol
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/070,057
Inventor
Andrew Mortlock
Frederic Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to US11/070,057 priority Critical patent/US20060046987A1/en
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JUNG, FREDERIC HENRI, MORTLOCK, ANDREW
Publication of US20060046987A1 publication Critical patent/US20060046987A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to certain quinazoline derivatives for use in the treatment of certain diseases in particular to proliferative disease such as cancer and in the preparation of medicaments for use in the treatment of proliferative disease, to novel quinazoline compounds and to processes for their preparation, as well as pharmaceutical compositions containing them as active ingredient.
  • CDKs cyclin dependent kinases
  • protein kinases that are structurally distinct from the CDK family have been identified which play critical roles in regulating the cell cycle and which also appear to be important in oncogenesis. These include the newly identified human homologues of the Drosophila aurora and S. cerevisiae Ip11 proteins. Drosophila aurora and S. cerevisiae Ip11, which are highly homologous at the amino acid sequence level, encode serine/threonine protein kinases. Both aurora and Ip11 are known to be involved in controlling the transition from the G2 phase of the cell cycle through mitosis, centrosome function, formation of a mitotic spindle and proper chromosome separation/segregation into daughter cells.
  • aurora 1 and aurora 2 encode cell cycle regulated protein kinases. These show a peak of expression and kinase activity at the G2/M boundary (aurora 2) and in mitosis itself (aurora1).
  • aurora 2 Several observations implicate the involvement of human aurora proteins , and particularly aurora 2 in cancer.
  • the aurora 2 gene maps to chromosome 20q13, a region that is frequently amplified in human tumours including both breast and colon tumours.
  • Aurora 2 may be the major target gene of this amplicon, since aurora 2 DNA is amplified and aurora 2 mRNA overexpressed in greater than 50% of primary human colorectal cancers. In these tumours aurora 2 protein levels appear greatly elevated compared to adjacent normal tissue.
  • the present invention provides the use of a compound of formula (I) or a salt, ester or amide thereof,
  • Such medicaments are useful in the treatment of proliferative disease such as cancer, and in particular cancers where aurora 2 is upregulated such as colon or breast cancers.
  • alkyl when used either alone or as a suffix includes straight chained, branched structures. Unless otherwise stated, these groups may contain up to 10, preferably up to 6 and more preferably up to 4 carbon atoms.
  • alkenyl and alkynyl refer to unsaturated straight or branched structures containing for example from 2 to 10, preferably from 2 to 6 carbon atoms. Cyclic moieties such as cycloalkyl, cycloalkenyl and cycloalkynyl are similar in nature but have at least 3 carbon atoms. Terms such as “alkoxy” comprise alkyl groups as is understood in the art.
  • halo includes fluoro, chloro, bromo and iodo.
  • aryl groups include aromatic carbocylic groups such as phenyl and naphthyl.
  • heterocyclyl includes aromatic or non-aromatic rings, for example containing from 4 to 20, suitably from 5 to 8 ring atoms, at least one of which is a heteroatom such as oxygen, sulphur or nitrogen.
  • Examples of such groups include furyl, thienyl, pyrrolyl, pyrrolidinyl, imidazolyl, triazolyl, thiazolyl, tetrazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, quinolinyl, isoquinolinyl, quinoxalinyl, benzothiazolyl, benzoxazolyl, benzothienyl or benzofuryl.
  • Heteroaryl refers to those groups described above which have an aromatic character.
  • aralkyl refers to aryl substituted alkyl groups such as benzyl.
  • hydrocarbyl which refers to any structure comprising carbon and hydrogen atoms.
  • these may be alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkoxy, aralkyl, cycloalkyl, cycloalkenyl or cycloalkynyl.
  • the term “functional group” refers to reactive substituents such as nitro, cyano, halo, oxo, ⁇ CR 78 R 79 , C(O) x R 77 , OR 77 , S(O) y R 77 , NR 78 R 79 , C(O)NR 78 R 79 , OC(O)NR 78 R 79 , ⁇ NOR 77 , —NR 77 C(O) x R 78 , —NR 77 CONR 78 R 79 , —N ⁇ CR 78 R 79 , S(O) y NR 78 R 79 or —NR 77 S(O) y R 78 where R 77 , R 78 and R 79 are independently selected from hydrogen or optionally substituted hydrocarbyl, or R 78 and R 79 together form an optionally substituted ring which optionally contains further heteroatoms such as S(O) y oxygen and nitrogen, x is an integer of 1 or 2,
  • Suitable optional substituents for hydrocarbyl groups R 77 , R 78 and R 79 include halo, perhaloalkyl such as trifluoromethyl, mercapto, hydroxy, carboxy, alkoxy, aryl, heteroaryl, heteroaryloxy, alkenyloxy, alkynyloxy, alkoxyalkoxy, aryloxy (where the aryl group may be substituted by halo, nitro, or hydroxy), cyano, nitro, amino, mono- or di-alkyl amino, oximino or S(O) y where y is as defined above.
  • R 4 is hydrogen
  • R 1 is hydrogen or a group set out for R 2 or R 3 below. Frequently, R 1 is hydrogen.
  • At least one group R 1 , R 2 or R 3 , preferably R 3 comprises a chain of at least 3 and preferably at least 4 optionally substituted carbon atoms or heteroatoms such as oxygen, nitrogen or sulphur. Most preferably the chain is substituted by a polar group which assists in solubility.
  • R 3 is a group X 1 R 9 .
  • X 1 is oxygen and R 9 is selected from a group of formula (1) or (10) above.
  • Particular groups R 9 are those in group (1) above, especially alkyl such as methyl or halo substituted alkyl, or those in group (10) above.
  • at least one of R 2 or R 3 is a group —OC 1-5 alkylR 33 and R 33 is a heterocyclic ring such as an N-linked morpholine ring such as 3-morpholinopropoxy.
  • R 2 is selected from, halo, cyano, nitro, tifluoromethyl, C 1-3 alkyl, —NR 9 R 10 (wherein R 9 and R 10 , which may be the same or different, each represents hydrogen or C 1-3 alkyl), or a group —X 1 R 11 .
  • Preferred examples of —X 1 R 11 for R 2 include those listed above in relation to R 3 .
  • R 5 examples include rings containing one or more heteroatoms selected from sulphur, oxygen and nitrogen. Such rings include pyrrole, pyrazole, pyrazolone, imidazole, oxazole, furan, tetrazole, triazole, thiazole, thiophene, or thiadiazole, any of which may be optionally substituted. In particular, R 5 includes at least one nitrogen or sulphur heteroatoms. Preferred rings for R 5 include pyrrole, pyrazole, imidazole, triazole, thiazole, thiophene, or thiadiazole.
  • R 5 is a sulphur containing ring.
  • R 5 is optionally substituted thiazole, optionally substituted thiophene or optionally substituted thiadiazole and preferably, optionally substituted thiazole or optionally substituted thiophene.
  • R 5 is a substituted thiazole or substituted thiophene group.
  • R 5 is a group of formula (a), (b), (c) or (d) and preferably (a) or (b): where R 60 , R 61 and R 62 are independently selected from hydrogen or a substituent group and * indicates the point of attachment to the group X in formula (I).
  • R 60 , R 61 or R 62 is a substituent group and the others are either hydrogen or a small substituent such as C 1-3 alkyl, for instance methyl.
  • R 62 is hydrogen.
  • R 61 is other than hydrogen,
  • R 5 is an optionally substituted nitrogen containing ring such as a group of formula (f), (g), (h), (i) or (j):
  • Suitable substituents for groups R 5 include optionally substituted hydrocarbyl, optionally substituted heterocylyl or a functional group as defined above.
  • R 63 and R 64 examples include the group —(CH 2 ) q R 70 where q and R 70 are as defined below in relation to formula (II).
  • R 63 or R 64 is hydrogen, or methyl, ethyl or propyl optionally substituted with hydroxy and preferably one of R 63 or R 64 is hydrogen.
  • the other is suitably a larger substituent for example of at least 4 carbon or heteroatoms, and is optionally substituted hydrocarbyl or optionally substituted heterocyclyl.
  • Particular optionally substituted hydrocarbyl groups for R 63 or R 64 include alkyl, cycloalkyl, alkenyl, or aryl any of which is optionally substituted with a functional group as defined above, or in the case of aryl groups, with an alkyl group and in the case of alkyl group, with an aryl or heterocyclic group either of which may themselves be optionally substituted with alkyl or a functional group.
  • optionally substituted aryl groups R 63 or R 64 include phenyl optionally substituted with one or more groups selected from C 1-6 alkyl group such as methyl or ethyl (either of which may be optionally substituted with a functional group such as hydroxy), or a functional group as defined above (such as halo like fluoro, chloro or bromo, hydroxy, alkoxy such as methoxy, trifluoromethyl, nitro, cyano, trifluromethoxy, CONH 2 , C(O)CH 3 , amino, or dimethylamino).
  • C 1-6 alkyl group such as methyl or ethyl
  • a functional group as defined above such as halo like fluoro, chloro or bromo, hydroxy, alkoxy such as methoxy, trifluoromethyl, nitro, cyano, trifluromethoxy, CONH 2 , C(O)CH 3 , amino, or dimethylamino.
  • R 63 or R 64 is an optionally substituted alkyl group, it is suitably a C 1-6 alkyl group, optionally substituted with one or more functional groups (such as cyano, hydroxy, alkoxy, in particular methoxy, COOalkyl such as COOCH 3 ), or aryl optionally substituted with a functional group as defined above (in particular in relation to R 63 or R 64 themselves, or an optionally substituted heterocyclic group such as N-methyl pyrrole.
  • one or more functional groups such as cyano, hydroxy, alkoxy, in particular methoxy, COOalkyl such as COOCH 3
  • aryl optionally substituted with a functional group as defined above (in particular in relation to R 63 or R 64 themselves, or an optionally substituted heterocyclic group such as N-methyl pyrrole.
  • R 63 and R 64 is optionally substituted cycloalkyl, it is suitable cyclohexyl optionally substituted with a functional group such as hydroxy.
  • R 63 and R 64 is optionally substituted alkenyl, it is suitably prop-2-enyl.
  • R 63 or R 64 is optionally substituted heterocyclyl, or R 63 and R 64 together form a heterocyclic group, then this may be aromatic or non-aromatic and includes in particular, piperidine, piperazine, morpholino, pyrrolidine or pyridine any of which may be optionally substituted with a functional group such as hydroxy, alkoxy such as methoxy, or alkyl such as methyl which may itself be substituted with for instance a hydroxy group.
  • R 5 is substituted by one or more groups selected from nitro, halo, C 1-6 alkyl, optionally substituted C 1-6 alkoxy, C 1-4 alkoxymethyl, di(C 1-4 alkoxy)methyl, C 1-6 alkanoyl, trifluoromethyl, cyano, amino, C 2-6 alkenyl, C 2-6 alkyl, a phenyl group, a benzyl group or a 5-6-membered heterocyclic group with 1-3 heteroatoms, selected independently from O, S and N, which heterocyclic group may be aromatic or non-aromatic and may be saturated (linked via a ring carbon or nitrogen atom) or unsaturated (linked via a ring carbon atom), and which phenyl, benzyl or heterocyclic group may bear on one or more ring carbon atoms up to 5 substituents selected from hydroxy, halogeno, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkanoyloxy, trifluoro
  • R 5 is substituted with at least one group which has at least 4 atoms which may be carbon or heteroatoms forming a chain.
  • a particular example of such a substituent is optionally substituted alkoxy or alkoxy methyl.
  • Suitable substituents for the alkoxy group include those listed above in relation to R 77 , R 78 and R 79 .
  • R 5 is a group of sub-formula (II) where p and q are independently 0 or 1, and r is 0, 1, 2, 3 or 4 and, R1′, R1′′ and T are as previously defined above;
  • a preferred example of a substituent of formula (II) is a group where q is 0.
  • a particular example of a group R 70 in formula (II) is phenyl.
  • R 5 is a group of formula (VI) where R 71 and R 72 are independently selected from hydrogen or C 1-4 alkyl, or R 71 and R 72 together form a bond, and R 73 is a group OR 74 , NR 75 R 76 where R 74 , R 75 and R 76 are independently selected from optionally substituted hydrocarbyl or optionally substituted heterocyclic groups, and R 75 and R 76 may additionally form together with the nitrogen atom to which they are attached, an aromatic or non-aromatic heterocyclic ring which may contain further heteroatoms.
  • R 71 and R 72 in sub-formula (VI) are hydrogen.
  • R 73 are groups of formula NR 75 R 76 where one of R 75 or R 76 is hydrogen and the other is optionally substituted C 1-6 alkyl, optionally substituted aryl or optionally substituted heterocyclyl.
  • R 75 or R 76 is hydrogen and the other is C 1-6 alkyl optionally substituted with trifluoromethyl, C 1-3 alkoxy such as methoxy, cyano, thioC 1-4 alkyl such as methylthio, or heterocyclyl optionally substituted with hydrocarbyl, such as indane, furan optionally substituted with C 1-4 alkyl such as methyl.
  • one of R 75 or R 76 is hydrogen and the other is an optionally substituted heterocyclic group such as pyridine, or a phenyl group optionally substituted with for example one or more groups selected from halo, nitro, alkyl such as methyl, or alkoxy such as methoxy.
  • Suitable pharmaceutically acceptable salts of compounds of Formula (I) or Formula (IA) include acid addition salts such as methanesulfonate, fumarate, hydrochloride, hydrobromide, citrate, maleate and salts formed with phosphoric and sulphuric acid. There may be more than one cation or anion depending on the number of charged functions and the valency of the cations or anions.
  • An in vivo hydrolysable ester of a compound of the Formula (I) or Formula (IA) containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol.
  • Suitable pharmaceutically acceptable esters for carboxy include C 1-6 alkyl esters such as methyl or ethyl esters, C 1-6 alkoxymethyl esters for example methoxymethyl, C 1-6 alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C 3-8 cycloalkoxy-carbonyloxyC 1-6 alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C 1-6 alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.
  • C 1-6 alkyl esters such as methyl or ethyl esters
  • C 1-6 alkoxymethyl esters for example methoxymethyl
  • An in vivo hydrolysable ester of a compound of the Formula (I) or Formula (IA) containing a hydroxy group includes inorganic esters such as phosphate esters and ⁇ -acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group.
  • inorganic esters such as phosphate esters and ⁇ -acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group.
  • ⁇ -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxymethoxy.
  • Suitable amides are derived from compounds of Formula (I) or Formula (IA) which have a carboxy group which is derivatised into an amide such as a N—C 1-6 alkyl and N,N—di-(C 1-6 alkyl)amide such as N-methyl, N-ethyl, N-propyl, N,N-dimethyl, N-ethyl-N-methyl or N,N-diethylamide.
  • Esters which are not in vivo hydrolysable may be useful as intermediates in the production of the compounds of Formula (I) or Formula (IA).
  • N° NRR′ 540 N-ethylaniline 541 3-chloro-4-fluoro-N-methylaniline 542 ethyl-2-(3-chloro-4-fluoroanilino)acetate 543 2-anilinoacetronitrile 544 3-anilinoproponitrile 545 N-(2-tert-butoxyethyl)-3-chloro-4-fluoroaniline 546 N-allylaniline 547 N-ethyl-3,4-(methylmedioxy)aniline 548 ethyl-4-(N-butylamino)benzate 549 N-ethyl-M-toluidine 550 N-(2-hydroxy′′thyl)-3-chloro-4-fluoroaniline
  • R 1 , R 2 , R 3 , and R 4 are as defined in relation to formula (I) and R 85 is a group NR 86 R 87 where R 86 and R 87 are independently selected from alkyl such as methyl, with a compound of formula (VIII) H 2 N—R 5 ′ (VIII) where R 5 ′ is a group R 5 as defined in relation to formula (I) or a precursor group thereof; and thereafter if desired or necessary, converting a precursor group R 5 ′ to a group R 5 and/or modifying substituents on the group R 5 .
  • the reaction is suitably effected in an organic solvent such as an acetic acid at elevated temperatures, conveniently at the reflux temperature of the solvent.
  • Examples of reactions in which a precursor group R 5 ′ is converted to a group R 5 and/or substituents on the group R 5 are modified are standard chemical reactions, such as conversion of esters to acids, and thereafter, if required to the preferred amides. Examples of is such reactions are provided hereinafter.
  • Compounds of formula (VII) are suitably prepared by reacting a compound of formula (IX) with an appropriate acetal such as N,N-dimethylformamide dimethyl acetal.
  • the reaction is suitably effected in an organic solvent such as benzene, at elevated temperature, conveniently at the reflux temperature of the solvent.
  • compounds of formula (I) where X is NH may be prepared by rearranging a compound of formula (X) where R 1 , R 2 , R 3 and R 4 are as defined in relation to formula (I) and R 5 ′ is as defined in relation to formula (VIII) above, and thereafter if desired or necessary, converting a precursor group R 5 ′ to a group R 5 and/or modifying substituents on the group R 5 , for example as described generally above.
  • the rearrangement reaction is suitably effected in an organic solvent such as an alkyl alcohol, in particular methanol, ethanol or cyclohexanol, acetic acid, or dimethylformamide, using a strong base such as sodium hydroxide, sodium acetate, sodium methylate, or dimethylamine. Elevated temperatures, for example of from 20°-120° C. and preferably at about 75° C. are employed.
  • Compounds of formula (XI) are suitably prepared by reacting a compound of formula (IX) as defined above, with a trialkylorthoformate such as trimethylorthoformate.
  • the reaction is suitably effected at elevated temperature, for example of from 50° C. to 120° C., and preferably at about 100° C., in the presence of a catalytic amount of an acid such as p-toluene sulphonic acid.
  • the nitrile of formula (XIV) may be derived by reaction of the corresponding formamide with hydroxylamine as illustrated hereinafter.
  • Compounds of Formula (I) and Formula (IA) are inhibitors of aurora 2 kinase. As a result, these compounds can be used to treat disease mediated by these agents, in particular proliferative disease.
  • a method for inhibiting aurora 2 kinase in a warm blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of Formula (I) or Formula (IA), or a pharmaceutically acceptable salt, or an in vivo hydrolysable ester thereof.
  • Certain compounds of formula (I) are novel and these form a further aspect of the invention.
  • the invention further comprises a compound of formula (IA) or a salt, ester or amide thereof,
  • At least one of R 1 ′, R 2 ′, R 3 ′ and R 4 ′ is other than hydrogen.
  • R 5a is selected from the groups of sub-formulae (a)-(j) as set out above.
  • R 5a is pyrrole, imidazole, triazole, thiazole, thiophene, or thiadiazole, any of which may be optionally substituted.
  • R 5a is substituted by at least one group of formula (k), (II) of (VI) above.
  • the compounds are used in methods of treatment of proliferative disease such as cancer and in particular cancers such as colorectal or breast cancer where aurora 2 is upregulated.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (IA) as defined herein, or a pharmaceutically acceptable salt, or an in vivo hydrolysable ester thereof, in combination with at pharmaceutically acceptable carrier.
  • Preferred or particular compounds of formula (IA) for use in the compositions of the invention are as described above in relation to preferred compounds of formula (I).
  • compositions of the invention maybe in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).
  • oral use for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs
  • compositions of the invention maybe obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art.
  • compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.
  • Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p -hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal track, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.
  • inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate
  • granulating and disintegrating agents such as corn starch or algenic acid
  • binding agents such as starch
  • Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil such as peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxyethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol mono
  • the aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).
  • preservatives such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin).
  • the oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present.
  • the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these.
  • Suitable emulsifying agents maybe, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening, flavouring and preservative agents.
  • Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.
  • sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.
  • compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above.
  • a sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.
  • Suppository formulations may be prepared by mixing the active ingredient with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable excipients include, for example, cocoa butter and polyethylene glycols.
  • Topical formulations such as creams, ointments, gels and aqueous or oily solutions or suspensions, may generally be obtained by formulating an active ingredient with a conventional, topically acceptable, vehicle or diluent using conventional procedure well known in the art
  • compositions for administration by insufflation may be in the form of a finely divided powder containing particles of average diameter of, for example, 30 ⁇ or much less, the powder itself comprising either active ingredient alone or diluted with one or more physiologically acceptable carriers such as lactose.
  • the powder for insufflation is then conveniently retained in a capsule containing, for example, 1 to 50 mg of active ingredient for use with a turbo-inhaler device, such as is used for insufflation of the known agent sodium cromoglycate.
  • Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets.
  • Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.
  • the amount of active ingredient that is combined with one or tore excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration.
  • a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.
  • Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient.
  • the size of the dose for therapeutic or prophylactic purposes of a compound of the Formula I will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine. As mentioned above, compounds of the Formula I are useful in treating diseases or medical conditions which are due alone or in part to the effects of aurora 2 kinase.
  • a further aspect of the invention comprises a compound of Formula (I) or Formula (IA) as defined above, or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, for use in the preparation of a medicament for the treatment of proliferative disease.
  • Preferred compounds of Formula (I) or Formula (IA) for this purpose are as described above.
  • the acid 201 (86.5 mg, 0.25 mmol) in DMF (1 ml) was reacted with various amines (2.6 mmol) in presence of O-(7-azabenzotriazol-1yl) N,N,N′,N′,-tetramethyluronium hexafluorophosphate (98 mg, 0.26 mmol), DIEA (33 mg, 0.26 mmol) at room temperature for 0.5 hour.
  • a solution of NaHCO 3 (1 ml) and water (7 ml) was added to the mixture. The mixture was left overnight, and the precipitated solid was then recovered by filtration, washed with water and dried under vacuum in presence of P 2 O 5 , to give compounds of formula C as listed below.
  • Vanilline (30.4 g, 0.2 mol) was solubilized in DMF (200 ml) in presence of K 2 CO 3 at 50° C. N-(3-chloropropyl)morpholine was slowly added over 30 minutes to this mixture, which was heated over night at 80° C. Formed KCl was removed by filtration, the solvent was evaporated, and the residual orange oil dissolved in AcOEt, washed with water 2 ⁇ , dried over MgSO 4 , filtered and concentrated. The residual oil crystallises to give title compound as a white solid (45.6 g, 82%).
  • the aldehyde E (5.6 g, 20 mmol) was added to a solution of sodium acetate (3.3 g, 40 mmol) and hydroxylamine hydrochloride (2.8 g, 40 mmol) in acetic acid (25 ml). The mixture was refluxed for 18 hours, cooled, diluted with water and extracted with methylene chloride, dried over MgSO 4 , filtered, concentrated, to give title compound (5.1 g, 93%).
  • nitrile F 37.2 g, 135 mmol
  • acetic acid 100 ml
  • nitric acid 180 ml
  • the mixture was stirred at room temperature over night.
  • a solution of potassium hydroxide (10N, 370 ml) was then added slowly to the solution at 0° leading to a final pH of 11-12.
  • the reaction was extracted with CH 2 Cl 2 , the organic phases were dried over MgSO 4 , filtered, evaporated to give a yellow solid which was washed with ether, dried to give title compound (22 g, 50%).
  • the ester 203 (122 mg, 0.25 mmol) was suspended in ethanol (5 ml) and reacted with sodium hydroxide (10N, 0.5 ml) at 80° C. for 1 hour. The reaction mixture was cooled, acidified (pH 3.5), the yellow precipitate was filtered, washed with water, dried under vacuum, to give title compound (100 mg, 87%).
  • Ester 205 (2 g, 4.1 mmol) was suspended in ethanol (20 ml). 2N sodium hydroxide (4.1 ml, 8.2 mmol) was added to the suspension which was stirred for 3 hours at room temperature. HCl 2N was added to the solution, the yellow precipitate was filtered, washed with water, ethanol, ether and dried under vacuum, to give title compound (1.98 g, 99%).
  • the acid 206 (83 mg, 0.17 mmol) in DMF (0.8 ml) was reacted with amine (0.17 mmol) in presence of O-(7-azabenzotriazol-1-yl) N,N,N′,N′-tetramethyluronium hexafluorophosphate (78 mg, 0.204 mmol), DIEA (52 mg, 0.4 mmol), for 6 hours at room temperature.
  • the reaction mixture was then treated with a solution of NaHCO 3 (6 ml) with stirring for 2 hours, washed with water, cooled to 5° C., and the solid filtered, triturated with ether, dried under vacuum over P 2 O 5 to give title compounds.
  • Ester 208 (1.6 g, 3.4 mmol) in suspension in ethanol (32 ml) was reacted with sodium hydroxide (6N, 6 ml) at 75° C. for 1 hour. The cooled solution was acidified with HCl (6N) to pH 4. The solid was filtered, washed with EtOH, ether, dried, to give a yellow solid (1.65 g, 86%).
  • Ester 210 (360 mg, 0.74 mmol) in ethanol (10 ml) was reacted with sodium hydroxide (6N, 1 ml) at room temperature for 1 hour. HCl (6N) was then added to the solution cooled to 0° C., and the pH adjusted to 3-4. The solid was recovered by filtration, washed with ethanol, ether, dried under vacuum, to give title compound as a dihydrochloride (550 mg, 83%).
  • the acid 211 (87 mg, 0.13 mmol) in DMF (1 ml) was reacted with amine (0.169 mmol) in presence of O-(7-azabensotriazol-1-yl) N,N,N′,N′-tetramethyluronium hexafluorophosphate (69 mg, 0.182 mmol), diisopropylethylamine (84 mg, 0.65 mmol) over night, at room temperature.
  • the reaction mixture was diluted with water (5 ml) and a concentrated solution of sodium bicarbonate (1 ml). The solid was filtered, washed with water, ethanol, ether, and dried under vacuum, to give title compounds.
  • the solution was concentrated to dryness, the residues were washed with methylene chloride, methanol, filtered. Alumine was added to the methylene chloride/methanol solution, and the solvent was evaporated. Purification of the compounds was carried out by chromatography over alumine, eluent CH 2 Cl 2 /MeOH: 98/2 to 95/5, to give title compounds.
  • Ester V (1.1 g, 2.3 mmol) in methanol (20 ml) was treated with sodium hydroxide (2N, 20 ml) at 75° C. for 4 hours, and at room temperature over night. Methanol was evaporated, and the remaining aqueous solution was kept for 24 hours at 5° C. The solid was filtered, washed with water, MeOH/CH 2 Cl 2 : 1/1, dried under vacuum to give title compound (0.9 g, 87%).
  • Acid 212 (80 mg, 0.18 mmol) in DMF (1.5 ml) was reacted with amine (0.216 mmol) in presence of O-(7-azabenzotriazol-1-yl) N,N,N′,N′-tetramethyluronium hexafluorophosphate (80 mg, 0.21 mmol), DIEA (80 ⁇ l, 0.46 mmol), for 3 hours at room temperature.
  • the reaction mixture was then treated with a solution of NaHCO 3 (2 ml) with stirring for 0.5 hour, the solid filtered, washed with water, ether, dried under vacuum over P 2 O 5 , to give title compound.
  • the ester 213 (72 mg, 0.2 mmol) in methanol (2 ml) was treated with sodium hydroxide (2N, 2 ml) at 75° C. for 1.5 hour.
  • the reaction mixture was cooled to room temperature, and the pH adjusted to 3 by addition of HCl 2N.
  • the solid was recovered by filtration, washed with water, dried under vacuum in presence of P 2 O 5 , to give title compound (83 mg, 100%).
  • Ester 250 (1.34 g, 3 mmol) was treated with sodium hydroxide (6N, 3 ml) in ethanol (25 ml) at 75° for 2 hours. The solution was then cooled to room temperature, acidified to pH 3 with HCl (6N), the precipitate was recovered by filtration, washed with ethanol, ether, dried under vacuum to give title compound (636 mg, 42%).
  • Acid 251 (79 mg, 0.15 mmol) in DMF (1 ml) was reacted with O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (62 mg, 0.165 mmol), the appropriate amine (1.65 mmol) and DIEA (68 mg, 0.525 mmol) at room temperature for 1.5 hour.
  • the reaction mixture was then diluted with water (4 ml) and an aqueous solution of sodium bicarbonate (1 ml). The solid was recovered by filtration, redissolved in tetrahydrofuran, methylene chloride, and concentrated, the precipitated solid was recovered, washed with ether, dried under vacuum, to give title compound.
  • Ester 256 (1.34 g, 3 mmol) in ethanol (25 ml) was treated with sodium hydroxide (6N, 3 ml) at 75° C. for 2 hours. The solution was cooled, and acidified with hydrochloric acid (6N) to pH 3. The precipitate was filtered, washed with ethanol, ether, dried under vacuum over P 2 O 5 , to give title compound (0.63 g, 42%).
  • Acid 257 (75 mg, 0.15 mmol) in DMF (0.7 ml) was reacted with O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (68 mg, 0.18 mmol), aniline (17 mg, 0.18 mmol) and DIEA (62 mg, 0.48 mmol) at room temperature over night.
  • the reaction mixture was then diluted with a saturated solution of sodium bicarbonate (5 ml), and stirred for 1 hour. The solid was filtered, washed with water, dried under vacuum over P 2 O 5 , to give title compound (30 mg, 40%).
  • Acid 261 (88 mg, 0.16 mmol) in DMF (1 ml) was reacted with O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (73 mg, 0.19 mmol), the appropriate amine (0.18 mmol) and DIEA (82 mg, 0.4 mmol) at room temperature for 3 hours.
  • the solution was then diluted with a saturated solution of sodium bicarbonate (4 ml) and stirred at room temperature for 3 hours. The precipitate was filtered, washed with water, dried under vacuum over P 2 O 5 , to give title compound.
  • Triazole ester Z 1 (80 mg, 0.17 mmol) in dimethylformamide (3 ml) was treated with dimethylamine acetate (0.52 mmol) at 70° C. for 20 minutes. The mixture was cooled, the solvent evaporated, and the residue purified by silica gel chromatography, eluent CH 2 Cl 2 /MeOH/NH3, 90/10/1 to give title product (60 mg, 75%)
  • Triazole ester 268 (900 mg, 1.97 mmol) in methanol (20 ml), was treated with sodium hydroxyde (2N, 20 ml) at 80° C. for 1.5 hour. The mixture was cooled, and acidified to pH 2.5 with hydrochloric acid (6N), the solid was recovered by filtration dried under vacuum over P 2 O 5 to give title compound (843 mg, 100%).
  • Acid 269 120 mg, 0.28 mmol in DMF (2 ml) was reacted with aniline (0.025 ml, 0.28 mmol) in presence of O-(7-azabenzotriazol-1-yl) N,N,N′,N′,-tetramethyluronium hexafluorophosphate (106 mg, 0.28 mmol) and DIEA (0.12 ml, 0.7 mmol) at room temperature for 4 hours.
  • the solvent was evaporated, the residue dissolved in methylene chloride/methanol, and treated with a methanolic solution of dimethylamine (2M, 1 ml) at room temperature over night.
  • the solvent was evaporated, and the residue purified by flash silica gel chromatography, eluent CH 2 Cl 2 /MeOH, 90/10 to give title compound (12 mg, 9%).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The use of a compound of formula (I) or a salt, ester or amide thereof; where X is O, or S, S(O) or S(O)2, or NR6 where R6 is hydrogen or C1-6alkyl; R5 is an optionally substituted 5-membered heteroaromatic ring, R1, R2, R3, R4 are independently selected from various specified moieties, in the preparation of a medicament for use in the inhibition of aurora 2 kinase. Certain compounds are novel and these, together with pharmaceutical compositions containing them are also described and claimed.

Description

  • The present invention relates to certain quinazoline derivatives for use in the treatment of certain diseases in particular to proliferative disease such as cancer and in the preparation of medicaments for use in the treatment of proliferative disease, to novel quinazoline compounds and to processes for their preparation, as well as pharmaceutical compositions containing them as active ingredient.
  • Cancer (and other hyperproliferative disease) is characterised by uncontrolled cellular proliferation. This loss of the normal regulation of cell proliferation often appears to occur as the result of genetic damage to cellular pathways that control progress through the cell cycle.
  • In eukaryotes, the cell cycle is largely controlled by an ordered cascade of protein phosphorylation. Several families of protein kinases that play critical roles in this cascade have now been identified. The activity of many of these kinases is increased in human tumours when compared to normal tissue. This can occur by either increased levels of expression of the protein (as a result of gene amplification for example), or by changes in expression of co activators or inhibitory proteins.
  • The first identified, and most widely studied of these cell cycle regulators have been the cyclin dependent kinases (or CDKs). Activity of specific CDKs at specific times is essential for both initiation and coordinated progress through the cell cycle For example, the CDK4 protein appears to control entry into the cell cycle (the G0-G1-S transition) by phosphorylating the retinoblastoma gene product pRb. This stimulates the release of the transcription factor E2F from pRb, which then acts to increase the transcription of genes necessary for entry into S phase. The catalytic activity of CDK4 is stimulated by binding to a partner protein, Cyclin D. One of the first demonstrations of a direct link between cancer and the cell cycle was made with the observation that the Cyclin D1 gene was amplified and cyclin D protein levels increased (and hence the activity of CDK4 increased) in many human tumours (Reviewed in Sherr, 1996, Science 274: 1672-1677; Pines, 1995, Seminars in Cancer Biology 6: 63-72). Other studies (Loda et al., 1997, Nature Medicine 3(2): 231-234; Gemma et al., 1996, International Journal of Cancer 68(5): 605-11; Elledge et al. 1996, Trends in Cell Biology 6; 388-392) have shown that negative regulators of CDK function are frequently down regulated or deleted in human tumours again leading to inappropriate activation of these kinases.
  • More recently, protein kinases that are structurally distinct from the CDK family have been identified which play critical roles in regulating the cell cycle and which also appear to be important in oncogenesis. These include the newly identified human homologues of the Drosophila aurora and S. cerevisiae Ip11 proteins. Drosophila aurora and S. cerevisiae Ip11, which are highly homologous at the amino acid sequence level, encode serine/threonine protein kinases. Both aurora and Ip11 are known to be involved in controlling the transition from the G2 phase of the cell cycle through mitosis, centrosome function, formation of a mitotic spindle and proper chromosome separation/segregation into daughter cells. The two human homologues of these genes, termed aurora 1 and aurora 2, encode cell cycle regulated protein kinases. These show a peak of expression and kinase activity at the G2/M boundary (aurora 2) and in mitosis itself (aurora1). Several observations implicate the involvement of human aurora proteins , and particularly aurora 2 in cancer. The aurora 2 gene maps to chromosome 20q13, a region that is frequently amplified in human tumours including both breast and colon tumours. Aurora 2 may be the major target gene of this amplicon, since aurora 2 DNA is amplified and aurora 2 mRNA overexpressed in greater than 50% of primary human colorectal cancers. In these tumours aurora 2 protein levels appear greatly elevated compared to adjacent normal tissue. In addition, transfection of rodent fibroblasts with human aurora 2 leads to transformation, conferring the ability to grow in soft agar and form tumours in nude mice (Bischoff et al., 1998, The EMBO Journal. 17(11): 3052-3065). Other work (Zhou et al., 1998, Nature Genetics. 20(2): 189-93) has shown that artificial overexpression of aurora 2 leads to an increase in centrosome number and an increase in aneuploidy.
  • Importantly, it has also been demonstrated that abrogation of aurora 2 expression and function by antisense oligonucleotide treatment of human tumour cell lines. (WO 97/22702 and WO 99/37788) leads to cell cycle arrest in the G2 phase of the cell cycle and exerts an antiproliferative effect in these tumour cell lines. This indicates that inhibition of the function of aurora 2 will have an antiproliferative effect that may be useful in the treatment of human tumours and other hyperproliferative diseases.
  • A number of quinazoline derivatives have been proposed hitherto for use in the inhibition of various kinases. Examples of such proposals are included in WO 92/20642 and EP-B-584222 which relates to bicyclic compounds which inhibit epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinase, WO 95/15758 which describes the use of bis ring systems for the selective inhibition of CSF-1R tyrosine kinase activity, and WO 99/09016, WO 97/03069 and U.S. Pat. No. 570,158 which describe the use of certain quinazoline compounds as tyrosine kinase inhibitors in other contexts.
  • The applicants have found a series of compounds which inhibit the effect of the aurora 2 kinase and which are thus of use in the treatment of proliferative disease such as cancer, in particular in such diseases such as colorectal or breast cancer where aurora 2 kinase is known to be active.
  • The present invention provides the use of a compound of formula (I)
    Figure US20060046987A1-20060302-C00001
    or a salt, ester or amide thereof,
    • where X is O, or S, S(O) or S(O)2, or NR6 where R6 is hydrogen or C1-6alkyl;
    • R5 is an optionally substituted 5-membered heteroaromatic ring,
    • R1, R2, R3, R4 are independently selected from, halo, cyano, nitro, trifluoromethyl, C1-3alkyl, —NR7R8 (wherein R7 and R8, which may be the same or different, each represents hydrogen or C1-3alkyl), or —X1R9 (wherein X1 represents a direct bond, —O—, —CH2—, —OCO—, carbonyl, —S—, —SO—, —SO2—, —NR10CO—, —CONR11—, —SO2NR12—, —NR13SO2— or —NR14— (wherein R10, R11, R12, R13 and R14 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl), and R9 is selected from one of the following groups:
    • 1) hydrogen or C1-5alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro or amino,
    • 2) C1-5alkylX2COR15 (wherein X2 represents —O— or —NR16— (in which R15 represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R16 represents C1-3alkyl, —NR17R18 or —OR19 (wherein R17, R18 and R19 which maybe the same or different each represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl));
    • 3) C1-5alkylX3R20 (wherein X3 represents —O—, —S—, —SO—, —SO2—, —OCO—, —NR2CO—, —CONR22—, —SO2NR23—, —NR24SO2— or —NR25— (wherein R21, R22, R23, R24 and R25 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R20 represents hydrogen, C1-3alkyl, cyclopentyl, cyclohexyl or a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C1-3alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C1-4alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy);
    • 4) C1-5alkylX4C1-5alkylX5R26 (wherein X4 and X5 which may be the same or different are each —O—, —S—, —SO—, —SO2—, —NR27CO—, —CONR28—, —SO2NR29—, —NR30SO2— or —NR31— (wherein R27, R28, R29, R30 and R31 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R26 represents hydrogen or C1-3alkyl);
    • 5) R32 (wherein R32 is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl, C1-4alkoxy, C1-4alkoxyC1-4alkyl and C1-4alkylsulphonylC1-4alkyl);
    • 6) C1-5alkylR32 (wherein R32 is as defined hereinbefore),
    • 7) C2-5alkenylR32 (wherein R32 is as defined hereinbefore);
    • 8) C2-5alkynylR32 (wherein R32 is as defined hereinbefore);
    • 9) R33 (wherein R33 represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents on an available carbon atom selected from hydroxy, halogeno, amino, C1-4alkyl, C1-4alkoxy, C1-4hydroxyalkyl, C1-4aminoalkyl, C1-4alkylamino, C1-4hydroxyalkoxy, carboxy, trifluoromethyl, cyano, —CONR34R35 and —NR36COR37 (wherein R34, R35, R36 and R37, which may be the same or different, each represents hydrogen, C1-4alkyl or C1-3alkoxyC2-3alkyl));
    • 10) C1-5alkylR33 (wherein R33 is as defined hereinbefore);
    • 11) C2-5alkenylR33 (wherein R33 is as defined hereinbefore);
    • 12) C2-5alkynylR33 (wherein R33 is as defined hereinbefore);
    • 13) C1-5alkylX6R33 (wherein X6 represents —O—, —S—, —SO—, —SO2—, —NR38CO—, —CONR39—, —SO2NR40, —NR41SO2—or —NR42— (wherein R38, R39, R40, R41 and R42 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R33 is as defined hereinbefore);
    • 14) C2-5alkenylX7R33 (wherein X7 represents —O—, —S—, —SO—, —SO2—, —NR43CO—, —CONR44—, —SO2NR45—, —NR46SO2— or —NR47— (wherein R43, R44, R45, R46and R47 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R33 is as defined hereinbefore);
    • 15) C2-5alkynylX8R33 (wherein X8 represents —O—, —S—, —SO—, —SO2—, —NR48CO—, —CONR49—, —SO2NR50—, —NR51SO2— or —NR52— (wherein R48, R49, R50, R51 and R52 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R33 is as defined hereinbefore);
    • 16) C1-3alkylX9C1-3alkylR33 (wherein X9 represents —O—, —S—, —SO—, —SO2—, —NR53CO—, —CONR54—, —SO2NR55—, —NR56SO2— or —NR57— (wherein R53, R54, R55, R56and R57 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R33 is as defined hereinbefore); and
    • 17) C1-3alkylX9C1-3alkylR32 (wherein X9 and R28 are as defined hereinbefore):
  • in the preparation of a medicament for use in the inhibition of aurora 2 kinase. In particular, such medicaments are useful in the treatment of proliferative disease such as cancer, and in particular cancers where aurora 2 is upregulated such as colon or breast cancers.
  • In this specification the term ‘alkyl’ when used either alone or as a suffix includes straight chained, branched structures. Unless otherwise stated, these groups may contain up to 10, preferably up to 6 and more preferably up to 4 carbon atoms. Similarly the terms “alkenyl” and “alkynyl” refer to unsaturated straight or branched structures containing for example from 2 to 10, preferably from 2 to 6 carbon atoms. Cyclic moieties such as cycloalkyl, cycloalkenyl and cycloalkynyl are similar in nature but have at least 3 carbon atoms. Terms such as “alkoxy” comprise alkyl groups as is understood in the art.
  • The term “halo” includes fluoro, chloro, bromo and iodo. References to aryl groups include aromatic carbocylic groups such as phenyl and naphthyl. The term “heterocyclyl” includes aromatic or non-aromatic rings, for example containing from 4 to 20, suitably from 5 to 8 ring atoms, at least one of which is a heteroatom such as oxygen, sulphur or nitrogen. Examples of such groups include furyl, thienyl, pyrrolyl, pyrrolidinyl, imidazolyl, triazolyl, thiazolyl, tetrazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, quinolinyl, isoquinolinyl, quinoxalinyl, benzothiazolyl, benzoxazolyl, benzothienyl or benzofuryl.
  • “Heteroaryl” refers to those groups described above which have an aromatic character. The term “aralkyl” refers to aryl substituted alkyl groups such as benzyl.
  • Other expressions used in the specification include “hydrocarbyl” which refers to any structure comprising carbon and hydrogen atoms. For example, these may be alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkoxy, aralkyl, cycloalkyl, cycloalkenyl or cycloalkynyl.
  • The term “functional group” refers to reactive substituents such as nitro, cyano, halo, oxo, ═CR78R79, C(O)xR77, OR77, S(O)yR77, NR78R79, C(O)NR78R79, OC(O)NR78R79, ═NOR77, —NR77C(O)xR78, —NR77CONR78R79, —N═CR78R79, S(O)yNR78R79 or —NR77S(O)yR78 where R77, R78 and R79 are independently selected from hydrogen or optionally substituted hydrocarbyl, or R78 and R79 together form an optionally substituted ring which optionally contains further heteroatoms such as S(O)y oxygen and nitrogen, x is an integer of 1 or 2, y is 0 or an integer of 1-3.
  • Suitable optional substituents for hydrocarbyl groups R77, R78 and R79 include halo, perhaloalkyl such as trifluoromethyl, mercapto, hydroxy, carboxy, alkoxy, aryl, heteroaryl, heteroaryloxy, alkenyloxy, alkynyloxy, alkoxyalkoxy, aryloxy (where the aryl group may be substituted by halo, nitro, or hydroxy), cyano, nitro, amino, mono- or di-alkyl amino, oximino or S(O)y where y is as defined above.
  • Preferably R4 is hydrogen.
  • Suitably R1 is hydrogen or a group set out for R2 or R3 below. Frequently, R1 is hydrogen.
  • In a preferred embodiment, at least one group R1, R2 or R3, preferably R3, comprises a chain of at least 3 and preferably at least 4 optionally substituted carbon atoms or heteroatoms such as oxygen, nitrogen or sulphur. Most preferably the chain is substituted by a polar group which assists in solubility.
  • Suitably R3 is a group X1R9. Preferably in this case, X1 is oxygen and R9 is selected from a group of formula (1) or (10) above. Particular groups R9 are those in group (1) above, especially alkyl such as methyl or halo substituted alkyl, or those in group (10) above. In one preferred embodiment, at least one of R2 or R3 is a group —OC1-5alkylR33 and R33 is a heterocyclic ring such as an N-linked morpholine ring such as 3-morpholinopropoxy.
  • Suitably R2 is selected from, halo, cyano, nitro, tifluoromethyl, C1-3alkyl, —NR9R10 (wherein R9 and R10, which may be the same or different, each represents hydrogen or C1-3alkyl), or a group —X1R11. Preferred examples of —X1R11 for R2 include those listed above in relation to R3.
  • Other examples for R2 and R3 include methoxy or 3,3,3-trifluoroethoxy.
  • Preferably X is NH or O and is most preferably NH.
  • Examples of 5-membered aromatic rings R5 include rings containing one or more heteroatoms selected from sulphur, oxygen and nitrogen. Such rings include pyrrole, pyrazole, pyrazolone, imidazole, oxazole, furan, tetrazole, triazole, thiazole, thiophene, or thiadiazole, any of which may be optionally substituted. In particular, R5 includes at least one nitrogen or sulphur heteroatoms. Preferred rings for R5 include pyrrole, pyrazole, imidazole, triazole, thiazole, thiophene, or thiadiazole.
  • In a particular embodiment, R5 is a sulphur containing ring. Suitably R5 is optionally substituted thiazole, optionally substituted thiophene or optionally substituted thiadiazole and preferably, optionally substituted thiazole or optionally substituted thiophene.
  • More preferably, R5 is a substituted thiazole or substituted thiophene group.
  • In particular, R5 is a group of formula (a), (b), (c) or (d) and preferably (a) or (b):
    Figure US20060046987A1-20060302-C00002
    where R60, R61 and R62 are independently selected from hydrogen or a substituent group and * indicates the point of attachment to the group X in formula (I). In particular, one of R60, R61 or R62 is a substituent group and the others are either hydrogen or a small substituent such as C1-3 alkyl, for instance methyl. Suitably R62 is hydrogen. Preferably R61 is other than hydrogen,
  • Alternatively, R5 is an optionally substituted nitrogen containing ring such as a group of formula (f), (g), (h), (i) or (j):
    Figure US20060046987A1-20060302-C00003
  • Suitable substituents for groups R5 include optionally substituted hydrocarbyl, optionally substituted heterocylyl or a functional group as defined above.
  • In particular, R60, R61 or R62 is a group of sub-formula (k)
    Figure US20060046987A1-20060302-C00004
    where p and q are independently 0 or 1 and wherein R1′ and R1″ are independently hydrogen, hydroxy, optionally substituted alkyl, optionally substituted cycloalkyl, halogen, cyano, optionally substituted alkyl, optionally substituted alkyenyl. The optionally substituted alkyl or alkynyl may be substituted with halo, nitro, cyano, hydroxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl, C1-4 alkyl, C2-4alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, C1-4 alkoxy, C1-4 alkanoyl C1-4 alkanoyloxy, N—(C1-4 alkyl), N(C1-4 alkyl)2, C1-4 alkanoylamino, (C1-4 alkanoyl)2amino, N—(C1-4alkyl)carbamoyl, N,N—(C1-4)2carbamoyl, C1-4)S, C1-4S(O), (C1-4alkyl)S(O)2, (C1-4) alkoxycarbonyl, N—(C1-4 alkyl)sulfamoyl, N,N—C1-4 alkyl)sulfamoyl, C1-4 alkylsulfonylamino, or heterocyclyl. R is preferably C1-4 alkyl, C2-4alkenyl, or C2-4 alkynyl, and R1′ can form with R1″ a 3 to 6 membered ring.
  • T is C═O, SOn, C(═NOR)CO, C(O)C(O), C═NCN, CV═NO or wherein n=0, 1 or 2 and V is independently R63 or N(R63)R64 wherein R63 and R64 are independently selected from hydrogen, optionally substituted hydrocarbyl or optionally substituted heterocyclyl, or R63 and R64 together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring.
  • Examples of groups for R63 and R64 include the group —(CH2)qR70 where q and R70 are as defined below in relation to formula (II).
  • Suitably one of R63 or R64 is hydrogen, or methyl, ethyl or propyl optionally substituted with hydroxy and preferably one of R63 or R64 is hydrogen. In this case, the other is suitably a larger substituent for example of at least 4 carbon or heteroatoms, and is optionally substituted hydrocarbyl or optionally substituted heterocyclyl. Particular optionally substituted hydrocarbyl groups for R63 or R64 include alkyl, cycloalkyl, alkenyl, or aryl any of which is optionally substituted with a functional group as defined above, or in the case of aryl groups, with an alkyl group and in the case of alkyl group, with an aryl or heterocyclic group either of which may themselves be optionally substituted with alkyl or a functional group. Examples of optionally substituted aryl groups R63 or R64 include phenyl optionally substituted with one or more groups selected from C1-6 alkyl group such as methyl or ethyl (either of which may be optionally substituted with a functional group such as hydroxy), or a functional group as defined above (such as halo like fluoro, chloro or bromo, hydroxy, alkoxy such as methoxy, trifluoromethyl, nitro, cyano, trifluromethoxy, CONH2, C(O)CH3, amino, or dimethylamino).
  • When R63 or R64 is an optionally substituted alkyl group, it is suitably a C1-6 alkyl group, optionally substituted with one or more functional groups (such as cyano, hydroxy, alkoxy, in particular methoxy, COOalkyl such as COOCH3), or aryl optionally substituted with a functional group as defined above (in particular in relation to R63 or R64 themselves, or an optionally substituted heterocyclic group such as N-methyl pyrrole.
  • When R63 and R64 is optionally substituted cycloalkyl, it is suitable cyclohexyl optionally substituted with a functional group such as hydroxy.
  • When R63 and R64 is optionally substituted alkenyl, it is suitably prop-2-enyl.
  • When R63 or R64 is optionally substituted heterocyclyl, or R63 and R64 together form a heterocyclic group, then this may be aromatic or non-aromatic and includes in particular, piperidine, piperazine, morpholino, pyrrolidine or pyridine any of which may be optionally substituted with a functional group such as hydroxy, alkoxy such as methoxy, or alkyl such as methyl which may itself be substituted with for instance a hydroxy group.
  • Alternatively at least one of R60, R61 or R62 is a functional group, and in particular, one of R60, R61 or R62 is a functional group a group of formula (CR2)pC(O)xR77 where R, p, x and R77 are as defined above, and in particular x is 2 and R77 is hydrogen or alkyl such as methyl.
  • Alternatively, R5 is substituted by one or more groups selected from nitro, halo, C1-6alkyl, optionally substituted C1-6 alkoxy, C1-4alkoxymethyl, di(C1-4alkoxy)methyl, C1-6alkanoyl, trifluoromethyl, cyano, amino, C2-6alkenyl, C2-6alkyl, a phenyl group, a benzyl group or a 5-6-membered heterocyclic group with 1-3 heteroatoms, selected independently from O, S and N, which heterocyclic group may be aromatic or non-aromatic and may be saturated (linked via a ring carbon or nitrogen atom) or unsaturated (linked via a ring carbon atom), and which phenyl, benzyl or heterocyclic group may bear on one or more ring carbon atoms up to 5 substituents selected from hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino, nitro, C2-4alkanoyl, C1-4alkanoylamino, C1-4alkoxycarbonyl, C1-4alkylsulphanyl, C1-4alkylsulphinyl, C1-4alkylsulphonyl, carbamoyl, N—C1-4alkylcarbamoyl, N,N—di(C1-4alkyl)carbamoyl, aminosulphonyl, N—C1-4-alkylaminosulphonyl, N,N-di(C1-4alkyl)aminosulphonyl, C1-4alkylsulphonylamino, and a saturated heterocyclic group selected from morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl imidazolidinyl and pyrazolidinyl, which saturated heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino, nitro and C1-4alkoxycarbonyl.
  • Suitably R5 is substituted with at least one group which has at least 4 atoms which may be carbon or heteroatoms forming a chain. A particular example of such a substituent is optionally substituted alkoxy or alkoxy methyl. Suitable substituents for the alkoxy group include those listed above in relation to R77, R78 and R79.
  • A further particular substituent group for R5 is a group of sub-formula (II)
    Figure US20060046987A1-20060302-C00005
    where p and q are independently 0 or 1, and r is 0, 1, 2, 3 or 4 and, R1′, R1″ and T are as previously defined above;
    • R70 is hydrogen, hydroxy (other than where q is 0), C1-6alkyl, C1-6alkoxy, amino, N—C1-6alkylamino, N,N—(C1-6alkyl)2amino, hydroxyC2-6alkoxy, C1-6alkoxyC2-6alkoxy, aminoC2-6alkoxy, N—C1-6alkylaminoC2-6alkoxy, N,N—(C1-6alkyl)2aminoC2-6alkoxy or C3-7cycloalkyl,
    • or R70 is of the Formula (III):
      -K-J  (III)
      wherein J is aryl, heteroaryl or heterocyclyl and K is a bond, oxy, imino, N—(C1-6alkyl)imino, oxyC1-6alkylene, iminoC1-6alkylene, N—(C1-6alkyl)iminoC1-6alkylene, —NHC(O)—, —SO2NH—, —NHSO2— or —NHC(O)—C1-6alkylene-,
    • and any aryl, heteroaryl or heterocyclyl group in a R70 group may be optionally substituted by one or more groups selected from hydroxy, halo, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl, formyl, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, —O—(C1-3alkyl)—O—, C1-6alkylS(O)n— (wherein n is 0-2), N—C1-6alkylamino, N,N—(C1-6alkyl)2amino, C1-6alkoxycarbonyl, N—C1-6alkylcarbamoyl, N,N—(C1-6alkyl)2carbamoyl, C2-6alkanoyl, C1-6alkanoyloxy, C1-6alkanoylamino, N—C1-6alkylsulphamoyl, N,N—C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino and C1-6alkylsulphonyl-N—(C1-6alkyl)amino,
    • or any aryl, heteroaryl or heterocyclyl group in a R70 group may be optionally substituted with one or more groups of the Formula (IV):
      —B1—(CH2)p-A1  (IV)
      wherein A1 is halo, hydroxy, C1-6alkoxy, cyano, amino, N—C1-6alkylamino, N,N—(C1-6alkyl)2amino, carboxy, C1-6alkoxycarbonyl, carbamoyl, N—C1-6alkylcarbamoyl or N,N—(C1-6alkyl)2carbamoyl, p is 1-6, and B1 is a bond, oxy, imino, N—(C1-6alkyl)imino or —NHC(O)—, with the proviso that p is 2 or more unless B1 is a bond or —NHC(O)—;
    • or any aryl, heteroaryl or heterocyclyl group in a R70 group may be optionally substituted with one or more groups of the Formula (V):
      -E1-D1  (V)
      wherein D1 is aryl, heteroaryl or heterocyclyl and E1 is a bond, C1-6alkylene, oxyC1-6alkylene, oxy, imino, N—(C1-6alkyl)imino, iminoC1-6alkylene, N—(C1-6alkyl)-iminoC1-6alkylene, C1-6alkylene-oxyC1-6alkylene, C1-6alkylene-iminoC1-6alkylene, C1-6alkylene-N—(C1-6alkyl)-iminoC1-6alkylene, —NHC(O)—, —NHSO2—, —SO2NH— or —NHC(O)—C1-6alkylene-, and any aryl, heteroaryl or heterocyclyl group in a substituent on D1 may be optionally substituted with one or more groups selected from hydroxy, halo, C1-6alkyl, C1-6alkoxy, carboxy, C1-6alkoxycarbonyl, carbamoyl, N—C1-6alkylcarbamoyl, N—(C1-6alkyl)2carbamoyl, C2-6alkanoyl, amino, N—C1-6alkylamino and N,N—(C1-6alkyl)2amino,
    • and any C3-7cycloalkyl or heterocyclyl group in a R70 group may be optionally substituted with one or two oxo or thioxo substituents,
    • and any of the R70 groups defined hereinbefore which comprises a CH2 group which is attached to 2 carbon atoms or a CH3 group which is attached to a carbon atom may optionally bear on each said CH2 or CH3 group a substituent selected from hydroxy, amino, C1-6alkoxy, N—C1-6alkylamino, N,N—(C1-6alkyl)2amino and heterocyclyl.
  • A preferred example of a substituent of formula (II) is a group where q is 0.
  • A particular example of a group R70 in formula (II) is phenyl.
  • Another preferred substituent group for R5 is a group of formula (VI)
    Figure US20060046987A1-20060302-C00006
    where R71 and R72 are independently selected from hydrogen or C1-4alkyl, or R71 and R72 together form a bond, and R73 is a group OR74, NR75R76 where R74, R75 and R76 are independently selected from optionally substituted hydrocarbyl or optionally substituted heterocyclic groups, and R75 and R76 may additionally form together with the nitrogen atom to which they are attached, an aromatic or non-aromatic heterocyclic ring which may contain further heteroatoms.
  • Suitable optional substituents for hydrocarbyl or heterocyclic groups R74, R75 and R76 include functional groups as defined above. Heterocyclic groups R74, R75 and R76 may further be substituted by hydrocarbyl groups.
  • In particular, R71 and R72 in sub-formula (VI) are hydrogen.
  • Particular examples of R73 are groups OR74 where R74 is C1-4alkyl.
  • Further examples of R73 are groups of formula NR75R76 where one of R75 or R76 is hydrogen and the other is optionally substituted C1-6alkyl, optionally substituted aryl or optionally substituted heterocyclyl.
  • In particular, one of R75 or R76 is hydrogen and the other is C1-6alkyl optionally substituted with trifluoromethyl, C1-3 alkoxy such as methoxy, cyano, thioC1-4alkyl such as methylthio, or heterocyclyl optionally substituted with hydrocarbyl, such as indane, furan optionally substituted with C1-4 alkyl such as methyl.
  • In another embodiment, one of R75 or R76 is hydrogen and the other is an optionally substituted heterocyclic group such as pyridine, or a phenyl group optionally substituted with for example one or more groups selected from halo, nitro, alkyl such as methyl, or alkoxy such as methoxy.
  • Suitable pharmaceutically acceptable salts of compounds of Formula (I) or Formula (IA) include acid addition salts such as methanesulfonate, fumarate, hydrochloride, hydrobromide, citrate, maleate and salts formed with phosphoric and sulphuric acid. There may be more than one cation or anion depending on the number of charged functions and the valency of the cations or anions. Where the compound of Formula (I) or Formula (IA) includes an acid functionality, salts may be base salts such as an alkali metal salt for example sodium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, N-methylpiperidine, N-ethylpiperidine, procaine, dibenzylamine, N,N-dibenzylethylamine or amino acids for example lysine. A preferred pharmaceutically acceptable salt is a sodium salt.
  • An in vivo hydrolysable ester of a compound of the Formula (I) or Formula (IA) containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol.
  • Suitable pharmaceutically acceptable esters for carboxy include C1-6alkyl esters such as methyl or ethyl esters, C1-6alkoxymethyl esters for example methoxymethyl, C1-6alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C3-8cycloalkoxy-carbonyloxyC1-6alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C1-6alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.
  • An in vivo hydrolysable ester of a compound of the Formula (I) or Formula (IA) containing a hydroxy group includes inorganic esters such as phosphate esters and α-acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group. Examples of α-acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxymethoxy. A selection of in vivo hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N-(dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl.
  • Suitable amides are derived from compounds of Formula (I) or Formula (IA) which have a carboxy group which is derivatised into an amide such as a N—C1-6alkyl and N,N—di-(C1-6alkyl)amide such as N-methyl, N-ethyl, N-propyl, N,N-dimethyl, N-ethyl-N-methyl or N,N-diethylamide.
  • Preferred compounds of Formula (I) or Formula (IA) are those that are stable in mouse, rat, or human serum, preferably those that are stable in human serum.
  • Esters which are not in vivo hydrolysable may be useful as intermediates in the production of the compounds of Formula (I) or Formula (IA).
  • Particular examples of compounds of Formula (I) or Formula (IA) are set out in Tables 1 to 30 below.
    TABLE 1
    Figure US20060046987A1-20060302-C00007
    Compound No NRR′
    1
    Figure US20060046987A1-20060302-C00008
    2
    Figure US20060046987A1-20060302-C00009
    3
    Figure US20060046987A1-20060302-C00010
    4
    Figure US20060046987A1-20060302-C00011
    5
    Figure US20060046987A1-20060302-C00012
    6
    Figure US20060046987A1-20060302-C00013
    7
    Figure US20060046987A1-20060302-C00014
    8
    Figure US20060046987A1-20060302-C00015
    9
    Figure US20060046987A1-20060302-C00016
    10
    Figure US20060046987A1-20060302-C00017
    11
    Figure US20060046987A1-20060302-C00018
    12
    Figure US20060046987A1-20060302-C00019
    13
    Figure US20060046987A1-20060302-C00020
    14
    Figure US20060046987A1-20060302-C00021
    15
    Figure US20060046987A1-20060302-C00022
    16
    Figure US20060046987A1-20060302-C00023
    17
    Figure US20060046987A1-20060302-C00024
    18
    Figure US20060046987A1-20060302-C00025
    19
    Figure US20060046987A1-20060302-C00026
    20
    Figure US20060046987A1-20060302-C00027
    21
    Figure US20060046987A1-20060302-C00028
    22
    Figure US20060046987A1-20060302-C00029
    23
    Figure US20060046987A1-20060302-C00030
    24
    Figure US20060046987A1-20060302-C00031
    25
    Figure US20060046987A1-20060302-C00032
    26
    Figure US20060046987A1-20060302-C00033
    27
    Figure US20060046987A1-20060302-C00034
    28
    Figure US20060046987A1-20060302-C00035
    29
    Figure US20060046987A1-20060302-C00036
    30
    Figure US20060046987A1-20060302-C00037
    31
    Figure US20060046987A1-20060302-C00038
    32
    Figure US20060046987A1-20060302-C00039
    33
    Figure US20060046987A1-20060302-C00040
    34
    Figure US20060046987A1-20060302-C00041
    35
    Figure US20060046987A1-20060302-C00042
    36
    Figure US20060046987A1-20060302-C00043
    37
    Figure US20060046987A1-20060302-C00044
    38
    Figure US20060046987A1-20060302-C00045
    39
    Figure US20060046987A1-20060302-C00046
    40
    Figure US20060046987A1-20060302-C00047
    41
    Figure US20060046987A1-20060302-C00048
    42
    Figure US20060046987A1-20060302-C00049
    43
    Figure US20060046987A1-20060302-C00050
    44
    Figure US20060046987A1-20060302-C00051
    45
    Figure US20060046987A1-20060302-C00052
    46
    Figure US20060046987A1-20060302-C00053
    47
    Figure US20060046987A1-20060302-C00054
    48
    Figure US20060046987A1-20060302-C00055
    49
    Figure US20060046987A1-20060302-C00056
    50
    Figure US20060046987A1-20060302-C00057
  • TABLE 2
    Figure US20060046987A1-20060302-C00058
    Compound No NRR′
    51
    Figure US20060046987A1-20060302-C00059
    52
    Figure US20060046987A1-20060302-C00060
    53
    Figure US20060046987A1-20060302-C00061
    54
    Figure US20060046987A1-20060302-C00062
    55
    Figure US20060046987A1-20060302-C00063
    56
    Figure US20060046987A1-20060302-C00064
    57
    Figure US20060046987A1-20060302-C00065
    58
    Figure US20060046987A1-20060302-C00066
  • TABLE 3
    Figure US20060046987A1-20060302-C00067
    Compound No NRR′
    59
    Figure US20060046987A1-20060302-C00068
    60
    Figure US20060046987A1-20060302-C00069
    61
    Figure US20060046987A1-20060302-C00070
    62
    Figure US20060046987A1-20060302-C00071
    63
    Figure US20060046987A1-20060302-C00072
    64
    Figure US20060046987A1-20060302-C00073
    65
    Figure US20060046987A1-20060302-C00074
    66
    Figure US20060046987A1-20060302-C00075
  • TABLE 4
    Figure US20060046987A1-20060302-C00076
    Compound No NRR′
    67
    Figure US20060046987A1-20060302-C00077
    68
    Figure US20060046987A1-20060302-C00078
    69
    Figure US20060046987A1-20060302-C00079
    70
    Figure US20060046987A1-20060302-C00080
    71
    Figure US20060046987A1-20060302-C00081
    72
    Figure US20060046987A1-20060302-C00082
    73
    Figure US20060046987A1-20060302-C00083
  • TABLE 5
    Figure US20060046987A1-20060302-C00084
    Compound No NRR′
    74
    Figure US20060046987A1-20060302-C00085
    75
    Figure US20060046987A1-20060302-C00086
    76
    Figure US20060046987A1-20060302-C00087
    77
    Figure US20060046987A1-20060302-C00088
    78
    Figure US20060046987A1-20060302-C00089
  • TABLE 6
    Figure US20060046987A1-20060302-C00090
    Compound No. NRR′
    79
    Figure US20060046987A1-20060302-C00091
    80
    Figure US20060046987A1-20060302-C00092
    81
    Figure US20060046987A1-20060302-C00093
    82
    Figure US20060046987A1-20060302-C00094
    83
    Figure US20060046987A1-20060302-C00095
    84
    Figure US20060046987A1-20060302-C00096
    85
    Figure US20060046987A1-20060302-C00097
    86
    Figure US20060046987A1-20060302-C00098
  • TABLE 7
    Figure US20060046987A1-20060302-C00099
    No. R2 R3 R60 R61
    200 OCH3 OCH3 CH2COOCH2CH3 H
    201 OCH3 OCH3 CH2COOH H
    202 OCH3 OCH3 CH3 COOCH2CH3
    203 OCH3 O(CH2)3-N-mor- CH3 COOCH2CH3
    pholino
    204 OCH3 O(CH2)3-N-mor- CH3 COOH
    pholino
    205 OCH3 O(CH2)3-N-mor- CH2COOCH2CH3 H
    pholino
    2061 OCH3 O(CH2)3-N-mor- COOCH2CH3 H
    pholino
    207 OCH3 O(CH2)3-N-mor- COOH H
    pholino
    208 OCH3 O(CH2)3-N-mor- H COOCH2CH3
    pholino
    209 OCH3 O(CH2)3-N-mor- H COOH
    pholino
    210 OCH3 O(CH2)3-N-mor- CH2COOCH2CH3 CH3
    pholino
    211 OCH3 O(CH2)3-N-mor- CH2COOH CH3
    pholino
  • TABLE 8
    Figure US20060046987A1-20060302-C00100
    No. R2 R3 R61
    212 OCH3 O(CH2)3-N-morpholino COOH
    213
    Figure US20060046987A1-20060302-C00101
    214 OCH3 OCH3 COOH
  • TABLE 9
    Figure US20060046987A1-20060302-C00102
    Compound No R′′′ R″
    250 CH3 OCH3
    251 CH3 OH
    252 CH3
    Figure US20060046987A1-20060302-C00103
    253 CH3
    Figure US20060046987A1-20060302-C00104
    254 CH3
    Figure US20060046987A1-20060302-C00105
    255 CH3
    Figure US20060046987A1-20060302-C00106
    256 H OCH2CH3
    257 H OH
    258 H
    Figure US20060046987A1-20060302-C00107
    259 H
    Figure US20060046987A1-20060302-C00108
  • TABLE 10
    Figure US20060046987A1-20060302-C00109
    Compound No R″
    260 COOEt3
    261 COOH
    262
    Figure US20060046987A1-20060302-C00110
    263
    Figure US20060046987A1-20060302-C00111
    264
    Figure US20060046987A1-20060302-C00112
    265
    Figure US20060046987A1-20060302-C00113
    266
    Figure US20060046987A1-20060302-C00114
    267
    Figure US20060046987A1-20060302-C00115
  • TABLE 11
    Figure US20060046987A1-20060302-C00116
    Compound No R″
    268 COOCH2CH3
    269 COOH
    270
    Figure US20060046987A1-20060302-C00117
    271
    Figure US20060046987A1-20060302-C00118
    272
    Figure US20060046987A1-20060302-C00119
  • TABLE 12
    Figure US20060046987A1-20060302-C00120
    Compound No. R′′′
    300 H
    301 COOCH2CH3
  • TABLE 13
    Figure US20060046987A1-20060302-C00121
    N° NRR′
    302 4-methoxyaniline
    303 4-methylaniline
    304 2-aminopyridine
    305 2-aminobenzyl alcohol
    306 4-methoxybenzylamine
    307 3-nitroaniline
    308 Aminoacetonitrile
    309 2-methyl-5-nitroaniline
    310 Cyclopropylamine
    311 4-nitrobenzylamine
    312 2-anilinoethanol
    313 Furfurylamine
    314 3-chloroaniline
    315 2-methoxyaniline
    316 thiophene-2-methylamine
    317 Neopentylamine
    318 2,6-difluorobenzylamine
    319 2-methylallylamine
    320 2-methyl-4-fluoroaniline
    321 2-fluoro-5-methylaniline
    322 4-fluorobenzylamine
    323 3,4-difluorobenzylamine
    324 3-methylaniline
    325 2-(methylthio)aniline
    326 5-aminoindole
    327 3-aminobenzonitrile
    328 2,4-difluorobenzylamine
    329 3-(2-aminoethyl)pyridine
    330 N-methylisobutylamine
    331 2-aminobenzylamine
    332 3-methylbutylamine
    333 1-aminomethyl-1-cyclohexanol
    334 2-aminomethylpyrazine
    335 3-methoxyaniline
    336 4-chlorobenzylamine
  • TABLE 14
    Figure US20060046987A1-20060302-C00122
    N° NRR′
    337 Aniline
    338 3-chloro-4-fluoroaniline
    339 4-chloroaniline
    340 3,4-difluoroaniline
    341 3-methoxyaniline
    342 2-chloroaniline
    343 4-methoxyaniline
    344 4-methylaniline
    345 2-methylaniline
    346 2-aminopyridine
    347 2-aminobenzylalcohol
    348 2-amino-3-methyl-1-butanol
    349 2-anilino ethanol
    350 3-chloro-4-methylaniline
    351 3-nitroaniline
    352 aminoacetonitrile
    353 2-methyl-5-nitroaniline
    354 2-amino-5-chloropyridine
    355 4-trifluoromethylaniline
    356 3-chloroaniline
    357 2-methoxyaniline
    358 2-fluoroaniline
    359 thiophene-2-methylamine
    360 2-amino-1-phenylethanol
    361 3-(1-hydroxyethyl)aniline
    362 neopentylamine
    363 3-fluoro-4-methoxyaniline
    364 2-methyl-4-fluoroaniline
    365 2,5-difluoroaniline
    366 2-fluoro-4-chloroaniline
    367 2-fluoro-4-methylaniline
    368 3-methylaniline
    369 2-(methylthio)aniline
    370 5-aminoindole
    371 2,4-difluoroaniline
    372 2-fluoro-4-methylaniline
    373 3-cyanoaniline
    374 2-methyl-5-fluoroaniline
    375 2-methyl-5-chloroaniline
  • TABLE 15
    Figure US20060046987A1-20060302-C00123
    N° NRR′
    376 aniline
    377 3-chloro-4-fluoroaniline
    378 2-aminopyridine
    379 3,4-difluoroaniline
    380 2-chloroaniline
    381 4-methylaniline
    382 2-methylaniline
    383 4-chloroaniline
    384 4-fluoroaniline
    385 2-amino-6-methylpyridine
    386 3-methoxyaniline
    387 2-amino-5-chloropyridine
    388 3-chloroaniline
    389 2-fluoroaniline
    390 3-fluoro-4-methoxyaniline
    391 2-methyl-4-fluoroaniline
    392 2-amino-4-methylpyridine
    393 2,5-difluoroaniline
    394 2-fluoro-4-chloroaniline
    395 2-fluoro-5-methylaniline
    396 3-methylaniline
    397 2,4-difluoroaniline
    398 2-fluoro-4-methylaniline
    399 3-cyanoaniline
    400 2-methyl-5-fluoroaniline
    401 3,5-difluoroaniline
    402 3-fluoroaniline
  • TABLE 16
    Figure US20060046987A1-20060302-C00124
    N° NRR′
    403 Aniline
    404 3,4-dfifluoroaniline
    405 2-aminopyridine
    406 3-chloro-4-fluoroaniline
    407 2-chloroaniline
    408 4-methylaniline
    409 2-methylaniline
    410 4-chloroaniline
    411 4-fluoroaniline
    412 2-amino-6-methylpyridine
    413 3-methoxyaniline
    414 2-amino-5-chloropyridine
    415 3-chloroaniline
    416 2-fluoroaniline
    417 3-cyanoaniline
    418 2-fluoro-4-methylaniline
    419 3-fluoro-4-methoxyaniline
    420 2-methyl-4-fluoroaniline
    421 2-amino-4-methylpyridine
    422 2,5-difluoroaniline
    423 2-fluoro-4-chloroaniline
    424 2-fluoro-5-methylaniline
    425 3-methylaniline
    426 2,4-difluoroaniline
    427 2-methyl-5-fluoroaniline
    428 3,5-difluoroaniline
    429 3-fluoroaniline
  • TABLE 17
    Figure US20060046987A1-20060302-C00125
    N° R″ NRR′
    430 pyrrolidine 3-chloroaniline
    431 pyrrolidine 3,4-difluoroaniline
    432 dimethylamine 3,5-difluoroaniline
    433 2-amino-2-methyl-1-propanol 3-chloro-4-fluoroaniline
    434 2-amino-2-methyl-1-propanol 3-fluoroaniline
    435 4-hydroxypiperidine 3,4-difluoroaniline
    436 N,N-dimethylethylenediamine 3,4-difluoroaniline
    437 piperidine 3,4-difluoroaniline
    438 2-methylaminoethanol 3,4-difluoroaniline
    439 1,2-diamino-2-methylpropane 3,4-difluoroaniline
    440 cyclohexylamine 3,4-difluoroaniline
    441 N,N,N′-trimethylethylenediamine 3,4-difluoroaniline
    442 D-prolinol 3,4-difluoroaniline
    443 L-prolinol 3,4-difluoroaniline
    444 3-pyrrolidinol 3,4-difluoroaniline
    445 1-(2-aminoethyl)pyrrolidine 3,4-difluoroaniline
    446 1-acetylpiperazine 3,4-difluoroaniline
    447 1-(2-morpholinoethyl)piperazine 3,4-difluoroaniline
    448 2-(2-hydroxyethyl)piperidine 3,4-difluoroaniline
    449 1-(2-hydroxyethyl)piperazine 3,4-difluoroaniline
    450 cyclopentylamine 3,4-difluoroaniline
    451 4-(2-hydroxyethyl)piperidine 3,4-difluoroaniline
    452 L-amine tert-butyester 3,4-difluoroaniline
    453 3-hydroxypiperidine 3,4-difluoroaniline
    454 4-hydroxymethylpiperidine 3,4-difluoroaniline
    455 1-amino-2-propanol 3,4-difluoroaniline
    456 L-alanine-tert-butylester 3-chloroaniline
    457 2-methylaminoethanol 3-chloroaniline
    458 1,2-diamino-2-methylpropane 3-chloroaniline
    459 cyclohexylamine 3-chloroaniline
    460 N,N-dimethylethylenediamine 3-chloroaniline
    461 N,N,N′-trimethylethylenediamine 3-chloroaniline
    462 D-prolinol 3-chloroaniline
    463 L-prolinol 3-chloroaniline
    464 4-hydroxypiperidine 3-chloroaniline
    465 3-pyrrolidinol 3-chloroaniline
    466 1-(2-aminoethyl)pyrrolidine 3-chloroaniline
    467 4-hydroxymethylpiperidine 3-chloroaniline
    468 1-(2-hydroxyethyl)piperazine 3-chloroaniline
    469 cyclopentylamine 3-chloroaniline
    470 4-(2-hydroxyethyl)piperidine 3-chloroaniline
    471 3-hydroxypiperidine 3-chloroaniline
    472 (S)-1-amino-2-porpanol 3-chloroaniline
    473 (R)-1-amino-2-propanol 3-chloroaniline
    474 piperazine 3-chloroaniline
    475 2-(2-hydroxyethyl)piperidine 3-chloroaniline
    476 2-amino-2-methyl-1-propanol 3-chloroaniline
    477 1-(2-dimethylaminoethyl)piperazine 3-chloroaniline
    478 dimethylamine 3-chloroaniline
    479 aminomethylcyclopropane 3-chloroaniline
    480 piperidine 3-chloroaniline
    481 1-(2-dimethylaminoethyl)piperazine 3,5-difluoroaniline
    482 (S)-(+)-2-Pyrrolidine methanol 3,5-difluoroaniline
    483 4-hydroxypiperidine 3,5-difluoroaniline
    484 3-pyrrolidinol 3,5-difluoroaniline
    485 1-(2-aminoethyl)pyrrolidine 3,5-difluoroaniline
    486 4-hydroxymethylpiperidine 3,5-difluoroaniline
    487 2-(2-hydroxyethyl)piperidine 3,5-difluoroaniline
    488 1-(2-hydroxyethyl)piperazine 3,5-difluoroaniline
    489 4-(2-hydroxyethyl)piperidine 3,5-difluoroaniline
    490 3-hydroxypiperidine 3,5-difluoroaniline
    491 N,N,N′-trfimethylethylenediamine 3,5-difluoroaniline
    492 piperidine 3,5-difluoroaniline
    493 pyrrolidine 3,5-difluoroaniline
    494 2-amino-2-methyl-1-propanol 3,5-difluoroaniline
    495 2-methylaminoethanol 3,5-difluoroaniline
    496 N,N-dimethylethylenediamine 3,5-difluoroaniline
    497 (S)-(+)-1-amino-2-propanol 3,5-difluoroaniline
    498 (R)-(−)-1-amino-2-propanol 3,5-difluoroaniline
    499 piperazine 3,5-difluoroaniline
    500 N-allylpiperazine 3,5-difluoroaniline
    501 (R)-(−)-2-pyrrolidinemethanol 3,5-difluoroaniline
    502 cyclopentylamine 3,5-difluoroaniline
    503 2-methylaminoethanol 3-chloro-4-fluoroaniline
    504 N,N,N′-trimethylethylenediamine 3-chloro-4-fluoroaniline
    505 N-allylpiperazine 3-chloro-4-fluoroaniline
    506 4-hydroxypiperidine 3-chloro-4-fluoroaniline
    507 3-pyrrolidinol 3-chloro-4-fluoroaniline
    508 1-(2-aminoethyl)pyrrolidine 3-chloro-4-fluoroaniline
    509 N-acetylpiperazine 3-chloro-4-fluoroaniline
    510 2-(2-hydroxyethyl)piperidine 3-chloro-4-fluoroaniline
    511 1-(2-hydroxyethyl)piperazine 3-chloro-4-fluoroaniline
    512 cyclopentylamine 3-chloro-4-fluoroaniline
    513 4-(2-hydroxyethyl)piperidine 3-chloro-4-fluoroaniline
    514 3-hydroxypiperidine 3-chloro-4-fluoroaniline
    515 4-hydroxymethylpiperidine 3-chloro-4-fluoroaniline
    516 1-amino-2-propanol 3-chloro-4-fluoroaniline
    517 piperazine 3-chloro-4-fluoroaniline
    518 1-(2-morpholinoethyl)piperazine 3-chloro-4-fluoroaniline
    519 pyrrolidine 3-chloro-4-fluoroaniline
    520 2-methylaminoethanol 3-fluoroaniline
    521 1,2-diamino-2-methylpropane 3-fluoroaniline
    522 N,N-dimethylethylenediamine 3-fluoroaniline
    523 N,N,N′-trimethylethylenediamine 3-fluoroaniline
    524 N-allylpiperazine 3-fluoroaniline
    525 4-hydroxypiperidine 3-fluoroaniline
    526 3-pyrrolidinol 3-fluoroaniline
    527 1-(aminoethyl)pyrrolidine 3-fluoroaniline
    528 N-acetylpiperazine 3-fluoroaniline
    529 1-(2-hydroxyethyl)piperazine 3-fluoroaniline
    530 cyclopentylamine 3-fluoroaniline
    531 4-(2-hydroxyethyl)piperidine 3-fluoroaniline
    532 3-hydroxypiperidine 3-fluoroaniline
    533 4-hydroxymethylpiperidine 3-fluoroaniline
    534 1-amino-2-propanol 3-fluoroaniline
    535 (R)-(−)-2-pyrrolidinemethanol 3-fluoroaniline
    536 (S)-(+)-2-pyrrolidinemethanol 3-fluoroaniline
    537 piperazine 3-fluoroaniline
    538 1-(2-morpholinoethyl)piperazine 3-fluoroaniline
    539 2-amino-2-methyl-1-propanol 3-fluoroaniline
  • TABLE 18
    Figure US20060046987A1-20060302-C00126
    N° NRR′
    540 N-ethylaniline
    541 3-chloro-4-fluoro-N-methylaniline
    542 ethyl-2-(3-chloro-4-fluoroanilino)acetate
    543 2-anilinoacetronitrile
    544 3-anilinoproponitrile
    545 N-(2-tert-butoxyethyl)-3-chloro-4-fluoroaniline
    546 N-allylaniline
    547 N-ethyl-3,4-(methylmedioxy)aniline
    548 ethyl-4-(N-butylamino)benzate
    549 N-ethyl-M-toluidine
    550 N-(2-hydroxy″thyl)-3-chloro-4-fluoroaniline
  • TABLE 19
    Figure US20060046987A1-20060302-C00127
    N° NRR′
    551 aniline
    552 3-chloro-4-fluoroaniline
    553 2-aminopyridine
    554 3,4-difluoroaniline
  • TABLE 20
    Figure US20060046987A1-20060302-C00128
    N° R″ NRR′
    555 piperidine 3-chloro-4-fluoroaniline
    556 pyrrolidine 3-chloro-4-fluoroaniline
    557 4-hydroxypiperidine 3-chloro-4-fluoroaniline
    558 piperazine 3-chloro-4-fluoroaniline
    559 cyclopentylamine 3-chloro-4-fluoroaniline
    560 2-amino-2-methyl-1-propanol 3-chloro-4-fluoroaniline
    561 piperidine 3,4-difluoroaniline
    562 pyrrolidine 3,4-difluoroaniline
    563 4-hydroxypiperidine 3,4-difluoroaniline
    565 cyclopentylamine 3,4-difluoroaniline
    566 pyrrolidine 3-chloroaniline
    567 4-hydroxypiperidine 3-chloroaniline
    568 cyclopentylamine 3-chloroaniline
    569 2-amino-2-methyl-1-propanol 3-chloroaniline
    570 piperazine 3-chloroaniline
    571 OMe 3-chloroaniline
    572 piperidine 3-chloroaniline
    573 piperidine 3,5-difluoroaniline
    574 pyrrolidine 3,5-difluoroaniline
    575 2-amino-2-methyl-1-propanol 3,5-difluoroaniline
    576 piperazine (acetate) 3,5-difluoroaniline
    577 piperazine 3,5-difluoroaniline
    578 pyrrolidine 3-fluoroaniline
    579 piperidine 3-fluoroaniline
    580 piperazine 3-fluoroaniline
    581 piperazine (acetate) 3-fluoroaniline
    582 cyclopentylamine 3-fluoroaniline
  • TABLE 21
    Figure US20060046987A1-20060302-C00129
    N° NRR′
    583 3,5-difluoroaniline
    584 3-chloroaniline
    585 3-chloro-4-fluoroaniline
    586 3,4-difluoroaniline
  • TABLE 22
    Figure US20060046987A1-20060302-C00130
    N° R″ X NRR′
    587 morpholine OH aniline
    588 morpholine OH 3,4-difluoroaniline
    589 N—Me-piperazine OH 3,4-difluoroaniline
    590 piperidine OH 3-fluoroaniline
    591 piperidine OH 3-chloroaniline
    592 N—Me-piperazine ═N—OH 3,4-difluoroaniline
  • TABLE 23
    Figure US20060046987A1-20060302-C00131
    N° NRR′
    593 2-aminopyridine
    594 4-methylaniline
    595 2-methylaniline
    596 3-methoxyaniline
    597 2-hydroxymethylaniline
    598 3-nitroaniline
    599 4-trifluoromethylaniline
    600 3-chloroaniline
    601 2-methoxyaniline
    602 3-(2-hydroxyethyl)aniline
    603 3-fluoro-4-methoxyaniline
    604 2-methyl-4-fluoroaniline
    605 2-fluoro-5-methylaniline
    606 3-cyanoaniline
    607 isoamylamine
    608 2-chloroaniline
  • TABLE 24
    Figure US20060046987A1-20060302-C00132
    N° NRR′
    609 aniline
    610 4-fluoroaniline
    611 3-hydroxyaniline
    612 3-(methylthio)aniline
    613 4-fluoro-3-chloroaniline
    614 2,4-difluorobenzylamine
    615 3-fluoroaniline
  • TABLE 25
    Figure US20060046987A1-20060302-C00133
    N° NRR′
    616 aniline
    617 4-fluoroaniline
    618 allylamine
  • TABLE 26
    Figure US20060046987A1-20060302-C00134
    N° NRR′
    619 aniline
    620 allylamine
  • TABLE 27
    Figure US20060046987A1-20060302-C00135
    N° R2 R4 R5
    621 COOMe H H
  • TABLE 28
    Figure US20060046987A1-20060302-C00136
    N° R3 R4 R5
    622 CONH2 H isopropyl
    623 H H COO allyl
    624 CONH2 H H
    625 CONH2 H ethyl
  • TABLE 29
    Figure US20060046987A1-20060302-C00137
    R4 R5
    626 Ph H
    627 Me COCH3
    628 CF3 COOEt
    629 Ph COOEt
    630 —(CH2)4-
    631 4-acetylaminophenyl H
    632 CF3 Ph
    633 CF3 H
    634 tert-butyl H
    635 Me Me
    636 Me H
    637 Me —C(═N—OH)—Me
    638 H —NHCOO-tert-butyl
    639 Me —C(═NOMe)—Me
    640 Me —C(═NOPh)—Me
    641 H 4-methoxyphenyl
    642 H Ph
    643 H Et
    644 H isopropyl
    645 H —CH2Ph
    646 H Me
    647 H n-butyl
    648 H CHO
    649 H —CH═N—OH
  • TABLE 30
    Figure US20060046987A1-20060302-C00138
    X R5
    650 S tert-butyl
    651 S cyclopropyl
    652 S —S—CH2—CH3
    653 S —Ph
    654 NH —NH—Ph
  • Other compounds of Formula (I) or Formula (IA), in particular those in which R5 carriers a carboxy or carboxyl ester substituent are described below in the Examples.
  • Compounds of Formula (I) or Formula (IA) may be prepared by various methods which would be apparent from the literature. For example compounds of formula (I) where X is NH may be prepared by reacting a compound of formula (VII)
    Figure US20060046987A1-20060302-C00139
  • where R1, R2, R3, and R4 are as defined in relation to formula (I) and R85 is a group NR86R87 where R86 and R87 are independently selected from alkyl such as methyl, with a compound of formula (VIII)
    H2N—R5′  (VIII)
    where R5′ is a group R5 as defined in relation to formula (I) or a precursor group thereof; and thereafter if desired or necessary, converting a precursor group R5′ to a group R5 and/or modifying substituents on the group R5. The reaction is suitably effected in an organic solvent such as an acetic acid at elevated temperatures, conveniently at the reflux temperature of the solvent.
  • Examples of reactions in which a precursor group R5′ is converted to a group R5 and/or substituents on the group R5 are modified are standard chemical reactions, such as conversion of esters to acids, and thereafter, if required to the preferred amides. Examples of is such reactions are provided hereinafter.
  • Compounds of formula (VII) are suitably prepared by reacting a compound of formula (IX)
    Figure US20060046987A1-20060302-C00140
    with an appropriate acetal such as N,N-dimethylformamide dimethyl acetal. The reaction is suitably effected in an organic solvent such as benzene, at elevated temperature, conveniently at the reflux temperature of the solvent.
  • Alternatively, compounds of formula (I) where X is NH may be prepared by rearranging a compound of formula (X)
    Figure US20060046987A1-20060302-C00141
    where R1, R2, R3 and R4 are as defined in relation to formula (I) and R5′ is as defined in relation to formula (VIII) above, and thereafter if desired or necessary, converting a precursor group R5′ to a group R5 and/or modifying substituents on the group R5, for example as described generally above.
  • The rearrangement reaction is suitably effected in an organic solvent such as an alkyl alcohol, in particular methanol, ethanol or cyclohexanol, acetic acid, or dimethylformamide, using a strong base such as sodium hydroxide, sodium acetate, sodium methylate, or dimethylamine. Elevated temperatures, for example of from 20°-120° C. and preferably at about 75° C. are employed.
  • Compounds of formula (X) are suitably obtained by reacting a compound of formula (XI)
    Figure US20060046987A1-20060302-C00142
    where R1, R2, R3 and R4 are as defined in relation to formula (I) and R86 is an alkyl group such as methyl; with a compound of formula (XII)
    H2N—R5′  (XII)
    where R5′ is as defined in relation to formula (VIII). The reaction is suitably effected in an organic solvent such as methylene chloride, in the presence of a salt such as pyridinium hydrochloride. Moderate temperatures for example of from 0°-50° C. and conveniently ambient temperature are employed.
  • Compounds of formula (XI) are suitably prepared by reacting a compound of formula (IX) as defined above, with a trialkylorthoformate such as trimethylorthoformate. The reaction is suitably effected at elevated temperature, for example of from 50° C. to 120° C., and preferably at about 100° C., in the presence of a catalytic amount of an acid such as p-toluene sulphonic acid.
  • Compounds of formula (IX) are either known compounds or they can be prepared by conventional methods. In particular, compounds of formula (IX) may be prepared by reduction of the corresponding nitro compound of formula (XIII)
    Figure US20060046987A1-20060302-C00143
    where R1, R2, R3 and R4 are as defined in relation to formula (I). Suitable reaction conditions are illustrated hereinafter.
  • Compounds of formula (XIII) may be obtained by nitration of a compound of formula (XIV)
    Figure US20060046987A1-20060302-C00144
    for example, using nitric acid as the nitrating agent. Again, suitable reaction conditions are illustrated hereinafter.
  • The nitrile of formula (XIV) may be derived by reaction of the corresponding formamide with hydroxylamine as illustrated hereinafter.
  • Compounds of Formula (I) and Formula (IA) are inhibitors of aurora 2 kinase. As a result, these compounds can be used to treat disease mediated by these agents, in particular proliferative disease.
  • According to a further aspect of the present invention there is provided a method for inhibiting aurora 2 kinase in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of Formula (I) or Formula (IA), or a pharmaceutically acceptable salt, or an in vivo hydrolysable ester thereof.
  • Certain compounds of formula (I) are novel and these form a further aspect of the invention. Thus the invention further comprises a compound of formula (IA)
    Figure US20060046987A1-20060302-C00145
    or a salt, ester or amide thereof,
    • where X is as defined in relation to formula (I);
    • R1′, R2′, R3′, R4′ are equivalent to R1, R2, R3, R4 as defined in relation to formula (I) and R5a is an optionally substituted 5-membered heteroaromatic ring, subject to the following provisos:
    • (i) that where R5a is a pyrazole group, it carries a substituting of formula (k), (II) of (VI) above,
    • (ii) that where X is NH and R5a is a substituted pyrazolone or tetrazolyl group, at least one of R1′, R2′, R3′ and R4′ is other than hydrogen; or
    • (iii) that where X is O and R5a is 1-methyl-4-nitro-1H-imidazol-5-yl, at least one of R1′, R2′, R3′ and R4′ is other than hydrogen.
  • Preferably at least one of R1′, R2′, R3′ and R4′ is other than hydrogen.
  • Suitably R5a is selected from the groups of sub-formulae (a)-(j) as set out above.
  • Preferably R5a is pyrrole, imidazole, triazole, thiazole, thiophene, or thiadiazole, any of which may be optionally substituted.
  • In particular, R5a is substituted by at least one group of formula (k), (II) of (VI) above.
  • Other preferred or particular groups and substituents in formula (IA) are as set out for the equivalent groups in formula (I) above.
  • According to a further aspect of the invention there is provided a compound of the formula (IA) as defined herein, or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, for use in a method of treatment of the human or animal body by therapy. In particular, the compounds are used in methods of treatment of proliferative disease such as cancer and in particular cancers such as colorectal or breast cancer where aurora 2 is upregulated.
  • The invention also provides a pharmaceutical composition comprising a compound of formula (IA) as defined herein, or a pharmaceutically acceptable salt, or an in vivo hydrolysable ester thereof, in combination with at pharmaceutically acceptable carrier. Preferred or particular compounds of formula (IA) for use in the compositions of the invention are as described above in relation to preferred compounds of formula (I).
  • The compositions of the invention maybe in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).
  • The compositions of the invention maybe obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.
  • Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal track, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.
  • Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxyethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present.
  • The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable emulsifying agents maybe, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavouring and preservative agents.
  • Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.
  • The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.
  • Suppository formulations may be prepared by mixing the active ingredient with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Suitable excipients include, for example, cocoa butter and polyethylene glycols.
  • Topical formulations, such as creams, ointments, gels and aqueous or oily solutions or suspensions, may generally be obtained by formulating an active ingredient with a conventional, topically acceptable, vehicle or diluent using conventional procedure well known in the art
  • Compositions for administration by insufflation may be in the form of a finely divided powder containing particles of average diameter of, for example, 30μ or much less, the powder itself comprising either active ingredient alone or diluted with one or more physiologically acceptable carriers such as lactose. The powder for insufflation is then conveniently retained in a capsule containing, for example, 1 to 50 mg of active ingredient for use with a turbo-inhaler device, such as is used for insufflation of the known agent sodium cromoglycate.
  • Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.
  • For further information on Formulation the reader is referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.
  • The amount of active ingredient that is combined with one or tore excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient. For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.
  • The size of the dose for therapeutic or prophylactic purposes of a compound of the Formula I will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine. As mentioned above, compounds of the Formula I are useful in treating diseases or medical conditions which are due alone or in part to the effects of aurora 2 kinase.
  • In using a compound of the Formula I for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.5 mg to 75 mg per kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous administration, a dose in the range, for example, 0.5 mg to 30 mg per kg body weight will generally be used. Similarly, for administration by inhalation, a dose in the range, for example, 0.5 mg to 25 mg per kg body weight will be used. Oral administration is however preferred.
  • A further aspect of the invention comprises a compound of Formula (I) or Formula (IA) as defined above, or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, for use in the preparation of a medicament for the treatment of proliferative disease. Preferred compounds of Formula (I) or Formula (IA) for this purpose are as described above.
  • The following Examples illustrate the invention.
    Figure US20060046987A1-20060302-C00146
    Compound B
  • The amino nitrile A (534 mg, 3 mmol) in benzene (15 ml) was reacted with N,N-dimethylformamide dimethyl acetal (535 mg, 4.5 mmol) at 90° C., in a Dean Stark equipped flask. After 4.5 hours reflux, the solution was concentrated, and the residual oil triturated with ether to give the title compound as a solid (680 mg, 90%).
  • 1HNMR (CDCl3): 3.08 (s, 6H); 3.86 (s, 3H); 3.91 (s, 3H); 6.48 (s, 1H); 6.94 (s, 1H); 7.58 (s, 1H).
  • MS ES+: 234 (M+H)+
  • Compound 200
  • A mixture of amidine B (1.4 g, 6 mmol), ethyl 2-amino-4-thiazoleacetate (1.4 g, 7.5 mmol) in acetic acid (14 ml) was heated at 130° C. for 3 hours. The solvent was removed under vacuum, the residue was triturated in ethanol (5 ml) and a solution of NaHCO3 (pH 8) for 10 minutes. The solid was recovered by filtration, washed with water, dissolved in CH2Cl2, and dried over MgSO4. CH2Cl2 was evaporated, the residual oil treated with ether and pet. ether to give title compound (1.8 g, 80%).
  • 1H NMR (DMSO-d6): 1.2 (t, 3H); 3.74 (s, 2H); 3.95 (s, 6H); 4.1 (q, 2H); 7.02 (s, 1H); 7.26 (s, 1H); 8.14 (s, 1H); 8.68 (s, 1H).
  • Compound 201
  • Ester 200 (1.8 g, 4.8 mmol) was reacted with 2N NaOH (4.8 ml, 9.6 mmol) in ethanol (20 ml) at room temperature for 2 hours. The mixture was cooled to room temperature, acidified with EtOH, HCl (2N) to pH 3. Stirring was carried on for 15 minutes, and a yellow solid of title compound was recovered by filtration (1.7 g, 100%).
  • 1HNMR (DMSO-d6): 3.71 (s, 2H); 3.96 (s, 3H); 3.97 (s, 3H); 7.11 (s, 1H); 7.28 (s, 1H); 8.3 (brs, 1H); 8.88 (s, 1H).
  • Synthesis of Amide c, General Procedure
  • The acid 201 (86.5 mg, 0.25 mmol) in DMF (1 ml) was reacted with various amines (2.6 mmol) in presence of O-(7-azabenzotriazol-1yl) N,N,N′,N′,-tetramethyluronium hexafluorophosphate (98 mg, 0.26 mmol), DIEA (33 mg, 0.26 mmol) at room temperature for 0.5 hour. A solution of NaHCO3 (1 ml) and water (7 ml) was added to the mixture. The mixture was left overnight, and the precipitated solid was then recovered by filtration, washed with water and dried under vacuum in presence of P2O5, to give compounds of formula C as listed below.
    • EXAMPLE 1
  • Using the reaction described in the General Scheme 1, starting with 4-aminomethyl pyridine (27 mg, 0.25 mmol) yielded Compound No. 1 in Table 1 (50 mg, 46%).
  • 1HNMR (DMSO-d6): 3.64 (s, 2H); 3.95 (s, 3H); 3.96 (s, 3H); 4.32 (d, 2H); 6.98 (s, 1H); 7.26 (m, 3H); 8.15 (s, 1H); 8.49 (m, 3H); 8.68 (s, 1H).
    • EXAMPLE 2
  • An analogous reaction to that described in the General Scheme 1, starting with morpholine (23 mg, 0.26 mmol) yielded Compound No 2 in Table 1 (70 mg, 67%).
  • 1HNMR (DMSO-d6, TFA): 3.55 (br m, 8H); 3.88 (s, 2H); 3.97 (s, 3H); 4.0 (s, 3H); 7.15 (s, 1H); 7.27 (s, 1H); 7.92 (s, 1H); 9.07 (s, 1H).
    • EXAMPLE 3
  • An analogous reaction to that described in the General Scheme 1, starting with 4-fluoroaniline (29 mg, 0.26 mmol) yielded the Compound No. 3 in Table 1 (75 mg, 68%).
  • 1H NMR (DMSO-d6): 3.74 (s, 2H); 3.93 (s, 6H); 7.00 (s, 1H); 7.15 (t, 2H); 7.25 (s, 1H); 7.64 (m, 2H); 8.12 (s, 1H); 8.67 (s, 1H); 10.20 (s, 1H).
  • MS ES+: 440 (M+H)+
    • EXAMPLE 4
  • An analogous reaction to that described in the General Scheme 1, starting with N,N-dimethyl-1,4phenylenediamine (35 mg, 0.26 mmol) yielded Compound 4 in Table 1 (65 mg, 56%).
  • 1HNMR (DMSO-D6, TFA): 3.2 (s, 6H); 3.9 (s, 2H); 3.97 (s, 3H); 4.0 (s, 3H); 7.27 (s, 1H); 7.3 (s, 1H); 7.65 (d, 2H); 7.8 (d, 2H); 7.99 (s, 1H).
  • MS ES+: 465 (M+H)+
    • EXAMPLE 5
  • An analogous reaction to that described in the General Scheme 1, starting with 4-methoxy-aniline (32 mg, 0.26 mmol) yielded Compound 5 in Table 1 (80 mg, 71%).
  • 1HNMR (DMSO-d6): 3.71 (s, 5H); 3.93 (s, 3H); 3.94 (s, 3H); 6.88 (d, 2H); 6.99 (s, 1H); 7.25 (s, 1H); 7.53 (d, 2H); 8.13 (s, 1H); 8.67 (s, 1H); 9.99 (s, 1H).
  • MS ES+: 452 (M+H)+
    • EXAMPLE 6
  • An analogous reaction to that described in the General Scheme 1, starting with 5-methoxy-2-methylaniline (36 mg, 0.26 mmol) yielded Compound 6 in Table 1 (87 mg, 75%).
  • 1HNMR (DMSO-d6): 2.13 (s, 3H); 3.69 (s, 3H); 3.81 (s, 2H); 3.96 (s, 6H); 6.65 (m, 1H); 7.05 (m, 1H); 7.09 (d, 1H); 7.21 (s, 1H); 7.26 (s, 1H); 8.13 (s, 1H); 8.68 (s, 1H); 9.3 (s, 1H).
  • MS ES+: 466 (M+H)+
    • EXAMPLE 7
  • An analogous reaction to that described in the General Scheme 1, starting with aminoacetaldehyde dimethyl acetal (27 mg, 0.26 mmol) yielded Compound 7 in Table 1 (80 mg, 74%).
  • 1HNMR (DMSO-d6): 3.2 (t, 2H); 3.29 (s, 3H); 3.31 (s, 3H); 3.55 (s, 2H); 3.94 (s, 6H); 4.37 (t, 1H); 6.92 (s, 1H); 7.26 (s, 1H); 8.02 (t, 1H); 8.14 (s, 1H); 8.67 (s, 1H).
  • MS ES+: 434 (M+H)+
    • EXAMPLE 8
  • An analogous reaction to that described in the General Scheme 1, starting with 3-trifluoromethylaniline (42 mg, 0.26 mmol) yielded Compound 8 in Table 1 (72 mg, 59%).
  • 1HNMR (DMSO-D6): 3.80 (s, 2H); 3.93 (s, 3H); 3.94 (s, 3H); 7.04 (s, 1H); 7.26 (s, 1H); 7.41 (d, 1H); 7.55 (t, 1H); 7.81 (d, 1H); 8.13 (s, 1H); 8.69 (s, 1H); 10.50 (s, 1H).
  • MS ES+: 490 (M+H)+
    • EXAMPLE 9
  • An analogous reaction to that described in General Scheme 1, starting with N-methypiperazine (26 mg, 0.26 mmol) yielded Compound 9 in Table 1 (65 mg, 61%).
  • 1HNMR (DMSO-d6): 2.73 and 2.77 (two t, 4H); 2.86 and 3.10 (two s, 3H); 3.56 and 3.74 (two t, 4H); 3.79 and 3.84 (two s, 2H); 3.95 (s, 6H); 6.95 (m, 1H); 7.26 (s, 1H); 8.14 (s, 1H); 8.68 (s, 1H).
  • MS ES+: 429 (M+H)+
    • EXAMPLE 10
  • An analogous reaction to that described in General Scheme 1, starting with 2-methoxyethylamine (20 mg, 0.26 mmol) yielded Compound 10 in Table 1 (68 mg, 67%).
  • 1HNMR (DMSO-d6): 3.25 (s, 3H); 3.3 (m, 6H); 3.54 (s, 2H); 3.94 (s, 6H); 6.92 (s, 1H); 7.26 (s, 1H); 8.0 (t, 1H); 8.14 (s, 1H); 8.67 (s, 1H).
  • MS ES+: 404 (M+H)+
    • EXAMPLE 11
  • An analogous reaction to that described in General Scheme 1, starting with 2-(2-aminoethyl)-N-methylpyrrole (32 mg, 0.26 mmol) yielded Compound 11 in Table 1 (93 mg, 82%).
  • 1HNMR (DMSO-d6): 3.3 (m, 4H); 3.5 (s, 2H); 3.94 (s, 6H); 5.78 (s, 1H); 5.84 (m, 1H); 6.58 (s, 1H); 6.89 (s, 1H); 7.24 (s, 1H); 8.01 (t, 1H); 8.13 (s, 1H); 8.66 (s, 1H).
  • MS ES+: 453 (M+H)+
    • EXAMPLE 12
  • An analogous reaction to that described in the General Scheme 1, starting with 3-(methylamino)propionitrile (22 mg, 0.26 mmol) yielded Compound 12 in Table 1 (60 mg, 58% ).
  • 1HNMR (DMSO-d6): 2.15 (s, 3H); 3.45 (m, 4H); 3.77 (s, 2H); 3.96 (s, 6H); 6.91 (s, 1H); 7.25 (s, 1H); 8.14 (s, 1H); 8.67 (s, 1H).
  • MS ES+: 413 (M+H)+
    • EXAMPLE 13
  • An analogous reaction to that described in General Scheme 1, starting with 4-fluorobenzylamine (33 mg, 0.26 mmol) yielded Compound 13 in Table 1 (81 mg, 81%).
  • 1HNMR (DMSO-d6): 3.59 (s, 2H); 3.95 (m, 6H); 4.27 (d, 2H); 6.94 (s, 1H); 7.15 (m, 2H); 7.26 (s, 1H); 7.31 (m, 2H); 7.95 (s, 1H); 8.14 (s, 1H); 8.41 (t, 1H); 8.67 (s, 1H).
  • MS ES+: 454 (M+H)+
    • EXAMPLE 14
  • An analogous reaction to that described in General Scheme 1, starting with 4-hydroxypiperidine (26 mg, 0.26 mmol) yielded Compound 14 in Table 1 (86 mg, 80%).
  • 1HNMR (DMSO-d6): 1.21 (m, 2H); 1.65 (m, 2H); 3.02 (m, 1H); 3.16 (m, 1H); 3.65 (m, 1H); 3.78 (m, 3H); 4.71 (d, 1H); 6.91 (s, 1H); 7.26 (s, 1H); 8.14 (s, 1H); 9.67 (s, 1H).
  • MS ES+: 430 (M+H)+
    • EXAMPLE 15
  • An analogous reaction to that described in General Scheme 1, starting with 3-aminoacetophenone (35 mg, 0.26 mmol) yielded Compound 15 in Table 1 (92 mg, 79%).
  • 1HNMR (DMSO-d6): 2.59 (s, 3H); 3.78 (s, 2H); 3.90 (s, 3H); 3.93 (s, 3H); 7.02 (s, 1H); 7.26 (s, 1H); 7.47 (t, 1H); 7.67 (d, 1H); 7.89 (d, 1H); 8.12 (s, 1H); 8.2 (s, 1H); 8.68 (s, 1H); 10.36 (s, 1H).
  • MS ES+: 464 (M+H)+.
    • EXAMPLE 16
  • An analogous reaction to that described in General Scheme 1, starting with 3,5-difluoroaniline (34 mg, 0.26 mmol) yielded Compound 16 in Table 1 (71 mg, 64%).
  • 1HNMR (DMSO-d6, TFA): 3.90 (s, 2H); 3.93 (s, 3H); 3.97 (s, 3H); 6.89 (m, 1H); 7.27 (s, 1H); 7.29 (s, 1H); 7.35 (m, 2H); 7.96 (m, 1H); 9.10 (s, 1H).
  • MS ES+: 458 (M+H)+
    • EXAMPLE 17
  • An analogous reaction to that described in General Scheme 1, starting with 3-cyanoaniline (31 mg, 0.26 mmol) yielded Compound 17 in Table 1 (90 mg, 84%).
  • MS ES+: 447 (M+H)+
    • EXAMPLE 18
  • An analogous reaction to that described in General Scheme 1, starting with 2-fluoroaniline (29 mg, 0.26 mmol) yielded Compound 18 in Table 1 (86 mg, 82%).
  • MS ES+: 440 (M+H)+
    • EXAMPLE 19
  • An analogous reaction to that described in General Scheme 1, starting with 3-(1-hydroxyethyl)aniline (36 mg, 0.26 mmol) yielded Compound 19 in Table 1 (92 mg, 82%).
  • MS ES+: 466 (M+H)+
    • EXAMPLE 20
  • An analogous reaction to that described in General Scheme 1, starting with 2,3-difluoroaniline (34 mg, 0.26 mmol) yielded Compound 20 in Table 1 (51 mg, 47%).
  • 1HNMR (DMSO-d6, TFA): 3.98 (s, 3H); 4.01 (s, 3H); 4.03 (s, 2H); 7.19 (m, 2H); 7.27 (s, 1H); 7.29 (s, 1H); 7.73 (m, 1H); 7.99 (s, 1H); 9.11 (s, 1H).
  • MS ES+: 458 (M+H)+
    • EXAMPLE 21
  • An analogous reaction to that described in General Scheme 1, starting with 2-methyl-4-fluoroaniline (33 mg, 0.26 mmol) yielded Compound 21 in Table 1 (94 mg, 86%).
  • MS ES+: 454 (M+H)+
    • EXAMPLE 22
  • An analogous reaction to that described in General Scheme 1, starting with 2-fluoro-3-chloroaniline (38 mg, 0.26 mmol) yielded Compound 22 in Table 1 (60 mg, 53%).
  • 1HNMR (DMSO-d6, TFA): 3.95 (s, 3H); 3.98 (s, 3H); 4.01 (s, 2H); 7.20 (m, 1H); 7.24 (s, 1H); 7.26 (s, 1H); 7.31 (m, 1H); 7.88 (m, 1H); 7.96 (s, 1H); 9.08 (s, 1H).
  • MS ES+: 474 (M+H)+
    • EXAMPLE 23
  • An analogous reaction to that described in General Scheme 1, starting with 2,5-difluoroaniline (34 mg, 0.26 mmol) yielded Compound 23 in Table 1 (52 mg, 48%).
  • 1HNMR (DMSO-d6, TFA): 3.97 (s, 3H); 4.00 (s, 2H); 4.01 (s, 3H); 6.97 (m, 1H); 7.26 (s, 1H); 7.29 (s, 1H); 7.33 (m, 1H); 7.94 (m, 1H); 7.98 (s, 1H); 9.11 (s, 1H).
  • MS ES+: 458(M+H)+
    • EXAMPLE 24
  • An analogous reaction to that described in General Scheme 1, starting with 3-aminobenzamide (36 mg, 0.26 mmol) yielded Compound 24 in Table 1 (94 mg, 84%).
  • MS ES+: 465 (M+H)+
    • EXAMPLE 25
  • An analogous reaction to that described in General Scheme 1, starting with 4-aminophenol (29 mg, 0.26 mmol) yielded Compound 25 in Table 1 (89 mg, 84%).
  • 1HNMR (DMSO-d6, TFA): 3.81 (s, 2H); 3.97 (s, 3H); 4.00 (s, 3H); 6.71 (d, 2H); 7.23 (s, 1H); 7.27 (s, 1H); 7.40 (d, 2H); 7.95 (s, 1H); 9.09 (s, 1H).
  • MS ES+: 438 (M+H)+
    • EXAMPLE 26
  • An analogous reaction to that described in General Scheme 1, starting with 2-fluoro-5-methylaniline (33 mg, 0.26 mmol) yielded Compound 26 in Table 1 (88 mg, 81%).
  • MS ES+: 454 (M+H)+
    • EXAMPLE 27
  • An analogous reaction to that described in General Scheme 1, starting with 2-bromo-4-fluoroaniline (50 mg, 0.26 mmol) yielded Compound 27 in Table 1 (68 mg, 55%).
  • 1HNMR (DMSO-d6, TFA): 3.89 (s, 2H); 3.94 (s, 3H); 3.97 (s, 3H); 7.21 (m, 1H); 7.25 (s, 1H); 7.6 (s, 1H); 7.61 (m, 1H); 7.92 (m, 1H); 7.95 (s, 1H); 9.07 (s, 1H).
  • MS ES+: 518, 520 (M+H)+
    • EXAMPLE 28
  • An analogous reaction to that described in General Scheme 1, starting with 3,4-difluoroaniline (34 mg, 0.26 mmol) yielded Compound 28 in Table 1 (81 mg, 74%).
  • MS ES+: 458 (M+H)+
    • EXAMPLE 29
  • An analogous reaction to that described in General Scheme 1, starting with isonipecotamide (34 mg, 0.26 mmol) yielded Compound 29 in Table 1 (96 mg, 88%).
  • MS ES+: 457 (M+H)+
    • EXAMPLE 30
  • An analogous reaction to that described in General Scheme 1, starting with 4-trifluoromethoxyaniline (47 mg, 0.26 mmol) yielded Compound 30 in Table 1 (105 mg, 87%).
  • MS ES+: 506 (M+H)+
    • EXAMPLE 31
  • An analogous reaction to that described in General Scheme 1, starting with 5-amino-2-methoxypyridine (33 mg, 0.26 mmol) yielded Compound 31 in Table 1 (86 mg, 79%).
  • MS ES+: 453 (M+H)+
    • EXAMPLE 32
  • An analogous reaction to that described in General Scheme 1, starting with 2,4-difluoroaniline (34 mg, 0.26 mmol) yielded Compound 32 in Table 1 (81 mg, 74%).
  • MS ES+: 458 (M+H)+
    • EXAMPLE 33
  • An analogous reaction to that described in General Scheme 1, starting with 4-aminoresorcinol hydrochloride (43 mg, 0.26 mmol) yielded Compound 33 in Table 1 (84 mg, 77%).
  • MS ES+: 454 (M+H)+
    • EXAMPLE 34
  • An analogous reaction to that described in General Scheme 1, starting with 3-aminopyridine (25 mg, 0.26 mmol) yielded Compound 34 in Table 1 (101 mg, 100%).
  • MS ES+: 423 (M+H)+
    • EXAMPLE 35
  • An analogous reaction to that described in General Scheme 1, starting with 4-chloroaniline (34 mg, 0.26 mmol) yielded Compound 35 in Table 1 (109 mg, 100%).
  • MS ES+: 456, 458 (M+H)+.
    • EXAMPLE 36
  • An analogous reaction to that described in General Scheme 1, starting with pyrrolidine (19 mg, 0.26 mmol) yielded Compound 36 in Table 1 (33 mg, 35%).
  • MS ES+: 400 (M+H)+
    • EXAMPLE 37
  • An analogous reaction to that described in General Scheme 1, starting with 3-methoxyaniline (33 mg, 0.26 mmol) yielded Compound 37 in Table 1 (94 mg, 87%).
  • 1HNMR (DMSO-d6, TFA): 3.72 (s, 3H); 3.87 (s, 2H); 3.96 (s, 3H); 4.0 (s, 3H); 6.64 (m, 1H); 7.14 (d, 1H); 7.21 (d, 1H); 7.22 (s, 1H); 7.24 (s, 1H); 7.27 (s, 1H); 7.95 (s, 1H); 9.09 (s, 1H).
  • MS ES+: 452 (M+H)+
    • EXAMPLE 38
  • An analogous reaction to that described in General Scheme 1, starting with 3-hydroxy-4-methoxyaniline (37 mg, 0.26 mmol) yielded Compound 38 in Table 1 (95 mg, 85%).
  • MS ES+: 468 (M+H)+
    • EXAMPLE 39
  • An analogous reaction to that described in General Scheme 1, starting with 3-nitroaniline (36 mg, 0.26 mmol) yielded Compound 39 in Table 1 (87 mg, 78%).
  • MS ES+: 467 (M+H)+
    • EXAMPLE 40
  • An analogous reaction to that described in General Scheme 1, staring with 1-methyl-3-nitroaniline (40 mg, 0.26 mmol) yielded Compound 40 in Table 1 (50 mg, 44%).
  • MS ES+: 481 (M+H)+
    • EXAMPLE 41
  • An analogous reaction to that described in General Scheme 1, starting with 2-anilinoethanol (36 mg, 0.26 mmol) yielded Compound 41 in Table 1 (45 mg, 41%).
  • MS ES+: 466 (M+H)+
    • EXAMPLE 42
  • An analogous reaction to that described in General Scheme 1, starting with 4-trifluoromethylaniline (43 mg, 0.26 mmol) yielded Compound 42 in Table 1 (86 mg, 73%).
  • MS ES+: 490 (M+H)+
    • EXAMPLE 43
  • An analogous reaction to that described in General Scheme 1, starting with 3-amino-6-chloropyridine (33 mg, 0.26 mmol) yielded Compound 43 in Table 1 (90 mg, 82%).
  • 1HNMR (DMSO-d6, TFA): 3.92 (s, 2H; 3.96 (s, 3H); 4.0 (s, 3H); 7.27 (s, 1H); 7.28 (s, 1H); 7.46 (d, 1H); 7.98 (s, 1H); 8.1 (d, 1H); 8.65 (d, 1H); 9.1 (s, 1H).
  • MS ES+: 457, 459 (M+H)+
    • EXAMPLE 44
  • An analogous reaction to that described in General Scheme 1, starting with 2-methoxy-5-chloroaniline (42 mg, 0.26 mmol) yielded Compound 44 in Table 1 (90 mg, 77%).
  • MS ES+: 486, 488 (M+H)+
    • EXAMPLE 45
  • An analogous reaction to that described in General Scheme 1, starting with 2-methylaminoethanol (20 mg, 0.26 mmol) yielded Compound 45 in Table 1 (83 mg, 86%).
  • MS ES+: 404 (M+H)+
    • EXAMPLE 46
  • An analogous reaction to that described in General Scheme 1, starting with 4-aminopyridine (25 mg, 0.26 mmol) yielded Compound 46 in Table 1 (101 mg, 100%).
  • MS ES+: 423 (M+H)+
    • EXAMPLE 47
  • An analogous reaction to that described in General Scheme 1, starting with 3-methyl-4-bromoaniline (49 mg, 0.26 mmol) yielded Compound 47 in Table 1 (120 mg, 97%).
  • MS ES+: 516, 517 (M+H)+
    • EXAMPLE 48
  • An analogous reaction to that described in General Scheme 1, starting with 2-chloro-5-methoxyaniline (42 mg, 0.26 mmol) yielded Compound 48 in Table 1 (65 mg, 56%).
  • 1HNMR (DMSO-d6, TFA): 3.73 (s, 2H); 3.98 (m, 9H); 6.78 (m, 1H); 7.28 (s, 2H); 7.39 (d, 1H); 7.50 (d, 1H); 7.98 (s, 1H); 9.10 (s, 1H).
  • MS ES+: 486, 488 (M+H)+
    • EXAMPLE 49
  • An analogous reaction to that described in General Scheme 1, starting with 4-aminotoluene (28 mg, 0.26 mmol) yielded Compound 49 in Table 1 (89 mg, 85%).
  • MS ES+: 436 (M+H)+
    • EXAMPLE 50
  • An analogous reaction to that described in General Scheme 1, starting with R(−)-2-pyrrolidinemethanol (27 mg, 0.26 mmol) yielded Compound 50 in Table 1 (81 mg, 78%).
  • MS ES+: 430 (M+M)+
    • EXAMPLE 50A
  • Preparation of Compound 202
    Figure US20060046987A1-20060302-C00147
  • Amidine B (117 mg, 0.5 mmol) in acetic acid (12 ml) was reacted with ethyl-2-amino-4-methylthiazol-5-carboxylate (112 mg, 0.6 mmol) at 130° C. for 3 hours. The solvent was evaporated, the residue was taken up into ethanol, and stirred for 10 minutes with a solution of NaHCO3. The solid was recovered by filtration, washed with water, ether and dried under vacuum, to give title compound as a yellow solid (157 mg, 84%).
  • 1HNMR (DMSO-d6): 1.31 (t, 3H); 2.6 (s, 3H); 3.96 (s, 6H); 4.27 (q, 2H); 7.28 (s, 1H); 8.11 (s, 1H); 8.77 (s, 1H).
  • MS ES+: 375 (M+H)+
    Figure US20060046987A1-20060302-C00148
    Compound E
  • Vanilline (30.4 g, 0.2 mol) was solubilized in DMF (200 ml) in presence of K2CO3 at 50° C. N-(3-chloropropyl)morpholine was slowly added over 30 minutes to this mixture, which was heated over night at 80° C. Formed KCl was removed by filtration, the solvent was evaporated, and the residual orange oil dissolved in AcOEt, washed with water 2×, dried over MgSO4, filtered and concentrated. The residual oil crystallises to give title compound as a white solid (45.6 g, 82%).
  • 1HNMR (DMSO-d6, TFA): 2.22 (m, 2H); 3.13 (t, 2H); 3.32 (t, 2H); 3.52 (d, 2H); 3.67 (t, 2H); 3.84 (s, 3H); 4.02 (d, 2H); 4.18 (t, 2H); 7.20 (d, 1H); 7.43 (d, 1H); 7.58 (d, 1H); 9.90 (s, 1,H).
  • MS ES+: 280 (M+H)+
  • Compound F
  • The aldehyde E (5.6 g, 20 mmol) was added to a solution of sodium acetate (3.3 g, 40 mmol) and hydroxylamine hydrochloride (2.8 g, 40 mmol) in acetic acid (25 ml). The mixture was refluxed for 18 hours, cooled, diluted with water and extracted with methylene chloride, dried over MgSO4, filtered, concentrated, to give title compound (5.1 g, 93%).
  • 1HNMR (DMSO-d6, TFA): 2.19 (m, 2H); 3.12 (t, 2H); 3.29 (t, 2H); 3.50 (d, 2H); 3.67 (t, 2H); 3.81 (s, 3H); 4.01 (d, 2H); 4.15 (t, 2H); 7.12 (d, 1H); 7.39 (s, 1H); 7.41 (d, 1H).
  • MS ES+: 277 (M+H)+
  • Compound G
  • The nitrile F (37.2 g, 135 mmol) in acetic acid (100 ml) was added to a solution of nitric acid (d=1.42) 180 ml, at such a rate to maintain the temperature below 30° C. The mixture was stirred at room temperature over night. A solution of potassium hydroxide (10N, 370 ml) was then added slowly to the solution at 0° leading to a final pH of 11-12. The reaction was extracted with CH2Cl2, the organic phases were dried over MgSO4, filtered, evaporated to give a yellow solid which was washed with ether, dried to give title compound (22 g, 50%).
  • 1HNMR (DMSO-d6, TFA): 2.2 (m, 2H); 3.13 (t, 2H); 3.3 (t, 2H); 3.53 (d, 2H); 3.67 (t, 2H); 3.99 (s, 3H); 4.01 (d, 2H); 4.31 (t, 2H); 7.74 (s, 1H); 7.90 (s, 1H).
  • Compound H
  • Compound G (21 g, 65 mmol) in solution in CH2Cl2 (250 ml), was reacted with sodium hydrosulfite (92 g, 458 mmol) in solution in water (250 ml) in presence of tetrabutyl ammonium chloride (12.7 g, 45.8 mmol) at room temperature, overnight. Sodium hydroxide (2N) was then added, and the reaction mixture was extracted with CH2Cl2, the organic phase was washed with water, dried over MgSO4, filtered, evaporated. The residue was purified by silica gel chromatography, eluent: AcOEt/CH2Cl2: 50/50 followed by MeOH/AcOEt/CH2Cl2 5/45/50 to 20/30/50 to give title compound (12.5 g, 66%).
  • 1HNMR (DMSO-d6, TFA): 2.2 (m, 2H); 3.13 (t, 2H); 3.31 (t, 2H); 3.53 (d, 2H); 3.68 (t, 2H); 3.71 (s, 3H); 4.05 (m, 4H); 6.56 (s, 1H); 7.02 (s, 1H).
  • MS ES+: 292 (M+H)+
  • Compound J
  • The amino nitrile H (2.91 g, 10 mmol) in solution in toluene (50 ml) was reacted with N,N-dimethylformamide dimethyl acetal (1.79 g, 15 mmol), at 105° C. for 5 hours, in a Dean Stark equipped flask. The solvent was evaporated, the residue triturated with ether to give title compound (3.4 g, 98%).
  • 1HNMR (DMSO-d6): 1.87 (m, 2H); 2.36 (m, 6H); 2.95 (s, 3H); 3.04 (s, 3H); 3.56 (t, 4H); 3.72 (s, 3H); 4.06 (t, 2H); 6.72 (s, 1H); 7.07 (s, 1H); 7.89 (s, 1H).
  • MS ES+: 347 (M+H)+
  • Compound 203
  • Amidine J (173 mg, 0.5 mmol) was dissolved in AcOH (1.7 ml) in presence of ethyl-2-amino-4-methyl thiazole-5-carboxylate (112 mg, 0.6 mmol) and heated at 130° C. for 3 hours. The solvent was removed by evaporation, and the residual solid was stirred in ethanol and a diluted solution of NaHCO3 for 10 minutes. The solid was washed with water, dried over P2O5 under vacuum, to give a yellow powder of title compound (170 mg, 70%).
  • 1HNMR (DMSO-d6, TFA): 1.32 (t, 3H); 2.30 (m, 2H); 2.68 (s, 3H); 3.16 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.68 (t, 2H); 3.99 (s, 3H); 4.03 (d, 2H); 4.32 (m, 4H); 7.38 (s, 1H); 8.01 (s, 1H); 9.26 (s, 1H).
  • MS ES+: 488 (M+H)+
  • Compound 204
  • The ester 203 (122 mg, 0.25 mmol) was suspended in ethanol (5 ml) and reacted with sodium hydroxide (10N, 0.5 ml) at 80° C. for 1 hour. The reaction mixture was cooled, acidified (pH 3.5), the yellow precipitate was filtered, washed with water, dried under vacuum, to give title compound (100 mg, 87%).
  • 1HNMR (DMSO-d6, TFA): 2.32 (m, 2H); 2.62 (s, 3H); 3.16 (t, 2H); 3.36 (t, 2H); 3.57 (d, 2H); 3.71 (t, 2H); 3.99 (s, 3H); 4.03 (d, 2H); 4.33 (t, 2H); 7.35 (s, 1H); 7.98 (s, 1H); 9.23 (s, 1H).
  • MS ES+: 460 (M+H)+
    Figure US20060046987A1-20060302-C00149
    Compound 205
  • Amidine J (2.08 g, 6 mmol) was reacted with ethyl 2-amino-4-thiazolacetate (1.34 g, 7.2 mmol) in acetic acid (2 ml) at 130° C. for 4 hours, under argon. The solvent was evaporated, the residual oil was triturated in ether/petr. ether, and the solid filtered. This solid was suspended in water at pH 9 NaHCO3) and extracted with CH2Cl2, dried, evaporated, to give title compound (2 g, 68%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.16 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 3.87 (s, 2H); 4.0 (s, 3H); 4.04 (d, 2H); 4.15 (q, 2H); 4.31 (t, 2H); 7.28 (s, 1H); 7.34 (s, 1H); 8.06 (s, 1H); 9.15 (s, 1H).
  • MS ES+: 488 (M+H)+
  • Compound 206
  • Ester 205 (2 g, 4.1 mmol) was suspended in ethanol (20 ml). 2N sodium hydroxide (4.1 ml, 8.2 mmol) was added to the suspension which was stirred for 3 hours at room temperature. HCl 2N was added to the solution, the yellow precipitate was filtered, washed with water, ethanol, ether and dried under vacuum, to give title compound (1.98 g, 99%).
  • 1HNMR (DMSO-d6, TFA): 2.31 (m, 2H); 3.16 (t, 2H); 3.55 (d, 2H); 3.71 (t, 2H); 3.79 (s, 2H); 4.0 (s, 3H); 4.03 (d, 2H); 4.31 (t, 2H); 7.25 (s, 1H); 7.34 (s, 1H); 8.01 (s, 1H); 9.12 (s, 1H).
  • MS ES+: 460 (M+H)+
  • Synthesis of Amides K, General Procedure
  • The acid 206 (83 mg, 0.17 mmol) in DMF (0.8 ml) was reacted with amine (0.17 mmol) in presence of O-(7-azabenzotriazol-1-yl) N,N,N′,N′-tetramethyluronium hexafluorophosphate (78 mg, 0.204 mmol), DIEA (52 mg, 0.4 mmol), for 6 hours at room temperature. The reaction mixture was then treated with a solution of NaHCO3 (6 ml) with stirring for 2 hours, washed with water, cooled to 5° C., and the solid filtered, triturated with ether, dried under vacuum over P2O5 to give title compounds.
    • EXAMPLE 51
  • An analogous reaction to that described in General Scheme 3, starting with aniline (19 mg, 0.2 mmol) yielded Compound 51 in Table 2 (73 mg, 81%).
  • 1HNMR (DMSO-d6, TFA): 2.29 (m, 2H); 3.16 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.68 (t, 2H); 3.88 (s, 2H); 3.98 (s, 3H); 4.03 (d, 2H); 4.3 (t, 2H); 7.09 (t, 1H); 7.27 (s, 1H); 7.33 (m, 3H); 7.63 (d, 2H); 7.99 (s, 1H); 9.12 (s, 1H).
  • MS ES+: 535 (M+H)+.
    • EXAMPLE 52
  • An analogous reaction to that described in General Scheme 3, starting with 4-fluoroaniline (23 mg, 0.2 mmol) yielded Compound 52 in Table 2 (79 mg, 84%).
  • 1HNMR (DMSO-d6-TFA): 2.29 (m, 2H); 3.15 (t, 2H); 3.34 (t, 2H); 3.54 (d, 2H); 3.67 (t, 2H); 3.87 (s, 2H); 3.98 (s, 3H); 4.02 (d, 2H); 4.3 (t, 2H); 7.17 (t, 2H); 7.27 (s, 1H); 7.32 (s, 1H); 7.63 (m, 2H); 7.99 (s, 1H); 9.11 (s, 1H).
  • MS ES+: 553 (M+H)+.
    • EXAMPLE 53
  • An analogous reaction to that described in General Scheme 3, starting with 4-dimethylaminoaniline (28 mg, 0.2 mmol) yielded Compound 53 in Table 2 (52 mg, 53%).
  • 1HNMR (DMSO-d6-TFA): 2.3 (m, 2H); 3.15 (t, 2H); 3.19 (s, 6H); 3.34 (t, 2H); 3.54 (d, 2H); 3.68 (t, 2H); 3.91 (s, 2H); 3.98 (s, 3H); 4.03 (d, 2H); 4.30 (t, 2H); 7.28 (s, 1H); 7.33 (s, 1H); 7.64 (d, 1H); 7.77 (d, 1H); 8.01 (s, 1H); 9.12 (s, 1H).
  • MS ES+: 578 (M+H)+
    • EXAMPLE 54
  • An analogous reaction to that described in General Scheme 3, starting with 4-chloroaniline (26 mg, 0.2 mmol) yielded Compound 54 in Table 2(72 mg, 75%).
  • 1HNMR (DMSO-d6, TFA): 2.31 (m, 2H); 3.14 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.68 (t, 2H); 3.89 (s, 2H); 3.98 (s, 3H); 4.03 (d, 2H); 4.3 (t, 2H); 7.27 (s, 1H); 7.32 (s, 1H); 7.38 (d, 1H); 7.65 (d, 1H); 8.0 (s, 1H); 9.12 (s, 1H).
  • MS ES−: 567, 569 (M−H −.
    • EXAMPLE 55
  • An analogous reaction to that described in General Scheme 3, starting with 3-amino-6-chloropyridine (26 mg, 0.2 mmol) yielded Compound 55 in Table 2(80 mg, 83%).
  • 1HNMR (DMSO-d6, TFA): 2.28 (m, 2H); 3.16 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.68 (t, 2H); 3.93 (s, 2H); 3.98 (s, 3H); 4.04 (d, 2H); 4.3 (t, 2H); 7.29 (s, 1H); 7.33 (s, 1H); 7.49 (d, 1H); 8.01 (s, 1H); 8.09 (d, 1H); 8.66 (d, 1H); 9.13 (s, 1H).
  • MS ES+: 570, 572 (M+H)+.
    • EXAMPLE 56
  • An analogous reaction to that described in General Scheme 3, starting with morpholine (18 mg, 0.2 mmol) yielded Compound 56 in Table 2 (14 mg, 16%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.17 (t, 2H); 3.37 (t, 2H); 3.6 (m, 12H); 3.9 (s, 2H); 3.99 (s, 3H); 4.03 (d, 2H); 4.3 (t, 2H); 7.17 (s, 1H); 7.3 (s, 1H); 7.95 (s, 1H); 9.09 (s, 1H).
  • MS ES+: 529 (M+H)+
    • EXAMPLE 57
  • An analogous reaction to that described in General Scheme 3, starting with pyrrolidine (14 mg, 0.2 mmol) yielded Compound 57 in Table 2 (73 mg, 84%).
  • 1HNMR (DMSO-d6, TFA): 1.82 (m, 2H); 1.93 (m, 2H); 2.28 (m, 2H); 3.16 (t, 2H); 3.36 (m, 4H); 3.55 (m, 4H); 3.68 (t, 2H); 3.71 (s, 2H); 3.99 (s, 3H); 4.04 (d, 2H); 4.3 (t, 2H); 7.17 (s, 1H); 7.3 (s, 1H); 7.94 (s, 1H); 9.08 (s, 1H).
  • MS ES+: 513 (M+H)+
    • EXAMPLE 58
  • An analogous reaction to that described in General Scheme 3, starting with cyclohexylamine (20 mg, 0.2 mmol) yielded Compound 58 in Table 2 (80 mg, 87%).
  • 1HNMR (DMSO-d6, TFA): 1.25 (m, 4H); 1.75 (m, 4H); 2.3 (m, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.56 (d, 2H); 3.6 (s, 2H); 3.69 (t, 2H); 3.99 (s, 3H); 4.04 (d, 2H); 4.3 (t, 2H); 7.15 (s, 1H); 7.97 (s, 1H); 9.09 (s, 1H);
  • MS ES+: 541 (M+H)+
    Figure US20060046987A1-20060302-C00150
    Compound 2061
  • The amidine J (1.38 g, 4 mmol) in acetic acid (14 ml) was reacted with ethyl 2-amino-4-thiazolcarboxylate (0.72 g, 4.2 mmol) at 130° C. for 6 hours. The solvent was evaporated, the residue dissolved in ethanol, and stirred with a saturated solution of NaHCO3. The mixture was extracted with CH2Cl2, dried, and purified by silica gel chromatography, eluent CH2Cl2/MeOH 98/2→90/10 , to give title compound (0.738 g, 52%).
  • 1HNMR (DMSO-d6, TFA): 1.34 (t, 3H); 2.28 (m, 2H); 3.16 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.68 (t, 2H); 4.03 (s, 3H); 4.04 (d, 2H); 4.34 (m, 4H); 7.45 (s, 1H); 8.33 (s, 1H); 8.44 (s, 1H); 9.26 (s, 1H).
  • MS ES+: 474 (M+H)+
  • Compound 207
  • Ester 2061 (946 mg, 2 mmol) in suspension in ethanol (20 ml) was treated with sodium hydroxide (6N, 4 ml) at 75° C. for 45 minutes. The reaction mixture was then cooled to room temperature, acidified (pH 3) with 6N HCl. The precipitate was filtered, washed with ethanol, triturated with ether, dried under vacuum, to give title compound (795 mg, 80%).
  • 1HNMR (DMSO-d6, TFA): 2.34 (m, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.76 (t, 2H); 4.03 (m, 5H); 4.35 (t, 2H); 7.48 (s, 1H); 8.26 (s, 1H); 8.41 (s, 1H); 9.29 (s, 1H).
  • Synthesis of Amides of General Structure M, General Procedure
  • The acid 207 (79 mg, 0.16 mmol) in DMF (1 ml) was reacted with amine (0.19 mmol) in presence of O-(7-azabenzotriazol-1-yl) N,N,N′,N′-tetramethyluronium hexafluorophosphate (73 mg, 0.19 mmol), DIEA (52 mg, 0.4 mmol), for 1 hour at room temperature. The reaction mixture was then treated with a solution of NaHCO3 (5 ml) with stirring for 0.5 hour, and the solid filtered, dried under vacuum over P2O5. For the compounds which did not precipitate, the solution was concentrated to dryness, the residues were washed with methylene chloride/methanol, filtered. Alumine was added to the methylene chloride/methanol solution and the solvent evaporated. Purification of the compounds was carried out by chromatography over alumine, eluent CH2Cl2; CH2Cl2/MeOH: 95/5, to give title compounds.
    • EXAMPLE 59
  • An analogous reaction to that described in General Scheme 4, starting with aniline (18 mg, 0.19 mmol) yielded Compound 59 in Table 3(50 mg, 60%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.16 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 4.03 (d, 2H); 4.05 (s, 3H); 4.34 (t, 2H); 7.14 (t, 1H); 7.39 (t, 2H); 7.45 (s, 1H); 7.8 (d, 2H); 8.29 (s, 1H); 8.41 (s, 1H); 9.29 (s, 1H).
  • MS ES+: 521 (M+H)+.
    • EXAMPLE 60
  • An analogous reaction to that described in General Scheme 4, starting with 4-fluoroaniline (21 mg, 0.19 mmol) yielded Compound 60 in Table 3 (70 mg, 82%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.16 (t, 2H); 3.33 (t, 2H); 3.56 (d, 2H); 3.68 (t, 2H); 4.03 (d, 2H); 4.04 (s, 3H); 4.35 (t, 2H); 7.22 (t, 2H); 7.45 (s, 1H); 7.83 (m, 2H); 8.28 (s, 1H); 8.4 (s, 1H); 9.27 (s, 1H).
  • MS ES+: 539 (M+H)+
    • EXAMPLE 61
  • An analogous reaction to that described in General Scheme 4, starting with 4-chloroaniline (24 mg, 0.19 mmol) yielded Compound 61 in Table 3 (70 mg, 79%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.15 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.68 (t, 2H); 4.04 (m, 5H); 4.35 (t, 2H); 7.45 (m, 3H); 7.84 (d, 2H); 8.29 (s, 1H); 8.4 (s, 1H); 9.27 (s, 1H).
  • MS ES+: 555, 557 (M+H)+
    • EXAMPLE 62
  • An analogous reaction to that described in General Scheme 4, starting with cyclohexylamine (19 mg, 0.19 mmol) yielded Compound 62 in Table 3 (60 mg, 72%).
  • 1HNMR (DMSO-d6, TFA): 1.32 (m, 5H); 1.62 (m, 1H); 1.73 (m, 2H); 1.87 (m, 2H); 2.33 (m, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.68 (t, 2H); 3.75 (m, 1H); 4.03 (s, 3H); 4.05 (d, 2H); 4.33 (t, 2H); 7.42 (s, 1H); 8.07 (s, 1H); 8.32 (s, 1H); 9.24 (s, 1m).
  • MS ES+: 527 (M+H)+
    • EXAMPLE 63
  • An analogous reaction to that described in General Scheme 4, staring with 3-(methylamino)-propionitrile (16 mg, 0.19 mmol) yielded Compound 63 in Table 3 (40 mg, 49%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 2.88 5m, 3H); 3.14 (m, 4H); 3.35 (t, 2H); 3.54 (d, 2H); 3.71 (t, 2H); 3.75 (m, 2H); 4.02 (s, 3H); 4.04 (d, 2H); 4.33 (t, 2H); 7.44 (s, 1H); 7.85 (s, 1H); 8.37 (s, 1H); 9.27 (s, 1H).
  • MS ES+: 512 (M+H)+
    • EXAMPLE 64
  • An analogous reaction to that described in General Scheme 4, starting with 4-hydroxypiperidine (19 mg, 0.19 mmol) yielded Compound 64 in Table 3 (45 mg, 54 M).
  • 1HNMR (DMSO-d6, TFA): 1.36 (m, 2H); 1.78 (m, 2H); 2.3 (m, 2H); 3.15 (t, 2H); 3.29 (m, 2H); 3.37 (t, 2H); 3.54 (d, 2H); 3.68 (t, 2H); 3.77 (m, 2H); 3.84 (m, 1H); 4.02 (s, 3H); 4.04 (d, 2H); 4.33 (t, 2H); 7.42 (s, 1H); 7.75 (s, 1H); 8.35 (s, 1H); 9.27 (s, 1H).
  • MS ES+: 529 (M+H)+.
    • EXAMPLE 65
  • An analogous reaction to that described in General Scheme 4, starting with 4-aminopyridine (18 mg, 0.19 mmol) yielded Compound 65 in Table 3 (35 mg, 42%).
  • 1HNMR (DMSO-d6, TFA): 2.29 (m, 2H); 3.15 (t, 2H); 3.34 (t, 2H); 3.55 (d, 2H); 3.68 (t, 2H); 4.03 (m, 5H); 4.34 (t, 2H); 7.48 (s, 1H); 8.41 (d, 2H); 8.43 (s, 1H); 8.52 (s, 1H); 8.81 (d, 2H); 9.24 (s, 1H).
  • MS ES+: 522 (M+H)+
    • EXAMPLE 66
  • An analogous reaction to that described in General Scheme 4, staring with 2-chloroaniline (24 mg, 0.19 mmol) yielded Compound 66 in Table 3 (25 mg, 28%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.17 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 4.04 (d, 2H); 4.05 (s, 3H); 4.35 (t, 2H); 7.24 (t, 1H); 7.42 (t, 1H); 7.47 (s, 1H); 7.6 (d, 1H) (M+H)+.
    Figure US20060046987A1-20060302-C00151
    Compound 208
  • The amidine J (1.52 g, 4.4 mmol) in AcOH (15 ml) was reacted with ethyl 2-amino-5-thiazolcarboxylate (757 mg, 4.4 mmol) at 130° C. under argon for 3 hours. The solvent was evaporated, the residual oil was dissolved in methylene chloride and purified by silica gel chromatography, eluent CH2Cl2, CH2Cl2/MeOH: 95/5, to give title compound as a yellow solid (1.44 g, 70%).
  • 1HNMR (DMSO-d6, TFA): 1.33 (t, 3H); 2.3 (m, 2H); 3.15 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.68 (t, 2H); 4.01 (s, 3H); 4.03 (d, 2H); 4.35 (m, 4H); 7.41 (s, 1H); 8.14 (s, 1H); 8.44 (s, 1H); 9.3 (s, 1H).
  • MS ES+: 474 (M+H)+
  • Compound 209
  • Ester 208 (1.6 g, 3.4 mmol) in suspension in ethanol (32 ml) was reacted with sodium hydroxide (6N, 6 ml) at 75° C. for 1 hour. The cooled solution was acidified with HCl (6N) to pH 4. The solid was filtered, washed with EtOH, ether, dried, to give a yellow solid (1.65 g, 86%).
  • 1HNMR (DMSO-d6, TFA): 2.28 (m, 2H); 3.12 (t, 2H); 3.32 (t, 2H); 3.51 (d, 2H); 3.66 (t, 2H); 3.97 (s, 3H); 3.99 (d, 2H); 4.31 (t, 2H); 7.37 (s, 1H); 8.06 (s, 1H); 8.32 (s, 1H); 9.24 (s, 1H).
  • MS ES+: 446 (M+H)+
  • Synthesis of Amides of General Structure P, General Procedure
  • The acid 209 (95 mg, 0.17 mmol) in DMF, 1 ml was reacted with amine (0.2 mmol) in presence of O-(7-azabenzotriazol-1-yl) N,N,N′,N′-tetramethyluronium hexafluorophosphate (91 mg, 0.24 mmol), DIEA (110 mg, 0.85 mmol) for 14 hours at room temperature and 5 hours at 50° C. The reaction mixture was then treated with a solution of NaHCO3 (1 ml) with stirring for 0.5 hour, and concentrated. The residue was washed with methylene chloride/methanol (1/1, 25 ml). Alumine was added to the organic phase, which was then evaporated. Purification of the compound was carried out by chromatography over alumine, eluent CH2Cl2, CH2Cl2/MeOH/95/5, to give title compounds.
    • EXAMPLE 67
  • An analogous reaction to that described in General Scheme 5, starting with aniline (19 mg, 0.2 mmol) yielded Compound 67 in Table 4 (30 mg, 34%).
  • 1HNMR DMSO-d6, TFA): 2.31 (m, 2H); 3.16 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 4.02 (s, 3H); 4.04 (d, 2H); 4.33 (t, 2H); 7.14 (t, 1H); 7.39 (m, 3H); 7.73 (d, 2H); 8.05 (s, 1H); 8.61 (s, 1H); 9.28 (s, 1H).
  • MS ES+: 521 (M+H)+
    • EXAMPLE 68
  • An analogous reaction to that described in General Scheme 5, starting with 4-fluoroaniline (23 mg, 0.2 mmol) yielded Compound 68 in Table 4 (58 mg, 64%).
  • 1HNMR (DMSO-d6, TFA): 2.31 (m, 2H); 3.16 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 4.01 (s, 3H); 4.03 (d, 2H); 4.32 (t, 2H); 7.20 (t, 1H); 7.38 (s, 1H); 7.73 (m, 1H); 8.05 (s, 1H); 8.57 (s, 1H); 9.28 (s, 1H).
  • MS ES+: 539 (M+H)+
    • EXAMPLE 69
  • An analogous reaction to that described in General Scheme 5, starting with 4-chloroaniline (26 mg, 0.2 mmol) yielded Compound 69 in Table 4(32 mg, 34%).
  • 1HNMR (DMSO-d6, TFA): 2.32 (m, 2H); 3.16 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 4.01 (s, 3H); 4.03 (d, 2H); 4.33 (t, 2H); 7.39 (s, 1H); 7.44 (d, 2H); 7.76 (d, 2H) . 8.06 (s, 1H); 8.6 (s, 1H); 9.29 (s, 1H).
  • MS ES+: 555, 557 (M+H)+
    • EXAMPLE 70
  • An analogous reaction to that described in General Scheme 5, starting with alkylamine (12 mg, 0.2 mmol) yielded Compound 70 in Table 4 (32 mg, 39%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.16 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.7 (t, 2H); 3.92 (d, 2H); 4.0 (s, 3H); 4.03 (d, 2H); 4.33 (t, 2H); 5.16 (d, 1H); 5.25 (d, 1H); 5.9 (m, 1H); 7.38 (s, 1H); 8.02 (s, 1H); 8.36 (s, 1H); 9.24 (s, 1H).
  • MS ES+: 485 (M+H) +
    • EXAMPLE 71
  • An analogous reaction to that described in General Scheme 5, starting with 3-(methylamino)-propionitrile (17 mg, 0.2 mmol) yielded Compound 71 in Table 4 (32 mg, 39%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 2.89 (m, 3H); 3.15 (t, 2H); 3.34 (m, 4H); 3.55 (d, 2H); 3.69 (t, 2H); 3.8 (m, 2H); 4.01 (s, 3H); 4.03 (d, 2H); 4.33 (t, 2H); 7.38 (s, 1H); 8.07 (s, 1H); 8.22 (s, 1H); 9.25 (s, 1H).
  • MS ES+: 512 (M+H)+
    • EXAMPLE 72
  • An analogous reaction to that described in General Scheme 5, starting with 4-hydroxypiperidine (20 mg, 0.2 mmol) yielded Compound 72 in Table 4 (12 mg, 13%).
  • 1HNMR (DMSO-d6, TFA): 1.45 (m, 2H); 1.82 (m, 2H); 2.31 (m, 2H); 3.15 (m, 4H); 3.35 (t, 2H); 3.4 (m, 2H); 3.54 (d, 2H); 3.7 (t, 2H); 3.79 (m, 1H); 4.01 (s, 3H); 4.03 (d, 2H); 4.32 (t, 2H); 7.38 (s, 1H); 8.06 (s, 1H); 8.09 (s, 1H); 9.23 (s, 1H).
  • MS ES+: 529 (M+H)+
    • EXAMPLE 73
  • An analogous reaction to that described in General Scheme 5, starting with 4-aminopyridine (19 mg, 0.2 mmol) yielded Compound 73 in Table 4 (50 mg, 57%).
  • 1HNMR (DMSO-d6-TFA): 2.29 (m, 2H); 3.17 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.7 (t, 2H); 4.02 (s, 3H); 4.03 (d, 2H); 4.34 (t, 2H); 7.46 (s, 1H); 8.15 (s, 1H); 8.27 (d, 2H); 8.78 (s, 1H); 8.8 (d, 2H); 9.31 (s, 1H).
  • MS ES+: 522 (M+H)+
    Figure US20060046987A1-20060302-C00152
    Compound 210
  • Amidine J (450 mg, 1.3 mmol) was reacted with methyl 2-amino-5-methyl-4-thiazolacetate (242 mg, 1.3 mmol) in acetic acid (5 ml) at 130° C. for 3 hours, under argon. The solvent was evaporated, ethylacetate and water were added to the residual oil, the pH adjusted to 9 with a saturated solution of sodium bicarbonate and the mixture extracted with ethylacetate. The organic phase was washed with a saturated solution of sodium chloride, dried over magnesium sulphate, filtered, concentrated. The residual oil was purified by silica gel chromatography, eluent CH2Cl2/MeOH: 98/2 to 95/5 to give title compound (380 mg, 60%).
  • 1HNMR (DMSO-d6, TEA): 2.3 (m, 2H); 2.35 (s, 3H); 3.15 (t, 2H); 3.34 (t, 2H); 3.55 (d, 2H); 3.68 (t, 2H); 3.68 (s, 3H); 3.83 (s, 2H); 3.98 (s, 3H); 4.03 (d, 2H); 4.29 (t, 2H); 7.31 (s, 1H); 7.96 (s, 1H); 9.06 (s, 1H).
  • MS ES+: 488 (M+H)+
  • Compound 211
  • Ester 210 (360 mg, 0.74 mmol) in ethanol (10 ml) was reacted with sodium hydroxide (6N, 1 ml) at room temperature for 1 hour. HCl (6N) was then added to the solution cooled to 0° C., and the pH adjusted to 3-4. The solid was recovered by filtration, washed with ethanol, ether, dried under vacuum, to give title compound as a dihydrochloride (550 mg, 83%).
  • 1HNMR (DMSO-d6, TFA): 2.34 (m, 5H); 3.13 (t, 2H); 3.32 (t, 2H); 3.52 (d, 2H); 3.74 (s, 2H); 3.78 (t, 2H); 3.98 (s, 3H); 4.01 (d, 2H); 4.31 (t, 2H); 7.37 (s, 1H); 7.91 (s, 1H); 9.03 (s, 1H).
  • MS ES+: 474 (M+H)+
  • Synthesis of Amides of General Structure Q, General Procedure
  • The acid 211 (87 mg, 0.13 mmol) in DMF (1 ml) was reacted with amine (0.169 mmol) in presence of O-(7-azabensotriazol-1-yl) N,N,N′,N′-tetramethyluronium hexafluorophosphate (69 mg, 0.182 mmol), diisopropylethylamine (84 mg, 0.65 mmol) over night, at room temperature. The reaction mixture was diluted with water (5 ml) and a concentrated solution of sodium bicarbonate (1 ml). The solid was filtered, washed with water, ethanol, ether, and dried under vacuum, to give title compounds. For the compounds which did not precipitate, the solution was concentrated to dryness, the residues were washed with methylene chloride, methanol, filtered. Alumine was added to the methylene chloride/methanol solution, and the solvent was evaporated. Purification of the compounds was carried out by chromatography over alumine, eluent CH2Cl2/MeOH: 98/2 to 95/5, to give title compounds.
    • EXAMPLE 74
  • An analogous reaction to that described in General Scheme 6, starting with aniline (16 mg, 0.17 mmol) yielded Compound 74 in Table 5 (50 mg, 70%).
  • 1HNMR (DMSO-d6, TFA): 2.28 (m, 2H); 2.37 (s, 3H); 3.15 (t, 2H); 3.34 (t, 2H); 3.56 (d, 2H); 3.68 (t, 2H); 3.84 (s, 2H); 3.96 (s, 3H); 4.03 (d, 2H); 4.28 (t, 2H); 7.07 (t, 1H); 7.29 (s, 1H); 7.3 (t, 2H); 7.61 (d, 2H); 7.89 (s, 1H); 9.02 (s, 1H).
  • MS ES+: 549 (M+H)+
    • EXAMPLE 75
  • An analogous reaction to that described in General Scheme 6, starting with 4-fluoroaniline (19 mg, 0.17 mmol) yielded Compound 75 in Table 5 (50 mg, 67%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 2.38 (s, 3H); 3.16 (t, 2H); 3.34 (t, 2H); 3.54 (d, 2H); 3.68 (t, 2H); 3.84 (s, 2H); 3.97 (s, 3H); 4.03 (d, 2H); 4.29 (t, 2H); 7.16 (t, 2H); 7.29 (s, 1H); 7.64 (m, 2H); 7.9 (s, 1H); 9.03 (s, 1H).
  • MS ES+: 567 (M+H)+.
    • EXAMPLE 76
  • An analogous reaction to that described in General Scheme 6, starting with 4-chloroaniline (22 mg, 0.17 mmol) yielded Compound 76 in Table 5 (45 mg, 59%).
  • 1HNMR (DMSO-d6, TFA): 2.28 (m, 2H); 2.37 (s, 3H); 3.15 (t, 2H); 3.34 (t, 2H); 3.55 (d, 2H); 3.68 (t, 2H); 3.85 (s, 2H); 3.97 (s, 3H); 4.03 (d, 2H); 4.29 (t, 2H); 7.29 (s, 1H); 7.37 (d, 2H); 7.65 (d, 2H); 7.9 (s, 1H); 9.03 (s, 1H).
  • MS ES+: 583 (M+H)+
    • EXAMPLE 77
  • An analogous reaction to that described in General Scheme 6, starting with 4-hydroxypiperidine (17 mg, 0.17 mmol) yielded Compound 77 in Table 5 (45 mg, 62%).
  • 1HNMR (DMSO-d6, TFA): 1.42 (m, 2H); 1.82 (m, 2H); 2.31 (m, 5H); 3.08 (m, 1H); 3.16 (t, 2H); 3.27 (m, 1H); 3.35 (t, 2H); 3.54 (d, 2H); 3.68 (t, 2H); 3.78 (m, 2H); 3.83 (s, 2H); 3.92 (m, 1H); 3.97 (s, 3H); 4.03 (d, 2H); 4.29 (t, 2H); 7.28 (s, 1H); 7.85 (s, 1H); 9.0 (s, 1H).
  • MS ES+: 557 (M+H)+.
    • EXAMPLE 78
  • An analogous reaction to that described in General Scheme 6, starting with 4-aminopyridine (16 mg, 0.17 mmol) yielded Compound 78 in Table 5 (35 mg, 49%).
  • 1HNMR (DMSO-d6, TFA): 2.29 (m, 2H); 2.39 (s, 3H); 3.15 (t, 2H); 3.34 (t, 2H); 3.55 (d, 2H); 3.68 (t, 2H); 3.96 (s, 3H); 4.02 (d, 2H); 4.04 (s, 2H); 4.29 (t, 2H); 7.33 (s, 1H); 7.92 (s, 1H); 8.1 (d, 2H); 8.76 (d, 2H); 9.06 (s, 1H).
  • MS ES+: 550 (M+H)+.
    Figure US20060046987A1-20060302-C00153
    Compound U
  • The amino nitrile H (2.91 g, 10 mmol) was reacted with trimethylorthoformate (10 ml) in presence of p-toluene-sulfonic acid (38 mg, 2 mmol) at 80° C. for 6 hours. The solvent was evaporated, the residue crystallised from ether to give title compound (3.01 g, 90.4%).
  • 1HNMR (DMSO-d6): 1.9 (t, 2H); 2.4 (m, 6H); 3.58 (t, 4H); 3.78 (s, 3H); 3.85 (s, 3H); 4.08 (t, 2H); 6.88 (s, 1H); 7.28 (s, 1H); 8.2 (s, 1H).
  • MS ES+: 334 (M+H)+
  • Compound V
  • Imidate U (0.25 g, 0.75 mmol) in CH2Cl2 (5 ml) was reacted with ethyl 2-amino-5-thiophenecarboxylate (0.13 g, 0.79 mmol) in presence of pyridinium hydrochloride (0.09 g 0.75 mmol), at room temperature over night. Ethyl acetate was then added, and the solid was recovered by filtration, washed with ethyl acetate, dried under vacuum, to give product (0.23 g, 65%).
  • 1HNMR (DMSO-d6, TFA): 1.33 (t, 3H); 2.28 (m, 2H); 3.12 (t, 2H); 3.32 (t, 2H); 3.53 (d, 2H); 3.73 (t, 2H); 3.96 (s, 3H); 4.02 (d, 2H); 4.37 (m, 4H); 7.45 (s, 1H); 7.67 (d, 1H); 7.95 (d, 1H); 8.12 (s, 1H); 8.52 (s, 1H).
  • MS ES+: 473 (M+H)+
  • Compound 212
  • Ester V (1.1 g, 2.3 mmol) in methanol (20 ml) was treated with sodium hydroxide (2N, 20 ml) at 75° C. for 4 hours, and at room temperature over night. Methanol was evaporated, and the remaining aqueous solution was kept for 24 hours at 5° C. The solid was filtered, washed with water, MeOH/CH2Cl2: 1/1, dried under vacuum to give title compound (0.9 g, 87%).
  • 1HNMR (DMSO-d6, TFA): 2.31 (m, 2H); 3.14 (t, 2H); 3.33 (t, 2H); 3.53 (d, 2H); 3.76 (t, 2H); 4.01 (d, 2H); 4.07 (s, 3H); 4.33 (t, 2H); 7.44 (s, 1H); 7.54 (d, 1H); 7.68 (d, 1H); 8.54 (s, 1H); 9.22 (s, 1H).
  • MS ES+: 445 (M+H)+
  • Synthesis of Amides of General Structure W, General Procedure
  • Acid 212 (80 mg, 0.18 mmol) in DMF (1.5 ml) was reacted with amine (0.216 mmol) in presence of O-(7-azabenzotriazol-1-yl) N,N,N′,N′-tetramethyluronium hexafluorophosphate (80 mg, 0.21 mmol), DIEA (80 μl, 0.46 mmol), for 3 hours at room temperature. The reaction mixture was then treated with a solution of NaHCO3 (2 ml) with stirring for 0.5 hour, the solid filtered, washed with water, ether, dried under vacuum over P2O5, to give title compound.
    • EXAMPLE 79
  • An analogous reaction to that described in General Scheme 7, starting with aniline (17 μl, 0.186 mmol) yielded Compound 79 in Table 6 (80 mg, 86%).
  • 1HNMR (DMSO-d6, TFA): 2.32 (m, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.53 (d, 2H); 3.69 (t, 2H); 4.01 (d, 2H); 4.03 (s, 3H); 4.3 (t, 2H); 7.7 (t, 1H); 7.32 (m, 4H); 7.73 (d, 2H); 7.98 (d, 1H); 8.18 (s, 1H); 9.22 (s, 1H).
  • MS ES+: 520 (M+H)+
    • EXAMPLE 80
  • An analogous reaction to that described in General Scheme 7, starting with 4-fluoroaniline (24 mg, 0.216 mmol) yielded Compound 80 in Table 6 (62 mg, 64%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.68 (t, 2H); 4.05 (m, 5H); 4.33 (t, 2H); 7.21 (t, 2H); 7.33 (d, 1H); 7.4 (s, 1H); 7.77 (m, 2H); 7.98 (d, 1H); 8.2 (s, 1H); 9.25 (s, 1H).
  • MS ES+: 538 (M+H)+.
    • EXAMPLE 81
  • An analogous reaction to that described in General Scheme 7, starting with 3-aminophenol (24 mg, 0.216 mmol) yielded Compound 81 in Table 6 (60 mg, 66%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.7 (t, 2H); 4.04 (d, 2H); 4.06 (s, 3H); 4.33 (t, 2H); 6.53 (m, 1H); 7.13 (m, 2H); 7.3 (d, 1H); 7.36 (d, 1H); 7.4 (s, 1H); 7.96 (s, 1H); 8.0 (d, 1H); 8.26 (s, 1H); 9.25 (s, 1H).
  • MS ES+: 536 (M+H)+.
    • EXAMPLE 82
  • An analogous reaction to that described in General Scheme 7, starting with 4-aminopyridine (20 mg, 0.216 mmol) yielded Compound 82 in Table 6 (16 mg, 19%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.68 (t, 2H); 4.03 (d, 2H); 4.05 (s, 3H); 4.32 (t, 2H); 7.01 (d, 1H); 7.03 (s, 1H); 8.18 (d, 1H); 8.22 (s, 1H); 8.3 (d, 2H); 8.76 (d, 2H); 9.3 (s, 1H).
  • MS ES+: 521 (M+H)+.
    • EXAMPLE 83
  • An analogous reaction to that described in General Scheme 7, starting with 4-amino-1-butanol (19 mg, 0.216 mmol) yielded Compound 83 in Table 6 (22 mg, 28%).
  • 1HNMR (DMSO-d6, TFA): 1.46 (m, 2H); 1.58 (m, 2H); 2.3 (m, 2H); 3.16 (t, 2H); 3.26 (t, 2H); 3.36 (t, 2H); 3.44 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 4.04 (m, 5H); 4.32 (t, 2H); 7.26 (d, 1H); 7.39 (s, 1H); 7.7 (d, 1H); 8.19 (s, 1H); 9.21 (s, 1H).
  • MS ES+: 516 (M+H)+
    • EXAMPLE 84
  • An analogous reaction to that described in General Scheme 7, starting with 3-aminobenzamide (29 mg, 0.216 mmol) yielded Compound 84 in Table 6 (60 mg, 77%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.67 (t, 2H); 4.03 (d, 2H); 4.05 (s, 3H); 4.32 (t, 2H>); 7.34 (d, 1H); 7.39 (s, 1H); 7.42 (t, 1H); 7.62 (d, 1H); 7.96 (d, 1H); 8.05 (d, 1H); 8.21 (m, 2H); 9.27 (s, 1H).
  • MS ES+: 563 (M+H)+.
    • EXAMPLE 85
  • An analogous reaction to that described in General Scheme 7, starting with alkylamine (12 mg, 0.216 mmol) yielded title Compound 85 in Table 6 (20 mg, 43%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.68 (t, 2H); 3.91 (d, 2H); 4.04 (m, 5H); 4.32 (t, 2H); 5.12 (d, 1H); 5.2 (d, 1H); 5.91 (m, 1H); 7.26 (d, 1H); 7.38 (s, 1H); 7.75 (d, 1H); 8.19 (s, 1H); 9.22 (s, 1H).
  • MS ES+: 484 (M+H)+.
    • EXAMPLE 86
  • An analogous reaction to that described in General Scheme 7, starting with Methyl-4-aminobutyrate (25 mg, 0.216 mmol) yielded Compound 86 in Table 6 (18 mg, 23%).
  • 1HNMR: 1.8 (t, 2H); 2.3 (m, 2H); 2.39 (t, 2H); 3.16 (t, 2H); 3.28 (t, 2H); 3.35 (t, 2H); 3.56 (d, 2H); 3.6 (s, 3H); 3.67 (t, 2H); 4.04 (m, 5H); 4.32 (t, 2H); 7.26 (d, 1H); 7.38 (s, 1H); 7.69 (d, 1H); 8.19 (s, 1H); 9.22 (s, 1H).
  • MS ES+: 544 (M+H)+.
    Figure US20060046987A1-20060302-C00154
    Compound S
  • Aminonitrile A (1.78 g, 10 mmol) was treated with trimethylorthoformate (10 ml) and a catalytic amount of p-toluene sulfonic acid at 100° C. for 1 hour. The mixture was cooled to room temperature, ethyl acetate was added, and the insoluble solid removed by filtration, the solvent was then evaporated, the residue triturated with ether to give title compound as a yellow solid (1.56 g, 71%).
  • 1HNMR (DMSO-d6): 3.77 (s, 3H); 3.83 (s, 3H); 3.84 (s, 3H); 6.87 (s, 1H); 7.26 (s, 1H); 8.19 (s, 1H).
  • MS ES+: 221 (M+H)+.
  • Compound 213
  • Imidate S (0.165 g, 0.75 mmol) was reacted with ethyl 2-amino-5-thiophenecarboxylate (0.13 g, 0.79 mmol) in methylene chloride (4 ml) in presence of pyridinium hydrochloride (88 mg, 0.75 mmol) at room temperature for 4 hours. The solvent was evaporated, and the residue was purified by silica gel chromatography, eluent: AcOEt/CH2Cl2, 1/1; followed by MeOH/AcOEt/CH2Cl2, 1/4/5, to give title compound (0.135 g, 50%).
  • 1HNMR (DMSO-d6, TFA): 1.33 (t, 3H); 3.95 (s, 3H); 4.03 (s, 3H); 4.38 (q, 2H); 7.43 (s, 1H); 7.67 (d, 1H); 7.95 (d, 1H); 8.05 (s, 1H); 8.52 (s, 1H).
  • MS ES+: 360 (M+H)+
  • Compound 214
  • The ester 213 (72 mg, 0.2 mmol) in methanol (2 ml) was treated with sodium hydroxide (2N, 2 ml) at 75° C. for 1.5 hour. The reaction mixture was cooled to room temperature, and the pH adjusted to 3 by addition of HCl 2N. The solid was recovered by filtration, washed with water, dried under vacuum in presence of P2O5, to give title compound (83 mg, 100%).
  • 1HNMR (DMSO-d6, TFA): 4.02 (s, 3H); 4.04 (s, 3H); 7.38 (s, 1H); 7.42 (d, 1H); 7.68 (d, 1H); 8.35 (s, 1H); 9.21 (s, 1H).
  • MS ES+: 332 (M+H)+.
    • EXAMPLE 87
  • Synthesis of Compound of General Formula T where NRR′=NHPh (Compound 87)
  • Quinazoline 214 (45 mg, 0.108 mmol) in DMF (1 ml) was reacted with aniline (12 μl, 0.13 mmol) in presence of O-(7-azabenzotriazol-1-yl) N,N,N′,N′-tetramethyluronium hexafluorophosphate (50 mg, 0.13 mmol), DIEA (75 μl, 0.43 mmol) for 1.5 hour at room temperature. A saturated solution of sodium bicarbonate (2 ml) was added to the mixture which was stirred for 0.5 hour. The solid was filtered, washed with water, and purified by chromatography over alumine, eluent AcOEt/CH2Cl2: 1/1 to MeOH/AcOt/CH2Cl2: 1/4/5, to give title compound (15 mg, 34%).
  • 1HNMR (DMSO-d6): 3.97 (s, 3H); 4.01 (s, 3H); 7.05 (d, 1H); 7.09 (t, 1H); 7.29 (s, 1H); 7.36 (t, 2H); 7.74 (d, 2H); 7.91 (d, 1H); 7.92 (s, 1H); 8.72 (s, 1H).
  • MS ES+: 406 (M+H)+
    • EXAMPLE 88
  • Synthesis of Compound 88 of General Formula T where NRR′ is NHPh(4-F)
  • An analogous reaction to that described in the Example 87, starting with quinazoline 213 (60 mg, 0.14 mmol), 4-fluoroaniline (17 μl, 0.17 mmol) yielded title compound (15 mg, 24%).
  • 1HNMR (DMSO-d6, TFA): 4.04 (s, 3H); 4.06 (s, 3H); 7.18 (t, 2H); 7.32 (d, 1H); 7.35 (s, 1H); 7.75 (t, 2H); 7.98 (d, 1H); 8.17 (s, 1H); 9.23 (s, 1H).
  • MS ES+: 425 (M+H)+.
    Figure US20060046987A1-20060302-C00155
    • EXAMPLE 89 Preparation of Compound 250 in Table 9
  • Amidine J (1.04 g, 3 mmol) in acetic acid (10 ml) was reacted with methyl 4-amino-1-methyl-2-pyrrolecarboxylate hydrochloride (686 mg, 3.6 mmol) and dimethylamine in methanol (1.25 M 2.9 ml, 3.6 mmol) at 130° C. for 5.5 hours. The solvent was evaporated, water and an aqueous solution of sodium bicarbonate were added to the residue, the precipitate was filtered, dried under vacuum over P2O5. The solid was redissolved in a large volume of tetrahydrofuran, methylene chloride, methanol, the solution was concentrated, the solid filtered, washed with ether, dried, to give title compound (1.18 g, 86%).
  • 1HNMR (DMSO-d6, TFA): 2.31 (m, 2H); 3.16 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 3.8 (s, 3H); 3.95 (s, 3H); 4.01 (s, 3H); 4.03 (d, 2H); 4.29 (t, 2H); 7.26 (d, 1H); 7.32 (s, 1H); 7.69 (d, 1H); 8.06 (s, 1H); 8.94 (s, 1H).
  • MS ES+: 456 [M+H]+
    • EXAMPLE 90 Preparation of Compound 251 in Table 9
  • Ester 250 (1.34 g, 3 mmol) was treated with sodium hydroxide (6N, 3 ml) in ethanol (25 ml) at 75° for 2 hours. The solution was then cooled to room temperature, acidified to pH 3 with HCl (6N), the precipitate was recovered by filtration, washed with ethanol, ether, dried under vacuum to give title compound (636 mg, 42%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.15 (t, 2H); 3.34 (t, 2H); 3.54 (d, 2H); 3.72 (t, 2H); 4.02 (m, 5H); 4.3 (t, 2H); 7.19 (s, 1H); 7.32 (s, 1H); 7.62 (s, 1H); 8.17 (s, 1H); 8.93 (s, 1H).
  • MS ES+: 428 [M+H]+
    • EXAMPLE 91 Synthesis of Amides N, General Procedure
  • Acid 251 (79 mg, 0.15 mmol) in DMF (1 ml) was reacted with O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (62 mg, 0.165 mmol), the appropriate amine (1.65 mmol) and DIEA (68 mg, 0.525 mmol) at room temperature for 1.5 hour. The reaction mixture was then diluted with water (4 ml) and an aqueous solution of sodium bicarbonate (1 ml). The solid was recovered by filtration, redissolved in tetrahydrofuran, methylene chloride, and concentrated, the precipitated solid was recovered, washed with ether, dried under vacuum, to give title compound.
    • EXAMPLE 92 Preparation of Compound 252 in Table 9
  • Compound 252 was obtained by reaction of the N-hydroxybenzotriazol ester of 251 (56 mg, 0.1 mmol) with aniline (11 mg, 0.12 mmol) in DMF (1 ml) at 105° C. for 3 hours. Water was added to the cooled reaction mixture, which was extracted with ethylacetate, the organic phase was washed with water, dried over MgSO4, filtered and concentrated to give title compound (12 mg, 23%). The N-hydroxybenzotriazol ester was obtained as described in the general procedure of Example 91.
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.68 (t, 2H); 3.97 (s, 3H); 4.02 (s, 3H); 4.04 (d, 2H); 4.29 (t, 2H); 7.08 (t, 1H); 7.33 (m, 3H); 7.4 (s, 1H); 7.63 (s, 1H); 7.74 (d, 2H); 8.1 (s, 1H); 8.93 (s, 1H).
  • MS ES+: 517 [M+H]+
    • EXAMPLE 93 Preparation of Compound 253 in Table 9
  • An analogous reaction to that described in Example 92, but starting with 4-fluoroaniline (22 mg, 0.195 mmol) yielded title compound (40 mg, 57%).
  • 1H NMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.17 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.72 (t, 2H); 3.97 (s, 3H); 4.02 (s, 3H); 4.04 (d, 2H); 4.3 (t, 2H); 7.18 (t, 2H); 7.34 (s, 1H); 7.4 (d, 1H); 7.63 (d, 1H); 7.76 (m, 1H); 8.11 (s, 1H); 8.94 (s, 1H).
  • MS ES+: 535 [M+H]+
    • EXAMPLE 94 Preparation of Compound 254 in Table 9
  • An analogous reaction to that described in Example 92, but starting with cyclohexylamine (16 mg, 0.17 mmol) yielded title compound (60 mg, 76%).
  • 1HNMR (DMSO-d6, TFA): 1.14 (m, 1H); 1.3 (m, 4H); 1.62 (m, 1H); 1.8 (m, 4H); 2.29 (m, 2H); 3.15 (t, 2H); 3.34 (t, 2H); 3.54 (d, 2H); 3.68 (m, 3H); 3.9 (s, 3H); 4.0 (s, 3H); 4.03 (d, 2H); 4.28 (t, 2H); 7.14 (d, 1H); 7.31 (s, 1H); 7.49 (d, 1H); 8.07 (s, 1H); 8.9 (s, 1H).
  • MS ES+: 523 [M+H]+
    • EXAMPLE 95 Preparation of Compound 255 in Table 9
  • An analogous reaction to that described in the Example 92, but starting with N,N-dimethyl-1,4-phenylenediamine (23 mg, 0.17 mmol) yielded title compound (61 mg, 73%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.15 (t, 2H); 3.21 (s, 6H); 3.35 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 3.97 (s, 3H); 4.01 (s, 3H); 4.03 (d, 2H); 4.29 (t, 2H); 7.35 (s, 1H); 7.45 (d, 1H); 7.66 (m, 3H); 7.93 (d, 2H); 8.1 (s, 1H); 8.93 (s, 1H).
  • MS ES+: 560 [M+H]+
    Figure US20060046987A1-20060302-C00156
    • EXAMPLE 96 Preparation of Compound 256 in Table 9
  • Amidine J (1.38 g, 4 mmol) in acetic acid (14 ml) was reacted with ethyl 4-amino-2-pyrrolecarboxylate (0.702 g, 4.56 mmol) at 130° C. for 5 hours. The solution was concentrated, the solid recovered by filtration and washed with ether. This solid was then treated with a diluted solution of sodium bicarbonate, filtered, washed with water and dried under vacuum over P2O5 to give title compound (1.34 g, 73%).
  • 1H NMR (DMSO-d6): 1.3 (t, 3H); 1.95 (t, 2H); 2.38 (m, 4H); 2.44.(t, 2H); 3.58 (m, 4H); 3.94 (s, 3H); 4.16 (d, 2H); 4.23 (q, 2H); 7.05 (d, 1H); 7.14 (s, 1H); 7.59 (d, 1H); 7.75 (s, 1H); 8.46 (s, 1H); 9.53 (s, 1H); 11.72 (s, 1H).
  • MS ES+: 456 [M+H]+
    • EXAMPLE 961 Preparation of Compound 257 in Table 9
  • Ester 256 (1.34 g, 3 mmol) in ethanol (25 ml) was treated with sodium hydroxide (6N, 3 ml) at 75° C. for 2 hours. The solution was cooled, and acidified with hydrochloric acid (6N) to pH 3. The precipitate was filtered, washed with ethanol, ether, dried under vacuum over P2O5, to give title compound (0.63 g, 42%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.15 (t, 2H); 3.34 (t, 2H); 3.54 (d, 2H); 3.72 (t, 2H); 4.02 (s, 3H); 4.03 (d, 2H); 4.3 (t, 2H); 7.19 (d, 1H); 7.32 (s, 1H); 7.62 (d, 1H); 8.17 (s, 1H); 8.93 (s, 1H).
  • MS ES+: 428 [M+H]+
    • EXAMPLE 97 Preparation of Compound 258 in Table 9
  • Acid 257 (75 mg, 0.15 mmol) in DMF (0.7 ml) was reacted with O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (68 mg, 0.18 mmol), aniline (17 mg, 0.18 mmol) and DIEA (62 mg, 0.48 mmol) at room temperature over night. The reaction mixture was then diluted with a saturated solution of sodium bicarbonate (5 ml), and stirred for 1 hour. The solid was filtered, washed with water, dried under vacuum over P2O5, to give title compound (30 mg, 40%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.16 (t, 2H); 3.37 (t, 2H); 3.54 (d, 2H); 3.69 (t, 2H); 4.01 (s, 3H); 4.03 (d, 2H); 4.31 (t, 2H); 7.08 (t, 1H); 7.35 (m, 3H); 7.46 (d, 1H); 7.56 (d, 1H); 7.77 (d, 1H); 8.1 (s, 1H); 8.93 (s, 1H).
  • MS ES+: 503 [M+H]+
    • EXAMPLE 98 Preparation of Compound 259 in Table 9
  • An analogous reaction to that described for the Example 97, but starting with cyclohexylamine (18 mg, 0.18 mmol) yielded title compound (30 mg, 39%).
  • 1HNMR (DMSO-d6, TFA): 1.13 (m, 1H); 1.3 (m, 4H); 1.63 (m, 1H); 1.8 (m, 4H); 2.3 (m, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.68 (t, 2H); 3.76 (m, 1H); 4.0 (s, 1H); 4.03 (d, 2H); 4.3 (t, 2H); 7.2 (d, 1H); 7.3 (s, 1H); 7.43 (d, 1H); 8.0 (s, 1H); 8.9 (s, 1H).
  • MS ES+: 509 [M+H]+
    Figure US20060046987A1-20060302-C00157
    • EXAMPLE 99 Preparation of Compound 260 in Table 10
  • Amidine J (1.04 g, 3 mmol) in acetic acid (10 ml) was reacted with ethyl 4-amino-1-methyl-2-imidazolecarboxylate hydrochloric acid (0.74 g, 3.6 mmol) in presence of dimethylamine/MeOH (1.25N, 2.9 ml, 3.6 mmol) at 130° C. for 3 hours. The solvent was evaporated, the residue triturated with ether and filtered. The solid was suspended in water, the pH adjusted to 9 with an aqueous solution of sodium bicarbonate, the suspension was filtered, washed with water, dried under vacuum over P2O5, to give title compound (1.1 g, 78%).
  • 1HNMR (DMSO-d6): 1.32 (t, 3H); 1.96 (m, 2H); 2.37 (m, 4H); 2.44 (t, 2H); 3.58 (m, 4H); 3.94 (s, 3H); 4.0 (s, 3H); 4.17 (t, 2H); 4.28 (q, 2H); 7.16 (s, 1H); 7.99 (s, 1H); 8.07 (s, 1H); 8.53 (s, 1H); 10.55 (s, 1H).
    • EXAMPLE 100 Preparation of Compound 261 in Table 10
  • Ester 260 (1.1 g, 2.34 mmol) in ethanol (23 ml) was reacted with sodium hydroxyde (6N, 2.3 ml) at 80° C. for 2.5 hours. The mixture was cooled, and acidified with hydrochloric acid (6N) to pH 3. The suspension was recovered by centrifugation, washed with ethanol, ether, dried under vacuum over P2O5, to give tide compound (930 mg, 73%).
  • 1HNMR (DMSO-d6, TFA): 2.31 (m, 2H); 3.16 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.76 (t, 2H); 4.01 (s, 3H); 4.05 (m, 5H); 4.32 (t, 2H); 7.41 (s, 1H); 8.03 (s, 1H); 8.38 (s, 1H); 9.0 (s, 1H).
  • MS ES+: 443 [M+H]+
    • EXAMPLE 101 Preparation of Compounds of General Structure L
  • Acid 261 (88 mg, 0.16 mmol) in DMF (1 ml) was reacted with O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (73 mg, 0.19 mmol), the appropriate amine (0.18 mmol) and DIEA (82 mg, 0.4 mmol) at room temperature for 3 hours. The solution was then diluted with a saturated solution of sodium bicarbonate (4 ml) and stirred at room temperature for 3 hours. The precipitate was filtered, washed with water, dried under vacuum over P2O5, to give title compound.
    • EXAMPLE 102 Preparation of Compound 262 in Table 10
  • An analogous reaction to that described in Example 101, but starting with aniline (17 mg, 0.18 mmol) yielded title compound (37 mg, 44%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.16 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 4.02 (m, 5H); 4.06 (s, 3H); 4.31 (t, 2H); 7.13 (t, 1H); 7.38 (m, 3H); 7.78 (d, 2H); 7.99 (s, 1H); 8.27 (s, 1H); 9.01 (s, 1H).
  • MS ES+: 518 [M+H ]+
    • EXAMPLE 103 Preparation of Compound 263 in Table 10
  • An analogous reaction to that described in Example 101, but starting with 4-fluoroaniline (20 mg, 0.18 mmol) yielded title compound (84 mg, 97%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.16 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 4.02 (s, 3H); 4.04 (d, 2H); 4.1 (s, 3H); 4.31 (t, 2H); 7.21 (t, 2H); 7.39 (s, 1H); 7.82 (m, 2H); 7.98 (s, 1H); 8.32 (s, 1H); 9.01 (s, 1H).
  • MS ES+: 536 [M+H]+
    • EXAMPLE 104 Preparation of Compound 264 in Table 10
  • An analogous reaction to that described in Example 101, but staring with N,N-dimethyl-1,4-phenylenediamine (24 mg, 0.18 mmol) yielded title compound (80 mg, 88%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.17 (t, 2H); 3.21 (s, 6H); 3.35 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 4.02 (m, 5H); 4.1 (s, 3H); 4.31 (t, 2H); 7.4 (s, 1H); 7.66 (d, 2H); 7.98 (d, 2H); 8.01 (s, 1H); 8.32 (s, 1H); 9.01 (s, 1H).
  • MS ES+: 561 [M+H]+
    • EXAMPLE 105 Reparation of Compound 265 in Table 10
  • An analogous reaction to that described in Example 101, but starting with 4-chloroaniline (23 mg, 0.18 mmol) yielded title compound (55 mg, 62%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.17 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 4.02 (s, 3H); 4.04 (d, 2H); 4.1 (s, 3H); 4.32 (t, 2H); 7.39 (s, 1H); 7.43 (d, 2H); 7.84 (d, 2H); 7.99 (s, 1H); 8.32 (s, 1H); 9.01 (s, 1H).
  • MS ES+: 552, 554 [M+H]+
    • EXAMPLE 106 Preparation of Compound 266 in Table 10
  • An analogous reaction to that described in Example 101, but starting with pyrrolidine (13 mg, 0.18 mmol) yielded title compound (50 mg, 62%).
  • 1HNMR (DMSO-d6, TFA): 1.85 (m, 4H); 2.28 (m, 2H); 3.15 (t, 2H); 3.32 (t, 2H); 3.5 (m, 4H); 3.66 (t, 2H); 3.89 (m, 5H); 3.98 (m, 5H); 4.27 (t, 2H); 7.33 (s, 1H); 7.85 (s, 1H); 8.29 (s, 1H); 8.96 (s, 1H).
  • MS ES+: 496 [M+H]+
    • EXAMPLE 107 Preparation of Compound 267 in Table 10
  • An analogous reaction to that described in Example 101, but starting with cyclohexylamine (18 mg, 0.18 mmol) yielded title compound (54 mg, 64%).
  • 1HNMR (DMSO-d6, TFA): 1.19 (m, 1H); 1.35 (m, 4H); 1.61 (m, 1H); 1.71 (m, 2H); 1.85 (m, 2H); 2.31 (m, 2H); 3.16 (t 2H); 3.34 (t, 2H); 3.54 (d, 2H); 3.69 (t, 2H); 3.75 (m, 1H); 4.01 (s, 3H); 4.04 (m, 5H); 4.3 (t, 2H); 7.37 (s, 1H); 7.9 (s, 1H); 8.29 (s, 1H); 8.99 (s, 1H).
  • MS ES+: 524 [M+H]+
    Figure US20060046987A1-20060302-C00158
    • EXAMPLE 108 Step (a) Preparation of Intermediates of General Formula Z1
  • Imidate U (2 g, 6 mmol) in dimethylformamide (40 ml) was reacted with ethyl 5-amino-4H-1,2,4-triazole-3-carboxylate hydrochloric acid (1.16 g, 6 mmol) in presence of sodium hydride (60%, 504 mg, 12.6 mmol) at 110° C. for 7 hours, under argon. The mixture was then cooled to room temperature, and acetic acid (1.03 ml, 18 mmol) was added, the solvent was evaporated under vacuum, the residue purified by silica gel chromatography, eluent: CH2Cl2/MeOH, 90/10 to give title compound (1.07 g, 39%).
  • 1H NMR (DMSO-d6, TFA): 1.39 (t, 3H); 2.28 (m, 2H); 3.15 (t, 2H); 3.32 (t, 2H); 3.56 (d, 2H); 3.68 (t, 2H); 3.98 (s, 3H); 4.05 (d, 2H); 4.37 (t, 2H); 4.52 (q, 2H); 7.49 (s, 1H); 8.12 (s, 1H); 8.71 (s, 1H).
  • MS ES+: 458 [M+H]+
  • Step (b): Preparation of Compound 268 in Table 11
  • Triazole ester Z1 (80 mg, 0.17 mmol) in dimethylformamide (3 ml) was treated with dimethylamine acetate (0.52 mmol) at 70° C. for 20 minutes. The mixture was cooled, the solvent evaporated, and the residue purified by silica gel chromatography, eluent CH2Cl2/MeOH/NH3, 90/10/1 to give title product (60 mg, 75%)
  • 1H NMR (DMSO-d6, TFA): 1.34 (t, 3H); 2.3 (m, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.68 (t, 2H); 4.0 (s, 3H); 4.04 (d, 2H); 4.36 (m, 4H); 7.48 (s, 1H); 8.26 (s, 1H); 9.01 (s, 1H).
  • MS ES+: 458 [M+H]+
    • EXAMPLE 109 Preparation of Compound 269 in Table 11
  • Triazole ester 268 (900 mg, 1.97 mmol) in methanol (20 ml), was treated with sodium hydroxyde (2N, 20 ml) at 80° C. for 1.5 hour. The mixture was cooled, and acidified to pH 2.5 with hydrochloric acid (6N), the solid was recovered by filtration dried under vacuum over P2O5 to give title compound (843 mg, 100%).
  • 1HNMR (DMSO-d6, TFA): 2.37 (m, 2H); 3.12 (t, 2H); 3.3 (t, 2H); 3.5 (d, 2H); 3.87 (t, 2H); 3.97 (d, 2H); 4.01 (s, 3H); 4.35 (t, 2H); 7.63 (s, 1H); 8.32 (s, 1H); 8.97 (s, 1H).
  • MS ES+: 430 (M+H)+.
    • EXAMPLE 110 Preparation of Compound 270 in Table 11
  • Acid 269 (120 mg, 0.28 mmol) in DMF (2 ml) was reacted with aniline (0.025 ml, 0.28 mmol) in presence of O-(7-azabenzotriazol-1-yl) N,N,N′,N′,-tetramethyluronium hexafluorophosphate (106 mg, 0.28 mmol) and DIEA (0.12 ml, 0.7 mmol) at room temperature for 4 hours. The solvent was evaporated, the residue dissolved in methylene chloride/methanol, and treated with a methanolic solution of dimethylamine (2M, 1 ml) at room temperature over night. The solvent was evaporated, and the residue purified by flash silica gel chromatography, eluent CH2Cl2/MeOH, 90/10 to give title compound (12 mg, 9%).
  • 1H NMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.18 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.68 (t, 2H); 4.01 (s, 3H); 4.03 (d, 2H); 4.33 (t, 2H); 7.16 (t, 1H); 7.39 (t, 2H); 7.45 (s, 1H); 7.83 (d, 2H); 8.2 (s, 1H); 8.95 (s, 1H).
  • MS ES+: 505 [M+H]+
    • EXAMPLE 111 Preparation of Compound 271 in Table 11
  • An analogous reaction to that described in Example 110, but starting with 4-fluoroaniline (0.13 ml, 1.4 mmol) yielded title compound (44 mg, 18%).
  • 1H NMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.68 (t, 2H); 4.0 (s, 3H); 4.04 (d, 2H); 4.33 (t, 2H); 7.23 (t, 2H); 7.44 (s, 1H); 7.86 (m, 1H); 8.18 (s, 1H); 8.93 (s, 1H).
  • MS ES+: 523[M−H]+
    • EXAMPLE 112 Preparation of Compound 272 in Table 11
  • An analogous reaction to that described in Example 110 but starting with alkylamine (0.13 ml, 1.75 mmol) yielded the title compound (26 mg, 10%).
  • 1H NMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.16 (t, 2H); 3.34 ((, 2H); 3.54 (d, 2H); 3.68 (t, 2H); 3.94 (d, 2H); 3.99 (s, 3H); 4.03 (d, 2H); 4.32 (t, 2H); 5.13 (d, 1H); 5.18 (d, 1H); 5.92 (m, 1H); 7.41 (s, 1H); 8.17 (s, 1H); 8.91 (s, 1H).
  • MS ES+: 469 [M+H]+
    Figure US20060046987A1-20060302-C00159
    • EXAMPLE 113 Preparation of Compound 300 in Table 12
  • Step 1 Preparation of Compound aa
  • Imidate u, (200 mg, 0.6 mmol) in DMF (4 ml) was condensed with 2-aminoimidazole, sulfate (160 mg, 0.6 mmol) in presence of sodium hydride (60%, 50 mg, 1.26 mmol) at 90° C. for 2 hours. The mixture was cooled, acetic acid (0.01 ml, 1.8 mmol) was added, the solvent was evaporated, and the residue purified by silica gel chromatography, eluent CH2Cl2/MeOH, 90/10 to give title compound (112 mg, 48%).
  • 1HNMR (DMSO-d6, TFA): 2.3 (m, 2H); 3.15 (t, 2H); 3.33 (t, 2H); 3.54 (d, 2H); 3.68 (t, 2H); 3.97 (s, 3H); 4.03 (d, 2H); 4.36 (t, 2H); 7.41 (s, 2H); 7.47 (s, 1H); 8.13 (s, 1H); 8.66 (s, 1H).
  • MS ES+: 385 [M+H]+
  • Step 2: Preparation of Compound 300
  • Imidazole aa (105 mg, 0.273 mmol) in DMF (2 ml) was heated at 80° C. for 0.3 hour in presence of dimethylamine acetate (0.819 mmol), the solvent was evaporated, and the residue was purified by silica gel chromatography, eluent CH2Cl2/MeOH sat. NH3, 90/10 to give title compound (78 mg, 74%).
  • 1HNMR (DMSO): 1.96 (m, 2H); 2.39 (m, 4H); 2.46 (t, 2H); 3.6 (m, 4H); 3.9 (s, 3H); 4.18 (t, 2H). 6.9 (s, 2H); 7.14 (s, 1H); 7.84.(s, 1H); 8.39 (s, 1H).
  • MS ES+: 385 [M+H]+
    • EXAMPLE 114 Preparation of Compound 301 in Table 12
  • Step 1: Preparation of Compound ab
  • Imidate u (250 mg, 0.751 mmol) in DMF (4 ml) was reacted with ethyl 2-aminoimidazole-4-carboxylate (117 mg, 0.751 mmol) in presence of sodium hydride (60%, 30 mg, 0.826 mmol) at 100° C. for 3 hours. The mixture was cooled, acetic acid (0.13 ml, 2.25 mmol) was added, the solvent was evaporated, and the residue purified by silica gel chromatography to give title compound (125 mg, 36%).
  • 1HNMR (DMSO-d6, TFA): 1.32 (t, 3H); 2.3 (m, 2H); 3.15 (t, 2H); 3.34 (t, 2H); 3.55 (d, 2H); 3.68 (t, 2H); 3.98 (s, 3H); 4.03 (d, 2H); 4.33 (q, 2H); 4.37 (t, 2H); 7.49 (s, 1H); 8.11 (s, 1H); 8.2 (s, 1H); 8.65 (s, 1H).
  • MS ES+: 457 [M+H]+
  • Step 2: Preparation of Compound 301 in Table 12
  • Imidazole 3 (122 mg, 0.268 mmol) in DMF (2 ml) was heated at 80° C. for 0.3 hour in presence of dimethylamine acetate (0.802 mmol). The solvent was evaporated, and the residue was purified by silica gel chromatography, eluent CH2Cl2/MeOH sat. NH3 95/5 to 90/10 to give title compound (105 mg, 86%).
  • 1HNMR (DMSO-d6, TFA): 1.32 (t, 3H); 2.3 (m, 2H); 3.15 (t, 2H); 3.34 (t, 2H); 3.54 (d, 2H); 3.68 (t, 2H); 3.94 (s, 3H); 4.03 (d, 2H); 4.27 (t, 2H); 4.33 (q, 2H); 7.27 (s, 1H); 7.84 (s, 1H); 7.92 (s, 1H); 8.76 (s, 1H).
  • MS ES+: 457 [M+H]+
    • EXAMPLE 115 Preparation of Compound 302 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 4-methoxyaniline (32 mg, 0.26 mmol) yielded compound 302 in Table 13 (24 mg, 21%).
  • MS ES+: 551 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.31 (t, 2H); 3.16 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 3.76 (s, 3H); 4.02 (s, 3H); 4.04 (d, 2H); 4.33 (t, 2H); 6.96 (d, 2H); 7.38 (s, 1H); 7.62 (d, 2H); 8.04 (s, 1H); 8.55 (s, 1H); 9.27 (s, 1H).
    • EXAMPLE 116 Preparation of Compound 303 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 4-methylaniline (28 mg, 0.26 mmol) yielded compound 303 in Table 13 (23 mg, 22%).
  • MS ES+: 535 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.29 (s, 3H); 2.33 (t, 2H); 3.17 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 4.01 (s, 3H); 4.04 (d, 2H); 4.33 (t, 2H); 7.19 (d, 2H); 7.38 (s, 1H); 7.60 (d, 2H); 8.05 (s, 1H); 8.58 (s, 1H); 9.28 (s, 1H).
    • EXAMPLE 117 Preparation of Compound 304 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 2-aminopyridine (24 mg, 0.26 mmol) yielded compound 304 in Table 13 (12 mg, 11%).
  • MS ES+: 522 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.32 (t, 2H); 3.16 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 4.02 (s, 3H); 4.04 (d, 2H); 4.34 (t, 2H); 7.33 (m, 1H); 7.41 (s, 1H); 8.07 (m, 2H); 8.09 (s, 1H); 8.46 (d, 1H); 8.81 (s, 1H); 9.30 (s, 1H).
    • EXAMPLE 118 Preparation of Compound 305 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 2-aminobenzyl alcohol (32 mg, 0.26 mmol) yielded compound 305 in Table 13 (54 mg, 60%).
  • MS ES+: 551 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.33 (t, 2H); 3.18 (t, 2H); 3.37 (t, 2H); 3.56 (d, 2H); 3.70 (t, 2H); 3.78 (s, 2H); 4.02 (s, 3H); 4.05 (d, 2H); 4.34 (t, 2H); 6.73 (d, 1H); 7.30 (m, 2H); 7.39 (s, 1H); 7.40 (m, 1H); 8.07 (s, 1H); 8.62 (s, 1H); 9.3 (s, 1H).
    • EXAMPLE 119 Preparation of Compound 306 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 4-methoxybenzylamine (36 mg, 0.26 mmol) yielded compound 306 in Table 13 (29 mg, 26%).
  • MS ES+: 565 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.28 (t, 2H); 3.14 (t, 2H); 3.31 (t, 2H); 3.50 (d, 2H); 3.68 (t, 2H); 3.69 (s, 3H); 3.94 (s, 3H); 3.98 (d, 2H); 4.26 (t, 2H); 4.37 (s, 2H); 6.89 (m, 2H); 7.12 (m, 2H); 7.35 (s, 1H); 7.90 (s, 1H); 8.31 (s, 1H); 9.15 (s, 1H).
    • EXAMPLE 120 Preparation of Compound 307 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 3-nitroaniline (36 mg, 0.26 mmol) yielded compound 307 in Table 13 (27 mg, 24%).
  • MS ES+: 566 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.30 (t, 2H); 3.17 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 4.02 (s, 3H); 4.04 (d, 2H); 4.33 (t, 2H); 7.40 (s, 1H); 7.71 (t, 1H); 7.99 (d, 1H); 8.08 (s, 1H); 8.14 (d, 1H); 8.64 (s, 1H); 8.71 (s, 1H); 9.31 (s, 1H).
    • EXAMPLE 121 Preparation of Compound 308 in Table 13
  • An analogous reaction to that described in general scheme 5, staring with aminoacetonitrile (24 mg, 0.26 mmol) yielded compound 308 in Table 13 (29 mg, 30%).
  • MS ES+: 484 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.31 (t, 2H); 3.16 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.68 (t, 2H); 4.00 (s, 3H); 4.02 (d, 2H); 4.32 (t, 2H); 4.37 (s, 2H); 7.39 (s, 1H); 8.06 (s, 1H); 8.36 (s, 1H); 9.27 (s, 1H).
    • EXAMPLE 122 Preparation of Compound 309 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 2-methyl-5-nitroaniline (40 mg, 0.26 mmol) yielded compound 309 in Table 13 (14 mg, 12%).
  • MS ES+: 580 (+H)+
  • 1H NMR (DMSO-d6, TFA): 2.31 (t, 2H); 3.16 (t, 2H); 3.36 (t, 2H; 3.54 (d, 2H); 3.68 (t, 2H); 4.01 (s, 3H); 4.03 (d, 2H); 4.32 (t, 2H); 7.39 (s, 1H); 7.58 (d, 1H); 8.04 (d, 1H); 8.08 (s, 1H); 8.34 (d, 1H); 8.62 (s, 1H); 9.29 (s, 1H).
    • EXAMPLE 123 Preparation of Compound 310 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with cyclopropylamine (15 mg, 0.26 mmol) yielded compound 310 in Table 13 (6 mg, 6%).
  • MS ES+: 485 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 0.68 (m, 2H); 0.74 (m, 2H); 2.27 (t, 2H); 2.67 (m, 1H); 3.12 (t, 2H); 3.31 (t, 2H); 3.51 (d, 2H); 3.69 (t, 2H); 3.95 (s, 3H); 3.98 (d, 2H); 4.29 (t, 2H); 7.32 (s, 1H); 7.96 (s, 1H); 8.24 (s, 1H); 9.20 (s, 1H).
    • EXAMPLE 124 Preparation of Compound 311 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 4-nitrobenzylamine (49 mg, 0.26 mmol) yielded compound 311 in Table 13 (5 mg, 4%).
  • MS ES+: 580 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.31 (t, 2H); 3.17 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 4.00 (s, 3H); 4.03 (d, 2H); 4.32 (t, 2H); 4.63 (s, 2H); 7.38 (s, 1H); 7.62 (d, 2H); 8.04 (s, 1H); 8.23 (d, 2H); 8.40 (s, 1H); 9.25 (s, 1H).
    • EXAMPLE 125 Preparation of Compound 312 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 2-anilinoethanol (36 mg, 0.26 mmol) yielded compound 312 in Table 13 (49 mg, 44%).
  • MS ES+: 565 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.31 (t 2H); 3.17 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.7 (m, 4H); 4.01 (s, 3H); 4.03 (d, 2H); 4.33 (t, 2H); 4.49 (t, 2H); 7.15 (t, 1H); 7.26 (d, 2H); 7.41 (t, 2H); 7.43 (s, 1H); 8.15 (s, 1H); 8.48 (s, 1H); 9.31 (s, 1H).
    • EXAMPLE 126 Preparation of Compound 313 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with furfurylamine (25 mg, 0.26 mmol) yielded compound 313 in Table 13 (20 mg, 19%).
  • MS ES+: 525 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.32 (t, 2H); 3.16 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.69 (t, 2H); 3.99 (s, 3H); 4.02 (d, 2H); 4.32 (t, 2H); 4.48 (s, 2H); 6.33 (d, 1H); 6.41 (d, 1H); 7.37 (s, 1H); 7.59 (s, 1H); 8.01 (s, 1H); 8.37 (s, 1H); 9.24 (s, 1H).
    • EXAMPLE 127 Preparation of Compound 314 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 3-chloroaniline (33 mg, 0.26 mmol) yielded compound 314 in Table 13 (21 mg, 19%).
  • MS ES+: 555, 557 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.31 (t, 2H); 3.17 (t, 2H); 3.36 (t, 2H); 3.54 (d, 2H); 3.69 (t, 2H); 4.02 (s, 31H); 4.04 (d, 2H); 4.32 (t, 2H); 7.20 (d, 1H); 7.39 (s, 1H); 7.42 (t, 1H); 7.63 (d, 1H); 7.91 (s, 1H); 8.07 (s, 1H); 8.61 (s, 1H); 9.30 (s, 1H).
    • EXAMPLE 128 Preparation of Compound 315 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 2-methoxyaniline (32 mg, 0.26 mmol) yielded compound 315 in Table 13 (67 mg, 61%).
  • MS ES+: 551 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.32 (t, 2H); 3.16 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 3.87 (s, 3H); 4.02 (s, 3H); 4.04 (d, 2H); 4.33 (t, 2H); 6.99 (t, 1H); 7.13 (d, 1H); 7.23 (t, 1H); 7.40 (s, 1H); 7.66 (d, 1H); 8.04 (s, 1H); 8.64 (s, 1H); 9.27 (s, 1H).
    • EXAMPLE 139 Preparation of Compound 316 in Table 13
  • An analogous reaction to that described in general scheme 5, staring with thiophene-2-methylamine (29 mg, 0.26 mmol) yielded compound 316 in Table 13 (25 mg, 23%).
  • MS ES+: 541 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.31 (t, 2H); 3.18 (t, 2H); 3.37 (t, 2H); 3.56 (d, 2H); 3.70 (t, 2H); 4.01 (s, 3H); 4.04 (d, 2H); 4.34 (t, 2H); 4.67 (s, 2H); 6.99 (m, 1H); 7.08 (m, 1H); 7.39 (s, 1H); 7.41 (d, 1H); 8.04 (s, 1H); 8.36 (s, 1H); 9.27 (s, 1H).
    • EXAMPLE 140 Preparation of Compound 317 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with neopentylamine (23 mg, 0.26 mmol) yielded compound 317 in Table 13 (31 mg, 30%).
  • MS ES+: 515 M+H)+
  • 1H NMR (DMSO-d6, TFA): 0.91 (s, 9H); 2.31 (t, 2H); 3.10 (s, 2H); 3.17 (t, 2H); 3.35 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 4.00 (s, 3H); 4.03 (d, 2H); 4.32 (t, 2H); 7.35 (s, 1H); 8.00 (s, 1H); 8.45 (s, 1H); 9.23 (s, 1H).
    • EXAMPLE 141 Preparation of Compound 318 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 2,6-difluorobenzylamine (37 mg, 0.26 mmol) yielded compound 318 in Table 13 (35 mg, 31%).
  • MS ES+: 571 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.31 (t, 2H); 3.17 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.68 (t, 2H); 3.99 (s, 3H); 4.03 (d, 2H); 4.31 (t, 2H); 4.54 (s, 2H); 7.11 (t, 2H); 7.36 (s, 1H); 7.42 (m, 1H); 8.00 (s, 1H); 8.35 (s, 1H); 9.24 (s, 1H).
    • EXAMPLE 142 Preparation of Compound 319 in Table 13
  • An analogous reaction to that described in general scheme 5, staring with 2-methylalkylamine (28 mg, 0.26 mmol) yielded compound 319 in Table 13 (16 mg, 16%).
  • MS ES+: 499 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 1.72 (s, 3H); 2.31 (t, 1H); 3.15 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 3.72 (s, 2H); 3.99 (s, 3H); 4.02 (d, 2H); 4.31 (t, 2H); 4.82 (s, 1H); 4.86 (s, 1H); 7.36 (s, 1H); 8.01 (s, 1H); 8.37 (s, 1H); 9.23 (s, 1H).
    • EXAMPLE 143 Preparation of Compound 320 in Table 13
  • An analogous reaction to that described in general scheme 5, staring with 2-methyl-fluoroaniline (33 mg, 0.26 mmol) yielded compound 320 in Table 13 (47 mg, 43%).
  • MS ES+: 553 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.26 (s, 3H); 2.31 (t, 1H); 3.16 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.68 (t, 2H); 4.01 (s, 3H); 4.03 (d, 2H); 4.33 (t, 2H); 7.07 (m, 1H); 7.18 (d, 1H); 7.36 (m, 1H); 7.38 (s, 1H); 8.06 (s, 1H); 8.53 (s, 1H); 9.27 (s, 1H).
    • EXAMPLE 144 Preparation of Compound 321 in Table 13
  • An analogous reaction to that described in general scheme 5, staring with 2-fluoro-5-methylaniline (33 mg, 0.26 mmol) yielded compound 321 in Table 13 (60 mg, 54%).
  • MS ES+: 553 (M+H)+
    • EXAMPLE 145 Preparation of Compound 322 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 4-fluorobenzylamine (33 mg, 0.26 mmol) yielded compound 322 in Table 13 (33 mg, 30%).
  • MS ES+: 553 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.31 (t, 1H); 3.15 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 3.99 (s, 3H); 4.02 (d, 2H); 4.33 (t, 2H); 4.47 (s, 2H); 7.15 (t, 2H); 7.36 (s, 1H); 7.37 (m, 2H); 8.02 (s, 1H); 8.36 (s, 1H); 9.24 (s, 1H).
    • EXAMPLE 146 Preparation of Compound 323 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 3,4-difluorobenzylamine (37 mg, 0.26 mmol) yielded compound 323 in Table 13 (17 mg, 15%).
  • MS ES+: 571 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.32 (t, 2H); 3.16 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 4.00 (s, 3H); 4.04 (d, 2H); 4.33 (t, 2H); 4.48 (s, 2H); 7.21 (m, 1H); 7.38 (s, 1H); 7.38 (m, 2H); 8.03 (s, 1H); 8.38 (s, 1H); 9.24 (s, 1H).
    • EXAMPLE 147 Preparation of Compound 324 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 3-methylaniline (28 mg 0.26 mmol) yielded compound 324 in Table 13 (57 mg, 53%).
  • MS ES+: 535 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.32 (m, 5H); 3.17 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 4.01 (s, 3H); 4.04 (d, 2H); 6.95 (d, 1H); 7.24 (t, 1H); 7.38 (s, 1H); 7.53 (m, 2H); 8.04 (s, 1H); 8.59 (s, 1H); 9.28 (s, 1H).
    • EXAMPLE 148 Preparation of Compound 325 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 2-(methylthio)aniline (36 mg, 0.26 mmol) yielded compound 325 in Table 13 (73 mg, 64%).
  • MS ES+: 567 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.31 (t, 2H); 2.44 (s, 3H); 3.16 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.68 (t, 2H); 4.01 (s, 3H); 4.03 (d, 2H); 4.32 (t, 2H); 7.22 (t, 1H); 7.37 (m, 4H); 8.06 (s, 1H); 8.52 (s, 1H); 9.27 (s, 1H).
    • EXAMPLE 149 Preparation of Compound 326 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 5-aminoindole (34 mg, 0.26 mmol) yielded compound 326 in Table 13 (16 mg, 15%).
  • MS ES+: 560 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.31 (t, 2H); 3.16 (t, 2H); 3:37 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 4.02 (s, 3H); 4.04 (d, 2H); 4.32 (t, 2H); 7.36 (m, 5H); 7.94 (s, 1H); 8.04 (s, 1H); 8.28 (s, 1H); 9.28 (s, 1H).
    • EXAMPLE 150 Preparation of Compound 327 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 3-aminobenzonitrile (31 mg, 0.26 mmol) yielded compound 327 in Table 13 (30 mg, 28%).
  • MS ES+: 546 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.31 (t, 2H); 3.17 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.67 (t, 2H); 4.02 (s, 3H); 4.04 (d, 2H); 4.33 (t, 2H); 7.40 (s, 1H); 7.60 (m, 2H); 7.97 (m, 1H); 8.08 (s, 1H); 8.21 (s, 1H); 8.61 (s, 1H); 9.30 (s, 1H).
    • EXAMPLE 151 Preparation of Compound 328 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 2,4-difluorobenzylamine (37 mg, 0.26 mmol) yielded compound 328 in Table 13 (27 mg, 24%).
  • MS ES+: 571 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.31 (t, 2H); 3.16 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.70 (t, 2H); 4.00 (s, 3H); 4.03 (d, 2H); 4.32 (t, 2H); 4.49 (s, 2H); 7.09 (m, 1H); 7.21 (m, 1H); 7.38 (s, 1H); 8.02 (s, 1H); 8.38 (s, 1H); 9.24 (s, 1H).
    • EXAMPLE 152 Preparation of Compound 329 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 3-(2-aminoethyl)pyridine (32 mg, 0.26 mmol) yielded compound 329 in Table 13 (33 mg, 30%).
  • MS ES+: 550 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.33 (t, 2H); 3.11 (t, 2H); 3.18 (t, 2H); 3.35 (t, 2H); 3.57 (d, 2H); 3.66 (t, 2H); 3.68 (t, 2H); 4.01 (s, 3H); 4.05 (d, 2H); 4.34 (t, 2H); 7.41 (s, 1H); 8.05 (s, 1H); 8.08 (dd, 2H); 8.28 (s, 1H); 8.59 (d, 1H); 8.87 (d, 1H); 8.95 (s, 1H); 9.25 (s, 1H).
    • EXAMPLE 153 Preparation of Compound 330 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with N-methylisobutylamine (23 mg, 0.26 mmol) yielded compound 330 in Table 13 (23 mg, 22%).
  • MS ES+: 515 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 0.88 (d, 6H); 2.02 (m, 1H); 2.31 (t, 2H); 3.16 (t, 2H); 3.27 (m, 5H); 3.36 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 4.00 (s, 3H); 4.03 (d, 2H); 4.32 (t, 2H); 7.37 (s, 1H); 8.03 (s, 1H); 8.18 (s, 1H); 9.23 (s, 1H).
    • EXAMPLE 154 Preparation of Compound 331 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 2-aminobenzylamine (32 mg, 0.26 mmol) yielded compound 331 in Table 13 (6 mg, 6%).
  • MS ES+: 550 (M+H)+
  • 1H NMR DMSO-d6, TFA): 2.31 (t, 2H); 3.16 (t, 2H); 3.37 (t, 2H); 3.56 (d, 2H); 3.70 (t, 2H); 4.00 (s, 3H); 4.03 (d, 2H); 4.32 (t, 2H); 4.47 (s, 2H); 7.41 (s, 1H; 7.46 (m, 4H); 8.06 (s, 1H); 8.42 (s, 1H); 9.24 (s, 1H).
    • EXAMPLE 155 Preparation of Compound 332 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 3-methylbutylamine (23 mg, 0.26 mmol) yielded compound 332 in Table 13 (48 mg, 47%).
  • MS ES+: 515 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 0.90 (d, 6H); 1.43 (q, 2H); 1.62 (m, 1H); 2.31 (t, 2H); 3.15 (t, 2H); 3.28 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H ); 3.68 (t, 2H); 3.99 (s, 3H); 4.02 (d, 2H ); 4.31 (t, 2H); 7.35 (s, 1H); 8.00 (s, 1H); 8.31 (s, 1H); 9.23 (s, 1H).
    • EXAMPLE 156 Preparation of Compound 333 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 1-aminomethyl-1-cyclohexanol (43 mg, 0.26 mmol) yielded compound 333 in Table 13 (7 mg, 6%).
  • MS ES+: 557 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 1.37 (m, 10H); 2.28 (t, 2H); 3.11 (t, 2H); 3.23 (s, 2H); 3.32 (t, 2H); 3.51 (d, 2H); 3.65 (t, 2H); 3.96 (s, 3H); 3.99 (d, 2H); 4.28 (t, 2H); 7.32 (s, 1H); 7.95 (s, 1H); 8.43 (s, 1H); 9.19 (s, 1H).
    • EXAMPLE 157 Preparation of Compound 334 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 2-aminomethylpyrazine (38 mg, 0.26 mmol) yielded compound 334 in Table 13 (25 mg, 24%).
  • MS ES+: 537 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.33 (t, 2H); 3.13 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 4.00 (s, 3H); 4.05 (d, 2H); 4.30 (t, 2H); 4.65 (s, 2H); 7.38 (s, 1H); 8.03 (s, 1H); 8.40 (s, 1H); 8.57 (d, 1H); 8.62 (d, 1H); 8.70 (s, 1H); 9.24 (s, 1H).
    • EXAMPLE 158 Preparation of Compound 335 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 3-methoxyaniline (32 mg, 0.26 mmol) yielded compound 335 in Table 13 (60 mg, 54%).
  • MS ES+: 551 (M+H)+
  • 1H NMR DMSO-d6, TFA): 2.31 (t, 2H); 3.17 (t, 2H); 3.37 (t, 2H); 3.58 (d, 2H); 3.70 (t, 2H); 3.79 (s, 3H); 4.03 (s, 3H); 4.06 (d, 2H); 4.34 (t, 2H); 6.73 (d, 1H); 7.29 (d, 1H); 7.32 (d, 1H); 7.41 (m, 2H); 8.07 (s, 1H); 8.62 (s, 1H); 9.30 (s, 1H).
    • EXAMPLE 159 Preparation of Compound 336 in Table 13
  • An analogous reaction to that described in general scheme 5, starting with 4-chlorobenzylamine (19 mg, 0.26 mmol) yielded compound 336 in Table 13 (31 mg, 54%).
  • MS ES+: 569, 571 (M+H)+
  • 1H NMR (DMSO-d6, TFA): 2.31 (t, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 4.00 (s, 3H); 4.03 (d, 2H); 4.32 (t, 1H); 4.48 (s, 2H); 7.42 (m, 5H); 8.02 (s, 1H); 8.37 (s, 1H); 9.24 (s, 1H).
    • EXAMPLE 160 Preparation of Compound 337 in Table 14
  • 4-((2-amino-1,3-thiazole-5-yl)acetic acid)-6-methoxy-7-(3-morpholinopropoxy)quinazoline (78 mg, 0.17 mmol) in DMF (1 ml), was reacted with aniline (19 mg, 0.2 mmol) in presence of 0-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (76 mg, 0.2 mmol) and DIEA (44 mg, 0.34 mmol) at 50° C. over night. The reaction mixture was cooled, treated with NaHCO3 (1 ml), concentrated. The yellow solid was recovered, dissolved in a mixture of CH2Cl2/MeOH (60/40) 20 ml. Alumina (3 g) was added to the mixture, the solvent was evaporated, and the solid was added on top of an alumina column which was eluted with CH2Cl2/MeOH (10/0 to 9/1) to give title compound (43 mg, 47%);
  • MS ES+: 535 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 3.16 (t, 2H); 3.37 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 3.99 (m, 5H); 4.04 (d, 2H); 4.30 (t, 2H); 7.08 (t, 1H); 7.32 (m, 3H); 7.62 (m, 3H); 7.91 (s, 1H); 9.09 (s, 1H).
  • 4-(ethyl(2-amino-1,3-thiazole-5-yl)acetate)-6-methoxy-7-(3-morpholinopropoxy)quinazoline.
  • Amidine J of scheme. 2 (4.5 g, 13 mmol) in acetic acid (45 ml) was reacted with ethyl (2-amino-1,3-thiazole-5-yl)acetate (2.54 g, 13.65 mmol) at reflux for 5.5 hour under argon. The mixture was concentrated, and the residue was purified over silicagel chromatography, eluant CH2Cl2/MeOH, 95/5 to 90/10 to give title compound (4.5 g, 63%).
  • 1HNMR (DMSOd6): 1.22 (t, 3H); 1.96 (t, 2H); 2.37 (m, 4H); 2.35 (t, 2H); 3.58 (m, 4H); 3.91 (s, 2H); 3.95 (s, 3H); 4.13 (q, 2H); 4.20 (t, 2H); 7.25 (s, 1H); 7.36 (s, 1H); 8.10 (s, 1H); 8.66 (s, 1H).
  • 4-((2-amino-1,3-thiazole-5-yl)acetic acid)-6-methoxy-7-(3-morpholinopropoxy)quinazoline.
  • 4-(ethyl(2-amino-1,3-thiazole-5-yl)acetate)-6-methoxy-7-(3-morpholinopropoxy)quinazoline (4.38 g, 8 mmol) in ethanol (44 ml) was treated with sodium hydroxyde (2N, 10 ml) at 50° C. for 4 hours. The mixture was cooled to room temperature and the pH adjusted to 3.5 with 2N HCl. The residue was dissolved in CH2Cl2/MeOH, 60/40, DIEA (3 g, 24 mmoles) was added, the mixture was stirred for 10 minutes, filtered, and the solution was concentrated to give an oily residue. This residue was dissolved in ethanol, and the solvent was partially evaporated. A cristalin solid was recovered, suspended in ethanol, washed with ether and dried under vacuum to give title compound (3.7 g, 100%).
  • 1HNMR (DMSOd6, TFA): 2.28 (t, 2H); 3.16 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.70 (t, 2H); 3.92 (s, 2H); 3.99 (s, 3H); 4.03 (d, 2H); 4.30 (t, 2H); 7.32 (s, 1H); 7.60 (s, 1H); 7.90 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 161 Preparation of Compound 338 in Table 14
  • An analogous reaction to that described in example 160 but starting with 3-chloro-4-fluoroaniline (30 mg, 0.2 mmol) yielded the title compound (24 mg, 24%).
  • MS ES+: 587 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 3.16 (t, 2H); 3.34 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 3.99 (m, 5H); 4.03 (d, 2H); 4.30 (t, 2H); 7.30 (s, 1H); 7.39 (t, 1H); 7.50 (m, 1H); 7.65 (s, 1H); 7.85 (s, 1H); 7.97 (d, 1H); 9.09 (s, 1H).
    • EXAMPLE 162 Preparation of Compound 339 in Table 14
  • An analogous reaction to that described in example 160 but starting with 4-chloroaniline (26 mg, 0.2 mmol) yielded title compound (73 mg, 76%).
  • MS ES+: 569 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (t, 2H); 3.16 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 3.89 (m, 5H); 4.04 (d, 2H); 4.30 (t, 2H); 7.30 (s, 1H); 7.39 (d, 2H); 7.64 (s, 1H); 7.65 (d, 2H); 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 163 Preparation of Compound 340 in Table 14
  • An analogous reaction to that described in example 160 but starting with 3,4-difluoroaniline (26 mg, 0.2 mmol) yielded title compound (75 mg, 77%).
  • MS ES+: 571 (M+H)+
  • 1HNMR (DMSOd6, TFA) 2.31 (t, 2H); 3.17 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.72 (t, 2H); 3.99 (m, 5H); 4.04 (d, 2H); 4.30 (t, 2H); 7.31 (s, 1H); 7.32 (m, 1H); 7.41 (q, 1H); 7.65 (s, 1H); 7.81 (m, 1H); 7.92 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 164 Preparation of Compound 341 in Table 14
  • An analogous reaction to that described in example 160 but starting with 3-methoxyaniline (25 mg, 0.2 mmol) yielded title compound (40 mg, 42%).
  • MS ES+: 565 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 3.16 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.70 (t, 2H); 3.74 (s, 3H); 3.97 (s, 2H); 3.99 (s, 3H); 4.04 (d, 2H); 4.31 (t, 2H); 6.68 (d, 1H); 7.15 (d, 1H); 7.23 (t, 1H); 7.29 (s, 1H); 7.33 (s, 1H); 7.64 (s, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 165 Preparation of Compound 342 in Table 14
  • An analogous reaction to that described in example 160 but starting with 2-chloroaniline (26 mg, 0.2 mmol) yielded title compound (15 mg, 16%).
  • MS ES+: 569 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.30 (t, 2H); 3.16 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 3.99 (s, 3H); 4.05 (m, 4H); 4.31 (t, 2H); 7.22 (t, 1H); 7.30 (s, 1H); 7.35 (t, 1H); 7.51 (d, 1H); 7.65 (s, 1H); 7.75 (d, 1H); 7.91 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 166 Preparation of Compound 343 in Table 14
  • An analogous reaction to that described in example 160 but starting with 4-methoxyaniline (26 mg, 0.21 mmol) yielded title compound (55 mg, 57%).
  • MS ES+: 565.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (t, 2H); 3.19 (t, 2H); 3.39 (t, 2H); 3.58 (d, 2H); 3.73 (t, 2H); 3.80 (s, 3H); 3.97 (s, 2H); 4.02 (s, 3H); 4.07 (d, 2H); 4.33 (t, 2H); 6.93 (d, 2H); 7.09 (s, 1H); 7.33 (s, 1H); 7.56 (d, 2H); 7.66 (s, 1H); 7.94 (s, 1H); 9.12 (s, 1H).
    • EXAMPLE 167 Preparation of Compound 344 in Table 14
  • An analogous reaction to that described in example 160 but starting with 4-methylaniline (23 mg, 0.21 mmol) yielded title compound (51 mg, 54%).
  • MS ES+: 549.7 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.29 (s, 3H); 2.31 (t, 2H); 3.19 (t, 2H); 3.38 (t, 2H); 3.58 (d, 2H); 3.72 (t, 2H); 3.99 (s, 2H); 4.02 (s, 3H); 4.04 (d, 2H); 4.33 (t, 2H); 7.16 (d, 2H); 7.33 (s, 1H); 7.54 (d, 2H); 7.67 (s, 1H); 7.94 (s, 1H); 9.12 (s, 1H).
    • EXAMPLE 168 Preparation of Compound 345 in Table 14
  • An analogous reaction to that described in example 160 but starting with 2-methylaniline (23 mg, 0.21 mmol) yielded title compound (42 mg, 45%).
  • MS ES+: 549.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.24 (s, 3H); 2.31 (t, 2H); 3.16 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 3.99 (s, 2H); 4.02 (s, 3H); 4.04 (d, 2H); 4.30 (t, 2H); 7.12 (t, 1H); 7.19 (t, 1H); 7.24 (d, 1H); 7.31 (s, 1H); 7.43 (t, 1H); 7.66 (s, 1H); 7.92 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 169 Preparation of Compound 346 in Table 14
  • An analogous reaction to that described in example 160 but starting with 2-aminopyridine (20 mg, 0.21 mmol) yielded title compound (12 mg, 13%).
  • MS ES+: 536.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 3.18 (t, 2H); 3.37 (t, 2H); 3.56 (d, 2H); 3.70 (t, 2H); 4.00 (m, 5H); 4.04 (d, 2H); 4.33 (t, 2H); 7.34 (s, 1H); 7.37 (t, 1H); 7.68 (s, 1H); 7.93 (d, 1H); 7.94 (s, 1H); 8.10 (t, 1H); 8.42 (d, 1H); 9.10 (s, 1H).
    • EXAMPLE 170 Preparation of Compound 347 in Table 14
  • An analogous reaction to that described in example 160 but starting with 2-aminobenzylalcohol (26 mg, 0.21 mmol) yielded title compound (24 mg, 24%).
  • MS ES+: 565.7 (M+H)+
  • 1HNMR (DMSOd6): 1.97 (t, 2H); 2.41 (m, 6H); 3.59 (m, 4H); 3.91 (s, 2H); 3.97 (s, 3H); 4.21 (t, 2H); 4.50 (d, 2H); 5.27 (t, 1H); 7.18 (t, 1H); 7.25 (d, 1H); 7.26 (s, 1H); 7.42 (m, 2H); 7.52 (d, 1H); 8.67 (s, 1H); 9.59 (s, 1H).
    • EXAMPLE 171 Preparation of Compound 348 in Table 14
  • An analogous reaction to that described in example 160 but starting with 2-amino-3-methyl-1-butanol (22 mg, 0.21 mmol) yielded title compound (25 mg, 27%).
  • MS ES+: 545.7 (M+H)+
  • 1HNMR (DMSOd6, TFA): 0.87 (d, 3H); 0.89 (d, 3H); 1.86 (m, 1H); 2.31 (t, 2H); 3.18 (t, 2H); 3.37 (t, 2H); 3.44 (2s, 2H); 3.57 (d, 2H); 3.63 (q, 1H); 3.70 (t, 2H); 3.80 (d, 2H); 4.01 (t, 3H); 4.07 (d, 2H); 4.31 (t, 2H); 7.32 (s, 1H); 7.58 (s, 1H); 7.92 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 172 Preparation of Compound 349 in Table 14
  • An analogous reaction to that described in example 160 but starting with 2-anilinoethanol (29 mg, 0.21 mmol) yielded title compound (11 mg, 11%).
  • MS ES+: 579.7 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 3.17 (t, 2H); 3.38 (t, 2H); 3.40 (m, 2H); 3.50 (t, 2H); 3.54 (d, 2H); 3.67 (m, 2H); 3.75 (t, 2H); 3.98 (s, 3H); 4.07 (d, 2H); 4.31 (t, 2H); 7.30 (s, 1H); 7.40 (s, 1H); 7.45 (m, 2H); 7.52 (m, 3H); 7.89 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 173 Preparation of Compound 350 in Table 14
  • An analogous reaction to that described in example 160 but starting with 3-chloro-4-methylamine (30 mg, 0.21 mmol) yielded title compound (3 mg, 3%).
  • MS ES+: 583.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (m, 5H); 3.20 (t, 2H); 3.40 (t, 2H); 3.60 (d, 2H); 3.72 (t, 2H); 4.01 (s, 2H); 4.02 (s, 3H); 4.07 (d, 2H); 4.33 (t, 2H); 7.32 (m, 2H); 7.42 (d, 1H); 7.68 (s, 1H); 7.87 (s, 1H); 7.95 (s, 1H); 9.13 (s, 1H).
    • EXAMPLE 174 Preparation of Compound 351 in Table 14
  • An analogous reaction to that described in example 160 but starting with 3-nitroaniline (29 mg, 0.21 mmol) yielded title compound (20 mg, 21%).
  • MS ES+: 580.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.33 (t, 2H); 3.20 (t, 2H); 3.39 (t, 2H); 3.60 (d, 2H); 3.73 (t, 2H); 4.02 (s, 3H); 4.06 (d, 2H); '; 4.09 (s, 2H); 4.34 (t, 2H); 7.34 (s, 1H); 7.67 (d, 1H); 7.70 (s, 1H); 7.95 (s, 1H); 7.98 (m, 2H); 8.74 (s, 1H); 9.15 (s, 1H).
    • EXAMPLE 175 Preparation of Compound 352 in Table 14
  • An analogous reaction to that described in example 160 but starting with aminoacetonitrile (19 mg, 0.21 mmol) yielded title compound (28 mg, 31%).
  • MS ES+: 498.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 3.18 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.70 (t, 2H); 3.84 (s, 2H); 3.99 (s, 3H); 4.04 (d, 2H); 4.21 (s, 2H); 4.31 (t, 2H); 7.31 (s, 1H); 7.60 (s, 1H); 9.10 (s, 1H).
    • EXAMPLE 176 Preparation of Compound 353 in Table 14
  • An analogous reaction to that described in example 160 but starting with 2-methyl-5-nitroaniline (32 mg, 0.21 mmol) yielded title compound (11 mg, 11%).
  • MS ES+: 594.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (t, 2H); 2.44 (s, 3H); 3.19 (t, 2H); 3.40 (t, 2H); 3.59 (d, 2H); 3.73 (t, 2H); 4.03 (s, 3H); 4.07 (d, 2H); 4.16 (s, 2H); 4.34 (t, 2H); 7.34 (s, 1H); 7.57 (d, 1H); 7.71 (s, 1H); 7.95 (s, 1H); 8.01 (d, 1H); 8.58 (s, 1H); 9.13 (s, 1H).
    • EXAMPLE 177 Preparation of Compound 354 in Table 14
  • An analogous reaction to that described in example 160 but starting with 2-amino-5-chloropyridine (27 mg, 0.21 mmol) yielded title compound (13 mg, 13%).
  • MS ES+: 570.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 3.17 (t, 2H); 3.37 (t, 2H); 3.57 (d, 2H); 3.70 (t, 2H); 3.99 (s, 3H); 4.04 (d, 2H); 4.07 (s, 2H); 4.31 (t, 2H); 7.02 (d, 1H); 7.36 (s, 1H); 7.64 (s, 1H); 7.92 (s, 1H); 7.98 (dd, 1H); 8.21 (d, 1H); 9.1 (s, 1H).
    • EXAMPLE 178 Preparation of Compound 355 in Table 14
  • An analogous reaction to that described in example 160 but starting with 4-trifluoromethylaniline (34 mg, 0.21 mmol) yielded title compound (26 mg, 25%);
  • MS ES+: 603.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.30 (t, 2H); 3.17 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.72 (t, 2H); 3.99 (s, 3H); 4.05 (m, 4H); 4.31 (t, 2H); 7.31 (s, 1H); 7.66 (s, 1H); 7.70 (d, 2H); 7.84 (d, 2H); 7.92 (s, 1H); 9.10 (s, 1H).
    • EXAMPLE 179 Preparation of Compound 356 in Table 14
  • An analogous reaction to that described in example 160 but starting with 3-chloroaniline (27 mg, 0.21 mmol) yielded title compound (47 mg, 48%).
  • MS ES+: 569.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.31 (t, 2H); 3.16 (t, 2H); 3.37 (t, 2H); 3.56 (d, 2 H); 3.69 (t, 2H); 3.99 (s, 3H); 4.00 (s, 2H); 4.04 (d, 2H); 4.31 (t, 2H); 7.14 (d, 1H); 7.30 (s, 1H); 7.37 (t, 1H); 7.47 (d, 1H); 7.65 (s, 1H); 7.87 (s, 1H); 7.92 (s, 1H); 9.10 (s, 1H).
    • EXAMPLE 180 Preparation of Compound 357 in Table 14
  • An analogous reaction to that described in example 160 but starting with 2-methoxyaniline (26 mg, 0.21 mmol) yielded title compound (44 mg, 46%).
  • MS ES+: 565.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.33 (t, 2H); 3.20 (t, 2H); 3.40 (t, 2H); 3.60 (d, 2H); 3.73 (t, 2H); 3.91 (s, 3H); 4.03 (s, 3H); 4.08 (d, 2H); 4.11 (s, 2H); 4.34 (t, 2H); 6.96 (t, 1H); 7.12 (m, 2H); 7.34 (s, 1H); 7.66 (s, 1H); 7.95 (s, 1H); 8.01 (d, 1H); 9.12 (s, 1H).
    • EXAMPLE 181 Preparation of Compound 358 in Table 14
  • An analogous reaction to that described in example 160 but starting with 2-fluoroaniline (23 mg, 0.21 mmol) yielded title compound (43 mg, 46%).
  • MS ES+: 553.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.31 (t, 2H); 3.18 (t, 2H); 3.37 (t, 2H); 3.57 (d, 2H); 3.70 (t, 2H); 4.00 (s, 3H); 4.05 (d, 2H); 4.08 (s, 2H); 4.31 (t, 2H); 7.19 (m, 2H); 7.28 (m, 1H); 7.31 (s, 1H); 7.64 (s, 1H); 7.93 (m, 2H); 9.06 (, 1H).
    • EXAMPLE 182 Preparation of Compound 359 in Table 14
  • An analogous reaction to that described in example 160 but starting with thiphene-2-methylamine (24 mg, 0.21 mmol) yielded title compound (50 mg, 53%).
  • MS ES+: 555.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.32 (t, 2H); 3.18 (t, 2H); 3.38 (t, 2H); 3.58 (d, 2H); 3.72 (t, 2H); 3.80 (s, 2H); 4.01 (s, 3H); 4.06 (d, 2H); 4.33,(t, 2H); 4.52 (s, 2H), 6.98 (dd, 1H); 7.02 (dd, 1H); 7.32 (s, 1H); 7.41 (dd, 1H); 7.60 (sq, 1H); 7.93 (s, 1H); 9.11 (s, 1H).
    • EXAMPLE 183 Preparation of Compound 360 in Table 14
  • An analogous reaction to that described in example 160 but starting with 2-amino-1-phenylethanol (29 mg, 0.21 mmol) yielded title compound (32 mg, 33%).
  • MS ES+: 579.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.31 (t, 2H); 3.18 (m, 3H); 3.36 (m, 3H); 3.56 (d, 2H); 3.69 (t, 2H); 3.74 (s, 2H); 3.99 (s, 3H); 4.05 (d, 2H); 4.30 (t, 2H); 4.66 (m, 1H); 7.3 (m, 6H); 7.53 (s, 1H); 7.90 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 184 Preparation of Compound 361 in Table 14
  • An analogous reaction to that described in example 160 but starting with 3-(1-hydroxyethyl)aniline (29 mg, 0.21 mmol) yielded title compound (50 mg, 50%).
  • MS ES+579.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 1.34 (d, 3H); 2.31 (t, 2H); 3.18 (t, 2H); 3.38 (t, 2H); 3.58 (d, 2H); 3.72 (t, 2H); 4.00 (s, 2H); 4.02 (s, 3H); 4.07 (d, 2H); 4.33 (t, 2H); 4.72 (q, 1H); 7.07 (d, 1H); 7.29 (t, 1H); 7.33 (s, 1H); 7.53 (d, 1H); 7.67 (s, 2H); 7.93 (s, 1H); 9.12 (s, 1H).
    • EXAMPLE 185 Preparation of Compound 362 in Table 14
  • An analogous reaction to that described in example 160 but starting with neopentylamine (18 mg, 0.21 mmol) yielded title compound (57 mg, 64%).
  • MS ES+: 529.7 (M+H)+
  • 1H NMR (DMSOd6, TPA): 0.89 (s, 9H); 2.33 (t, 2H); 2.97 (s, 2H); 3.19 (t, 2H); 3.39 (t, 2H); 3.59 (d, 2H); 3.80 (s, 2H); 4.02 (s, 3H); 4.07 (d, 2H); 4.32 (t, 2H); 7.33 (s, 1H); 7.60 (s, 1H); 7.93 (s, 1H); 9.11 (s, 1H).
    • EXAMPLE 186 Preparation of Compound 363 in Table 14
  • An analogous reaction to that described in example 160 but starting with 3-fluoro-4-methoxyaniline (30 mg, 0.21 mmol) yielded title compound (64 mg, 65%).
  • MS ES+: 583.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.31 (t, 2H); 3.17 (t, 2H); 3.37 (t, 2H); 3.57 (d, 2H); 3.70 (t, 2H); 3.82 (s, 3H); 3.96 (s, 2H); 4.00 (s, 3H); 4.04 (d, 2H); 4.31 (t, 2H); 7.15 (t, 1H); 7.30 (d, 1H); 7.31 (s, 1H); 7.61 (s, 1H); 7.64 (s, 1H); 7.91 (s, 1H); 9.10 (s, 1H).
    • EXAMPLE 187 Preparation of Compound 364 in Table 14
  • An analogous reaction to that described in example 160 but starting with 2-methyl-4-fluoroaniline (26 mg, 0.21 mmol) yielded title compound (60 mg, 62%).
  • MS ES+: 567.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.31 (t, 2H); 3.17 (t, 2H); 3.37 (t, 2H); 3.56 (d, 2H); 3.70 (t, 2H); 4.00 (s, 3H); 4.01 (s, 2H); 4.04 (d, 2H); 4.31 (t, 2H); 7.02 (t, 1H); 7.10 (d, 1H); 7.31 (s, 1H); 7.41,(q, 1H); 7.66 (s, 1H); 7.92 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 188 Preparation of Compound 365 in Table 14
  • An analogous reaction to that described in example 160 but starting with 2,5-difluoroaniline (27 mg, 0.21 mmol) yielded title compound (14 mg, 14%).
  • MS ES+: 571.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.31 (t, 2H); 3.19 (t, 2H); 3.39 (t, 2H); 3.58 (d, 2H); 3.72 (t, 2H); 4.01 (s, 3H); 4.06 (d, 2H); 4.12 (s, 2H); 4.33 (t, 2H); 7.00 (m, 1H); 7.33 (m, 2H); 7.65 (s, 1H); 7.95 (m, 2H); 9.11 (s, 1H).
    • EXAMPLE 189 Preparation of Compound 366 in Table 14
  • An analogous reaction to that described in example 160 but starting with 2-fluoro-4-chloroaniline (31 mg, 0.21 mmol) yielded title compound (12 mg, 12%).
  • MS ES+: 587.6 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.31 (t, 2H); 3.17 (t, 2H); 3.37 (t, 2H); 3.56 (d, 2H); 3.70 (t, 2H); 3.99 (s, 3H); 4.04 (m, 4H); 4.31 (t, 2H); 7.29 (d, 1H); 7.52 (dd, 1H); 7.64 (s, 1H); 7.97 (d, 1H); 9.09 (s, 1H).
    • EXAMPLE 190 Preparation of Compound 367 in Table 14
  • An analogous reaction to that described in example 160 but starting with 2-fluoro-4-methylaniline (26 mg, 0.21 mmol) yielded title compound (20 mg, 20%).
  • MS ES+: 567.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.31 (s, 3H); 2.32 (t, 2H); 3.20 (t, 2H); 3.39 (t, 2H); 3.59 (d, 2H); 3.73 (t, 2H); 4.03 (s, 3H); 4.07 (d, 2H); 4.09 (s, 2H); 4.34 (t, 2H); 7.02 (m, 1H); 7.18 (dd, 1H); 7.34 (s, 1H); 7.67 (s, 1H); 7.77 (d, 1H); 7.95 (s, 1H); 9.12 (s, 1H).
    • EXAMPLE 191 Preparation of Compound 368 in Table 14
  • An analogous reaction to that described in example 160 but starting with 3-methylaniline (23 mg, 0.21 mmol) yielded title compound (45 mg, 48%).
  • MS ES+: 549.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.31 (m, 5H); 3.19 (t, 2H); 3.39 (t, 2H); 3.58 (d, 2H); 3.72 (t, 2H); 4.00 (s, 2H); 4.02 (s, 3H); 4.07,(d, 2H); 4.33 (t, 2H); 6.93 (d, 1H); 7.24 (t, 1H); 7.33 (s, 1H); 7.43 (d, 1H); 7.51 (s, 1H); 7.67 (s, 1H); 7.94 (s, 1H); 9.12 (s, 1H).
    • EXAMPLE 192 Preparation of Compound 369 in Table 14
  • An analogous reaction to that described in example 160 but starting with 2-(methylthio)aniline (29 mg, 0.21 mmol) yielded title compound (13 mg, 13%).
  • MS ES+: 581.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.31 (t, 2H); 2.46 (s, 3H); 3.19 (t, 2H); 3.39 (t, 2H); 3.59 (d, 2H); 3.72 (t, 2H); 3.99 (s, 3H); 4.02 (s, 2H); 4.07 (d, 2H); 4.33 (t, 2H); 7.22 (t, 1H); 7.27 (t, 1H); 7.34 (s, 1H); 7.39 (d, 1H); 7.45 (d, 1H); 7.68 (s, 1H); 7.93 (s, 1H); 9.10 (s, 1H).
    • EXAMPLE 193 Preparation of Compound 370 in Table 14
  • An analogous reaction to that described in example 160 but starting with 5-aminoindole (28 mg, 0.21 mmol) yielded title compound (33 mg, 34%).
  • MS ES+: 574.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.31 (t, 2H); 3.18 (t, 2H); 3.36 (t, 2H); 3.57 (d, 2H); 3.70 (t, 2H); 3.97 (s, 2H); 4.00 (s, 3H); 4.03 (d, 2H); 4.31 (t, 2H); 7.32 (m, 6H); 7.65 (s, 1H); 7.91 (s, 1H); 9.10 (s, 1H).
    • EXAMPLE 194 Preparation of Compound 371 in Table 14
  • An analogous reaction to that described in example 160 but starting with 2,4-difluoroaniline (27 mg, 0.21 mmol) yielded title compound (28 mg, 29%).
  • MS ES+: 571.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.32 (t, 2H); 3.19 (t, 2H); 3.39 (t, 2H); 3.59 (d, 2H); 3.72 (t, 2H); 4.02 (s, 3H); 4.07 (d, 2H); 4.08 (s, 2H); 4.34 (t, 2H); 7.12 (t, 1H); 7.34 (s, 1H); 7.36 (m, 1H); 7.89 (m, 1H); 7.95 (s, 1H); 9.12 (s, 1H).
    • EXAMPLE 195 Preparation of Compound 372 in Table 14
  • An analogous reaction to that described in example 160 but starting with 2-fluoro-4-methylaniline (26 mg, 0.21 mmol) yielded title compound (35 mg, 37%).
  • MS ES+: 567.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.33 (s, 5H); 3.19 (t, 2H); 3.39 (t, 2H); 3.58 (d, 2H); 3.72 (t, 2H); 4.02 (s, 3H); 4.07 (s, 2H); 4.08 (d, 2H); 4.33 (t, 2H); 7.04 (d, 1H); 7.12 (d, 1H); 7.34 (s, 1H); 7.66 (s, 1H); 7.78 (t, 1H); 7.94 (s, 1H); 9.12 (s, 1H).
    • EXAMPLE 196 Preparation of Compound 373 in Table 14
  • An analogous reaction to that described in example 160 but starting with 3-cyanoaniline (25 mg, 0.21 mmol) yielded title compound (21 mg, 22%).
  • MS ES+: 560.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.31 (t, 2H); 3.19 (t, 2H); 3.39 (t, 2H); 3.58 (d, 2H); 3.72 (t, 2H); 4.02 (s, 3H); 4.06 (s, 2H); 4.07 (d, 2H); 4.33 (t, 2H); 7.34 (s, 1H); 7.6 (m, 2H); 7.69 (s, 1H); 7.85 (m, 1H); 7.95 (s, 1H); 8.18 (s, 1H); 9.13 (s, 1H).
    • EXAMPLE 197 Preparation of Compound 374 in Table 14
  • An analogous reaction to that described in example 160 but starting with 2-methyl-5-fluoroaniline (26 mg, 0.21 mmol) yielded title compound (15 mg, 16%).
  • MS ES+: 567.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.27 (s, 3H); 2.32 (t, 2H); 3:20 (t, 2H); 3.39 (t, 2H); 3.59 (d, 2H); 3.72 (t, 2H); 4.02 (s, 3H); 4.07 (d, 2H); 4.09 (s, 2H); 4.33 (t, 2H); 6.96 (t, 1H); 7.29 (t, 1H); 7.34 (s, 1H); 7.48 (d, 1H); 7.69 (s, 1H); 7.95 (s, 1H); 9.12 (s, 1H).
    • EXAMPLE 198 Preparation of Compound 375 in Table 14
  • An analogous reaction to that described in example 160 but starting with 2-methyl-5-chloroaniline (30 mg, 0.21 mmol) yielded title compound (20 mg, 21%).
  • MS ES+: 583.6 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.26 (s, 3H); 2.32 (t, 2H); 3.17 (t, 2H); 3.38 (t, 2H); 3.58 (d, 2H); 3.71 (t, 2H); 4.01 (s, 3H); 4.05 (d, 2H); 4.07 (s, 2H); 4.32 (t, 2H); 7.16 (dd, 1H); 7.27 (d, 1H); 7.31 (s, 1H); 7.65 (d, 1H); 7.65 (s, 1H); 7.93 (s, 1H); 9.10 (s, 1H).
    • EXAMPLE 199 Preparation of Compound 376 in Table 15
  • 4-((2-amino-1,3-thiazole-5-yl)acetic acid)-6-methoxy-7-((1-methyl-piperidine-4-yl)methoxy)quinazoline (89 mg, 0.2 mmol) in DMF (1.5 ml), was reacted with aniline (22 mg, 0.24 mmol) in presence of 0-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (99 mg, 0.26 mmol) and DIEA (50 mg, 0.4 mmol) at 60° C. over night. After cooling to room temperature the reaction mixture was diluted with dichloromethane, and purified by silicagel chromatography, eluting successively with CH2Cl2, CH2Cl2/MeOH 90/10, and CH2Cl2/MeOH sat. NH3 90/10 to give title compound (50 mg, 42%).
  • MS ES+: 519.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.58 (m, 2H); 2.02 (m, 2H); 2.13 (m, 1H); 2.80 (s, 3H); 3.03 (t, 2H); 3.52 (d, 2H); 3.98 (s, 2H); 3.98 (s, 3H); 4.10 (d, 2H); 7.06 (t, 1H); 7.29 (s, 1H); 7.33 (t, 2H); 7.60 (d, 2H); 7.61 (s, 1H); 7.90 (s, 1H); 9.08 (s, 1H).
  • The NMR spectrum of example 199 in presence of acid shows the existence of 2 forms in a ratio of approximately 9:1. Signals due to the minor form are seen at 1.95 (m) 3.23 (m) 3.32 (m) 4.28 (d) 9.38 (m).
  • 4-benzyloxy-3-methoxybenzonitrile.
  • 4-benzyloxy-3-methoxybenzaldehyde (4.84 g, 20 mmol) in acetic acid (25 ml) and sodium acetate (3.3 g, 40 mmol) was reacted with hydroxylamine hydrochloride (2.8 g, 40 mmol) at reflux for 6 hours. The mixture was cooled, diluted with water, extracted with methylene chloride, dried over MgSO4, concentrated to give title compound (4.8 g, 100%).
  • 1HNMR (DMSOd6): 3.83 (s, 3H); 5.20 (s, 2H); 7.21 (d, 1H); 7.40 (m, 7H).
  • 2-nitro-4-benzyloxy-5-methoxybenzonitrile
  • 4-benzyloxy-3-methoxybenzonitrile (4.78 g, 20 mmol) in acetic acid (10 ml) was slowly added to nitric acid (25 ml) at 20° C. to 30° C. The mixture was stirred at room temperature for 6 hours, basified (pH 10-11) with cooling (KOH 10N), extracted with methylene chloride, dried over MgSO4 evaporated. The solid was recristallysed in hot EtOAc, a yellow solid of title compound was obtained (3.62 g, 64%).
  • MS ES+: 285 (M+H)+
  • 1HNMR (DMSOd6): 3.97 (s, 3H); 5.33 (s, 2H); 7.40 (m, 5H); 7.71 (s, 1H); 8.01 (s, 1H).
  • 2-nitro-4-hydroxy-5-methoxybenzonitrile
  • 2-nitro-4-benzyloxy-5-methoxybenzonitrile (3 g, 10.6 mmol) was treated with trifluoroacetic acid (30 ml) at reflux for 0.5 hour. The solvent was evaporated, the residue triturated with ether to give a yellow solid of title compound (1.27 g, 62%).
  • 1HNMR (DMSOd6): 3.95 (s, 3H); 7.63 (s, 1H); 7.70 (s, 1H).
  • 2-nitro-4((1-tert-butyloxycarbonylpiperidin-4-yl)methoxy)-5-methoxybenzonitrile
  • 2-nitro-4-hydroxy-5-methoxybenzonitrile (388 mg, 2 mmol) in DMF (5 ml) and acetonitrile (5 ml) was reacted with 4-(4-tolylsulphonyloxymethyl)-1-tert-butyloxycarbonyl-piperidine (738 mg, 2 mmol) and K2CO3 (414 mg, 3 mmol) at 110° C. for 3.5 hours. The mixture was diluted with water, extracted with ethylacetate, washed HCl (2N), dried over MgSO4, evaporated to give title compound (630 mg, 80%).
  • 1HNMR (CDCl3): 1.31 (m, 2H); 1.47 (s, 9H); 1.85 (m, 2H); 2.07 (m, 1H); 2.77 (m, 2H); 3.96 (d, 2H); 3.99 (s, 3H); 4.19 (m, 2H); 7.19 (s, 1H); 7.75 (s, 1H).
  • 2-nitro-4-(1-piperidin-4-ylmethoxy)-5-methoxybenzonitrile.
  • 2-nitro-4-((1-tert-butyloxycarbonylpiperidin-4-yl)methoxy)-5-methoxybenzonitrile (1.17 g, 3 mmol) in CH2Cl2 (12 ml) was treated with TFA (2.4 ml) for 1 hour at room temperature. The solvent was evaporated, the residue was taken up in a mixture of CH2Cl2 and concentrated sodium bicarbonate, extracted with CH2Cl2. The organic phase was dried over MgSO4, concentrated to give title compound as a solid (770 mg, 88%).
  • 1HNMR (CDCl3): 1.33 (m, 2H); 1.86 (d, 2H); 2.03 (m, 1H); 2.71 (t, 2H); 3.15 (d, 2H); 3.96 (d, 2H); 3.99 (s, 3H); 7.18 (s, 1H); 7.76 (s, 1H).
  • 2-nitro-4-(1-methylpiperidin-4-ylmethoxy)-5-methoxybenzonitrile.
  • 2-nitro-4-(1-piperidin-4-ylmethoxy)-5-methoxybenzonitrile (771 mg, 2.65 mmol) in CH2Cl2 (8 ml) and MeOH (4 ml) was reacted for 0.5 hour with formaldehyde (13.3 M, 300 μl, 4 mmol), acetic acid (191 mg, 3.18 mmol) and NaBH(OAc)3 (674 mg, 3.18 mmol) slowly added over 15 minutes. The solution was evaporated, the oily residue was taken up in a mixture of Na2CO3 and ethylacetate, extracted with ethylacetate. The organic phase was dried over MgSO4, evaporated to give title compound as a yellow solid (698 mg, 86%).
  • 1HNMR (CDCl3): 4.7 (m, 2H); 1.88 (d, 2H); 1.90 (m, 1H); 2.0 (m, 2H); 2.3 (s, 3H); 2.91 (d, 2H); 2.95 (d, 2H); 2.99 (s, 3H); 7.18 (s, 1H); 7.76 (s, 1H).
  • 2-amino-4-(1-methylpiperidin-4-ylmethoxy)-5-methoxybenzonitrile
  • 2-nitro-4-(1-methylpiperidin-4-ylmethoxy)-5-methoxybenzonitrile (1.1 g, 3.6 mmol) in THF (20 ml) in presence of benzyltrimethylammonium chloride (334 mg, 1.8 mmol) was treated by a slow addition of Na2S2O4 (3.1 g, 18 mmol) in water (20 ml). After 0.5 h, HCl (6N, 20 ml) was added to the mixture, which was stirred at 60° C. for 5 h. The mixture was cooled to room temperature, extracted with ethylacetate. The aqueous phase was made basic with Na2CO3 (solid), and extracted with ethylacetate. The organic phase was dried over MgSO4, concentrated, to give a yellow solid (748 mg, 75%) of title compound.
  • 1HNMR (DMSOd6): 1.29 (m, 2H); 1.70 (m, 3H); 1.85 (t, 2H); 2.14 (s, 3H); 2.76 (d, 2H); 3.64 (s, 3H); 3.75 (d, 2H); 5.57 (s, 2H); 6.40 (s, 1H); 6.87 (s, 1H).
  • N′-(2-cyano-4-methoxy-5-(1-methylpiperidin-4-ylmethoxy)phenyl)-N,N-dimethylimidoformamide.
  • 2-amino-4-(1-methylpiperidin-4-ylmethoxy)-5-methoxy-benzonitrile (710 mg, 2.58 mmol) was reacted with DMF DMA (414 mg, 3.5 mmol) in toluene (15 ml) at reflux for 5 hours. The solution was concentrated, the oily residue triturated with ether to give a yellow solid of title compound (680 mg, 80%).
  • 1HNMR (DMSOd6): 1.28 (m, 2H); 1.72 (m, 3H); 1.85 (t, 2H); 2.14 (s, 3H); 2.76 (d, 2H); 2.95 (s, 3H); 3.05 (s, 3H); 3.72 (s, 3H); 3.86 (d, 2H); 6.71 (s, 1H); 7.07 (s, 1H); 7.89 (s, 1H).
  • 4-(methyl(2-amino-1,3-thiazole-5-yl)acetate)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline.
  • N′-(2-cyano-methoxy-5-(1-methylpiperidin-4-ylmethoxy)phenyl)-N,N-diemethylimidoformamide (627 mg, 1.9 mmol) was reacted with methyl-2-amino-1,3-thiazol-5-acetate (360 mg, 2.1 mmol) in acetic acid (6.3 ml) at reflux for 4.5 hour under nitrogen. The mixture was concentrated, and the oily residue purified by silicagel chromatography, Eluant: CH2Cl2/MeOH 90/10 and CH2Cl2/MeOH sat NH3 90/10 to give title compound (552 mg, 63%).
  • 1HNMR (DMSOd6): 1.35 (m, 2H); 1.76 (m, 3H); 1.87 (t, 2H); 2.16 (d, 2H); 2.78 (d, 2H); 3.67 (s, 3H); 3.93 (s, 2H); 3.96 (s, 3H); 4.01 (d, 2H); 7.24 (s, 1H); 7.36 (s, 1H); 8.10 (s, 1H); 8.66 (s, 1H).
  • 4-((2-amino-1,3-thiazole-5-yl)acetic acid)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline
  • 4-methyl(2-amino-1,3-thiazole-5-yl)acetate)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline (137 mg, 0.3 mmol) in ethanol (1.4 ml) was treated with NaOH (2N, 3.75 ml, 7.5 mmol) at room temperature for 0.5 hour. HCl (2N) was added to adjust the pH to 3. The solution was evaporated, the solid solubilized in CH2Cl2 (6 ml) MeOH (4 ml) DIEA (excess) was added. The insoluble was filtered, the filtrate was concentrated, ethanol was added, the solid filtered, washed with ether, to give title compound (102 mg, 77%).
  • MS ES+: 444.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.61 (m, 2H); 2.03 (d, 2H); 2.16 (m, 1H); 2.80 (s, 3H); 3.03 (t, 2H); 3.5 (d, 2H); 3.92 (s, 2H); 3.98 (s, 3H); 4.10 (d, 2H); 7.32 (s, 1H); 7.59 (s, 1H); 7.89 (s, 1H); 9.07 (s, 1H).
    • EXAMPLE 200 Preparation of Compound 377 in Table 15
  • An analogous reaction to that described in example 199 but starting with 3-chloro-4-fluoroaniline (44 mg, 0.3 mmol) yielded compound 377 in table 15 (63 mg, 60%)
  • MS ES+: 571 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.64 (m, 2H); 2.04 (m, 2H); 2.15 (m, 1H); 2.8 (s, 3H); 3.04 (t, 2H); 3.51 (d, 2H); 3.99 (s, 3H); 4.0 (s, 2H); 4.11 (d, 2H); 7.34 (s, 1H); 7.39 (t, 1H); 7.5 (m, 1H); 7.65 (s, 1H); 7.91 (dd, 1H); 9.09 (s, 1H).
    • EXAMPLE 201 Preparation of Compound 378 in Table 15
  • An analogous reaction to that described in example 199 but starting with 2-aminopyridine (40 mg, 0.42 mmol) yielded-compound 378 in table 15 (100 mg, 53%)
  • MS ES+: 520 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.65 (m, 2H); 2.02 (m, 2H); 2.15 (m, 1H); 2.78 (s, 3H); 3.02 (t, 2H); 3.48 (d, 2H); 3.99 (s, 3H); 4.1 (d, 2H); 4.14 (s, 2H); 7.32 (m, 1H); 7.39 (s, 1H); 7.66 (s, 1H); 7.91 (s, 1H); 7.97 (d, 1H); 8.16 (t, 1H); 8.4 (d, 1H); 9.079 (s, 1H).
    • EXAMPLE 202 Preparation of Compound 379 in Table 15
  • An analogous reaction to that described in example 199 but starting with 3,4-difluoroaniline (54 mg, 0.42 mmol) yielded compound 379 in table 15 (120 mg, 72%)
  • MS ES+: 555 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.63 (m, 2H); 2.02 (m, 2H); 2.15 (m, 1H); 2.79 (s, 3H); 3.03 (t, 2H); 3.49 (d, 2H); 3.99 (s, 3H); 4.0 (s, 2H); 4.10 (d, 2H); 7.35 (s, 1H); 7.39 (m, 2H); 7.64 (s, 1H); 7.82 (dd, 1H); 7.90 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 203 Preparation of Compound 380 in Table 15
  • An analogous reaction to that described in example 199 but starting with 2-chloroaniline (54 mg, 0.42 mmol) yielded compound 380 in table 15 (29 mg, 16%)
  • MS ES+: 553 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.62 (m, 2H); 2.03 (m, 2H); 2.15 (m, 1H); 2.81 (s, 3H); 3.04 (t, 2H); 3.51 (d, 2H); 4.0 (s, 3H); 4.08 (s, 2H); 4.11 (d, 2H); 7.24 (t, 1H); 7.31 (s, 1H); 7.34 (dd, 1H); 7.53 (d, 1H); 7.66 (s, 1H); 7.75 (d, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 204 Preparation of Compound 381 in Table 15
  • An analogous reaction to that described in example 199 but starting with 4-methylaniline (45 mg, 0.42 mmol) yielded compound 381 in table 15 (155 mg, 85%)
  • MS ES+: 533 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.65 (m, 2H); 2.02 (m, 2H); 2.16 (m, 1H); 2.27 (s, 3H); 2.8 (s, 3H); 3.05 (t, 2H); 3.50 (d, 2H); 3.97 (s, 2H); 3.99 (s, 3H); 4.11 (d, 2H); 7.14 (d, 2H); 7.34 (s, 1H); 7.52 (d, 2H); 7.63 (s, 1H); 7.91 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 205 Preparation of Compound 382 in Table 15
  • An analogous reaction to that described in example 199 but starting with 2-methylaniline (45 mg, 0.42 mmol) yielded compound 382 in table 15 (126 mg, 69%)
  • MS ES+: 533 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.62 (m, 2H); 2.02 (m, 2H); 2.15 (m, 1H); 2.24 (s, 3H); 2.8 (s, 3H); 3.04 (t, 2H); 3.51 (d, 2H); 3.99 (s, 3H); 4.02 (s, 2H); 4.10 (d, 2H); 7.11 (t, 1H); 7.19 (t, 1H); 7.24 (d, 1H); 7.33 (s, 1H); 7.43 (d, 1H); 7.65 (s, 1H); 7.91 (s, 1H); 9.07 (s, 1H).
    • EXAMPLE 206 Preparation of Compound 383 in Table 15
  • An analogous reaction to that described in example 199 but starting with 4-chloroaniline (54 mg, 0.42 mmol) yielded compound 383 in table 15 (128 mg, 68%)
  • MS ES+: 553 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.65 (m, 2H); 2.04 (m, 2H); 2.15 (m, 1H); 2.79 (s, 3H); 3.04 (t, 2H); 3.50 (d, 2H); 3.99 (s, 3H); 4.0 (s, 2H); 4.1 (d, 2H); 7.36 (s, 1H); 7.38 (d, 2H); 7.64 (s, 1H); 7.68 (d, 2H); 7.9 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 207 Preparation of Compound 384 in Table 15
  • An analogous reaction to that described in example 199 but starting with 4-fluoroaniline (47 mg, 0.42 mmol) yielded compound 384 in table 15 (136 mg, 84%)
  • MS ES+: 537 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.62 (m, 2H); 2.02 (m, 2H); 2.15 (m, 1H); 2.79 (s, 3H); 3.03 (t, 2H); 3.50 (d, 2H); 3.97 (s, 2H); 3.98 (s, 3H); 4.1 (d, 2H); 7.16 (t, 2H); 7.34 (s, 1H); 7.63 (s, 1H); 7.65 (m, 2H); 7.9 (s, 1H); 9.07 (s, 1H).
    • EXAMPLE 208 Preparation of Compound 385 in Table 15
  • An analogous reaction to that described in example 199 but starting with 2-amino-6-methylpyrimidine (45 mg, 0.42 mmol) yielded compound 385 in table 15 (91 mg, 57%)
  • MS ES+: 534 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.61 (m, 2H); 2.05 (m, 2H); 2.15 (m, 1H); 2.50 (s, 3H); 2.8 (s, 3H); 3.03 (t, 2H); 3.52 (d, 2H); 4.02 (s, 3H); 4.1 (s, 2H); 4.11 (d, 2H); 7.15 (m, 1H); 7.33 (s, 1H); 7.65 (s, 1H); 7.8 (m, 2H); 7.91 (s, 1H); 9.07 (s, 1H).
    • EXAMPLE 209 Preparation of Compound 386 in Table 15
  • An analogous reaction to that described in example 199 but starting with 3-methoxyaniline (52 mg, 0.42 mmol) yielded compound 386 in table 15 (125 mg, 67%)
  • MS ES+: 549 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.63 (m, 2H); 2.04 (m, 2H); 2.15 (m, 1H); 2.8 (s, 3H); 3.04 (t, 2H); 3.52 (d, 2H); 3.75 (s, 3H); 3.98 (s, 2H); 3.99 (s, 3H); 4.11 (d, 2H); 6.68 (m, 1H); 7.17 (d, 1H); 7.24 (t, 1H); 7.33 (s, 1H); 7.35 (d, 1H); 7.64 (s, 1H); 7.92 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 210 Preparation of Compound 387 in Table 15
  • An analogous reaction to that described in example 199 but starting with 2-amino-5-chloropyridine (54 mg, 0.42 mmol) yielded compound 387 in table 15 (22 mg, 11%)
  • MS ES+: 554(M+H)+
  • 1HNMR (DMSOd6, TFA): 1.61 (m, 2H); 2.03 (m, 2H); 2.15 (m, 1H); 2.8 (s, 3H); 3.03 (t, 2H); 3.5 (d, 2H); 3.98 (s, 3H); 4.07 (s, 2H); 4.11 (d, 2H); 7.30 (s, 1H); 7.63 (s, 1H); 7.9 (s, 1H); 7.93 (dd, 1H); 8.12 (d, 1H); 8.41 (d, 1H).
    • EXAMPLE 211 Preparation of Compound 388 in Table 15
  • An analogous reaction to that described in example 199 but starting with 3-chloroaniline (54 mg, 0.42 mmol) yielded compound 388 in Table 15 (130 mg, 69%).
  • MS ES+: 553 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.62 (m, 2H); 2.02 (m, 2H); 2.15 (m, 1H); 2.78 (s, 3H); 3.02 (t, 2H); 3.49 (d, 2H); 3.97 (s, 3H); 3.99 (s, 2H); 4.08 (d, 2H); 7.13 (d, 1H); 7.3 (s, 1H); 7.38 (t, 1H); 7.64 (s, 1H); 7.86 (s, 1H); 7.90 (s, 1H); 9.07 (s, 1H).
    • EXAMPLE 212 Preparation of Compound 389 in Table 15
  • An analogous reaction to that described in example 199 but starting with 2-fluoroaniline (47 mg, 0.42 mmol) yielded compound 389 in Table 15 (116 mg, 63%).
  • MS ES+: 537 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.64 (m, 2H); 2.04 (m, 2H); 2.15 (m, 1H); 2.79 (s, 3H); 3.03 (t, 2H); 3.50 (d, 2H); 3.99 (s, 3H); 4.07 (s, 2H); 4.10 (d, 2H); 7.19 (m, 2H); 7.25 (m, 1H); 7.35 (s, 1H); 7.63 (s, 1H); 7.90 (s, 1H); 7.91 (m, 1H); 9.07 (s, 1H).
    • EXAMPLE 213 Preparation of Compound 390 in Table 15
  • Analogous reaction to that described in example 199 but starting with 3-difluoro-4-methoxyaniline (59 mg, 0.42 mmol) yielded compound 390 in Table 15 (151 mg, 85%).
  • MS ES+: 567 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.62 (m, 2H); 2.01 (m, 2H); 2.15 (m, 1H); 2.79 (s, 3H); 3.03 (t, 2H); 3.51 (d, 2H); 3.81 (s, 3H); 3.96 (s, 2H); 3.98 (s, 3H); 4.10 (d, 2H); 7.14 (t, 1H); 7.28 (d, 1H); 7.34 (s, 1H); 7.59 (dd, 1H); 7.6 (s, 1H); 7.90 (s, 1H); 9.07 (s, 1H).
    • EXAMPLE 214 Preparation of Compound 391 in Table 15
  • An analogous reaction to that described in example 199 but starting with 2-methyl-4-fluoroaniline (53 mg, 0.42 mmol) yielded compound 391 in Table 15 (151 mg, 81%).
  • MS ES+: 551 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.62 (m, 2H); 2.02 (m, 2H); 2.15 (m, 1H); 2.33 (s, 3H); 2.79 (s, 3H); 2.93 (t, 2H); 3.48 (d, 2H); 3.97 (s, 3H); 3.99 (s, 2H), 4.09 (d, 2H); 7.01 (dt, 1H); 7.1 (dd, 1H); 7.37 (s, 1H); 7.39 (m, 1H); 7.64 (s, 1H); 7.89 (s, 1H); 9.05 (s, 1H).
    • EXAMPLE 215 Preparation of Compound 392 in Table 15
  • An analogous reaction to that described in example 199 but starting with 2-amino-4-methylpyridine (45 mg, 0.42 mmol) yielded compound 392 in Table 15 (119 mg, 66%).
  • MS ES+: 534 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.66 (m, 2H); 2.05 (m, 2H); 2.15 (m, 1H); 2.77 (s, 3H); 3.03 (t, 2H); 3.48 (d, 2H); 3.97 (s, 3H); 4.09 (d, 2H); 4.21 (s, 2H); 7.35 (m, 1H); 7.45 (s, 1H); 7.69 (s, 1H); 7.70 (s, 1H); 7.90 (s, 1H); 8.31 (d, 1H); 9.06 (s, 1H).
    • EXAMPLE 216 Preparation of Compound 393 in Table 15
  • An analogous reaction to that described in example 199 but starting with 2,5-difluoroaniline (54 mg, 0.42 mmol) yielded compound 393 in Table 15 (42 mg, 22%).
  • MS ES+: 555 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.60 (m, 2H); 2.02 (m, 2H); 2.15 (m, 1H); 2.81 (s, 3H); 3.04 (t, 2H); 3.52 (d, 2H); 3.99 (s, 3H); 4.10 (s, 2H); 4.11 (d, 2H); 7.02 (m, 2H); 7.32 (s, 1H); 7.34 (m, 1H); 7.64 (s, 1H); 7.91 (s, 1H); 7.92 (m, 1H); 9.08 (s, 1H).
    • EXAMPLE 217 Preparation of Compound 394 in Table 15
  • An analogous reaction to that described in example 199 but starting with 2-fluoro-4-chloroaniline (61 mg, 0.42 mmol) yielded compound 394 in Table 15 (97 mg, 50%).
  • MS ES+: 571 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.63 (m, 2H); 2.04 (m, 2H); 2.15 (m, 1H); 2.77 (s, 3H); 3.03 (t, 2H); 3.48 (d, 2H); 3.98 (s, 3H); 4.07 (s, 2H); 4.09 (d, 2H); 7.26 (d, 1H); 7.38 (s, 1H); 7.5 (dd, 1H); 7.62 (s, 1H); 7.89 (s, 1H); 7.96 (t, 1H); 9.06 (s, 1H).
    • EXAMPLE 218 Preparation of Compound 395 in Table 15
  • An analogous reaction to that described in example 199 but starting with 2-fluoro-5-methylaniline (53 mg, 0.42 mmol) yielded compound 395 in Table 15 (119 mg, 63%).
  • MS ES+: 551 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.63 (m, 2H); 2.03 (m, 2H); 2.15 (m, 1H); 2.28 (s, 3H); 2.77 (s, 3H); 3.03 (t, 2H); 3.49 (d, 2H); 3.98 (s, 3H); 4.05 (s, 2H); 4.09 (d, 2H); 6.98 (m, 1H); 7.15 (dd, 1H); 7.38 (s, 1H); 7.62 (s, 1H); 7.72 (m, 1H); 7.89 (s, 1H); 9.06 (s, 1H).
    • EXAMPLE 219 Preparation of Compound 396 in Table 15
  • An analogous reaction to that described in example 199 but starting with 3-methylaniline (45 mg, 0.42 mmol) yielded compound 396 in Table 15 (144g, 79%).
  • MS ES+: 533 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.64 (m, 2H); 2.04 (m, 2H); 2.15 (m, 1H); 2.3 (s, 3H); 2.79 (s, 3H); 3.04 (t, 2H); 3.51 (d, 2H); 3.98 (s, 2H); 3.99 (3H); 4.10 (d, 2H); 6.90 (d, 1H); 7.21 (t, 1H); 7.36 (s, 1H); 7.42 (d, 1H); 7.49 (s, 1H); 7.63 (s, 1H); 7.9 (s, 1H); 9.07 (s, 1H).
    • EXAMPLE 220 Preparation of Compound 397 in Table 15
  • An analogous reaction to that described in example 199 but starting with 2,4-difluoroaniline (54 mg, 0.42 mmol) yielded compound 397 in Table 15 (121 mg, 74%).
  • MS ES+: 555 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.63 (m, 2H); 2.03 (m, 2H); 2.15 (m, 1H); 2.78 (s, 3H); 3.03 (t, 2H); 3.5 (d, 2H); 3.98 (s, 3H); 4.04 (s, 2H); 4.1 (d, 2H); 7.08 (m, 1H); 7.33 (m, 1H); 7.36 (s, 1H); 7.63 (s, 1H); 7.86 (m, 1H); 7.90 (s, 1H); 9.07 (s, 1H).
    • EXAMPLE 221 Preparation of Compound 398 in Table 15
  • An analogous reaction to that described in example 199 but starting with 2-fluoro-4-methylaniline (53 mg, 0.42 mmol) yielded compound 398 in Table 15 (147 mg, 79%).
  • MS ES+: 551 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.63 (m, 2H); 2.04 (m, 2H); 2.15 (m, 1H); 2.3 (s, 3H); 2.79 (s, 3H); 3.04 (t, 2H); 3.51 (d, 2H); 3.99 (s, 3H); 4.04 (s, 2H); 4.1 (d, 2H); 6.99 (d, 1H); 7.10 (d, 1H); 7.35 (s, 1H); 7.62 (s, 1H); 7.75 (t, 1H); 7.90 (s, 1H); 9.07 (s, 1H).
    • EXAMPLE 222 Preparation of Compound 399 in Table 15
  • An analogous reaction to that described in example 199 but starting with 3-cyanoaniline (50 mg, 0.42 mmol) yielded compound 399 in Table 15 (118 mg, 71%).
  • MS ES+: 544 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.66 (m, 2H); 2.07 (m, 2H); 2.17 (m, 1H); 2.81 (s, 3H); 3.06 (t, 2H); 3.53 (d, 2H); 4.0 (s, 3H); 4.05 (s, 2H); 4.11 (d, 2H); 7.36 (s, 1H); 7.54 (m, 2H); 7.65 (s, 1H); 7.86 (dd, 1H); 7.92 (s, 1H); 8.18 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 223 Preparation of Compound 400 in Table 15
  • An analogous reaction to that described in example 199 but starting with 2-methyl-5-fluoroaniline (53 mg, 0.42 mmol) yielded compound 400 in Table 15 (107 mg, 57%).
  • MS ES+: 551 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.65 (m, 2H); 2.04 (m, 2H); 2.15 (m, 1H); 2.24 (s, 3H); 2.76 (s, 3H); 3.02 (t, 2H); 3.47 (d, 2H); 3.98 (s, 3H); 4.07 (s, 2H); 4.08 (d, 2H); 6.92 (m, 1H); 7.25 (t, 1H); 7.4 (s, 1H); 7.43 (m, 1H); 7.64 (s, 1H); 7.88 (s, 1H); 9.04 (s, 1H).
    • EXAMPLE 224 Preparation of Compound 401 in Table 15
  • An analogous reaction to that described in example 199 but starting with 3,5-difluoroaniline (54 mg, 0.42 mmol) yielded compound 401 in Table 15 (83 mg, 44%).
  • MS ES+: 555 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.66 (m, 2H); 2.02 (m, 2H); 2.16 (m, 1H); 2.76 (s, 3H); 3.03 (t, 2H); 3.45 (d, 2H); 3.97 (s, 3H); 4.03 (s, 2H); 4.08 (d, 2H); 6.90 (dd, 1H); 7.38 (m, 2H); 7.39 (s, 1H); 7.87 (s, 1H); 9.05 (s, 1H).
    • EXAMPLE 225 Preparation of Compound 402 in Table 15
  • An analogous reaction to that described in example 199 but starting with 3-fluoroaniline (47 mg, 0.42 mmol) yielded compound 402 in Table 15 (142 mg, 77%).
  • MS ES+: 537 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.62 (m, 2H); 2.03 (m, 2H); 2.15 (m, 1H); 2.78 (s, 3H); 3.02 (t, 2H); 3.49 (d, 2H); 3.98 (s, 3H); 4.0 (s, 2H); 4.1 (d, 2H); 6.9 (s, 1H); 7.35 (s, 1H); 7.36 (m, 2H); 7.62 (m, 1H); 7.64 (s, 1H); 7.9 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 226 Preparation of Compound 403 in Table 16
  • 4-((2-amino-1,3-thiazol-5-yl)acetic acid)-6-methoxy-7-(3-N-methylpiperazinylpropoxy)quinazoline (142 mg, 0.3 mmol) in NMP (1.5 ml) was reacted with aniline (42 μl, 0.45 mmol) in presence of 0-(7-azabenzotriazol-1-yl)-N,N,N′,N′,tetramethyluronium hexafluorophosphate (173 mg, 0.45 mmol) and diisopropylethylamine (105 μl, 0.6 mmol) at 65° C. under nitrogen over night. After cooling to room temperature, the reaction mixture was diluted with dichloromethane and purified by silicagel chromatography, eluant CH2Cl2, CH2Cl2/MeOH, 9/1, CH2Cl2/MeOH sat. NH3, 9/1 to give title compound (24 mg, 15%).
  • MS ES+: 548.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 2.94 (s, 3H); 3.2-4.2 (m, 8H); 3.45 (t, 2H); 3.99 (s, 5H); 4.30 (t, 2H); 7.08 (t, 1H); 7.31 (s, 1H); 7.33 (, 2H); 7.62 (d, 2H); 7.64 (s, 1H); 7.90 (s, 1H); 9.09 (s, 1H).
  • 2-nitro-4-(3-N-methylpiperazinylpropoxy)-5-methoxybenzonitrile
  • 2-nitro-4-hydroxy-5-methoxybenzonitrile (45 g, 25 mmol) in CH2Cl2 (125 ml) was reacted with ditertiobutylazodicarboxylate (6.9 g, 30 mmol) triphenylphosphine (7.86 g, 30 mmol) at room temperature for 2 hours. A solution of ether (2.3N HCl, 55 ml) was added. The solid was recovered, washed with CH2Cl2, ether. The solid was dissolved in MeOH, treated with MeOH/NH3, the solvent were evaporated, and the residue purified by silicagel chromatography eluant: CH2Cl2/AcOEt 50/50, CH2Cl2/MeOH 90/10, to give title compound (8.2 g, 98%).
  • MS ES+: 335.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.29 (t, 2H); 3.95 (s, 3H); 3.24 (m, 8H); 3.38 (t, 2H); 3.98 (s, 3H); 4.32 (t, 2H); 7.70 (s, 1H); 7.89 (s, 1H).
  • 2-amino-4-(3-N-methylpiperazinylpropoxy)-5-methoxy-benzonitrile.
  • 2-nitro-4-(3-N-methylpiperazinylpropoxy)-5-methoxybenzonitrile (1.67 g, 5 mmol), benzyltrimethylammonium chloride (0.46 g, 2.5 mmol) in methyl chloride (40 ml) was treated with sodium hydrosulfite (4.35 g, 5 mmol) in water (40 ml) at room temperature for 1 hour. HCl (6N, 28 ml) was added to the mixture which was heated at 60° C. for 2.5 hours. The mixture was cooled, extracted with ethylacetate. The aqueous phase was treated with Na2CO3 (solid), extracted with ethylacetate. The organic phase was dried over MgSO4, concentrated to give title compound (0.93 g, 61%).
  • MS ES+: 305.7 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.18 (t, 2H); 2.93 (s, 3H); 3.1-4.1 (m, 8H); 3.39 (t, 2H); 3.66 (s, 3H); 4.05 (t, 2H); 6.54 (s, 1H); 7.00 (s, 1H).
  • N′-(2-cyano-4-methoxy-5-(3-N-methylpiperazinylpropoxy)phenyl)-N,N-dimethylimidoformamide.
  • 2-amino-4-(3-N-methylpiperazinylpropoxy)-5-methoxybenzonitrile (16.4 g, 54 mmol) was reacted with dimethylformamide dimethyl acetal (12 ml, 90 mmol) in toluene (400 ml) at reflux for 4 hours. The solvent was evaporated to give title compound (19.4 g, 100%).
  • MS ES+: 360.7 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.28 (t, 2H); 2.96 (s, 3H); 3.26 (s, 3H); 3.35 (s, 3H); 3.40 (t, 2H); 3.1-4 (m, 8H); 3.88 (s, 3H); 4.21 (t, 2H); 7.32 (s, 1H); 7.53 (s, 1H); 8.56 (s, 1H).
  • 4-(methyl(2-amino-1,3-thiazole-5-yl)acetate)-6-methoxy-4-((3-N-methylpiperazinylpropoxy)quinazoline
  • N′-(2-cyano-4-methoxy-5-(3-N-piperazinylpropoxy)phenyl)-N,N-dimethylimidoformamide (9.7 g, 27 mmol) in acetic acid (100 ml) was reacted with methyl (2-amino-1,3-thiazole-5-yl)acetate (5.2 g, 30 mmol) at reflux for 4 hours. The solvent was evaporated and the residue purified by silicagel chromatography, Eluant: CH2Cl2/MeOH 99/1 to 97/3 to give title compound (9.15 g, 70%).
  • MS ES+: 487.6(M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (t, 2H); 2.97 (s, 3H); 3.2-4.2 (m, 8H); 3.48 (t, 2H); 3.97 (s, 2H); 4.00 (s, 3H); 4.33 (t, 2H); 7.36 (s, 1H); 7.61 (s, 1H); 7.93 (s, 1H); 9.10 (s, 1H).
  • 4-((2-amino-1,3-thiazole-5-yl)acetic acid)-6-methoxy-7-(3-(N-methylpiperazinylpropoxy)quinazoline
  • 4-(methyl(2-amino-1,3-thiazole-5-yl)acetate)-6-methoxy-7-(3-(N-methylpiperazinylpropoxy)quinazoline (8.25 g, 17 mmol) in ethanol (80 ml) was treated with sodium hydroxyde (2N, 42.5 ml, 85 mmol) at room temperature for 1 hour. Hydrochloride acid (2N) was added to the solution (pH 3). The solution was evaporated, the residue dissolved in ethanol and N-ethyl diisopropyl amine (8.9 ml, 51 mmol). Ether was added to the solution, the solid was recovered, dried to give title compound (7.44 g, 93%).
  • MS ES+: 473.5 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.30 (t, 2H); 2.94 (s, 3H); 3.2-4.1 (m, 8H); 3.45 (t, 2H); 3.89 (s, 2H); 3.97 (s, 3H); 4.29 (t, 2H); 7.30 (s, 1H); 7.56 (s, 1H); 7.90 (s, 1H); 9.06 (s, 1H).
    • EXAMPLE 227 Preparation of Compound 404 in Table 16
  • An analogous reaction to that described in example 226 but starting with 3,4-difluoroaniline (77 mg, 0.6 mmol) yielded title compound (105 mg, 60%).
  • MS ES+: 584.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (t, 2H); 2.94 (s, 3H); 3.2-4.1 (m, 8H); 3.44 (t, 2H); 3.99 (s, 5H); 4.30 (t, 2H); 7.32 (s, 1H); 7.32 (m, 1H); 7.40 (q, 1H); 7.65 (s, 1H); 7.81 (m, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 228 Preparation of Compound 405 in Table 16
  • An analogous reaction to that described in example 226 but starting with 2-aminopyridine (56 mg, 0.6 mmol) yielded title compound (53 mg, 36%).
  • MS ES+: 549.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.30 (t, 2H); 2.94 (s, 3H); 3.1-4.1 (m, 8H); 3.41 ('t, 2H); 3.99 (s, 3H); 4.02 (s, 2H); 4.32 (t, 2H); 7.21 (m, 1H); 7.34 (s, 1H); 7.64 (s, 1H); 7.91 (m, 2H); 8.03 (d, 1H); 8.37 (m, 1H); 9.98 (s, 1H).
    • EXAMPLE 229 Preparation of Compound 406 in Table 16
  • An analogous reaction to that described in example 226 but starting with 3-chloro-4-fluoroaniline (87 mg, 0.6 mmol) yielded title compound (134 mg, 74%).
  • MS ES+: 600.5 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 2.94 (s, 3H); 3.43 (t, 2H); 3.1-4.1 (m, 8H); 3.99 (s, 5H); 4.32 (t, 2H); 7.33 (s, 1H); 7.38 (t, 1H); 7.50 (m, 1H); 7.64 (s, 1H); 7.90 (s, 1H); 7.96 (m, 1H); 9.09 (s, 1H).
    • EXAMPLE 230 Preparation of Compound 407 in Table 16
  • An analogous reaction to that described in example 226 but starting with 3-chloroaniline (77 mg, 0.6 mmol) yielded title compound (46 mg, 26%).
  • MS ES+: 582.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 2.95 (s, 3H); 3.2-4.1 (m, 8H); 3.45 (t, 2H); 3.99 (s, 3H); 4.07 (s, 2H); 4.30 (t, 2H); 7.22 (t, 1H); 7.31 (s, 1H); 7.35 (t, 1H); 7.53 (d, 1H); 7.65 (s, 1H); 7.74 (d, 1H); 7.92 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 231 Preparation of Compound 408 in Table 16
  • An analogous reaction to that described in example 226 but starting with 4-methylaniline (64 mg, 0.6 mmol) yielded title compound (105 mg, 62%).
  • MS ES+: 562.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.26 (s, 3H); 2.31 (t, 2H); 2.95 (s, 3H); 3.1-4.1 (m, 8H); 3.43 (t, 2H); 3.95 (s, 2H); 3.98 (s, 3H); 4.30 (t, 2H); 7.12 (d, 2H); 7.31 (s, 1H); 7.50 (d, 2H); 7.63 (s, 1H); 7.90 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 232 Preparation of Compound 409 in Table 16
  • An analogous reaction to that described in example 226 but starting with 2-methylaniline (64 mg, 0.6 mmol) yielded title compound (127 mg, 75%).
  • MS ES+: 562.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.24 (s, 3H); 2.31 (t, 2H); 2.95 (s, 3H); 3.2-4.1 (m, 8H); 3.44 (t, 2H); 3.99 (s, 3H); 4.02 (s, 2H); 4.31 (t, 2H); 7.12 (t, 1H); 7.19 (t, 1H); 7.24 (d, 1H); 7.33 (s, 1H); 7.44 (d, 1H); 7.66 (s, 1H); 7.91 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 233 Preparation of Compound 410 in Table 16
  • An analogous reaction to that described in example 226 but starting with 4-chloroaniline (77 mg, 0.6 mmol) yielded title compound (101 mg, 58%).
  • MS ES+: 582.5 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (t, 2H); 2.95 (s, 3H); 3.1-4.1 (m, 8H); 3.44 (t, 2H); 4.00 (s, 5H); 4.31 (t, 2H); 7.33 (s, 1H); 7.40 (d, 2H); 7.65 (s, 1H); 7.66 (d, 2H); 7.92 (s, 1H); 9.10 (s, 1H).
    • EXAMPLE 234 Preparation of Compound 411 in Table 16
  • An analogous reaction to that described in example 226 but starting with 4-fluoroaniline (67 mg, 0.6 mmol) yielded title compound (97 mg, 57%).
  • MS ES+: 566.5 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 2.94 (s, 3H); 3.1-4.1 (m, 8H); 3.44 (t, 2H); 3.97 (s, 2H); 3.99 (s, 3H); 4.30 (t, 2H); 7.17 (t, 2H); 7.34 (s 1H); 7.64 (m, 3H); 7.90 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 235 Preparation of Compound 412 in Table 16
  • An analogous reaction to that described in example 226 but starting with 2-amino-6-methylpyridine (65 mg, 0.6 mmol) yielded title compound (70 mg, 42%).
  • MS ES+: 563.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.30 (t, 2H); 2.46 (s, 3H); 2.94 (s, 3H); 3.10-4.10 (m, 8H); 3.43 (t, 2H); 3.98 (s, 3H); 4.06 (s, 2H); 4.30 (t, 2H); 7.08 (d, 1H); 7.32 (s, 1H); 7.63 (s, 1H); 7.79 (t, 1H); 7.88 (d, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 236 Preparation of Compound 413 in Table 16
  • An analogous reaction to that described in example 226 but starting with 2-methoxyaniline (74 mg, 0.6 mmol) yielded title compound (99 mg, 57%).
  • MS ES+: 578.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.30 (t, 2H); 2.94 (s, 3H); 3.1-4.1 (m, 8H); 3.43 (t, 2H); 3.74 (s, 3H); 3.97 (s, 2H); 3.99 (s, 3H); 4.30 (t, 2H); 6.67 (d, 1H); 7.15 (d, 1H); 7.24 (t, 1H); 7.33 (s, 2H); 7.64 (s, 1H); 7.90 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 237 Preparation of Compound 414 in Table 16
  • An analogous reaction to that described in example 226 but starting with 2-amino-5-chloropyridine (77 mg, 0.6 mmol) yielded title compound (23 mg, 13%).
  • MS ES+: 583.5 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.30 (t, 2H); 2.94 (s, 3H); 3.10-4.10 (m, 8H); 3.45 (t, 2H); 3.98 (s, 3H); 4.06 (s, 2H); 4.30 (t, 2H); 7.31 (s, 1H); 7.63 (s, 1H); 7.90 (s, 1H); 7.91 (dd, 1H); 8.11 (d, 1H); 8.40 (d, 1H); 9.09 (s, 1H).
    • EXAMPLE 238 Preparation of Compound 415 in Table 16
  • An analogous reaction to that described in example 226 but starting with 3-chloroaniline (77 mg, 0.6 mmol) yielded title compound (96 mg, 55%).
  • MS ES+: 582.5 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 2.94 (s, 3H); 3.2-4.2 (m, 8H); 3.45 (t, 2H); 3.98 (s, 5H); 4.28 (t, 2H); 7.12 (d, 1H); 7.31 (s, 1H); 7.34 (t, 1H); 7.46 (d, 1H); 7.62 (s, 1H); 7.85 (s, 1H); 7.91 (s, 1H); 9.07 (s, 1H).
    • EXAMPLE 239 Preparation of Compound 416 in Table 16
  • An analogous reaction to that described in example 226 but starting with 2-fluoroaniline (67 mg, 0.6 mmol) yielded title compound (68 mg, 40%).
  • MS ES+: 596.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.28 (t, 2H); 2.91 (s, 3H); 3.1-4.1 (m, 8H); 3.40 (t, 2H); 3.95 (s, 3H); 4.03 (s, 2H); 4.26 (t, 2H); 7.13 (m, 2H); 7.25 (m, 2H); 7.28 (s, 1H); 7.60 (s, 1H); 7.87 (s, 1H); 9.05 (s, 1H).
    • EXAMPLE 240 Preparation of Compound 417 in Table 16
  • An analogous reaction to that described in example 226 but starting with 3-cyanoaniline (71 mg, 0.6 mmol) yielded title compound (101 mg, 63%).
  • MS ES+: 573.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 2.95 (s, 3H); 3.1-4.1 (m, 8H); 3.45 (t, 2H); 4.00 (s, 3H); 4.04 (s, 2H); 4.31 (t, 2H); 7.33 (s, 1H); 7.56 (s, 1H); 7.57 (m, 1H); 7.66 (s, 1H); 7.82 (m, 1H); 7.92 (s, 1H); 8.15 (s, 1H); 9.10 (s, 1H).
    • EXAMPLE 241 Preparation of Compound 418 in Table 16
  • An analogous reaction to that described in example 226 but starting with 2-fluoro-4-methylaniline (75 mg, 0.6 mmol) yielded title compound (109 mg, 63%).
  • MS ES+: 580.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.29 (m, 5H); 2.94 (s, 3H); 3.1-4.1 (m, 8H); 3.44 (t, 2H); 3.98 (s, 3H); 4.03 (s, 2H); 4.30 (t, 2H); 6.98 (d, 1H); 7.09 (d, 1H); 7.32 (s, 1H); 7.63 (s, 1H); 7.74 (t, 1H); 7.90 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 242 Preparation of Compound 419 in Table 16
  • An analogous reaction to that described in example 226 but starting with 3-fluoro-4-methoxyaniline (85 mg, 0.6 mmol) yielded title compound (121 mg, 68%).
  • MS ES+: 596.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 2.95 (s, 3H); 3.1-4.1 (m, 8H); 3.44 (t, 2H); 3.81 (s, 3H); 3.95 (s, 2H); 3.99 (s, 3H); 4.30 (t, 2H); 7.13 (t, 1H); 7.27 (m, 1H); 7.31 (s, 1H); 7.60 (m, 1H); 7.64 (s, 1H); 7.90 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 243 Preparation of Compound 420 in Table 16
  • An analogous reaction to that described in example 226 but starting with 2-methyl-4-fluoroaniline (75 mg, 0.6 mmol) yielded title compound (130 mg, 75%).
  • MS ES+: 580.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.23 (s, 3H); 2.29 (t, 2H); 2.95 (s, 3H); 3.1-4.1 (m, 8H); 3.44 (t, 2H); 3.99 (s, 3H); 4.00 (s, 2H); 4.30 (t, 2H); 7.01 (m, 1H); 7.09(dd, 1H); 7.32 (s, 1H); 7.40 (m, 1H); 7.65 (s, 1H); 7.91 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 244 Preparation of Compound 421 in Table 16
  • An analogous reaction to that described in example 226 but starting with 2-amino-4-methylpyridine (65 mg, 0.6 mmol) yielded title compound (87 mg, 52%).
  • MS ES+: 563.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.29 (t, 2H); 2.45 (s, 3H); 2.94 (s, 3H); 3.1-4.1 (m, 8H); 3.44 (t, 2H); 3.99 (s, 3H); 4.15 (s, 2H); 4.30 (t, 2H); 7.24 (d, 1H); 7.37 (s, 1H); 7.67 (s, 1H); 7.72 (s, 1H); 7.92 (s, 1H); 8.29 (d, 1H); 9.08 (s, 1H);
    • EXAMPLE 245 Preparation of Compound 422 in Table 16
  • An analogous reaction to that described in example 226 but starting with 2,5-difluoroaniline (77 mg, 0.6 mmol) yielded title compound (56 mg, 32%).
  • MS ES+: 584.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.30 (t, 2H); 2.94 (s, 3H); 3.1-4.1 (m, 8H); 3.43 (t, 2H); 3.98 (s, 3H); 4.10 (s, 2H); 4.30 (t, 2H); 7.0 (m, 1H); 7.32 (s, 1H); 7.33 (m, 1H); 7.64 (s, 1H); 7.91 (m, 2H); 9.09 (s, 1H).
    • EXAMPLE 246 Preparation of Compound 423 in Table 16
  • An analogous reaction to that described in example 226 but starting with 2-fluoro-4-chloroaniline (87 mg, 0.6 mmol) yielded title compound (69 mg, 38%).
  • MS ES+: 600.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (t, 2H); 2.94 (s, 3H); 3.2-4.2 (m, 8H); 3.44 (t, 2H); 3.99 (s, 3H); 4.07 (s, 2H); 4.30 (t, 2H); 7.20 (dd, 1H); 7.33 (s, 1H); 7.51 (dd, 1H); 7.64 (s, 1H); 7.91 (s, 1H); 7.97 (t, 1H); 9.09 (s, 1H).
    • EXAMPLE 247 Preparation of Compound 424 in Table 16
  • An analogous reaction to that described in example 226 but starting with 2-fluoro-5-methylaniline (75 mg, 0.6 mmol) yielded title compound (81 mg, 46%).
  • MS ES+: 580.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.27 (s, 3H); 2.32 (t, 2H); 2.94 (s, 3H); 3.1-4.1 (m, 8H); 3.44 (t, 2H); 3.99 (s, 3H); 4.05 (s, 2H); 4.30 (t, 2H); 6.97 (m, 1H); 7.13 (dd, 1H); 7.34 (s, 1H); 7.63 (s, 1H); 7.74 (d, 1H); 7.91 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 248 Preparation of Compound 425 in Table 16
  • An analogous reaction to that described in example 226 but starting with 3-methylaniline (64 mg, 0.6 mmol) yielded title compound (116 mg, 69%).
  • MS ES+: 584.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.28 (s, 3H); 2.31 (t, 2H); 2.95 (s, 3H); 3.1-4.1 (m, 8H); 3.45 (t, 2H); 3.96 (s, 2H); 3.98 (s, 3H); 4.30 (t, 2H); 6.88 (d, 1H); 7.19 (t, 1H); 7.30 (s, 1H); 7.39 (d, 1H); 7.47 (s, 1H); 7.62 (s, 1H); 7.91 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 249 Preparation of Compound 426 in Table 16
  • An analogous reaction to that described in example 226 but starting with 2,4-difluoroaniline (77 mg, 0.6 mmol) yielded title compound (84 mg, 48%).
  • MS ES+: 584.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 2.95 (s, 3H); 3.1-4.1 (m, 8H); 3.99 (s, 3H); 4.05 (s, 2H); 4.30 (t, 2H); 7.07 (t, 1H); 7.32 (m, 2H); 7.64 (s, 1H); 7.86 (m, 1H); 7.91 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 250 Preparation of Compound 427 in Table 16
  • An analogous reaction to that described in example 226 but starting with 2-methyl-5-fluoroaniline (75 mg, 0.6 mmol) yielded title compound (98 mg, 57%).
  • MS ES+: 580.6(M+H)+
  • 1HNMR (DMSOd6, TFA): 2.23 (s, 3H); 2.31 (t, 2H); 2.94 (s, 3H); 3.1-4.1 (m, 8H); 3.43 (t, 2H); 3.98 (s, 3H); 4.05 (s, 2H); 4.30 (t, 2H); 6.91 (m, 1H); 7.25 (t, 1H); 7.32 (s, 1H); 7.44 (dd, 1H); 7.65 (s, 1H); 7.91 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 251 Preparation of Compound 428 in Table 16
  • An analogous reaction to that described in example 226 but starting with 3,5-difluoroaniline (77 mg, 0.6 mmol) yielded title compound (54 mg, 31%).
  • MS ES+: 584.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 2.95 (s, 3H); 3.1-4.1 (m, 8H); 3.45 (t, 2H); 3.99 (s, 3H); 4.02 (s, 2H); 4.31 (t, 2H); 6.92 (m, 1H); 7.33 (s, 1H); 7.35 (m, 2H); 7.66 (s, 1H); 7.92 (s, 1H); 9.10 (s, 1H).
    • EXAMPLE 252 Preparation of Compound 429 in Table 16
  • An analogous reaction to that described in example 226 but starting with 3-fluoroaniline (67 mg, 0.6 mmol) yielded title compound (120 mg, 70%).
  • MS ES+: 566.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 2.94 (s, 3H); 3.2-4.2 (m, 8H); 3.44 (t, 2H); 3.98 (s, 3H); 3.99 (s, 2H); 4.30 (t, 2H); 6.90 (s, 1H); 7.34 (s, 1H); 7.36 (m, 2H); 7.61 (m, 1H); 7.64 (s, 1H); 7.90 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 253 Preparation of Compound 430 in Table 17
  • N-(3-chlorophenyl)-2-(2-(7-(3-chloropropoxy)-6-methoxyquinazoline-4-yl-amino),3-thiazole-5-yl)acetamide (141 mg, 0.22 mmol) in acetonitrile (2 ml) was reacted with pyrrolidine (3.3 mmol) in presence of potassium iodide (100 mg, 0.6 mmol) at 80° C. for 15 h/30 hours. When the reaction was completed (tlc) DMF (2 ml), silicagel (2 g) was added, the mixture evaporated, and the residue was purified by silica gel chromatography, eluant: CH2Cl2/MeOH 95/5, CH2Cl2/MeOH sat. NH3 90/10 to give title compound (81 mg, 29%).
  • MS ES+: 553.4, 554.4 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.90 (m, 2H); 2.06 (m, 2H); 2.26 (t, 2H); 3.09 (m, 2H); 3.36 (t, 2H); 3.67 (m, 2H); 3.99 (s, 3H); 4.00 (s, 2H); 4.29 (t, 2H); 7.14 (d, 1H); 7.30 (s, 1H); 7.37 (t, 1H); 7.47 (d, 1H); 7.65 (s, 1H); 7.85 (s, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
  • 3-methoxy-4-benzyloxybenzonitrile
  • 3-methoxy-4-benzyloxybenzoldehyde (4.87 g, 20 mmol) in acetic acid (25 ml) was treated with hydroxylamine HCl (2.8 g, 40 mmol), sodium acetate (3.3 g, 40 mmol) at reflux for 6 hours. The mixture was cooled, extracted with water and methylenechloride, dried over MgSO4, evaporated, to give title compound (4.8 g, 100%).
  • 1HNMR (DMSOd6, TFA): 3.72 (s, 3H); 5.15 (s, 2H); 7.18 (d, 1H); 7.39 (m, 7H).
  • 2-nitro-4-benzyloxy-5-methoxybenzonitrile.
  • 3-methoxy-4-benzyloxybenzonitrile (4.78 g, 20 mmol) in acetic acid (10 ml) was slowly added to nitric acid (d=1.42, 25 ml) at 20-30° with cooling in an ice bath. The mixture was then stirred at room temperature for 6 hours. The reaction mixture was treated with potassium hydroxyde (10N) at 0° C. The basic mixture (pH 10) was extracted with CH2Cl2, the organic phase was dried over MgSO4, concentrated to give title compound (3.62 g, 64%).
  • MS ES+: 285 (M+H)+
  • 1HNMR (DMSOd6, TFA): 3.97 (s, 3H); 5.33 (s, 2H); 7.42 (m, 5H); 7.70 (s, 1H); 8.03 (s, 1H).
  • 2-amino-4benzyloxy-5-methoxybenzonitrile.
  • 2-nitro-4-benzyloxy-5-methoxybenzonitrile (40 g, 125 mmol) tetrabutylammonium chloride (21 g, 75 mmol) in methylenechloride (500 ml) was treated with Na2S2O4 (180 g, 87.9 mmol) in H2O (700 ml), sodium hydrosulfite was added over 45 minutes, and the mixture was stirred for 2 hours at room temperature. Sodium hydroxyde was added (pH 8.2) the mixture was extracted with methylene chloride. The organic phase was made acidic with HCl-ether (2.3N, 250 ml), the solid was recovered, suspended in methanol (250 ml) and treated with a saturated solution of sodium bicarbonate (pH 8.1). The solid was recovered, washed with water, ether to give title compound (30.7 g, 97%).
  • 1HNMR (DMSOd6): 3.65 (s, 3H); 5.04 (s, 2H); 5.61 (s, 2H); 6.51 (s, 1H); 6.91 (s, 1H); 7.40 (m, 5H).
  • N′-(2-cyano-4-methoxy-5-benzyloxyphenyl)-N,N-dimethylimidoformamide.
  • 2-amino-4-benzyloxy-5-methoxy benzonitrile (102 g, 400 mmol) in toluene (1.5 l) was reacted with DMF-DMA (110 ml, 780 mmol) at reflux for 5 hours. The solvent was evaporated, the residue triturated with ether to give title compound as yellow solid.
  • 1HNMR (DMSOd6): 2.96 (s, 3H); 3.06 (s, 3H); 3.73 (s, 3H); 5.15 (s, 2H); 6.87 (s, 1H); 7.11 (s, 1H); 7.40 (m, 5H); 7.89 (s, 1H).
  • N′-(2-cyano-4-methoxy-5-hydroxyphenyl)-N,N-dimethylimidoformamide.
  • N′-(2-cyano-4-methoxy-5-benzyloxyphenyl)-N,N-dimethylimidoformamide (15.45 g, 50 mmol) in TPA (200 ml) was irradiated in a microwave oven at 75° C. for 45 minutes. The solvent was evaporated, the residue dissolved in dichloromethane washed with sodium bicarbonate, dried over magnesiumsulfate, evaporated to give a pale yellow solid (10.26 g, 94%).
  • HNMR (DMSOd6, TFA): 3.24 (s, 3H); 3.34 (s, 3H); 3.87 (s, 3H); 7.02 (s, 1H); 7.49 (s, 1H); 8.56 (s, 1H).
  • N′-(2-cyano-4-methoxy-5-(3-chloropropoxyphenyl)-N,N-dimethylimidoformamide.
  • N′-(2-cyano-4methoxy-5-hydroxyphenyl)-N,N-dimethylimidoformamide (439 mg, 2 mmol) in acetonitrile (5 ml) was reacted with 1-bromo-3-chloropropane (0.22 ml, 2.2 mmol) and cesium carbonate (1.95 g, 5.98 mmol) at 85° C. for 0.5 hour. The reaction mixture was evaporated, taken up in methylene chloride water, extracted with CH2Cl2, dried over MgSO4, evaporated to give title compound as a pale yellow solid (450 mg, 76%).
  • MS ES+: 296.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.26 (t, 2H); 3.26 (s, 3H); 3.37 (s, 3H); 3.81 (t, 2H); 3.87 (s, 3H); 4.23 (t, 2H); 7.34 (s, 1H); 7.53 (s, 1H); 8.56 (s, 1H).
  • g) N-(3-chlorophenyl)-2-(2-(7-(3-chloropropoxy)-6-methoxyquinazoline-4-ylamino)1,3-thiazol-5-yl)acetamide.
  • N′-(2-cyano-4-methoxy-5-(3-chloropropoxyphenyl)-N,N-dimethylimidoformamide (296 mg, 1 mmol) and 2-(2-amino-1,3-thiazol-5-yl)-N-(3-chlorophenyl)acetamide (268 mg, 1 mmol) in AcOH (1.5 ml, was irradiated in a microwave oven at 120° C. for 40 minutes. The mixture was cooled, the solid was filtered to give title compound (445 mg, 72%).
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 3.84 (t, 2H); 3.98 (s, 3H); 3.99 (s, 2H); 4.32 (t, 2H); 7.13 (d, 1H); 7.29 (s, 1H); 7.36 (t, 1H); 7.46 (d, 1H); 7.63 (s, 1H); 7.85 (s, 1H); 7.88 (s, 1H); 9.07 (s, 1H).
    • EXAMPLE 254 Preparation of Compound 431 in Table 17
  • An analogous reaction to that described in example 253 but starting with N-(3,4-difluorophenyl)-2-(2-(7-(3-chloropropoxy)-6-methoxyquinazoline-4-yl-amino)1,3-thiazole-5-yl)acetamide (52 mg, 0.1 mmol) and pyrrolidine (150 μl, 1.8 mmol) yielded title compound (26 mg, 47%).
  • 1HNMR (DMSOd6, TFA): 1.91 (m, 2H); 2.07 (m, 2H); 2.28 (t, 2H); 3.10 (m, 2H); 3.37 (t, 2H); 3.67 (m, 2H); 3.99 (s, 5H); 4.30 (t, 2H); 7.30 (s, 1H); 7.33 (m, 1H); 7.40 (q, 1H); 7.65 (s, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
  • Starting material N-(3,4-difluorophenyl)-2-(2-(7-(3-chloropropoxy)-6-methoxy quinazoline-4-yl-amino)1,3-thiazole-5-yl)acetamide was obtained by an analogous reaction to that described in example 130 but starting with 2-(2-amino-1,3-thiazol-5-yl)-N-(3,4-difluorophenyl)acetamide (540 mg, 2 mmol) to give title compound (980 mg, 78%).
  • MS ES+: 520.4, 522.4 (M+H)+
  • 1HNMR (DMSOd6): 1.26 (t, 2H); 3.82 (t, 2H); 3.88 (s, 2H); 3.97 (s, 3H); 4.29 (t, 2H); 7.29 (s, 1H); 7.32 (m, 1H); 7.36 (s, 1H); 7.39 (t, 1H); 7.80 (m, 1H); 8.12 (s, 1H); 8.68 (s, 1H).
    • EXAMPLE 255 Preparation of Compound 432 in Table 17
  • An analogous reaction to that described in example 253 but starting with N-(3,5-difluorophenyl)-2-(2-(7-(3-chloropropoxy)-6-methoxyquinazoline-4-yl-amino)1,3-thiazole-5-yl)acetamide (138 mg, 0.22 mmol) and dimethylamine (3.6 M in CH2Cl2, 3 ml, 3.6 mmol). yielded title compound (47 mg, 40%).
  • MS ES+: 529.5 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.25 (t, 2H); 3.28 (t, 2H); 3.99 (s, 3H); 4.01 (s, 2H); 4.28 (t, 2H); 6.93 (m, 1H); 7.30 (s, 1H); 7.34 (m, 2H); 7.65 (s, 1H); 7.90 (s, 1H); 9.09 (s, 1H).
  • Starting material N-(3,5-difluorophenyl)-2-(2-(7-(3-chloropropoxy)-6-methoxyquinazoline-4-yl-amino)1,3-thiazole-5-yl)acetamide was obtained by an analogous reaction to that described in example 130 but starting with 2-(2-amino-1,3-thiazole-5-yl)-N-(3,5-difluorophenyl)acetamide (810 mg, 3 mmol) to give title compound (630 mg, 40%).
  • MS ES+: 520.4, 522.4 (M+H)+
  • 1HNMR (DMSOd6): 2.26 (t, 2H); 3.84 (t, 2H); 3.92 (s, 2H); 3.98 (s, 3H); 4.30 (t, 2H); 6.94 (m, 1H); 7.30 (s, 1H); 7.35 (m, 2H); 7.40 (s, 1H); 8.14 (s, 1H); 8.69 (s, 1H); 10.64 (s, 1H).
    • EXAMPLE 256 Preparation of Compound 433 in Table 17
  • An analogous reaction to that described in example 253 but starting with N-(3-chloro-4-fluorophenyl)-2-(2-(7-(3-chloropropoxy)-6-methoxyquinazoline-4-yl-amino)1,3-thiazole-5-yl)acetamide (123 mg, 0.22 mmol) and 2-amino-2-methyl-1-propanol (89.1 mg, 3.3 mmol) yielded title compound (6 mg, 5%).
  • MS ES+: 589.4 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.24 (s, 6H); 2.22 (t, 2H); 3.10 (t, 2H); 3.45 (s, 2H); 3.98 (s, 3H); 4.31 (t, 2H); 7.29 (s, 1H); 7.38 (t, 1H); 7.50 (m, 1H); 7.64 (s, 1H); 7.91 (s, 1H); 7.97 (s, 1H); 9.09 (s, 1H).
  • Starting material N-(3-chloro-4-fluorophenyl)-2-(2-(7-(3-chloropropoxy)-6-methoxyquinazoline-4-yl-amino)1,3-thiazole-5-yl)acetamide was obtained by an analogous reaction to that described in example 130 but starting with 2-(2-amino-1,3-thiazole-5-yl)-N-(3-chloro-4-fluorophenyl)acetamide (2.29 g, 8.0 mmol) to give title compound (3.62 g, 84%).
  • MS ES+: 536.3, 538.3 (M+H)+
  • 1HNMR (DMSOd6): 2.26 (t, 2H); 3.82 (t, 2H); 3.88 (s, 2H); 3.96 (s, 3H); 4.29 (t, 2H); 7.28 (s, 1H); 7.38 (t, 1H); 7.39 (s, 1H); 7.48 (m, 1H); 7.93 (m, 1H); 8.12 (s, 1H); 8.67 (s, 1H); 10.47 (s, 1H).
    • EXAMPLE 257 Preparation of Compound 434 in Table 17
  • An analogous reaction to that described in example 253, but starting with N-(3-fluorophenyl)-2-(2-(7-(3-chloropropoxy)-6-methoxyquinazoline-4-yl-amino)1,3-thiazole-5-yl)acetamide (116 mg, 0.22 mmol) and 2-amino-2-methyl-1-propanol (89 mg, 3.3 mmol) yielded title compound (40 mg, 33%).
  • MS ES+: 555.5 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.22 (t, 2H); 3.09 (t, 2H); 3.16 (s, 2H); 3.97 (s, 3H); 4.30 (t, 2H); 6.86 (t, 1H); 7.28 (s, 1H); 7.33 (m, 2H); 7.58 (m, 1H); 7.62 (s, 1H); 7.91 (s, 1H); 9.07 (s, 1H).
  • Starting material N-(3-fluorophenyl)-2-(2-(7-(3-chloropropoxy)-6-methoxyquinazoline-4-yl-amino)1,3-thiazole-5-yl)acetamide was obtained by an analogous reaction to that described in example 253 but starting with 2-(2-amino-1,3-thiazole-5-yl)-N-(3-fluorophenyl)acetamide (2.01 g, 8 mmol) to give title compound (3.08 g, 77%).
  • MS ES+: 502.4, 504.4 (M+H)+
  • 1HNMR (DMSOd6): 2.28 (t, 2H); 3.84 (t, 2H); 3.90 (s, 2H); 3.98 (s, 3H); 4.31 (t, 2H); 6.91 (t, 1H); 7.30 (s, 1H); 7.35 (m, 2H); 7.39 (s, 1H); 7.63 (d, 1H); 8.14 (s, 1H); 8.69 (s, 1H); 10.48 (s, 1H).
    • EXAMPLE 258 Preparation of Compound 435 in Table 17
  • An analogous reaction to that described in example 254 but starting with 4-hydroxyperidine (405 mg, 4.0 mmol) yielded compound 435 in Table 17 (82 mg, 70%).
  • MS ES+: 585.5 (M+H)+
  • 1HNMR (DMSOd6): 1.43 (m, 2H); 1.73 (m, 2H); 1.95 (m, 2H); 2.03 (t, 2H); 2.44 (t, 2H); 2.74 (m, 2H); 3.38 (m, 1H); 3.90 (s, 2H); 3.97 (s, 3H); 4.20 (t, 2H); 4.53 (d, 1H); 7.26 (s, 1H); 7.31 (m, 1H); 7.39 (s, 1H); 7.42 (ddd, 1H); 7.83 (m, 1H); 8.12 (s, 1H); 8.68 (s, 1H); 10.50 (s, 1H).
    • EXAMPLE 259 Preparation of Compound 436 in Table 17
  • An analogous reaction to that described in example 254 but starting with N,N-dimethylenediamine (0.44 ml, 4.0 mmol) yielded compound 436 in Table 17 (40 mg, 35%).
  • MS ES+: 572.5 ((M+H)+
  • 1HNMR (DMSOd6): 1.95 (m, 2H); 2.14 (s, 6H); 2.33 (t, 2H); 2.63 (t, 2H); 2.73 (t, 2H); 3.89 (s, 2H); 3.97 (s, 3H); 4.22 (t, 2H); 7.26 (s, 1H); 7.34 (m, 1H); 7.38 (s, 1H); 7.41 (ddd, 1H); 7.82 (m, 1H); 8.11 (s, 1H); 8.67 (s, 1H); 10.50 (s, 1H).
    • EXAMPLE 260 Preparation of Compound 437 in Table 17
  • An analogous reaction to that described in example 254 but starting with piperidine (0.4 ml, 3.0 mmol) yielded compound 437 in Table 17 (67 mg, 59%).
  • MS ES+: 569.5 (M+H)+
  • 1HNMR (DMSOd6): 1.40 (m, 2H); 1.52 (m, 4H); 1.95 (m, 2H); 2.42 (m, 4H); 2.48 (t, 2H); 3.89 (s, 2H); 3.97 (s, 3H); 4.20 (t, 2H); 7.25 (s, 1H); 7.33 (m, 1H); 7.39 (s, 1H); 7.41 (ddd, 1H); 7.82 (m, 1H); 8.11 (s, 1H); 8.68 (s, 1H); 10.51 (s, 1H).
    • EXAMPLE 261 Preparation of Compound 438 in Table 17
  • An analogous reaction to that described in example 254 but starting with 2-methylaminoethanol (248 mg, 3.3 mmol) yielded compound 438 in Table 17 (23 mg, 19%).
  • MS ES+: 559 (M+H)+
  • 1HNMR (DMSOd6): 1.95 (m, 2H); 2.23 (s, 3H); 2.47 (m, 2H); 3.32 (m, 2H); 3.49 (m, 2H); 3.90 (s, 2H); 3.98 (s, 3H); 4.21 (t, 2H); 4.37 (m, 1H); 7.27 (s, 1H); 7.34 (m, 1H); 7.38 (s, 1H); 7.40 (dd, 1H); 7.82 (ddd, 1H); 8.13 (brs, 1H); 8.68 (s, 1H); 10.50 (s, 1H).
    • EXAMPLE 262 Preparation of Compound 439 in Table 17
  • An analogous reaction to that described in example 254 but starting with 1,2-diamino-2-methylpropane (291 mg, 3.3 mmol) yielded compound 439 in Table 17 (16 mg, 13%).
  • MS ES+: 572 (M+H)+
  • 1HNMR (DMSOd6): 1.10 (s, 6H); 1.96 (m, 2H); 2.48 (s, 2H); 2.75 (t, 2H); 3.89 (s, 2H); 3.97 (s, 3H); 4.26 (t, 2H); 7.27 (s, 1H); 7.34 (m, 1H); 7.37 (s, 1H); 7.42 (dd, 1H); 7.83 (ddd, 1H); 8.10 (s, 1H); 8.66 (s, 1H); 10.50 (s, 1H).
    • EXAMPLE 263 Preparation of Compound 440 in Table 17
  • An analogous reaction to that described in example 254 but starting with cyclohexylamine (327 mg, 3.3 mmol) yielded compound 440 in Table 17 (70 mg, 55%).
  • MS ES+: 583 (M+H)+
  • 1HNMR (DMSOd6): 1.12 (m, 1H); 1.27 (m, 4H); 1.63 (brd, 1H); 1.78 (m, 2H); 2.04 (m, 2H); 2.16 (m, 2H); 3.03 (m, 1H); 3.16 (t, 2H); 3.90 (s, 2H); 3.98 (s, 3H); 4.29 (t, 2H); 7.31 (s, 1H); 7.34 (m, 1H); 7.40 (s, 1H); 7.42 (dd, 1H); 7.82 (ddd, 1H); 8.16 (brs, 1H); 8.70 (s, 1H); 10.51 (s, 1H).
    • EXAMPLE 264 Preparation of Compound 441 in Table 17
  • An analogous reaction to that described in example 254 but starting with N,N,N′-trimethylethylenediamine (337 mg, 3.3 mmol) yielded compound 441 in Table 17 (63 mg, 49%).
  • MS ES+: 587 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.33 (m, 2H); 2.88 (s, 6H); 2.93 (s, 3H); 3.38 (m, 2H); 3.56 (m, 4H); 3.98 (s, 5H); 4.30 (t, 2H); 7.29 (m, 1H); 7.33 (s, 1H); 7.35 (dd, 1H); 7.63 (s, 1H); 7.80 (ddd, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 265 Preparation of Compound 442 in Table 17
  • An analogous reaction to that described in example 254 but starting with (R)-(−)-2-pyrrolidinemethanol (334 mg, 3.3 mmol) yielded compound 442 in Table 17 (90 mg, 70%).
  • MS ES+: 585 (M+H)30
  • 1HNMR (DMSOd6, TFA): 1.79 (m, 1H); 1.91 (m, 1H); 2.03 (m, 1H); 2.11 (m, 1H); 2.29 (m, 2H); 3.21 (m, 2H); 3.62 (m, 4H); 3.77 (m, 1H); 3.98 (s, 5H); 4.29 (t, 2H); 7.30 (s, 1H); 7.32 (m, 1H); 7.39 (dd, 1H); 7.64 (s, 1H); 7.80 (ddd, 1H); 7.90 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 266 Preparation of Compound 443 in Table 17
  • An analogous reaction to that described in example 254 but starting with (S)-(+)-2-pyrrolidinemethanol (334 mg, 3.3 mmol) yielded compound 443 in Table 17 (82 mg, 63%).
  • MS ES+: 585 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.76 (m, 1H); 1.88 (m, 1H); 2.01 (m, 1H); 2.10 (m, 1H); 2.26 (m, 2H); 3.21 (m, 2H); 3.59 (m, 4H); 3.74 (dd, 1H); 3.95 (s, 5H); 4.27 (t, 2H); 7.27 (s, 1H); 7.28 (m, 1H); 7.34 (dd, 1H); 7.60 (s, 1H); 7.77 (ddd, 1H); 7.88 (s, 1H); 9.05 (s, 1H).
    • EXAMPLE 267 Preparation of Compound 444 in Table 17
  • An analogous reaction to that described in example 254 but starting with 3-pyrrolidinol (288 mg, 3.3 mmol) yielded compound 444 in Table 17 (15 mg, 12%).
  • MS ES+: 571 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.85-2.04 (m, 2H); 2.28 (m, 2H); 3.03-3.54 (m, 4H); 3.75 (m, 2H); 3.99 (s, 5H); 4.28 (m, 2H); 4.40-4.52 (m, 1H); 7.29 (s, 1H); 7.33 (m, 1H); 7.39 (dd, 1H); 7.64 (s, 1H); 7.81 (ddd, 1H); 7.91 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 268 Preparation of Compound 445 in Table 17
  • An analogous reaction to that described in example 254 but starting with 1-(2-aminoethyl)pyrrolidine (377 mg, 3.3 mmol) yielded compound 445 in Table 17 (20 mg, 15%).
  • MS ES+: 598 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.92 (m, 2H); 2.06 (m, 2H); 2.24 (m, 2H); 3.11 (m, 2H); 3.23 (t, 2H); 3.42 (m, 2H); 3.49 (m, 2H); 3.52 (m, 2H; 4.00 (s, 5H); 4.32 (t, 2H); 7.32 (s, 1H); 7.33 (m, 1H); 7.39 (dd, 1H); 7.65 (s, 1H); 7.81 (ddd, 1H); 7.92 (s, 1H); 9.10 (s, 1H).
    • EXAMPLE 269 Preparation of Compound 446 in Table 17
  • An analogous reaction to that described in example 254 but starting with 1-acetylpiperazine (423 mg, 3.3 mmol) yielded compound 446 in Table 17 (100 mg, 74%).
  • MS ES+: 612 (M+H)+
  • 1HNMR (DMSOd6): 2.00 (s, 5H); 2.35 (m, 2H); 2.42 (m, 2H); 3.92-3.06 (m, 1H); 3.45 (m, 4H); 3.56 (t, 1H); 3.90 (s, 2H); 3.98 (s, 3H); 4.23 (t, 2H); 7.28 (s, 1H); 7.34 (m, 1H); 7.40 (s, 1H); 7.42 (dd, 1H); 7.83 (ddd, 1H); 8.13 (brs, 1H); 8.69 (s, 1H).
    • EXAMPLE 270 Preparation of Compound 447 in Table 17
  • An analogous reaction to that described in example 254 but starting with 1-(2-morpholinoethyl)-piperazine (658 mg, 3.3 mmol) yielded compound 447 in Table 17 (44 mg, 29%).
  • 5 MS ES+: 683 (M+H)+
  • 1HNMR (DMSOd6): 1.98 (m, 2H); 2.30-2.70 (m, 18H); 3.58 (m, 4H); 3.90 (s, 2H); 3.97 (s, 3H); 4.21 (t, 2H); 7.26 (s, 1H); 7.33 (m, 1H); 7.40 (s, 1H); 7.41 (dd, 1H); 7.82 (ddd, 1H); 8.13 (brs, 1H); 8.69 (s, 1H); 10.54 (s, 1H).
    • EXAMPLE 271 Preparation of Compound 448 in Table 17
  • An analogous reaction to that described in example 254 but starting with 2-piperidineethanol (426 mg, 3.3 mmol) yielded compound 448 in Table 17 (19 mg, 14%).
  • MS ES+: 613 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.45-1.92 (m, 7H); 2.00-2.15 (m, 1H); 2.20-2.40 (m, 2H); 3.10-3.70 (m, 7H); 3.99 (s, 5H); 4.30 (m, 2H); 7.30 (s, 1H); 7.34 (m, 1H); 7.40 (dd, 1H); 7.64 (s, 1H); 7.81 (ddd, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 272 Preparation of Compound 449 in Table 17
  • An analogous reaction to that described in example 254 but starting with 1-(2-hydroxyethyl)piperazine (430 mg, 3.3 mmol) yielded compound 449 in Table 17 (90 mg, 66%).
  • MS ES+: 614 (M+H)+
  • 1HNMR (DMSOd6): 1.96 (m, 2H); 2.35-2.47 (m, 12H); 3.49 (q, 2H); 3.90 (s, 2H); 3.97 (s, 3H); 4.20 (t, 1H); 4.37 (t, 1H); 7.25 (s, 1H); 7.33 (m, 1H); 7.39 (s, 1H); 7.41 (dd, 1H); 7.81 (ddd, 1H); 8.12 (brs, 1H); 8.68 (s, 1H); 10.50 (s, 1H); 12.03 (brs, 1H).
    • EXAMPLE 273 Preparation of Compound 450 in Table 17
  • An analogous reaction to that described in example 254 but starting with cyclopentylamine (281 mg, 3.3 mmol) yielded compound 450 in Table 17 (43 mg, 34%).
  • MS ES+: 614 (M+H)+
  • 1HNMR (DMSOd6): 1.53 (m, 4H); 1.69 (m, 2H); 1.93 (m, 2H); 2.10 (m, 2H); 3.00 (m, 2H); 3.38 (m, 2H); 3.90 (s, 2H); 3.98 (s, 3H); 4.28 (t, 2H); 7.30 (s, 1H); 7.32 (m, 1H); 7.42 (dd, 1H); 7.81 (ddd, 1H); 8.15 (brs, 1H); 8.70 (s, 1H); 10.51 (s, 1H).
    • EXAMPLE 274 Preparation of Compound 451 in Table 17
  • An analogous reaction to that described in example 254 but starting with 4-(2-hydroxyethyl)piperidine (426 mg, 3.3 mmol) yielded compound 451 IN Table 17 (53 mg, 39%).
  • MS ES+: 613 (M+H)+
  • 1HNMR (DMSOd6): 1.14 (m, 2H); 1.36 (m, 3H); 1.63 (brd, 2H); 1.87 (m, 2H); 1.95 (m, 2H); 2.45 (m, 1H); 2.86 (m, 2H); 3.44 (m, 2H); 3.90 (s, 2H); 3.97 (s, 3H); 4.20 (t, 2H); 4.32 (t, 1H); 7.26 (s, 1H); 7.31 (m, 1H); 7.40 (s, 1H); 7.42 (dd, 1H); 7.82 (ddd, 1H); 8.13 (brs, 1H); 8.68 (s, 1H); 10.50 (s, 1H); 12.02 (brs, 1H).
    • EXAMPLE 275 Preparation of Compound 452 in Table 17
  • An analogous reaction to that described in example 254 but starting with L-alanine-T-butylester hydrochloride (599 mg, 3.3 mmol) and treating the crude reaction mixture with a 1:1 solution of CH2Cl2-TFA (4 ml) yielded compound 452 in Table 17 (75 mg, 60%).
  • MS ES+: (573 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.48 (d, 3H); 2.24 (m, 2H); 3.22 (m, 2H); 3.97 (s, 5H); 4.15 (q, 1H); 4.30 (m, 2H); 7.30 (s, 1H); 7.34 (m, 1H); 7.40 (dd, 1H); 7.64 (s, 1H); 7.81 (ddd, 1H); 7.90 (s, 1H); 9.08 (s, 1H); 10.60 (s, 1H).
    • EXAMPLE 276 Preparation of Compound 453 in Table 17
  • An analogous reaction to that described in example 254 but starting with 3-hydroxypiperidine (334 mg, 3.3 mmol) yielded compound 453 in Table 17 (84 mg, 65%).
  • MS ES+: 585 (M+H)+
  • 1HNMR (DMSOd6): 1.07 (m, 1H); 1.41 (m, 1H); 1.62 (m, 1H); 1.76 (m, 2H); 1.87 (m, 1H); 1.95 (m, 2H); 2.47 (m, 2H); 2.68 (m, 1H); 2.85 (m, 1H); 3.48 (m, 1H ); 3.90 (s, 2H); 3.98 (s, 3H); 4.20 (t, 2H); 4.59 (d, 1H); 7.26 (s, 1H); 7.31 (m, 1H); 7.39 (s, 1H); 7.42 (dd, 1H); 7.81 (ddd, 1H); 8.12 (brs, 1H); 8.68 (s, 1H); 10.50 (s, 1H); 12.02 (brs, 1H).
    • EXAMPLE 277 Preparation of Compound 454 in Table 17
  • An analogous reaction to that described in example 254 but starting with 4-hydroxymethylpiperidine (380 mg, 3.3 mmol) yielded compound 454 in Table 17 (42 mg, 32%).
  • MS ES+: 599 (M+H)+
  • 1HNMR (DMSOd6): 1.13 (m, 2H); 1.33 (m, 1H); 1.62 (brd, 2H); 1.90 (m, 2H); 1.95 (m, 2H); 2.44 (m, 2H); 2.88 (m, 2H); 3.22 (t, 2H); 3.86 (s, 2H); 3.93 (s, 3H); 4.17 (t, 2H); 4.38 (t, 1H); 7.22 (s, 1H); 7.31 (m, 1H); 7.36 (s, 1H); 7.38 (dd, 1H); 7.80 (ddd, 1H); 8. 09 (brs, 1H); 8.65 (s, 1H); 10.46 (s, 1H); 12.00 (brs, 1H).
    • EXAMPLE 278 Preparation of Compound 455 in Table 17
  • An analogous reaction to that described in example 254 but starting with 1-amino-2-propanol (248 mg, 3.3 mmol) yielded compound 455 in Table 17 (52 mg, 42%).
  • MS ES+: 573 (M+H)+
  • 1HNMR (DMSOd6): 1.06 (d, 3H); 1.95 (m, 2H); 2.48 (m, 2H); 2.72 (t, 2H); 3.68 (m, 1H); 3.89 (s, 2H); 3.97 (s, 3H); 4.23 (t, 2H); 4.46 (m, 1H); 7.26 (s, 1H); 7.32 (m, 1H); 7.38 (s, 1H); 7.41 (dd, 1H); 7.81 (ddd, 1H); 8.11 (s, 1H); 8.67 (s, 1H); 10.49 (s, 1H).
    • EXAMPLE 279 Preparation of Compound 456 in Table 17
  • An analogous reaction to that described in example 253 but starting with L-alanine-t-butylester hydrochloride (599 mg, 3.3 mmol) and treating the crude reaction mixture with CH2Cl2-TFA (1/1, 4 ml) yielded compound 456 in Table 17 (106 mg, 84%).
  • MS ES+: 571 (M+H)+
  • 1HNMR DMSOd6, TFA): 1.40 (d, 3H); 2.25 (m, 2H); 3.20 (m, 2H); 3.98 (s, 3H); 4.00 (s, 2H); 4.14 (m, 1H); 4.31 (t, 2H); 7.13 (dd, 1H); 7.32 (s, 1H); 7.35 (t, 1H); 7.47 (dd, 1H); 7.63 (s, 1H); 7.86 (t, 1H); 7.90 (s, 1H); 8.30 (m, 1H); 9.08 (s, 1H); 10.60 (s, 1H).
    • EXAMPLE 280 Preparation of Compound 457 in Table 17
  • An analogous reaction to that described in example 253 but starting with 2-methylaminoethanol (248 mg, 3.3 mmol) yielded compound 457 in Table 17 (86 mg, 70%).
  • MS ES+: 557 (M+H)+
  • 1HNMR (DMSOd6): 1.93 (m, 2H); 2.20 (s, 3H); 2.43 (t, 2H); 2.48 (m, 1H); 2.55 (m, 1H); 3.47 (dd, 2H); 3.89 (s, 2H); 3.96 (s, 3H); 4.19 (t, 2H); 4.34 (t, 1H); 7.13 (brd, 1H); 7.25 (s, 1H); 7.35 (t, 1H); 7.38 (s, 1H); 7.47 (s, 1H); 7.84 (s, 1H); 8.11 (dd, 1H); 8.66 (s, 1H); 10.44 (s, 1H); 12.00 (dd, 1H).
    • EXAMPLE 281 Preparation of Compound 458 in Table 17
  • An analogous reaction to that described in example 253 but starting with 1,2-diamino-2-methylpropane (291 mg, 3.3 mmol) yielded compound 458 in Table 17 (21 mg, 17%).
  • MS ES+: 570 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.39 (s, 1H); 2.28 (m, 2H); 3.23 (m, 4H); 3.98 (s, 3H); 4.00 (s, 2H); 4.32 (m, 2H); 7.14 (ddd, 1H); 7.31 (s, 1H); 7.36 (t, 1H); 7.47 (ddd, 1H); 7.64 (s, 1H); 7.86 (t, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 282 Preparation of Compound 459 in Table 17
  • n analogous reaction to that described in example 253 but starting with cyclohexylamine (327 mg, 3.3 mmol) yielded compound 459 in Table 17 −85 mg, 66%).
  • MS ES+: 581 (M+H)+
  • 1HNMR (DMSOd6): 1.13 (m, 1H); 1.26 (m, 4H); 1.62 (brd, 1H); 1.77 (m, 2H); 2.03 (m, 2H); 2.15 (m, 2H); 3.07 (m, 1H); 3.14 (t, 2H); 3.90 (s, 2H); 3.97 (s, 3H); 4.29 (t, 2H); 7.13 (brd, 1H); 7.29 (s, 1H); 7.36 (t, 1H); 7.39 (s, 1H); 7.46 (dd, 1H); 8.16 (dd, 1H); 8.26 (brs, 1H); 8.69 (s, 1H); 10.45 (s, 1H).
    • EXAMPLE 283 Preparation of Compound 460 in Table 17
  • An analogous reaction to that described in example 253 but starting with N,N-dimethylethylenediamine (291 mg, 3.3 mmol) yielded compound 460 in Table 17 (41 mg, 32%).
  • MS ES+: 570 (M+H)+
  • 1HNMR (DMSOd6): 2.00 (m, 1H); 2.17 (s, 6H); 2.38 (t, 2H); 2.72 (t, 2H); 2.81 (t, 2H); 3.91 (s, 2H); 3.98 (s, 3H); 4.24 (t, 2H); 7.14 (dd, 1H); 7.27 (s, 1H); 7.37 (t, 1H); 7.40 (s, 1H); 7.49 (dd, 1H); 7.86 (t, 1H); 8.13 (s, 1H); 8.69 (s, 1H); 10.50 (s, 1H).
    • EXAMPLE 284 Preparation of Compound 461 in Table 17
  • An analogous reaction to that described in example 253 but starting with N,N,N′-trimethylethylenediamine (337 mg, 3.3 mmol) yielded compound 461 in Table 17 (11 mg, 8%)
  • MS ES+: 584 (M+H)+
  • 1HNMR (DMSOd6): 1.91 (m, 2H); 2.12 (s, 6H); 2.20 (s, 3H); 2.33 (m, 3H); 2.42 (m, 3H); 3.76 (s, 2H); 3.91 (s, 3H); 4.12 (t, 2H); 6.98 (s, 1H); 7.11 (dd, 1H); 7.16 (s, 4H); 7.35 (t, 1H); 7.52 (dd, 1H); 7.83 (s, 1H); 7.88 (t, 1H); 8.37 (s, 1H); 10.56 (s, 1H).
    • EXAMPLE 285 Preparation of Compound 462 in Table 17
  • An analogous reaction to that described in example 253 but starting with (R)-(−)-2-pyrrolidinemethanol (334 mg, 3.3 mmol) yielded compound 462 in Table 17 (76 mg, 59%).
  • MS ES+: 583 ((M+H)+
  • 1HNMR (DMSOd6, TFA): 1.77 (m, 1H); 1.89 (m, 1H); 2.02 (m, 1H); 2.4 (m, 1H); 2.29 (m, 2H); 3.21 (m, 2H); 3.62 (m, 4H); 3.76 (m, 1H); 3.98 (s, 3H); 3.99 (s, 2H); 4.29 (t, 2H); 7.13 (dd, 1H); 7.29 (s, 1H); 7.35 (t, 1H); 7.46 (dd, 1H); 7.63 (s, 1H); 7.85 (t, 1H); 7.90 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 286 Preparation of Compound 463 in Table 17
  • An analogous reaction to that described in example 253 but starting with (S)-(+)-2-pyrrolidinemethanol (334 mg, 3.3 mmol) yielded compound 463 in Table 17 (72 mg, 56%).
  • MS ES+: 583 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.78 (m, 1H); 1.90 (m, 1H); 2.03 (m, 1H); 2.13 (m, 1H); 2.30 (m, 2H); 3.23 (m, 2H); 3.62 (m, 4H); 3.77 (m, 1H); 3.98 (s, 3H); 4.00 (s, 2H); 4.30 (t, 2H); 7.14 (dd, 1H); 7.30 (s, 1H); 7.36 (t, 1H); 7.46 (dd, 1H); 7.64 (s, 1H); 7.85 (s, 1H); 7.90 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 287 Preparation of Compound 464 in Table 17
  • An analogous reaction to that described in example 253 but starting with 4-hydroxypiperidine (334 mg, 3.3 mmol) yielded compound 464 in Table 17 (63 mg, 49%).
  • MS ES+: 583 (M+H)+
  • 1HNMR (DMSOd6): 1.41 (m, 2H); 1.73 (m, 2H); 1.96 (m, 2H); 2.04 (m, 2H); 2.74 (m, 2H); 2.50 (m, 2H); 3.43 (s, 1H); 3.91 (s, 2H); 3.97 (s, 3H); 4.20 (t, 2H); 4.54 (d, 1H); 7.14 (d, 1H); 7.26 (s, 1H); 7.37 (t, 1H); 7.40 (s, 1H); 7.49 (d, 1H); 7.86 (t, 1H); 8.13 (brs, 1H); 8.69 (s, 1H); 10.46 (s, 1H).
    • EXAMPLE 288 Preparation of Compound 465 in Table 17
  • An analogous reaction to that described in example 253 but starting with 3-pyrrolidinol (288 mg, 3.3 mmol) yielded compound 465 in Table 17 (57 mg, 45%).
  • MS ES+: 569 (M+H)+
  • 1HNMR (DMSOd6): 1.56 (m, 1H); 1.99 (m, 4H); 2.36 (m, 1H); 2.56 (m, 4H); 2.74 (m, 1H); 3.91 (s, 2H); 3.98 (s, 3H); 4.21 (t, 2H); 4.70 (d, 1H); 7.14 (dd, 1H); 7.26 (s, 1H); 7.37 (t, 1H); 7.40 (s, 1H); 7.49 (dd, 1H); 7.86 (t, 1H); 8.12 (s, 1H); 8.68 (s, 1H); 10.47 (s, 1H); 12.03 (brs, 1H).
    • EXAMPLE 289 Preparation of Compound 466 in Table 17
  • An analogous reaction to that described in example 253 but starting with 1-(2-aminoethyl)pyrrolidine (377 mg, 3.3 mmol) yielded compound 466 in Table 17 (39 mg, 29%).
  • MS ES+: 596 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.91 (m, 2H); 2.06 (m, 2H); 2.24 (m, 2H); 3.11 (m, 2H); 3.23 (t, 2H); 3.42 (m, 2H); 3.48 (m, 2H); 3.67 (m, 2H); 3.98 (s, 3H); 3.99 (s, 2H); 4.31 (t, 2H); 7.14 (d, 1H); 7.31 (s, 1H); 7.35 (t, 1H); 7.47 (d, 1H); 7.64 (s, 1H); 7.85 (t, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 290 Preparation of Compound 467 in Table 17
  • An analogous reaction to that described in example 253 but starting with 4-hydroxymethylpiperidine (380 mg, 3.3 mmol) yielded compound 467 in Table 17 (64 mg, 49%).
  • MS ES+: 597 (M+H)+
  • 1HNMR (DMSOd6): 1.14 (m, 2H); 1.35 (m, 1H); 1.65 (brd, 2H); 1.88 (m, 2H); 1.97 (m, 2H); 2.47 (m, 2H); 2.90 (brd, 2H); 3.25 (t, 2H); 3.91 (s, 2H); 3.97 (s, 3H); 4.20 (t, 2H); 4.41 (t, 1H); 7.14 (d, 1H); 7.25 (s, 1H); 7.37 (t, 1H); 7.39 (s, 1H); 7.48 (s, 1H); 7.86 (s, 1H); 8.12 (brs, 1H); 8.68 (s, 1H); 10.46 (s, 1H); 12.03 (s, 1H).
    • EXAMPLE 291 Preparation of Compound 468 in Table 17
  • An analogous reaction to that described in example 253 but starting with 1-(2-hydroxyethyl)piperazine (430 mg, 3.3 mmol) yielded compound 468 in Table 17 (63 mg, 47%).
  • MS ES+: 612 (M+H)+
  • 1HNMR (DMSOd6): 1.96 (m, 2H); 2.41 (m, 12H); 3.50 (q, 2H); 3.91 (s, 2H); 3.97 (s, 3H); 4.20 (t, 2H); 4.37 (t, 1H); 7.14 (dd, 1H); 7.25 (s, 1H); 7.37 (t, 1H); 7.39 (s, 1H); 7.48 (d, 1H); 7.86 (t, 1H); 8.12 (brs, 1H); 8.68 (s, 1H); 10.46 (s, 1H); 12.04 (s, 1H).
    • EXAMPLE 292 Preparation of Compound 469 in Table 17
  • An analogous reaction to that described in example 253 but starting with cyclopentylamine 281 mg, 3.3 mmol) yielded compound 469 in Table 17 (77 mg, 61%).
  • MS ES+: 567 (M+H)+
  • 1HNMR (DMSOd6): 1.58 (m, 4H); 1.73 (m, 2H); 2.00 (m, 2H); 2.17 (m, 2H); 3.12 (t, 2H); 3.56 (m, 1H); 3.92 (s, 3H); 3.99 (s, 3H); 4.31 (t, 2H); 7.15 (d, 1H); 7.31 (s, 1H); 7.37 (t, 1H); 7.41 (s, 1H); 7.48 (d, 1H); 7.86 (s, 1H); 8.16 (brs, 1H); 8.71 s, 1H); 10.47 (s, 1H); 12.03 (brs, 1H).
    • EXAMPLE 293 Preparation of Compound 470 in Table 17
  • An analogous reaction to that described in example 253 but starting with 4-(2-hydroxyethyl)piperidine (426 mg, 3.3 mmol) yielded compound 470 in Table 17 (78 mg, 58%)
  • MS ES+: 611 (M+H)+
  • 1HNMR (DMSOd6): 1.16 (m, 2H); 1.36 (m, 3H); 1.63 (d, 2H); 1.88 (t, 2H); 1.96 (m, 2H); 2.44 (t, 2H); 2.87 (d, 2H); 3.44 (m, 2H); 3.9 (s, 2H); 3.97 (s, 3H); 4.20 (t, 2H); 4.33 (t, 1H); 7.14 (d, 1H); 7.25 (s, 1H); 7.37 (t, 1H); 7.40 (s, 1H); 7.49 (d, 1H); 7.86 (t, 1H); 8.12 (brs, 1H); 8.68 (s, 1H); 10.46 (s, 1H); 12.04 (s, 1H).
    • EXAMPLE 294 Preparation of Compound 471 in Table 17
  • An analogous reaction to that described in example 253 but starting with 3-hydroxypiperidine (339 mg, 3.3 mmol) yielded compound 471 in Table 17 (117 mg, 91%).
  • MS ES+: 583 (M+H)+
  • 1HNMR (DMSOd6): 1.07 (m, 1H); 1.41 (m, 1H); 1.62 (m, 1H); 1.70-1.90 (m, 3H); 1.95 (m, 2H); 2.46 (m, 2H); 2.67 (m, 1H); 2.83 (brd, 1H); 3.47 (m, 1H); 3.89 (s, 2H); 3.96 (s, 3H); 4.20 (t, 2H); 4.57 (d, 1H); 7.13 (ddd, 1H); 7.24 (s, 1H); 7.36 (t, 1H); 7.38 (s, 1H); 7.47 (d, 1H); 7.84 (t, 1H); 8.11 (brs, 1H); 8.67 (s, 1H); 10.46 (s, 1H); 12.00 (brs, 1H).
    • EXAMPLE 295 Preparation of Compound 472 in Table 17
  • An analogous reaction to that described in example 253 but starting with (S)-1-amino-2-propanol (248 mg, 3.3 mmol) yielded compound 472 in Table 17 (55 mg, 45%).
  • MS ES+: 557 (M+H)+
  • 1HNMR (DMSOd6): 1.06 (d, 3H); 1.96 (m, 2H); 2.48 (m, 2H); 2.73 (t, 2H); 3.70 (m, 1H); 3.91 (s, 2H); 3.97 (s, 3H); 4.24 (t, 2H); 4.48 (brs, 1H); 7.14 (d, 1H); 7.27 (s, 1H); 7.37 (t, 1H); 7.39 (s, 1H); 7.49 (d, 1H); 7.86 (t, 1H); 8.12 (s, 1H); 8.68 (s, 1H); 10.46 (s, 1H).
    • EXAMPLE 296 Preparation of Compound 473 in Table 17
  • An analogous reaction to that described in example 253 but starting with (R)-1-amino-2-propanol (248 mg, 3.3 mmol) yielded compound 473 in Table 17 (84 mg, 68%).
  • MS ES+: 557 (M+H)+
  • 1HNMR (DMSOd6): 1.04 (d, 3H); 1.93 (m, 2H); 2.45 (m, 2H); 2.70 (t, 2H); 3.67 (m, 1H); 3.88 (s, 2H); 3.95 (s, 3H); 4.21 (t, 2H); 4.46 (brs, 1H); 7.12 (d, 1H); 7.24 (s, 1H); 7.35 (t, 1H); 7.37 (s, 1H); 7.47 (d, 1H); 7.84 (t, 1H); 8.09 (s, 1H); 8.65 (s, 1H); 10.45 (s, 1H).
    • EXAMPLE 297 Preparation of Compound 474 in Table 17
  • An analogous reaction to that described in example 253 but starting with tert-butyl-1-piperazinecarboxylate (615 mg, 3.3 mmol) and treating the crude reaction mixture with hydrochloric acid in 1,4 dioxane (4.0 M, 2 ml) yielded compound 474 (3 HCl) in Table 17 (89 mg, 61%.
  • MS ES+: 568 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.34 (m, 2H); 3.25-3.68 (m, 10H); 3.99 (s, 3H); 4.01 (s, 2H); 4.33 (t, 2H); 7.14 (dd, 1H); 7.35 (s, 1H); 7.37 (t, 1H); 7.49 (d, 1H); 7.65 (s, 1H); 7.86 (t, 1H); 7.91 (s, 1H); 9.09 (s, 1H); 10.66 (s, 1H).
    • EXAMPLE 298 Preparation of Compound 475 in Table 17
  • An analogous reaction to that described in example 253 but starting with 2-(2-hydroxyethyl)piperidine (426 mg, 3.3 mmol) yielded compound 475 in Table 17 (29 mg, 22%).
  • MS ES+: 611 (M+H)+
  • 1HNMR (DMSOd6): 1.30 (m, 2H); 1.48 (m, 4H); 1.60 (m ,2H); 1.76 (m, 1H); 1.93 (m, 2H); 2.26 (m, 1H); 2.48 (m, 1H); 2.79 (m, 2H); 3.46 (m, 2H); 3.89 (s, 2H); 3.96 (s, 3H); 4.18 (t, 2H); 4.40 (brs, 1H); 7.13 (d, 1H); 7.24 (s, 1H); 7.35 (t, 1H); 7.38 (s, 1H); 7.47 (d, 1H); 7.84 (s, 1H); 8.11 (brs, 1H); 8.67 (s, 1H); 10.44 (s, 1H).
    • EXAMPLE 299 Preparation of Compound 476 in Table 17
  • An analogous reaction to that described in example 253 but starting with 2-amino-2-methyl-1-propanol (294 mg, 3.3 mmol) yielded compound 476 in Table 17 (49 mg, 39%).
  • MS ES+: 571 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.25 (s, 6H); 2.22 (m, 2H); 3.10 (m, 2H); 3.46 (s, 2H); 3.99 (s, 3H); 4.00 (s, 2H); 4.32 (t, 2H); 7.15 (d, 1H); 7.30 (s, 1H); 7.37 (t, 1H); 7.47 (d, 1H); 7.65 (s, 1H); 7.86 (s, 1H); 7.91 (s, 1H); 9.09 (s, 4H); 10.56 (s, 1H).
    • EXAMPLE 300 Preparation of Compound 477 in Table 17
  • An analogous reaction to that described in example 253 but starting with 1-(2-dimethylaminoethylpiperazine (519 mg, 3.3 mmol) yielded compound 477 in Table 17 (19 mg, 15%).
  • MS ES+: 639 (M+H)+
  • 1HNMR (DMSOd6): 1.96 (m, 2H); 2.13 (s, 6H); 2.30-2.52 (m, 14H); 3.89 (s, 2H); 3.95 (s, 3H); 4.18 (t, 2H); 7.13 (d, 1H); 7.23 (s, 1H); 7.35 (t, 1H); 7.38 (s, 1H); 7.84 (t, 1H); 8.10 (s, 1H); 8.67 (s, 1H); 10.45 (s, 1H).
    • EXAMPLE 301 Preparation of Compound 478 in Table 17
  • An analogous reaction to that described in example 253 but starting with a solution of dimethylamine in chloroform (3,6M, 3 ml, 3.6 mmol) yielded compound 478 in Table 17 (44 mg, 34%)
  • MS ES+: 527 (M+H)+
  • 1HNMR (DMSOd6): 1.95 (m, 2H); 2.17 (s, 6H); 2.41 (t, 2H); 3.89 (s, 2H); 3.96 (s, 3H); 4.18 (t, 2H); 7.12 (d, 1H); 7.23 (s, 1H); 7.35 (t, 1H); 7.38 (s, 1H); 7.47 (d, 1H); 7.84 (t, 1H); 8.11 (s, 1H); 8.67 (s, 1H); 10.45 (s, 1H).
    • EXAMPLE 302 Preparation of Compound 479 in Table 17
  • An analogous reaction to that described in example 253 but starting with aminomethylcyclopropane (234 mg, 3.3 mmol) yielded compound 479 in Table 17 (88 mg, 65%).
  • MS ES+: 553 (M+H)+
  • 1HNMR (DMSOd6): 0.18 (m, 2H); 0.46 (m, 2H); 0.94 (m, 1H); 2.01 (m, 2H); 2.51 (d, 2H); 2.79 (t, 2H); 3.94 (s, 2H); 4.01 (s, 3H); 4.28 (t, 2H); 7.18 (d, 1H); 7.31 (s, 1H); 7.41 (t, 1H); 7.43 (s, 1H); 7.53 (d, 1H); 7.90 (s, 1H); 8.16 (s, 1H); 8.72 (s, 1H); 10.53 (s, 1H).
    • EXAMPLE 303 Preparation of Compound 480 in Table 17
  • An analogous reaction to that described in example 253 but starting with piperidine (344 mg, 4.0 mmol) yielded compound 480 in Table 17 (52 mg, 40%).
  • MS ES−: 565 (M−H)+
  • 1HNMR (DMSOd6, TFA): 1.43 (m, 1H); 1.69 (m, 3H); 1.87 (d, 2H); 2.30 (m, 2H); 2.96 (t, 2H); 3.27 (t, 2H); 3.55 (d, 2H); 3.99 (s, 3H); 4.00 (s, 2H); 4.31 (t, 2H); 7.15 (d, 1H); 7.31 (s, 1H); 7.37 (t, 1H); 7.47 (d, 1H); 7.65 (s, 1H); 7.86 (s, 1H); 7.91 (s, 1H); 9.09 (s, 1H); 10.56 (s, 1H).
    • EXAMPLE 304 Preparation of Compound 481 in Table 17
  • An analogous reaction to that described in example 255 but starting with 1-(2-dimethylaminomethyl)piperazine (281 mg, 3.3 mmol) yielded compound 481 in Table 17 (81 mg, 64%).
  • MS ES+: 641 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.33 (m, 2H); 2.80-3.70 (m, 14H); 2.84 (s, 6H); 3.98 (s, 3H); 4.01 (s 2H); 4.30(brt, 1H); 6.90 (m, 1H); 7.32(s, 2H); 7.35 (dd, 1H); 7.64(s, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 305 Preparation of Compound 482 in Table 17
  • An analogous reaction to that described in example 255 but starting with (S)-(+)-2-pyrrolidinemethanol (334 mg, 3.3 mmol) yielded compound 482 in Table 17 (58 mg, 45%).
  • MS ES+: 585 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.79 (m, 1H); 1.90 (m, 1H); 2.02 (m, 1H); 2.13 (m, 1H); 2.30 (m, 2H); 3.33 (m, 2H); 3.62 (m, 4H); 3.77 (dd, 1H); 3.99 (s, 3H); 4.01 (s, 2H); 4.30 (brt, 2H); 6.91 (t, 1H); 7.30 (s, 1H); 7.35 (dd, 2H); 7.64 (s, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 306 Preparation of Compound 483 in Table 17
  • An analogous reaction to that described in example 255 but starting with 4-hydroxypiperidine (334 mg, 3.3 mmol) yielded compound 483 in Table 17 (28 mg, 22%).
  • MS ES+: 585 (M+H)+
  • 1HNMR (DMSOd6): 1.40 (m, 2H); 1.73 (m, 2H); 1.96 (m, 2H); 2.03 (m, 2H); 2.45 (m, 2H); 2.74 (m, 2H); 3.45 (m, 1H); 3.92 (s, 2H); 3.97 (s, 3H); 3.97 (t, 2H); 4.54 (d, 1H); 6.95 (m, 1H); 7.26 (s, 1H); 7.36 (dd, 2H); 7.40 (s, 1H); 8.14 (brs, 1H); 8.68 (s, 1H); 10.65 (s, 1H); 12.04 (brs, 1H).
    • EXAMPLE 307 Preparation of Compound 484 in Table 17
  • An analogous reaction to that described in example 255 but starting with 3-pyrrolidinol (288 mg, 3.3 mmol) yielded compound 484 in Table 17 (30 mg, 23%).
  • MS ES+: 571 (M+H)+
  • 1HNMR (DMSOd6): 1.57 (m, 1H); 1.97 'm, 4H); 2.37 (m, 1H); 2.58 (m, 4H); 2.74 (m, 1H); 3.92 (s, 2H); 3.98 (s 3H); 4.22 (brt, 2H); 4.72 (brs, 1H); 6.95 (m, 1H); 7.26 (s, 1H); 7.36 (dd, 2H); 7.40 (s, 1H); 8.13 (brs, 1H); 8.69 (s, 1H); 10.65 (s, 1H); 12.04 (brs, 1H).
    • EXAMPLE 308 Preparation of Compound 485 in Table 17
  • An analogous reaction to that described in example 255 but starting with 1-(2-aminoethyl)pyrrolidine (377 mg, 3.3 mmol) yielded compound 485 in Table 17 (25 mg, 19%)
  • MS ES+: 598 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.91 (m, 2H); 2.06 (m, 2H); 2.24 (m, 2H); 3.11 (m, 2H); 3.23 (t, 2H); 3.41 (1 m, 2H); 3.49 (m, 2H); 3.67 (m, 2H); 3.99 (s, 3H); 4.01 (s, 2H); 4.31 (t, 2H); 6.89 (t, 1H); 7.32 (s, 1H); 7.34 (d, 2H); 7.64 (s, 1H); 7.92 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 309 Preparation of Compound 486 in Table 17
  • An analogous reaction to that described in example 255 but starting with 4-hydroxymethylpyperidine (380 mg, 3.3 mmol) yielded compound 486 in Table 17 (62 mg, 47%).
  • MS ES+: 599 (M+H)+
  • 1HNMR (DMSOd6): 1.14 (m, 2H); 1.34 (m, 1H); 1.65 (d, 2H); 1.88 (t, 2H); 1.96 (m, 2H); 2.45 (t, 2H); 2.90 (d, 2H); 3.25 (t, 2H); 3.92 (s, 2H); 3.97 (s, 3H); 4.20 (t, 2H); 4.41 (t, 1H); 6.94 (m, 1H); 7.26 (s, 1H); 7.36 (dd, 2H); 7.40 (s, 1H); 8.13 (brs, 1H); 8.68 (s, 1H); 10.64 (s, 1H); 12.07 (brs, 1H).
    • EXAMPLE 310 Preparation of Compound 487 in Table 17
  • An analogous reaction to that described in example 255 but starting with 2-(2-hydroxyethyl)piperidine (426 mg, 3.3 mmol) yielded compound 487 in Table 17 (61 mg, 45%).
  • MS ES+: 613 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.47-1.90 (m, 7H); 2.09 (m, 1H); 2.27 (m, 2H); 3.08-3.70 (m, 7H); 3.99 (s, 3H); 4.00 (s, 2H); 4.30 (m, 2H); 6.84 (m, 1H); 7.29 (d, 1H); 7.34 (dd, 1H); 7.62 (s, 1H); 7.92 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 311 Preparation of Compound 488 in Table 17
  • An analogous reaction to that described in example 255 but starting with 1-(2-hydroxyethyl)piperazine (430 mg, 3.3 mmol) yielded compound 488 in Table 17 (124 mg, 92%).
  • MS ES+: 614 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.96 (m, 2H); 2.40 (m, 12H); 2.70 (m, 1H); 3.48 (m, 2H); 3.90 (s, 2H); 3.95 (s, 3H); 4.18 (t, 2H); 4.35 (brt, 1H); 6.43 (m, 1H); 7.23 (s, 1H); 7.34 (dd, 2H); 7.38 (s, 1H); 8.10 (s, 1H); 8.66 (s, 1H); 10.63 (s, 1H).
    • EXAMPLE 312 Preparation of Compound 489 in Table 17
  • An analogous reaction to that described in example 255 but starting with 4-(2-hydroxyethyl)piperidine (426 mg, 3.3 mmol) yielded compound 489 in Table 17 (54 mg, 40%).
  • MS ES+: 613 (M+H)+
  • 1HNMR (DMSOd6): 1.15 (m, 2H); 1.36 (m, 3H); 1.63 (brd, 2H); 1.88 (m, 2H); 1.96 (m, 2H); 2.44 (m, 2H); 2.87 (brd, 2H); 3.44 (m, 2H); 3.92 (s, 2H); 3.97 (s, 3H); 4.20 (t, 2H); 4.33 (t, 1H); 6.95 (m, 1H); 7.26 (s, 1H); 7.36 (dd, 2H); 7.40 (s, 1H); 8.13 (brs, 1H); 8.68 (s, 1H); 10.64 (s, 1H); 12.04 (brs, 1H).
    • EXAMPLE 313 Preparation of Compound 490 in Table 17
  • An analogous reaction to that described in example 255 but starting with 3-hydroxypiperidine (334 mg, 3.3 mmol) yielded compound 490 in Table 17 (53 mg, 41%).
  • MS ES+: 559 (M+H)+
  • 1HNMR (DMSOd6): 1.09 (m, 1H); 1.43 (m, 1H); 1.64 (m, 1H); 1.79 (m, 2H); 1.87 (m, 1H); 1.96 (m, 2H); 2.47 (m, 2H); 2.69 (m, 2H); 2.85 (m, 2H); 3.49 (m, 1H); 3.92 (s, 2H); 3.98 (s, 3H); 4.21 (t, 2H); 4.60 (d, 1H); 6.95 (t, 1H); 7.26 (s, 1H); 7.36 (d, 2H); 7.40 (s, 1H); 8.13 (brs, 1H); 8.69 (s, 1H); 10.65 (s, 1H); 12.04 (brs, 1H).
    • EXAMPLE 314 Preparation of Compound 491 in Table 17
  • An analogous reaction to that described in example 255 but starting with N,N,N′-trimethylethylenediamine (337 mg, 3.3 mmol) yielded compound 491 in Table 17 (54 mg, 42%).
  • MS ES+: 586 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (m, 1H); 2.34 (m, 1H); 2.88 (s, 6H); 2.93 (s, 3H); 3.39 (m, 2H); 3.56 (m, 4H); 3.99 (s, 3H); 4.01 (s, 2H); 4.30 (t, 2H); 6.91 (m, 1H); 7.33 (s, 1H); 7.35 (dd, 2H); 7.64 (s, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 315 Preparation of Compound 492 in Table 17
  • An analogous reaction to that described in example 255 but starting with piperidine (281 mg, 3.3 mmol) yielded compound 492 in Table 17 (81 mg, 64%).
  • MS ES+: 569 (M+H)+
  • 1HNMR (DMSOd6): 1.38 (m, 2H); 1.50 (m, 4H); 2.34 (brs, 4H); 2.41 (t, 2H); 3.90 (s, 2H); 3.96 (s, 3H); 4.19 (t, 2H); 6.93 (t, 1H); 7.24 (s, 1H); 7.34 (d, 2H); 7.38 (s, 1H); 8.11 (brs, 1H); 8.67 (s, 1H); 10.63 (s, 1H); 11.98 (brs, 1H).
    • EXAMPLE 316 Preparation of Compound 493 in Table 17
  • An analogous reaction to that described in example 255 but starting with pyrrolidine (235 mg, 3.3 mmol) yielded compound 493 in Table 17 (66 mg, 54%).
  • MS ES+: 555 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.90 (m, 2H); 2.06 (m, 2H); 2.28 (m, 2H); 3.09 (m, 2H); 3.36 (m, 2H); 3.68 (m, 2H); 3.99 (s, 3H); 4.01 (s, 2H); 4.29 (t, 2H); 6.93 (m, 1H); 7.30 (s, 1H); 7.34 (dd, 2H); 7.65 (s, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 317 Preparation of Compound 494 in Table 17
  • An analogous reaction to that described in example 255 but starting with 2-amino-2-methyl-1-propanol (294 mg, 3.3 mmol) yielded compound 494 in Table 17 (28 mg, 22%).
  • MS ES+: 573 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.24 (s, 6H); 2.23 (m, 2H); 3.10 (t, 2H); 3.45 (s, 2H); 3.99 (s, 3H); 4.01 (s, 2H); 4.31 (t, 2H); 6.91 (m, 1H); 7.30 (s, 1H); 7.34 (dd, 2H); 7.64 (s, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 318 Preparation of Compound 495 in Table 17
  • An analogous reaction to that described in example 255 but starting with 2-methylaminoethanol (248 mg, 3.3 mmol) yielded compound 495 in Table 17 (33 mg, 27%).
  • MS ES+: 559 (M+H)+
  • 1HNMR (DMSOd6): 1.95 (m, 2H); 2.24 (s, 3H); 2.48 (m, 2H); 2.45 (m, 2H); 3.49 (m, 2H); 3.93 (s, 2H); 3.98 (s, 3H); 4.21 (t, 2H); 4.38 (m, 1H); 6.95 (m, 1H); 7.27 (s, 1H); 7.36 (dd, 2H); 7.40 (s, 1H); 8.13 (brs, 1H); 8.69 (s, 1H); 10.65 (s, 1H); 12.04 (brs, 1H).
    • EXAMPLE 319 Preparation of Compound 496 in Table 17
  • An analogous reaction to that described in example 255 but starting with N,N-dimethylethylenediamine (291 mg, 3.3 mmol) yielded compound 496 in Table 17 (22 mg, 17%).
  • MS ES+: 572 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.23 (m, 2H); 2.89 (s, 6H); 3.22 (m, 2H); 3.41 (s, 4H); 3.96 (s, 3H); 4.01 (s, 2H); 4.31 (t, 2H); 6.92 (m, 1H); 7.31 (s, 1H); 7.35 (dd, 2H); 7.64 (s, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 320 Preparation of Compound 497 in Table 17
  • An analogous reaction to that described in example 255 but starting with (S(-(+)-1-amino-2-propanol (248 mg, 3.3 mmol) yielded compound 497 in Table 17 (32 Mg, 26%).
  • MS ES+: 559 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.15 (d, 3H); 2.24 (m, 2H); 2.83 (dd, 1H); 3.06 (dd, 1H); 3.15 (t, 2H); 3.95 (m, 1H); 3.99 (s, 3H); 4.01 (s, 3H); 4.29 (t, 1H); 6.92 (m, 1H); 7.28 (s, 1H); 7.34 (dd, 2H); 7.65 (s, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 321 Preparation of Compound 498 in Table 17
  • An analogous reaction to that described in example 255 but starting with (R)-(−)-1-amino-2-propanol (248 mg, 3.3 mmol) yielded compound 498 in Table 17 (40 mg, 32%).
  • MS ES+: 559 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.15 (d, 3H); 2.24 (m, 2H); 2.83 (dd, 1H); 3.06 (dd, 1H); 3.15 (t, 2H); 3.95 (m, 1H); 3.99 (s, 3H); 4.01 (s, 3H); 4.29 (t, 1H); 6.90 (m, 1H); 7.28 (s, 1H); 7.34 (dd, 2H); 7.64 (s, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 322 Preparation of Compound 499 in Table 17
  • An analogous reaction to that described in example 255 but starting with tert-butyl-1-piperazine carboxylate (615 mg, 3.3 mmol) and treating the crude reaction mixture with hydrochloric acid in 1,4-dioxane (4M, 2 ml) yielded compound 499 in Table 17 (66 mg, 45%, 3 HCl).
  • MS ES+: 570 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.35 (m, 2H); 3.20-3.94 (m, 10H); 3.99 (s, 3H); 4.03 (s, 2H); 4.33 (t, 2H); 6.93 (m, 1H); 7.36 (s, 1H); 7.37 (dd, 2H); 7.65 (s, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 323 Preparation of Compound 500 in Table 17
  • An analogous reaction to that described in example 255 but starting with N-alkylpiperazine (416 mg, 3.3 mmol) yielded compound 500 in Table 17 (33 mg, 25%).
  • MS ES+: 610 (M+H)+
  • 1HNMR (DMSOd6): 1.96 (m, 2H); 2.30-2.50 (m, 10H); 2.93 (d, 2H); 3.92 (s, 2H); 3.97 (s, 3H); 4.20 (t, 2H); 5.12 (d, 1H); 5.18 (d, 1H); 5.82 (m, 1H); 6.95 (m, 1H); 7.25 (s, 1H); 7.35 (dd, 2H); 7.40 (s, 1H); 8.12 (s, 1H); 8.68 (s, 1H); 10.64 (s, 1H); 11.99 (brs, 1H).
    • EXAMPLE 324 Preparation of Compound 501 in Table 17
  • An analogous reaction to that described in example 255 but starting with (R)-(−)-2-pyrrolidinemethanol (334 mg, 3.3 mol) yielded compound 501 in Table 17 (51 mg, 40%).
  • MS ES+: 585 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.57 (m, 1H); 1.67 (m, 2H); 1.82 (m, 1H); 1.96 (m, 2H); 2.18 (q, 1H); 2.45 (m, 3H); 2.98 (m, 1H); 3.10 (m, 1H); 3.20 (m, 1H); 3.92 (s, 2H); 3.98 (s, 3H); 4.22 (t, 2H); 4.35 (brs, 1H); 6.95 (m, 1H); 7.27 (s, 1H); 7.36 (dd, 2H); 7.40 (s, 1H); 8.13 (s, 1H); 8.68 (s, 1H); 10.66 (s, 1H); 12.00 (brs, 1H).
    • EXAMPLE 325 Preparation of Compound 502 in Table 17
  • An analogous reaction to that described in example 255 but starting with cyclopentylamine (281 mg, 3.3 mmol) yielded compound 502 in Table 17 (28 mg, 22%).
  • MS ES+: 569 (M+H)+
  • 1HNMR (DMSOd6): 1.31 (m, 2H); 1.47 (m, 2H); 1.62 (m, 2H); 1.73 (m, 2H); 1.93 (m, 2H); 2.70 (t, 2H); 3.03 (m, 1H); 3.92 (s, 2H); 3.97 (s, 3H); 4.23 (t, 2H); 6.94 (m, 1H); 7.26 (s, 1H); 7.36 (dd, 2H); 7.39 (s, 1H); 8.11 (s, 1H); 8.67 (s, 1H); 10.66 (s, 1H).
    • EXAMPLE 326 Preparation of Compound 503 in Table 17
  • An analogous reaction to that described in example 256 but starting with 2-methylaminoethanol (248 mg, 3.3 mmol) yielded compound 503 in Table 17 (31 mg, 24%).
  • MS ES+: 575 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (m, 2H); 2.88 (s, 3H); 3.16-3.45 (m, 4H); 3.77 (t, 2H); 3.99 (s, 5H); 4.29 (t, 2H); 7.30 (s, 1H); 7.38 (t, 1H); 7.50 (m, 1H); 7.64 (s, 1H); 7.91 (s, 1H); 7.97 (dd, 1H); 9.09 (s, 1H).
    • EXAMPLE 327 Preparation of Compound 504 in Table 17
  • An analogous reaction to that described in example 256 but starting with N,N,N′-trimethylethylenediamine (337 mg, 3.3 mmol) yielded compound 504 in Table 17 (28 mg, 21%).
  • MS ES+: 602 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (m, 2H); 2.89 (s, 6H); 2.93 (s, 3H); 3.38 (m, 2H); 3.56 (brs, 4H); 3.99 (s, 5H); 4.30 (t, 2H); 7.35 (s, 1H); 7.39 (t, 1H); 7.50 (m, 1H); 7.65 (s, 1H); 7.91 (s, 1H); 7.97 (dd, 1H); 9.09 (s, 1H).
    • EXAMPLE 328 Preparation of Compound 505 in Table 17
  • An analogous reaction to that described in example 256 but starting with N-alkylpyperazine (416 mg, 3.3 mmol) yielded compound 505 in Table 17 (42 mg, 30%).
  • MS ES+: 626 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.33 (m, 2H); 3.20-3.80 (m, 10H); 3.91 (d, 2H); 3.99 (s, 5H); 4.32 (t, 2H); 5.60 (m, 2H); 5.94 (m, 1H); 7.33 (s, 1H); 7.39 (t, 1H); 7.50 (m, 1H); 7.65 (s, 1H); 7.91 (s, 1H); 7.97 (dd, 1H); 9.09 (s, 1H).
    • EXAMPLE 329 Preparation of Compound 506 in Table 17
  • An analogous reaction to that described in example 256 but starting with 4-hydroxypiperidine (334 mg, 3.3 mmol) yielded compound 506 in Table 17 (32 mg, 25%).
  • MS ES+: 601 (M+H)+
  • 1HNMR (DMSOd6): 1.41 (m, 2H); 1.73 (m, 2H); 1.96 (m, 2H); 2.03 (m, 2H); 2.45 (m, 2H); 2.74 (m, 2H); 3.46 (m, 1H); 3.90 (s, 2H); 3.98 (s, 3H); 4.21 (t, 2H); 4.55 (brs, 1H); 7.26 (s, 1H); 7.40 (s, 1H); 7.41 (t, 1H); 7.51 (m, 1H); 7.97 (dd, 1H); 8.13 (brs, 1H); 8.69 (s, 1H); 10.49 (s, 1H); 12.03 (brs, 1H).
    • EXAMPLE 330 Preparation of Compound 507 in Table 17
  • An analogous reaction to that described in example 256 but starting with 3-pyrrolidinol (288 mg, 3.3 mmol) yielded compound 507 in Table 17 (24 mg, 19%).
  • MS ES+: 587 (M+H)+
  • 1HNMR (DMSOd6): 1.57 (m, 1H); 1.98 (m, 3H); 2.30-2.81 (m, 6H); 3.38 (m, 1H); 3.90 (s, 2H); 3.98 (s, 3H); 4.22 (t, 2H); 4.74 (brs, 1H); 7.27 (s, 1H); 7.39 (s, 1H); 7.40 (t, 1H); 7.50 (m, 1H); 7.96 (dd, 1H); 8.13 (brs, 1H); 8.69 (s, 1H); 10.49 (s, 1H); 12.05 (brs, 1H).
    • EXAMPLE 331 Preparation of Compound 508 in Table 17
  • An analogous reaction to that described in example 256 but starting with 1-(2-aminoethyl)pyrrolidine (377 mg, 3.3 mmol) yielded compound 508 in Table 17 (18 mg, 13%).
  • MS ES+: 614 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.91 (m, 2H); 2.06 (m, 2H); 2.23 (m, 2H); 3.11 (m, 2H); 3.22 (t, 2H); 3.41 (m, 2H); 3.47 (m, 2H); 3.67 (m, 2H); 3.98 (s, 5H); 4.30 (t, 2H); 7.30 (s, 1H); 7.36 (t, 1H); 7.49 (m, 1H); 7.63 (s, 1H); 7.91 (s, 1H). 7.95 (dd, 1H); 9.09 (s, 1H).
    • EXAMPLE 332 Preparation of Compound 509 in Table 17
  • An analogous reaction to that described in example 256 but starting with N-acetylpiperazine (423 mg, 3.3 mmol) yielded compound 509 in Table 17 (113 mg, 82%).
  • MS ES+: 628 (M+H)+
  • 1HNMR (DMSOd6): 1.98 (m, 2H); 2.00 (s, 3H); 2.36 (t, 2H); 2.42 (t, 2H); 2.92 (t, 0.5H); 2.99 (t, 0.5H); 3.45 (m, 4H); 3.55 (t, 1H); 3.90 (s, 2H); 3.98 (s, 3H); 4.23 (t, 2H); 7.27 (s, 1H); 7.40 (s, 1H); 7.41 (t, 1H); 7.52 (m, 1H); 7.97 (dd, 1H); 8.13 (s, 1H); 8.69 (s, 1H); 10.51 (s, 1H).
    • EXAMPLE 333 Preparation of Compound 510 in Table 17
  • An analogous reaction to that described in example 256 but starting with 2-(2-hydroxyethyl)piperidine (426 mg, 3.3 mmol) yielded compound 510 in Table 17 (34 mg, 24%).
  • MS ES+: 629 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.48-1.90 (m, 7H); 2.08 (m, 1H); 2.27 (m, 2H); 3.09-3.69 (m, 7H); 3.99 (s, 5H); 4.30 (m, 2H); 7.30 (d, 1H); 7.38 (t, 1H); 7.50 (m, 1H); 7.64 (s, 1H); 7.91 (s, 1H); 7.97 (dd, 1H); 9.09 (s, 1H).
    • EXAMPLE 334 Preparation of Compound 511 in Table 17
  • An analogous reaction to that described in example 256 but starting with 2-(2-hydroxyethyl)piperazine (430 mg, 3.3 mmol) yielded compound 511 in Table 17 (80 mg, 58%).
  • MS ES+: 630 (M+H)+
  • 1HNMR (DMSOd6): 1.96 (m, 2H); 2.42 (m, 12H); 3.49 (dd, 2H); 3.90 (s, 2H); 3.97 (s, 3H); 4.20 (t, 2H); 4.37 (t, 1H); 7.25 (s, 1H); 7.39 (s, 1H); 7.40 (t, 1H); 7.51 (m, 1H); 7.97 (dd, 1H); 8.12 (s, 1H); 8.68 (s, 1H); 10.42 (s, 1H); 12.02 (brs, 1H).
    • EXAMPLE 335 Preparation of Compound 512 in Table 17
  • An analogous reaction to that described in example 256 but starting with cyclopentylamine (281 mg, 3.3 mmol) yielded compound 512 in Table 17 (12 mg, 9%).
  • MS ES+: 585 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.59 (m, 4H); 1.73 (m, 2H); 2.00 (m, 2H); 2.21 (m, 2H); 3.13 (t, 2H); 3.56 (m, 1H); 3.99 (s, 5H); 4.31 (t, 2H); 7.29 (s, 1H); 7.37 (t, 1H); 7.49 (m, 1H); 7.64 (s, 1H); 7.92 (s, 1H); 7.96 (dd, 1H); 9.09 (s, 1H).
    • EXAMPLE 336 Preparation of Compound 513 in Table 17
  • An analogous reaction to that described in example 256 but starting with 4-(2-hydroxyethyl)piperidine (426 mg, 3.3 mmol) yielded compound 513 in Table 17 (54 mg, 39%).
  • MS ES+: 629 (M+H)+
  • 1HNMR (DMSOd6): 1.15 (m, 2H); 1.36 (m, 3H); 1.63 (d, 2H); 1.88 (t, 2H); 1.96 (m, 2H); 2.44 (t, 2H); 2.87 (d, 2H); 3.44 (m, 2H); 3.90 (s, 2H); 3.97 (s, 3H); 4.20 (t, 2HJ); 4.33 (t, 1H); 7.25 (s, 1H); 7.40 (s, 1H); 7.41 (t, 1H); 7.51 (m, 1H); 7.97 (dd, 1H); 8.12 (s, 1H); 8.68 (s, 1H); 10.48 (s, 1H); 12.03 (brs, 1H).
    • EXAMPLE 337 Preparation of Compound 514 in Table 17
  • An analogous reaction to that described in example 256 but starting with 3-hydroxypiperidine (334 mg, 3.3 mmol) yielded compound 514 in Table 17 (96 mg, 73%).
  • MS ES+: 601 (M+H)+
  • 1HNMR (DMSOd6): 1.09 (m, 1H); 1.43 (m, 1H); 1.63 (m, 1H); 1.78 (m, 2H); 1.87 (m, 1H); 1.96 (m, 2H); 2.47 (m, 2H); 2.68 (m, 1H); 2.84 (brd, 1H); 3.50 (m, 1H); 3.90 (s, 2H); 3.98 (s, 3H); 4.20 (t, 2H); 4.59 (d, 1H); 7.26 (s, 1H); 7.40 (s, 1H); 7.41 (t, 1H); 7.51 (m, 1H); 7.97 (dd, 1H); 8.13 (brs, 1H); 8.68 (s, 1H); 10.48 (s, 1H); 12.03 (brs, 1H).
    • EXAMPLE 338 Preparation of Compound 515 in Table 17
  • An analogous reaction to that described in example 256 but starting with 4-hydroxymethylpyperidine (380 mg, 3.3 mmol) yielded compound 515 in Table 17 (18 mg, 13%).
  • MS ES+: 615 (M+H)+
  • 1HNMR (DMSOd6): 1.15 (m, 2H); 1.35 (m, 1H); 1.65 (d, 2H); 1.88 (m, 2H); 1.97 (m, 2H); 2.46 (m, 2H); 2.91 (m, 2H); 3.25 (t, 2H); 3.90 (s, 2H); 3.97 (s, 3H); 4.21 (t, 2H); 4.41 (t, 1H); 7.26 (s, 1H); 7.40 (s, 1H); 7.41 (t, 1H); 7.50 (m, 1H); 7.97 (dd, 1H); 8.13 (brs, 1H); 8.68 (s, 1H); 10.49 (s, 1H); 12.03 (brs, 1H).
    • EXAMPLE 339 Preparation of Compound 516 in Table 17
  • An analogous reaction to that described in example 256 but starting with 1-amino-2-propanol (248 mg, 3.3 mmol) yielded compound 516 in Table 17 (14 mg, 11%).
  • MS ES+: 575 (M+H)+
  • 1HNMR (DMSOd6): 1.06 (d, 3H); 1.96 (m, 2H); 2.49 (m, 2H); 2.74 (t, 2H); 3.71 (m, 2H); 3.90 (s, 2H); 3.98 (s, 3H); 4.24 (t, 2H); 4.50 (brs, 1H); 7.27 (s, 1H); 7.39 (s, 1H); 7.41 (t, 1H); 7.51 (m, 1H); 7.97 (dd, 1H); 8.12 (s, 1H); 8.68 (s, 1H); 10.49 (s, 1H).
    • EXAMPLE 340 Preparation of Compound 517 in Table 17
  • An analogous reaction to that described in example 256 but starting with tert-butyl-1-piperazinecarboxylate (615 mg, 3.3 mmol) and treating the crude reaction mixture with hydrochloric acid in 1,4-dioxane (4 M, 2 ml) yielded compound 517 in Table 17 (61 mg, 47%).
  • MS ES+: 586 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (m, 2H); 3.00-3.95 (m, 10 H) 3.99 (s, 5H); 4.31 (t, 2H); 7.32 (s, 1H); 7.39 (t, 1H); 7.50 (m, 1H); 7.65 (s, 1H); 7.91 (s, 1H); 7.97 (dd, 1H); 9.10 (s, 1H).
    • EXAMPLE 341 Preparation of Compound 518 in Table 17
  • An analogous reaction to that described in example 256 but starting with 1-(2-morpholinoethyl)piperazine (519 mg, 3.3 mmol) yielded compound 518 in Table 17 (69 mg, 48%).
  • MS ES+: 699 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (m, 2H); 2.98 (m, 2H); 3.10-37.5 (m, 16H); 3.86 (m, 4H); 3.99 (s, 5H); 4.31 (t, 2H); 7.33 (s, 1H); 7.39 (t, 1H); 7.50 (m, 1H); 7.65 (s, 1H); 7.92 (s, 1H); 7.97 (dd, 1H); 9.10 (s, 1H).
    • EXAMPLE 342 Preparation of Compound 519 in Table 17
  • An analogous reaction to that described in example 256 but starting with pyrrolidine (235 mg, 3.3 mmol) yielded compound 519 in Table 17 (55 mg, 44%).
  • MS ES+: 571 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.90 (m, 2H); 2.06 (m, 2H); 2.27 (m, 2H); 3.09 (m, 2H); 3.36 (t, 2H); 3.66 (m, 2H); 3.98 's, 5H); 4.29 (t, 2H); 7.29 (s, 1H); 7.39 (t, 1H); 7.50 (m, 1H); 7.64 (s, 1H); 7.90 (s, 1H); 7.96 (dd, 1H); 9.09 (s, 1H).
    • EXAMPLE 343 Preparation of Compound 520 in Table 17
  • An analogous reaction to that described in example 257 but starting with 2-methylaminoethanol (248 mg, 3.3 mmol) yielded compound 520 in Table 17 (34 mg, 29%).
  • MS ES+: 541 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.30 (m, 2H); 3.57 (s, 3H); 3.16-3.45 (m, 4H); 3.75 (t, 2H); 3.98 (s, 3H); 3.99 (s, 2H); 4.29 (t, 2H); 6.89 (t, 1H); 7.29 (s, 1H); 7.30-7.40 (m, 2H); 7.62 (d, 1H); 7.63 (s, 1H); 7.91 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 344 Preparation of Compound 521 in Table 17
  • An analogous reaction to that described in example 257 but starting with 1,2-diamino-2-methylpropane (291 mg, 3.3 mmol) yielded compound 521 in Table 17 (10 mg, 8%).
  • MS ES+: 554 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.39 (s, 6H); 2.27 (m, 2H); 3.22 (m, 4H); 3.97 (s, 3H); 3.98 (s, 2H); 4.32 (t, 2H); 6.89 (m, 1H); 7.29-7.39 (m, 3H); 7.62 (d, 1H); 7.63 (s, 1H); 7.92 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 345 Preparation of Compound 522 in Table 17
  • An analogous reaction to that described in example 257 but starting with N,N-dimethylethylenediamine (291 mg, 3.3 mmol) yielded compound 522 in Table 17 (26 mg, 22%).
  • MS ES+: 554 (M+H)+
  • 1HNMR (DMSOd6)): 1.95 (m, 2H); 2.15 (s, 6H); 2.33 (t, 2H); 2.63 (t, 2H); 2.73 (t, 2H); 3.90 (s, 2H); 3.97 (s, 3H); 4.23 (t, 2H); 6.91 (m, 1H); 7.26 (s, 1H); 7.31-7.42 (m, 2H); 7.39 (s, 1H); 7.64 (d, 1H); 8.11 (s, 1H); 8.68 (s, 1H); 10.48 (s, 1H).
    • EXAMPLE 346 Preparation of Compound 523 in Table 17
  • An analogous reaction to that described in example 257 but starting with N,N,N′-trimethylethylenediamine (337 mg, 3.3 mmol) yielded compound 523 in Table 17 (37 mg, 30%).
  • MS ES+: 568 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.34 (m, 2H); 2.88 (s, 6H); 2.93 (s, 3H); 3.38 (m, 2H); 3.55 (m, 4H); 3.98 (s, 3H); 3.99 (s, 2H); 4.29 (t, 2H); 6.89 (m, 1H); 7.29-7.41 (m, 2H); 7.33 (s, 1H); 7.63 (d, 1H); 7.64 (s, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 347 Preparation of Compound 524 in Table 17
  • An analogous reaction to that described in example 257 but starting with N-alkylpiperazine (416 mg, 3.3 mmol) yielded compound 524 in Table 17 (77 mg, 59%).
  • MS ES+: 592 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.34 (m, 2H); 3.00-3.08 (m, 8H); 2.86 (d, 2H); 3.92 (m, 2H); 3.98 (s, 3H); 3.99 (s, 2H); 4.31 (t, 2H); 5.53-5.66 (m, 2H); 5.60-5.87 (m, 1H); 6.89 (m, 1H); 7.31-7.40 (m, 3H); 7.62 (d, 1H); 7.63 (s, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 348 Preparation of Compound 525 in Table 17
  • An analogous reaction to that described in example 257 but starting with 4-hydroxypyperidine (334 mg, 3.3 mmol) yielded compound 525 in Table 17 (21 mg, 17%).
  • MS ES+: 567 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.59 (m, 1H); 1.85 (m, 2H); 2.01 (d, 1H); 2.28 (m, 2H); 3.03 (t, 1H); 3.21 (m, 1H); 3.28 (m, 2H); 3.40 (m, 1H ); 3.57 (d, 1H); 3.68 (m, 1H); 3.98 (s, 3H); 3.99 (s, 2H); 4.28 (t, 2H), 6.90 (t, 1H); 7.29 (s, 1H); 7.30-7.40 (m, 2H); 7.63 (d, 1H); 7.64 (s, 1H), 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 349 Preparation of Compound 526 in Table 17
  • An analogous reaction to that described in example 257 but starting with 3-pyrrolidinol (288 mg, 3.3 mmol) yielded compound 526 in Table 17 (18 mg, 15%).
  • MS ES+: 553 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.84-2.03 (m, 2H); 2.27 (m, 2H); 3.02-3.79 (m, 6H); 3.99 (s, 3H); 4.00 (s, 2H); 4.29 (m, 2H); 4.41-4.51 (m, 1H); 6.91 (m, 1H); 7.28 (d, 1H); 7.31-7.41 (m, 2H); 7.63 (d, 1H); 7.64 (s, 1H); 7.91 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 350 Preparation of Compound 527 in Table 17
  • An analogous reaction to that described in example 257 but starting with 1-(aminoethyl)pyrrolidine (377 mg, 3.3 mmol) yielded compound 527 in Table 17 (34 mg, 27%).
  • MS ES+: 580(M+H)+
  • 1HNMR (DMSOd6): 1.68 (m, 4H); 1.97 (m, 2H); 2.47 (m, 6H); 2.70 (t, 2H); 2.77 (t, 2H); 3.91 (s, 2H); 3.97 (s, 3H); 4.24 (t, 2H); 6.91 (m, 1H); 7.27 (s, 1H); 7.30-7.42 (m, 2H); 7.39 (s, 1H); 7.64 (d, 1H), 8.12 (s, 1H); 8.68 (s, 1H); 10.49 (s, 1H).
    • EXAMPLE 351 Preparation of Compound 528 in Table 17
  • An analogous reaction to that described in example 257 but starting with N-acetylpiperazine (423 mg, 3.3 mmol) yielded compound 528 in Table 17 (93 mg, 71%).
  • MS ES+: 594 (M+H)+
  • 1HNMR (DMSOd6): 1.99 (m, 2H); 2.00 (s, 3H); 2.35 (t, 2H); 2.41 (t, 2H); 2.49 (m, 2H); 3.45 (m, 4H); 3.91 (s, 2H); 3.97 (s, 3H); 4.23 (t, 2H); 6.92 (m, 1H); 7.27 (s, 1H); 7.32-7.42 (m, 2H); 7.40 (s, 1H); 7.63 (d, 1H); 8.13 (brs, 1H); 8.69 (s, 1H); 10.48 (s, 1H).
    • EXAMPLE 352 Preparation of Compound 529 in Table 17
  • An analogous reaction to that described in example 257 but starting with 1-(2-hydroxyethyl)piperazine (430 mg, 3.3 mmol) yielded compound 529 in Table 17 (91 mg, 69%).
  • MS ES+: 596 (M+H)+
  • 1HNMR (DMSOd6): 1.96 (m, 2H); 2.41 (m, 12H); 3.50 (q, 2H); 3.91 (s, 2H); 3.97 (s, 3H); 4.20 (t, 2H); 4.37 (t, 1H); 6.91 (t, 1H); 7.25 (s, 1H); 7.32-7.42 (m, 2H); 7.39 (s, 1H); 7.65 (d, 1H); 8.12 (s, 1H); 8.68 (s, 1H); 10.48 (s, 1H); 12.04 (brs, 1H).
    • EXAMPLE 353 Preparation of Compound 530 in Table 17
  • An analogous reaction to that described in example 257 but starting cyclopentylamine (281 mg, 3.3 mmol) yielded compound 530 in Table 17 (47 mg, 39%).
  • MS ES+: 551 (M+H)+
  • 1HNMR DMSOd6): 1.39 (m, 2H); 1.50 (m, 2H); 1.65 (m, 2H); 1.80 (m, 2H); 2.00 (m, 2H); 2.80 (t, 2H); 3.16 (m, 1H); 3.91 (s, 2H); 3.98(s, 3H); 4.25 (t, 2H); 6.98 (t, 1H); 7.28 (s, 1H); 7.31-7.42 (m, 2H); 7.40 (s, 1H); 7.64 (d, 1H); 8.13 (s, 1H); 8.69 (s, 1H); 10.49 (s, 1H).
    • EXAMPLE 354 Preparation of Compound 531 in Table 17
  • An analogous reaction to that described in example 257 but starting with 4-(2-hydroxyethyl)piperidine (426 mg, 3.3 mmol) yielded compound 531 in Table 17 (65 mg, 50%).
  • MS ES+: 595 (M+H)+
  • 1HNMR (DMSOd6): 1.15 (m, 2H); 1.36 (m, 3H); 1.63 (d, 2H); 1.88 (m, 2H); 1.96 (m, 2H); 2.44 (m, 2H); 2.87 (d, 2H); 3.44 (m, 2H); 3.91 (s, 2H); 3.97 (s, 3H); 4.20 (t, 2H); 4.33 (t, 1H); 6.91 (t, 1H); 7.25 (s, 1H); 7.32-7.42 (m, 2H); 7.40 (s, 1H); 7.63 (d, 1H); 8.12 (brs, 1H); 8.68 (s, 1H); 10.48 (s, 1H); 12.03 (s, 1H).
    • EXAMPLE 355 Preparation of Compound 532 in Table 17
  • An analogous reaction to that described in example 257 but starting with 3-hydroxypiperidine (334 mg, 3.3 mmol) yielded compound 532 in Table 17 (72 mg, 58%).
  • MS ES+: 567 (M+H)+
  • 1HNMR (DMSOd6): 1.09 (m, 1H); 1.43 (m, 1H); 1.63 (m, 1H); 1.78 (m, 2H); 1.87 (m, 1H); 1.96 (t, 2H); 2.47 (m, 2H); 2.69 (m, 1H); 2.85 (brd, 1H); 3.49 (m, 1H); 3.91 (s, 2H); 3.98 (s, 3H); 4.20 (t, 2H); 4.60 (d, 1H), 6.91 (t, 1H); 7.26 (s, 1H); 7.31-7.42 (m, 2H); 7.40 (s, 1H); 7.64 (d, 1H); 8.13 (brs, 1H); 8.68 (s, 1H); 10.48 (s, 1H); 12.02 (brs, 1H).
    • EXAMPLE 356 Preparation of Compound 533 in Table 17
  • An analogous reaction to that described in example 257 but starting with 4-hydroxymethylpyperidine (380 mg, 3.3 mmol) yielded compound 533 in Table 17 (56 mg, 44%).
  • MS ES+: 581 (M+H)+
  • 1HNMR (DMSOd6): 1.14 (m, 2H); 1.34 (m, 1H); 1.65 (d, 2H); 1.88 (t, 2H); 1.97 (m, 2H); 2.45 (t, 2H); 2.90 (d, 2H); 3.25 (t, 2H); 3.91 (s, 2H); 3.97 (s, 3H); 4.20 (t, 2H); 4.41 (t, 1H); 6.93 (t, 1H); 7.25 (s, 1H); 7.32-7.42 (m, 2H); 7.40 (s, 1H); 7.63 (d, 1H); 8.12 (brs, 1H); 8.68 (s, 1H); 10.48 (s, 1H); 12.03 (brs, 1H).
    • EXAMPLE 357 Preparation of Compound 534 in Table 17
  • An analogous reaction to that described in example 257 but starting with 1-amino-2-propanol (248 mg, 3.3 mmol) yielded compound 534 in Table 17 (36 mg, 30%).
  • MS ES+: 541 (M+H)+
  • 1HNMR (DMSOd6): 1.06 (d, 3H); 1.95 (m, 2H); 2.48 (m, 2H); 2.72 (t, 2H); 3.69 (m, 1H); 3.90 (s, 2H); 3.97 (s, 3H); 4.23 (t, 2H); 4.47 (brs, 1H); 6.91 (t, 1H); 7.26 (s, 1H); 7.32-7.41 (m, 2H); 7.39 (s, 1H); 7.63 (d, 1H); 8.11 (s, 1H); 8.67 (s, 1H); 10.48 (s, 1H).
    • EXAMPLE 358 Preparation of Compound 535 in Table 17
  • An analogous reaction to that described in example 257 but starting with (R)-(−)-2-pyrrolidinemethanol (334 mg, 3.3 mmol) yielded compound 535 in Table 17 (66 mg, 53%).
  • MS ES+: 567 (M+H)+
  • 1HNMR (DMSOd6): 1.57 (m, 1H); 1.67 (m, 2H); 2.82 (m, 1H); 1.96 (m, 2H); 2.18 (m, 1H); 2.45 (m, 2H); 2.98 (m, 1H); 3.10 (m, 1H); 3.20 (m, 1H); 3.41 (m, 1H); 3.91 (s, 2H); 3.98 (s, 3H); 4.22 (t, 2H); 4.35 (brs, 1H); 6.91 (t, 1H); 7.26 (s, 1H); 7.31-7.42 (m, 2H); 7.39 (s, 1H); 7.64 (d, 1H); 8.13 (s, 1H); 8.68 (s, 1H); 10.48 (s, 1H); 12.01 (brs, 1H).
    • EXAMPLE 359 Preparation of Compound 536 in Table 17
  • An analogous reaction to that described in example 257 but starting with (S)-(+)-2-pyrrolidinemethanol (334 mg, 3.3 mmol) yielded compound 536 in Table 17 (59 mg, 48%).
  • MS ES+: 567 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.78 (m, 1H); 1.90 (m, 1H); 2.03 (m, 1H); 2.13 (m, 1H); 2.31 (m, 2H); 3.23 (m, 2H); 3.61 (m, 4H); 3.77 (q, 1H); 3.98 (s, 3H); 3.99 (s, 2H); 4.29 (t, 2H); 6.89 (t, 1H); 7.29 (s, 1H); 7.30-7.40 (m, 2H); 7.63 (d, 1H); 7.64 (s, 1H); 7.91 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 360 Preparation of Compound 537 in Table 17
  • An analogous reaction to that described in example 257 but starting with t-butyl-1-pyperazinecarboxylate (615 mg, 3.3 mmol) and treating the crude reaction mixture with hydrochloric acid in 1,4-dioxane (4M, 2 ml) yielded compound 537 in Table 17 (35 mg, 27%).
  • MS ES+: 552 (M+H)+
  • 1HNMR (DMSOd6): 1.96 (m, 2H); 2.33 (brs, 4H); 2.42 (t, 2H); 2.73 (t, 4H); 3.89 (s, 2H); 3.95 (s, 3H); 4.19 (t, 2H); 6.89 (t, 1H); 7.24 (s, 1H); 7.32-7.42 (m, 2H); 7.37 (s, 1H); 7.62 (d, 1H); 8.10 (s, 1H); 8.66 (s, 1H); 10.47 (s, 1H).
    • EXAMPLE 361 Preparation of Compound 538 in Table 17
  • An analogous reaction to that described in example 257 but starting with 1-(2-morpholinoethyl)piperazine (519 mg, 3.3 mmol) yielded compound 538 in Table 17 (50 mg, 37%).
  • MS ES+: 665 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.33 (m, 2H); 2.99 (t, 2H); 3.05-3.75 (m, 16H); 3.86 (brs, 4H); 3.99 (s, 3H); 4.00 (s, 2H); 4.29 (t, 2H); 6.90 (t, 1H); 7.32 (s, 1H); 7.41-7.31 (m, 2H); 7.62 (d, 1H); 7.64 (s, 1H); 7.92 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 362 Preparation of Compound 539 in Table 17
  • An analogous reaction to that described in example 257 but starting with 2-amino-2-methyl-1-propanol (294 mg, 3.3 mmol) yielded compound 539 in Table 17 (40 mg, 33%).
  • MS ES+: 555 (M+H)+
  • 1HNMR (DMSOd6): 0.96 (s, 6H); 1.91 (m, 2H); 2.67 (t, 2H); 3.19 (s, 2H); 3.90 (s, 2H); 3.97 (s, 3H); 4.24 (t, 2H); 4.53 (brs, 1H); 6.91 (m, 1H); 7.26 (s, 1H); 7.36 (m, 2H); 7.38 (s, 1H); 7.63 (d, 1H); 8.11 (s, 1H); 8.67 (s, 1H); 10.48 (s, 1H).
    • EXAMPLE 363 Preparation of Compound 540 in Table 18
  • 4-((2-amino-1,3-thiazole-5-yl)acetic acid)-6-methoxy-7-(3-morpholinopropoxy)quinazoline (125 mg, 0.27 mmol) in DMF (2.5 ml) was reacted with N-ethylaniline (84.3 μl, 0.707 mmol) in presence of O-(7-azabenzotriazol-1-yl) -N,N,N′,N′-tetramethyluronium hexafluorophosphate (136 mg, 0.37 mmol) and DIEA (95 μl, 0.54 mmol) at 50° C. for 18 hours. The reaction mixture was cooled, sodium bicarbonate (sat., 1 ml) 3 g alumina were added, the mixture was evaporated to dryness, and the residue purified by chromatography over alumina, Eluant CH2Cl2, CH2Cl2/MeOH 99/1 to 95/5 to give title compound (68 mg, 44%)
  • MS ES+: 563.6 (M+H)+
  • 1H NMR (DMSOd6, TFA): 1.05 (t, 3H); 2.31 (t, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.65 (m, 6H); 3.97 (s, 3H); 4.03 (d, 2H); 4.29 (t, 2H); 7.31 (s, 1H); 7.38 (s, 1H); 7.40 (m, 2H); 7.46 (m, 1H); 7.53 (m, 2H); 7.87 (s, 1H); 9.06 (s, 1H).
    • EXAMPLE 364 Preparation of Compound 541 in Table 18
  • An analogous reaction to that described in example 363 but starting with 3-chloro-4-fluoro-N-methylaniline (97 mg, 0.35 mmol) yielded title compound (98 mg, 60%).
  • MS ES+: 601.5, 603.5 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.31 (t, 2H); 3.15 (t, 2H); 3.21 (s, 3H); 3.35 (t, 2H); 3.54 (d, 2H); 3.7 (m, 4H); 3.97 (s, 3H); 4.03 (d, 2H); 4.29 (t, 2H); 7.31 (s, 1H); 7.41 (s, 1H); 7.50 (m, 2H); 7.80 (m, 1H); 7.87 (s, 1H); 9.06 (s, 1H).
  • N-(tert-butyloxycarbonyl)-3-chloro-4-fluoroaniline
  • 3-chloro-4-fluoroaniline (2 g, 13.7 mmol) in THF (12.5 ml) under argon, was treated with NaHMDS (1 M, 27.5 ml, 27.5 mmol) at room temperature for 15 minutes. Di-tert-butyl dicarbonate in THF (10 ml) was slowly added to the reaction mixture, and the mixture stirred at room temperature for 45 minutes. The solvent was evaporated, diluted HCl (0.1 N) was added, and the mixture extracted with ethylacetate, dried, purified by silica gel chromatography, ether/petroleum ether 10-20/90-80 to give title compound (2.77 g, 82%).
  • 1H NMR (CDCl3): 1.49 (s, 9H); 6.42 (s, 1H); 7.01 (t, 1H); 7.01 (m, 1H); 7.54 (m, 1H).
  • 3-chloro-4-fluoro-N-methylaniline
  • To a solution of N-(tert-butyloxycarbonyl)-3-chloro-4-fluoroaniline (250 mg, 1.02 mmol) in THF (4 ml) at 0° C. was added sodium hydride (60%, 45 mg, 1.12 mmol), and the mixture was stirred for 20 minutes. Methyl iodide (70 μl, 1.12 mmol) was added to the mixture which was stirred at room temperature for 4 hours. The solvent was evaporated, a saturated solution of sodium chloride was added, and the mixture was extracted with CH2Cl2, dried, and purified by silica gel chromatography, ether/petroleum ether, 8/2 to give compound (235 mg). This compound was dissolved in CH2Cl2(2 ml) and TFA (2 ml), H2O (200 μl) was added, the mixture was stirred for 1 hour at room temperature, the solvent was evaporated, to give title compound (256 mg, 89%).
  • 1HNMR (CDCl3): 2.98 (s, 3H); 7.3 (m, 3H).
    • EXAMPLE 365 Preparation of Compound 542 in Table 18
  • An analogous reaction to that described in example 363 but starting with ethyl-2-(3-chloro-4-fluoroaniline)acetate (151 mg, 0.65 mmol) yielded title compound (10 mg, 4.5%).
  • MS ES+: 673.6 (M+H)+
  • 1H NMR (DMSOd6, TFA): 1.18 (t, 3H); 2.30 (t, 2H); 3.16 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.68 (t, 2H); 3.83 (s, 1H); 3.97 (s, 3H); 4.03 (m, 4H); 4.13 (s, 2H); 4.29 (t, 2H); 4.41 (s, 1H); 7.30 (s, 1H); 7.44 (s, 1H); 7.55 (m, 2H); 7.78 (m, 1H); 7.87 (s, 1H); 9.06 (s, 1H).
    • EXAMPLE 366 Preparation of Compound 543 in Table 18
  • An analogous reaction to that described in example 363 but starting with 2-anilinoacetonitrile (371 mg, 2.72 mmol) yielded title compound (110 mg, 18%).
  • MS ES+: 574.6 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.31 (t, 2H); 3.16 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.68 (t, 2H); 3.77 (s, 1H); 3.97 (s, 3H); 4.04 (d, 2H); 4.30 (t, 2H); 4.81 (s, 2H); 7.31 (s, 1H); 7.43 (s, 1H); 7.57 (m, 5H); 7.88 (s, 1H); 9.09 (s, 1H).
    • EXAMPLE 367 Preparation of Compound 544 in Table 18
  • An analogous reaction to that described in example 363 but starting with 3-anilinoacetonitrile (335 mg, 2.18 mmol) yielded title compound (100 mg, 18%).
  • MS ES+: 588.6 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.29 (t, 2H); 2.75 (t, 2H); 3.16 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.68 (m, 4H); 3.95 (t, 2H); 3.97 (s, 3H); 4.04 (d, 2H); 4.29 (t, 2H); 7.29 (s, 1H); 7.42 (s, 1H); 7.48 (m, 3H); 7.55 (m, 2H); 7.87 (s, 1H); 9.08 (s, 1H).
    • EXAMPLE 368 Preparation of Compound 545 in Table 18
  • An analogous reaction, to that described in example 363 but starting with N-(2-tert-butylethyl)-3-chloro-4-fluoroaniline (346 mg, 1.42 mmol) yielded title compound (147 mg, 30%).
  • MS ES+: 687.6 (M+H)+
  • 1H NMR (DMSOd6, TFA): 1.08 (s, 9H); 2.31 (t, 2H); 3.14 (t, 2H); 4.3-4.5 (m, 4H); 3.55 (d, 2H); 3.68 (m, 6H); 3.97 (s, 3H); 4.03 (d, 2H); 4.29 (t, 2H); 7.30 (s, 1H); 7.41 (s, 1H); 7.51 (m, 2H); 7.78 (m, 1H); 7.87 (s, 1H); 9.06 (s, 1H).
  • N-(2-hydroxyethyl)-3-chloro-4-fluoroaniline.
  • ethyl-2-(3-chloro-4-fluoroanilino)acetate (J. Med. Chem. 1965, 405-407) (2 g, 8.6 mmol) in THF (15 ml) ether (10 ml) was treated with LiAlH4 (460 mg, 12.1 mmol) at 40° C. for 4 hours. The mixture was then poured onto ice, treated with NaOH (2N, 10 ml), extracted with ethyl acetate, dried, evaporated to give title compound (1.48 g, 90%).
  • 1H NMR (CDCl3): 1.67 (s, 1H); 3.24 (t, 2H); 3.84 (t, 2H); 3.92 (s, 1H); 6.47 (m, 1H); 6.64 (m, 1H); 6.95 (t, 1H).
  • N-(2-tert-butoxyethyl)-3-chloro-4-fluoroaniline
  • N-2-hydroxyethyl-3-chloro-4-fluoroaniline (1.48 g, 7.81 mmol) in CH2Cl2 (20 ml) was reacted with N,N-diisopropyl O-tert-butyl-isourea (6.25 g, 31.2 mmol) at room temperature over night. The product was purified by silicagel chromatography, Eluant, ether/petroleum ether 5/95, 10/90 to give title compound (1.15 g, 60%).
  • 1H NMR (CDCl3): 1.20 (s, 9H); 3.18 (t, 2H); 3.55 (t, 2H); 4.00 (s, 1H); 6.44 (m, 1H); 6.62 (m, 1H); 6.93 (t, 1H).
    • EXAMPLE 369 Preparation of Compound 546 in Table 18
  • An analogous reaction to that described in example 363 but starting with N-alkylaniline (0.3 ml, 2.18 mmol) yielded title compound (252 mg, 50%).
  • MS ES+: 575.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.31 (t, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.68 (m, 4H); 3.97 (s, 3H); 4.03 (d, 2H); 4.28 (m, 4H); 5.12 (m, 2H); 5.82 (m, 1H); 7.30 (s, 1H); 7.38 (m, 3H); 7.40 (s, 1H); 7.51 (m, 2H); 7.87 (s, 1H); 9.07 (s, 1H).
    • EXAMPLE 370 Preparation of Compound 547 in Table 18
  • An analogous reaction to that described in example 363 but starting with N-ethyl-3,4-(methylenedioxy)aniline (320 μl, 2.18 mmol) yielded title compound (351 mg, 66%).
  • MS ES+: 607.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 1.04 (t, 3H); 2.31 (t, 2H); 3.16 (t, 2H); 3.34 (t, 2H); 3.54 (d, 2H); 3.68 (m, 6H); 3.97(s, 3H); 4.09 (d, 2H); 4.29 (t, 2H); 6.12 (s, 2H); 6.83 (d, 1H); 7.02 (m, 2H); 7.30 (s, 1H); 7.42 (s, 1H); 7.86 (s, 1H); 9.06 (s, 1H).
    • EXAMPLE 371 Preparation of Compound 548 in Table 18
  • An analogous reaction to that described in example 363 but starting with ethyl-4-(N-butylamino)benzoate (482 mg, 2.18 mmol) yielded title compound (58 mg, 10%).
  • MS ES+: 663.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 0.85 (t, 3H); 1.32 (m, 7H); 2.31 (t, 2H); 3.16 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.70 (m, 6H); 3.97 (s, 3H); 4.04 (d, 2H); 4.29 (t, 2H); 4.35 (s, 2H); 7.30 (s, 1H); 7.41 (s, 1H); 7.54 (d, 2H); 7.87 (s, 1H); 8.07 (d, 2H); 9.07 (s, 1H).
    • EXAMPLE 372 Preparation of Compound 549 in Table 18
  • An analogous reaction to that described in example 363 but starting with N-ethyl-m-toluidine (294 mg, 2.18 mmol) yielded title compound (294 mg, 58%).
  • MS ES+: 577.7 (M+H)+
  • 1H NMR (DMSOd6, TFA): 1.05 (t, 9H); 2.31 (t, 2H); 2.38 (s, 3H); 3.16 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.67 (m, 6H); 3.97 (s, 3H); 4.04 (d, 2H); 4.29 (t, 2H); 7.18 (m, 2H); 7.28 (d, 1H); 7.30 (s, 1H); 7.39 (s, 1H); 7.42 (d, 1H); 7.86 (s, 1H); 9.07 (s, 1H).
    • EXAMPLE 373 Preparation of Compound 550 in Table 18
  • Compound 545 (120 mg) in CH2Cl2 (2 ml) was treated with TFA (3 ml) and H2O (200 μl) at room temperature for 3 hours. The solvent was evaporated to give title compound (45 mg, 41%).
  • MS ES+: 631.6 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.29 (t, 2H); 3.16 (t, 2H); 3.35 (t, 2H); 3.51 (t, 2H); 3.54 (d, 2H); 3.70 (m, 6H); 3.97 (s, 3H); 4.03 (d, 2H); 4.30 (t, 2H); 7.30 (s, 1H); 7.42 (s, 1H); 7.54 (m, 2H); 7.78 (d, 1H); 7.87 (s, 1H); 9.06 (s, 1H).
    • EXAMPLE 374 Preparation of Compound 551 in Table 19
  • 4-((2-amino-4-methyl-1,3-thiazole-5-yl)acetic acid)-6-methoxy-7-(3-morpholinopropoxy)quinazoline (118 mg, 0.25 mmol) in DMF (1.5 ml) was reacted with aniline (32 mg, 0.35 mmol) in presence of O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (142 mg, 0.375 mmol) and DIEA (65 mg, 0.5 mmol) at 65° over night. The mixture was cooled, sodium bicarbonate was added, and the resulting mixture was evaporated. The residue was dissolved in CH2Cl2/MeOH 92/8 and purified by chromatography over alumina, Eluant CH2Cl2, CH2Cl2/MeOH 98/2 to 95/5 a second purification over silicagel was performed, Eluant CH2Cl2/MeOH 95/5 to 90/10 to give title compound (86 mg, 62%).
  • MS ES+: 549.6 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.31 (t, 2H); 2.34 (s, 3H); 3.15 (t, 2H); 3.34 (t, 2H); 3.54 (d, 2H); 3.72 (t, 2H); 3.90 (s, 2H); 3.98 (s, 3H); 4.03 (d, 2H); 4.30 (t, 2H); 7.08 (t, 2H); 7.29 (s, 1H); 7.31 (t, 2H); 7.62 (d, 2H); 7.85 (s, 1H); 9.05 (s, 1H).
  • 4-(ethyl(2-amino-4-methyl-1,3-thiazole-5-yl)acetate)-6-methoxy-7-(3-morpholinopropoxy)quinazoline
  • N′-(2-cyano-4-methoxy-5-(3-morpholinopropoxy)phenyl)-N,N-dimethylimidoformamide (1.38 g, 4 mmol) in acetic acid was reacted with ethyl-2-amino-4-methyl-1,3-thiazole-5-yl)acetate at reflux for 3.5 hours. The mixture was cooled, evaporated, HCl (1N) was added and the mixture extracted with ethylacetate. Sodium bicarbonate was cautiously added to the aqueous phase, which was extracted with ethylacetate. The organic fractions were dried, evaporated, the residue was purified by chromatography over alumina, Eluant CH2Cl2, CH2Cl2/AcOEt 1/1, CH2Cl2/AcOEt/MeOH 50/45/5 to give starting material as a yellow solid. (1.12 g, 52%).
  • MS ES+: 502.6 (M+H)+
  • 1H NMR (DMSOd6, TFA): 1.24 (t, 3H); 2.28 (m, 5H); 3.15 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 3.92 (s, 2H); 3.98 (s, 3H); 4.04 (d, 2H); 4.15 (q, 2H); 4.30 (t, 2H); 7.30 (s, 1H); 7.86 (s, 1H); 9.05 (s, 1H).
  • 4-((2-amino-4-methyl-1,3-thiazole-5-yl)acetic acid)-6-methoxy-7-(3-morpholinopropoxy)quinazoline
  • 4-(ethyl(2-amino-4-methyl-1,3-thiazole-5-yl)acetate)-6-methoxy-7-(3-morpholinopropoxy)quinazoline (1.1 g, 2.2 mmol) in ethanol (11 ml) was treated with NaOH (2N, 5.5 ml, 11 mmol) at room temperature for 1 hour. The mixture was then acidified with HCl (2N) to pH 3. The solution was evaporated, the solid suspended in CH2Cl2 (8 ml) MeOH (6 ml), and DIEA was added (852 mg, 6.6 mmol). The mixture was stirred for 10 minutes, filtered. The filtrate was concentrated, ethanol was added and the solid recovered to give title compound (980 mg, 94%).
  • MS ES+: 474.5 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.28 (m, 5H); 3.16 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.70 (t, 2H); 3.83 (s, 2H); 3.98 (s, 3H); 4.04 (d, 2H); 4.30 (t, 2H); 7.30 (s, 1H); 7.86 (s, 1H); 9.05 (s, 1H).
    • EXAMPLE 375 Preparation of Compound 552 in Table 19
  • An analogous reaction to that described in example 374 but starting with 3-chloro-4-fluoroaniline (51 mg, 0.35 mmol) yielded the title compound (60 mg, 40%).
  • MS ES+: 601.5 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.30 (t, 2H); 2.33 (s, 3H); 3.16 (t, 2H); 3.36 (t, 2H); (3.55) (d, 2H); 3.69 (t, 2H); 3.90 (s, 2H); 3.98 (s, 3H); 4.04 (d, 2H); 4.30 (t, 2H); 7.28 (s, 1H); 7.39 (t, 1H); 7.49 (m, 1H); 7.86 (s, 1H); 7.96 (m, 1H); 9.05 (s, 1H).
    • EXAMPLE 376 Preparation of Compound 553 in Table 19
  • An analogous reaction to that described in example 374 but starting with 2-aminopyridine (33 mg, 0.35 mmol) yielded the title compound (45 mg, 32%).
  • MS ES+: 550.6 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.31 (t, 2H); 2.35 (s, 3H); 3.16 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 3.98 (s, 3H); 4.04 (m, 4H); 4.30 (t, 2H); 7.30 (m, 2H); 7.87 (s, 1H); 7.95 (d, 1H); 8.05 (m, 1H); 8.40 (d, 1H); 9.04 (s, 1H).
    • EXAMPLE 377 Preparation of Compound 554 in Table 19
  • An analogous reaction to that described in example 374 but starting with 3,4 difluoroaniline (50 mg, 0.39 mmol) yielded the title compound (120 mg, 74%).
  • MS ES+: 585.6 (M+H)+
  • 1H NMR (DMSOd6, TFA): 2.30 (t, 2H); 2.33 (s, 3H); 3.16 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.67 (t, 2H); 3.90 (s, 2H); 3.98 (s, 3H); 4.05 (d, 2H); 4.31 (t, 2H); 7.28 (s, 1H); 7.32 (m, 1H); 7.40 (q, 1H); 7.80 (m, 1H); 7.86 (s, 1H); 9.05 (s, 1H).
    • EXAMPLE 378 Preparation of Compound 555 in Table 20
  • N′-(2-cyano-5-((2S)-2-hydroxy-3-piperidinylpropoxy)-4-methoxyphenyl)-N,N-dimethylimidoformamide (381 mg, 0.96 mmol) in acetic acid (6 ml) was irradiated in a microwave oven in presence of N-(4-fluoro-3-chlorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide (275 mg, 0.96 mmol) at reflux for 0.5 hour. The solvent was evaporated, and the residue purified by silica gel chromatography, eluant CH2Cl2/MeOH sat. NH3 95/5 to 93/7 to give title compound (230 mg, 40%).
  • MS ES+: 601.5 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.42 (m, 1H); 1.6-1.9 (m, 5H); 3.02 (m, 2H); 3.28 (m, 2H); 3.52 (m, 2H); 3.99 (s, 5H); 4.19 (d, 2H); 4.43 (m, 1H); 7.35 (s, 1H); 7.40 (t, 1H); 7.48 (m, 1H); 7.64 (s, 1H); 7.91 (s, 1H); 7.95 (m, 1H); 9.08 (s, 1H).
  • N′-(2-cyano-5-((2S)-2-hydroxy-3-piperidinylpropoxy)-4-methoxyphenyl)-N,N,-dimethylimidoformamide.
  • N′-(2-cyano-5-(2S)-oxiranylmethoxy-4-methoxyphenyl)-N,N-dimethylimidoformamide (850 mg, 3.09 mmol) in chloroform (6 ml) and ethanol (12 ml) was irradiated with piperidine (0.46 ml, 4.6 mmol) in a microwave oven at reflux for 10 minutes. The solvent was evaporated and the residue was purified by silica gel chromatography, eluant CH2Cl2/MeOH 90/10 to give title compound (954 mg, 86%).
  • MS ES+: 361.6 (M+H)+
  • 1HNMR (DMSOd6): 1.43 (m, 6H); 2.4 (m, 6H); 2.97 (s, 3H); 3.06 (s, 3H); 3.75 (s, 3H); 3.95 (d, 2H); 4.03 (m, 1H); 4.83 (s, 1H); 6.75 (s, 1H); 7.10 (s, 1H); 7.90 (s, 1H).
  • N′-(2-cyano-5-(2S)-oxiranylmethoxy-4-methoxyphenyl)-N,N-dimethylimidoformamide.
  • N′-(2-cyano-4-methoxy-5-hydroxyphenyl)-N,N-dimethyl-imidoformamide (1 g, 4.57 mmol) in DMF (25 ml) was reacted with (2S) glycidyl toxylate (1.15 g, 5.02 mmol) in presence of cesium carbonate (5.95 g, 18.3 mmol) at 60° C. under argon for 2 hours. The solvent was evaporated, water was added, and the mixture was extracted with ethylacetate, dried, concentrated and purified by silica gel chromatography, eluant CH2Cl2/AcOEt 80/20 to 70/30 to give title compound (1.18 g, 94%).
  • MS ES+: 276.6 (M+H)+
  • 1HNMR (DMSOd6): 2.70 (m, 1H); 2.86 (m, 1H); 2.95 (s, 3H); 3.01 (s, 3H); 3.35 (m, 1H); 3.75 (s, 3H); 3.90 (m, 1H); 4.37 (m, 1H); 6.75 (s, 1H); 7.11 (s, 1H); 7.89 (s, 1H).
  • Methyl-(2-tritylamino-1,3-thiazole-5-yl)acetate
  • Methyl-(2-amino-1,3-thiazole-5-yl)acetate (1 g, 5.8 mmol) in CH2Cl2 (15 ml) was reacted with triphenylmethyl chloride (1.73 g, 6.2 mmol) and triethylamine (0.89 ml, 6.4 mmol) at 0° C. for 1.5 hour. Water was added to the mixture which was extracted with ethyl acetate, dried, purified by silica gel chromatography to give title compound (2.21 g, 91%).
  • 1HNMR (DMSOd6): 3.58 (s, 3H); 3.59 (s, 2H); 6.57 (s, 1H); 7.23 (m, 15H); 8.40 (s, 1H).
  • (2-tritylamino-1,3-thiazol-5-yl)acetic acid
  • Methyl(2-tritylamino-1,3-thiazole-5-yl)acetate (2 g, 4.8 mmol) in THF (10 ml) and ethanol (10 ml) was reacted with sodium hydroxyde (1N, 7.2 ml, 7.2 mmol) at room temperature for 1.5 hour. The solvent was evaporated, HCl (6N) was added, the solid recovered by filtration to give title compound (1.96 g).
  • 1HNMR (DMSOd6): 3.63 (s, 2H); 5.70 (s, 1H); 7.32 (m, 15H).
  • N-(4-fluoro-3-chlorophenyl)-2-tritylamino-1,3-thiazole-5-yl)acetamide
  • (2-tritylamino-1,3-thiazol-5-yl)acetic acid (1.96 g, 4.9 mmol) in DMF (25 ml) was reacted with 3-chloro-4-fluoroaniline (1.07 g, 7.3 mmol) in presence of 0-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (2.42 g, 6.37 mmol) and DIEA (1.7 ml, 9.8 mmol) at 50° C. for 18 hours. DMF was evaporated, the residue taken up in CH2Cl2/EtOAc, washed with a saturated solution of sodium bicarbonate. The solid precipitating in the organic phase was recovered, the organic phase was evaporated, MeOH was added to the residue to give a solid, a second crop of title compound was thus recovered to give together (1.38 g, 53%).
  • 1HNMR (DMSOd6): 3.56 (s, 2H); 6.61 (s, 1H); 7.28 (m, 17H); 7.88 (m, 1H); 8.41 (s, 1H).
  • N-(4-fluoro-3-chlorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide
  • N-(4-fluoro-3-chlorophenyl)-2-(2-tritylamino-1,3-thiazole-5-yl)acetamide (12.28 g, 23 mmol) was dissolved in TFA (100 ml) and water (10 ml). The mixture was stirred at room temperature for 45 minutes. Water (300 ml) was added to the reaction mixture, a solid was recovered by filtration, washed with water and ether. The solid was dissolved in MeOH, and the solution treated with ammonia (pH 8), MeOH was then partially evaporated, water (300 ml) was added and a precipitate of title compound recovered, dried (5.37 g, 81%).
  • 1HNMR (DMSOd6): 3.64 (s, 2H); 6.76 (m, 3H); 7.38 (t, 1H); 7.48 (m, 1H); 7.92 (m, 1H).
    • EXAMPLE 379 Preparation of Compound 556 in Table 20
  • An analogous reaction to that described in example 378 but starting with N′-(2-cyano-5-((2S)-2-hydroxy-3-pyrrolidinylpropoxy)-4-methoxyphenyl)-N,N,-dimethylimido-formamide (267 mg, 0.77 mmol) yielded title compound (213 mg, 52%).
  • MS ES+: 587.5 (M+H)+
  • 1HNMR (DMSOd6): 1.68 (m, 4H); 2.5 (m, 5H); 2.66 (m, 1H); 3.88 (s, 2H); 3.96 (s, 3H); 4.00 (m, 1H); 4.07 (m, 1H); 4.20 (m, 1H); 4.95 (m, 1H); 7.26 (s, 1H); 7.36 (s, 1H); 7.37 (m, 1H); 7.47 (m, 1H); 7.95 (m, 1H); 8.11 (s, 1H); 8.66 (s, 1H).
  • N′-(2-cyano-5-((2S)-2-hydroxy-3-pyrrolinylpropoxy)-4-methoxyphenyl)-N,N-dimethylimidoformamide.
  • An analogous reaction to that described in example 378, but starting with pyrrolidine (1.4 ml, 16 mmol) yielded title compound (2.8 g, 74%).
  • MS ES+: 347.6 (M+H)+
  • 1HNMR (DMSOd6): 1.67 (m, 4H); 1.45 (m, 4H); 1.63 (m, 2H); 2.95 (s, 3H); 3.05 (s, 3H); 3.73 (s, 3H); 3.95 (m, 2H); 4.04 (m, 1H); 4.93 (m, 1H); 6.73 (s, 1H); 7.08 (s, 1H); 7.89 (s, 1H).
    • EXAMPLE 380 Preparation of Compound 557 in Table 20
  • An analogous reaction to that described in example 378 but starting with N′-(2-cyano-5-((2S)-2-hydroxy-3-(4-hydroxypiperidinyl)propoxy)-4-methoxy-phenyl)-N,N-dimethylimidoformamide (195 mg, 0.52 mmol) yielded title compound (88 mg, 30%).
  • MS ES+: 617.5, 619.5 (M+H)+
  • 1HNMR (DMSOd6): 1.40 (m, 2H); 1.70 (m, 2H); 2.13 (m, 2H); 2.43 (m, 2H); 2.77 (m, 2H); 3.43 (m, 1H); 3.88 (s, 2H); 3.96 (s, 3H); 4.03 (m, 2H); 4.19 (m, 1H); 4.52 (d, 1H); 4.87 (m, 1H); 7.27 (s, 1H); 7.39 (m, 2H); 7.49 (m, 1H); 7.99 (m, 1H); 8.67 (s, 1H).
  • N′-(2-cyano-5-((2S)-2-hydroxy-3-(4-hydroxypiperidinyl)propoxy)-4-methoxyphenyl)-N,N-dimethylimidoformamide
  • An analogous reaction to that described in example 378, but starting with 4-hydroxypiperidine (131 mg, 1.27 mmol) yielded title compound (200 mg, 58%).
  • MS ES+: 377.6 (M+H)+
  • 1HNMR (DMSOd6): 1.39 (m, 2H); 1.68 (m, 2H); 2.10 (m, 2H); 2.40 (m, 2H); 2.75 (m, 2H); 2.95 (s, 3H); 3.05 (s, 3H); 3.21 (s, 3H); 3.31 (m, 1H); 3.95 (m, 2H); 4.00 (m, 1H); 4.52 (m, 1H); 4.82 (m, 1H); 6.73 (s, 1H); 7.08 (s, 1H); 7.88 (s, 1H).
    • EXAMPLE 381 Preparation of Compound 558 in Table 20
  • An analogous reaction to that described in example 378, but starting with N′-(2-cyano-5-((2S)-2-hydroxy-3-(4-tert-butyloxycarbonylpiperazinyl)propoxy)-4-methoxyphenyl)-N,N-dimethylimidoformamide (355 mg, 0.77 mmol) yielded title compound (70 mg, 17%).
  • MS ES+: 602.4 (M+H)+
  • 1HNMR (DMSOd6): 2.42 (m, 6H); 2.73 (d, 4H); 3.88 (s, 2H); 3.96 (s, 3H); 4.04 (m, 2H); 4.19 (m, 1H); 4.90 (m, 1H); 7.28 (s, 1H); 7.37 (m, 2H); 7.47 (m, 1H); 7.94 (m, 1H); 8.11 (s, 1H); 8.66 (s, 1H).
  • N′-(2-cyano-5-((2S)-2-hydroxy-3-(4-tert-butyloxycarbonylpiperazinyl)propoxy)-4-methoxyphenyl)-N,N-dimethylimidoformamide.
  • An analogous reaction to that described in example 378, but starting with tert-butyloxycarbonylpiperazine (284 mg, 1.53 mmol) yielded title compound (444 mg, 88%).
  • MS ES+: 462.6 (M+H)+
  • 1HNMR (DMSOd6): 1.39 (s, 9H); 2.40 (m, 6H); 2.95 (s, 3H); 3.04 (s, 3H); 3.30 (m, 4H); 3.72 (s, 3H); 3.95 (m, 2H); 4.02 (m, 1H); 4.91 (d, 1H); 6.74 (s, 1H); 7.09 (s, 1H); 7.88 (s, 1H).
    • EXAMPLE 382 Preparation of Compound 559 in Table 20
  • An analogous reaction to that described in example 378 , but starting with N′-(2-cyano-5-((2S)-2-hydroxy-3-cyclopentylaminopropoxy)-4-methoxyphenyl)-N,N-dimethylimidoformamide (290 mg, 0.77 mmol) yielded title compound (226 mg, 54%).
  • MS ES+: 601.4 (M+H)+
  • 1HNMR (DMSOd6): 1.32 (m, 2H), 1.48 (m, 2H); 1.62 (m, 2H); 1.73 (m, 2H); 2.63 (m, 1H); 2.71 (m, 1H); 3.05 (m, 1H); 3.89 (s, 2H); 3.98 (m, 4H); 4.09 (m, 1H); 4.17 (m, 1H); 5.03 (m, 1H); 7.27 (s, 1H); 7.40 (m, 2H); 7.51 (m, 1H); 7.97 (m, 1H); 8.12 (s, 1H); 8.67 (s, 1H).
  • N′-(2-cyano-5-((2S)-2-hydroxy-3-cyclopentylaminopropoxy)-4-methoxyphenyl-N,N-dimethylimidoformamide.
  • An analogous reaction to that described in example 378, but starting with cyclopentylamine (2.7 ml, 27 mmol) yielded title compound (1.6 g, 82%).
  • MS ES+: 361.6 (M+H)+
  • 1HNMR (DMSOd6): 1.30 (m, 2H); 1.48 (m, 2H); 1.60 (m, 2H); 1.72 (m, 2H); 2.56 (m, 1H); 2.67 (m, 1H); 2.97 (s, 3H); 3.01 (m, 1H); 3.07 (s, 3H); 3.75 (s, 3H); 3.89 (m, 1H); 4.00 (m, 2H); 5.01 (m, 1H); 6.75 (s, 1H); 7.10 (s, 1H); 7.91 (s, 1H).
    • EXAMPLE 383 Preparation of Compound 560 in Table 20
  • An analogous reaction to that described in example 378, but starting with N′-(2-cyano-5-((2S)-2-hydroxy-3-((2-hydroxy-1,1-dimethylethyl)amino)propoxy-4-methoxyphenyl)-N,N-dimethylimidoformamide (350 mg, 0.77 mmol) yielded title compound (147 mg, 34%).
  • MS ES+: 305.4 (M+H)+
  • 1HNMR (DMSOd6): 0.97 (s, 3H); 0.98 (s, 3H); 2.63 (m, 2H); 3.19 (dd, 2H); 3.89 (m, 3H); 3.98 (s, 3H); 4.10 (m, 1H); 4.18 (m, 1H); 4.56 (m, 1H); 7.29 (s, 1H); 7.39 (m, 2H); 7.50 (m, 1H); 7.97 (m, 1H); 8.13 (s, 1H); 8.68 (s, 1H).
  • N′-(2-cyano-5-((2S)-2-hydroxy-3-((2-hydroxy-1,1-dimethylethyl)amino)propoxy)-4-methoxyphenyl)-N,N-dimethylimidoformamide.
  • An analogous reaction to that described in example 378, but starting with 2-amino-2-methyl-1-propanol (1.8 ml, 18.2 mmol) yielded title compound (1.25 g, 93%).
  • 1HNMR (DMSOd6): 0.93 (s, 3H); 0.94 (s, 3H); 2.58 (m, 2H); 3.19 (m, 2H); 3.73 (s, 3H); 3.80 (m, 1H); 3.97 (m, 1H); 4.03 (m, 1H); 4.50 (m, 1H); 4.95 (m, 1H); 6.75 (s, 1H); 7.10 (s, 1H); 7.91 (s, 1H).
    • EXAMPLE 384 Preparation of Compound 561 in Table 20
  • An analogous reaction to that described in example 378, but starting with N-(3,4-difluorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide (200 mg, 0.74 mmol) and acetic acid (3 ml) yielded title compound (263 mg, 60%).
  • MS ES+: 585.5 (M+H)+
  • 1HNMR (DMSOd6): 1.37 (m, 2H); 1.50 (m, 4H); 2.41 (m, 6H); 3.88 (s, 2H); 3.96 (s, 3H); 4.03 (m, 2H); 4.18 (d, 1H); 4.88 (m, 1H); 7.28 (s, 1H); 7.40 (s, 1H); 7.40 (m, 2H); 7.80 (m, 1H); 8.11 (s, 1H); 8.66 (s, 1H).
  • N-(3,4-difluorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide.
  • An analogous reaction to that described in example 378, but starting with N-(3,4-difluorophenyl)-2-(2-tritylamino-1,3-thiazole-5-yl)acetamide (1,75 g, 3.42 mmol) yielded title compound (642 mg, 70%).
  • 1HNMR (DMSOd6): 3.62 (s, 2H); 6.73 (s, 1H); 6.74 (s, 2H); 7.28 (m, 1H); 7.37 (q, 1H); 7.77 (m, 1H).
  • N-(3,4-difluorophenyl)-2-(2-tritylamino-1,3-thiazole-5-yl)acetamide.
  • An analogous reaction to that described in example 378, but starting with 3,4-difluoroaniline (0.97 ml, 9.75 mmol) yielded title compound (1.75 g, 46%).
  • MS ES+: 512.5 (M+H)+
  • 1HNMR (DMSOd6): 3.54 (s, 2H); 6.58 (s, 1H); 7.25 (m, 17H); 7.71 (m, 1H); 8.39 (s, 1H).
    • EXAMPLE 385 Preparation of Compound 562 in Table 20
  • An analogous reaction to that described in example 379 but starting with N-(3,4-difluorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide (200 mg, 0.74 mmol) yielded title compound (226 mg, 53%).
  • MS ES+: 571.5 (M+H)+
  • 1HNMR (DMSOd6): 1.70 (m, 4H); 2.52 (m, 5H); 2.68 (m, 1H); 3.89 (s, 2H); 3.98 (s, 3H); 4.06 (m, 2H); 4.21 (m, 1H); 4.95 (m, 1H); 7.28 (s, 1H); 7.33 (m, 1H); 7.39 (s, 1H); 7.40 (m, 1H); 7.81 (m, 1H); 8.12 (s, 1H); 8.68 (s, 1H).
    • EXAMPLE 386 Preparation of Compound 563 in Table 20
  • An analogous reaction to that described in example 380, but starting with N-(3,4-difluorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide (200 mg, 0.74 mmol) yielded title compound (220 mg, 49%).
  • MS ES+: 601.5(M+H)+
  • 1HNMR (DMSOd6): 1.40 (m, 2H); 1.70 (m, 2H); 2.12 (m, 2H); 2.40 (m, 2H); 2.78 (m, 2H); 3.43 (m, 1H); 3.88 (s, 2H); 3.96 (s, 3H); 4.03 (m, 2H); 4.18 (m, 1H); 4.51 (d, 1H); 4.87 (m, 1H); 7.27 (s, 1H); 7.32 (m, 1H); 7.38 (s, 1H); 7.40 (m, 1H); 7.80 (m, 1H); 8.11 (s, 1H); 8.67 (s, 1H).
    • EXAMPLE 387 Preparation of Compound 565 in Table 20
  • An analogous reaction to that described in example 382, but starting with N-(3,4-difluorophenyl)-2-(2(amino-1,3-thiazole-5-yl)acetamide (200 mg, 0.74 mmol) yielded title compound (233 mg, 53%).
  • MS ES+: 585.5 (M+H)+
  • 1HNMR (DMSOd6): 1.32 (m, 2H); 1.47 (m, 2H); 1.61 (m, 2H); 1.72 (m, 2H); 2.63 (m, 1H); 2.72 (m, 1H); 3.05 (m, 1H); 3.89 (s, 2H); 3.97 (m, 4H); 4.09 (m, 1H); 4.16 (m, 1H); 5.05 (m, 1H); 7.27 (s, 1H); 7.34 (m, 1H); 7.38 (s, 1H); 7.42 (m, 1H); 7.82 (m, 1H); 8.12 (s, 1H); 8.67 (s, 1H).
    • EXAMPLE 388 Preparation of Compound 566 in Table 20
  • An analogous reaction to that described in example 379 but starting with N-(3-chlorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide (200 mg, 0.74 mmol) yielded title compound (238 mg, 56%).
  • MS ES+: 569.5 (M+H)+
  • 1HNMR (DMSOd6): 1.70 (s, 1H); 2.52 (m, 5H); 2.68 (m, 1H); 3.90 (s, 2H); 3.98 (s, 3H); 4.06 (m, 2H); 4.21 (m, 1H); 4.97 (m, 1H); 7.14 (d, 1H); 7.27 (s, 1H); 7.37 (m, 2H); 7.48 (d, 1H); 7.85 (m, 1H); 8.12 (s, 1H); 8.68 (s, 1H).
  • N-(3-chlorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide.
  • An analogous reaction to that described in example 378, but starting with N-(3-chlorophenyl)-2-(2-tritylamino-1,3-thiazole-5-yl)acetamide (3.62 g, 7.1 mmol) yielded title compound (1.6 g, 84%).
  • 1HNMR (DMSOd6): 3.63 (s, 2H); 6.74 (m, 3H); 7.11 (m, 1H); 7.33 (t, 1H); 7.42 (d, 1H); 7.79 (m, 1H).
  • N-(3-chlrophenyl)-2-(2-tritylamino-1,3-thiazole-5-yl)acetamide.
  • An analogous reaction to that described in example 378, but starting with 3-chloroaniline (1.4 ml, 13 mmol) yielded title compound (3.62 g, 71%).
  • 1HNMR (DMSOd6): 3.55 (s, 2H); 6.59 (s, 1H); 7.21 (m, 18H); 7.76 (m, 1H); 8.39 (s, 1H).
    • EXAMPLE 389 Preparation of Compound 567 in Table 20
  • An analogous reaction to that described in example 380, but starting with N-(3-chlorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide (200 mg, 0.75 mmol) yielded title compound (156 mg, 35%).
  • MS ES+: 599.4, 601.4 (M+H)+
  • 1HNMR (DMSOd6): 1.40 (m, 2H); 1.70 (m, 2H); 2.12 (m, 2H); 2.42 (m, 2H); 2.77 (m, 2H); 3.42 (m, 1H); 3.89 (s, 2H); 3.96 (s, 3H); 4.02 (m, 2H); 4.18 (m, 1H); 4.52 (d, 1H); 4.89 (m, 1H); 7.12 (d, 1H); 7.26 (s, 1H); 7.35 (t, 1H); 7.38 (s, 1H); 7.46 (d, 1H); 7.84 (m, 1H); 8.11 (s, 1H); 8.67 (s, 1H).
    • EXAMPLE 390 Preparation of Compound 568 in Table 20
  • An analogous reaction to that described in example 382, but starting with N-(3-chlorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide (200 mg, 0.75 mmol) yielded title compound (255 mg, 58%).
  • MS ES+: 583.5, 585.5 (M+H)+
  • 1HNMR (DMSOd6): 1.32 (m, 2H); 1.48 (m, 2H); 1.62 (m, 2H); 1.73 (m, 2H); 2.63 (m, 1H); 2.72 (m, 1H); 3.04 (m, 1H); 3.90 (s, 2H); 3.97 (m, 4H); 4.09 (m, 1H); 4.16 (m, 1H); 5.05 (m, 1H); 7.12 (d, 1H); 7.27 (s, 1H); 7.37 (t, 1H); 7.39 (s, 1H); 7.48 (m, 1H); 8.12 (s, 1H); 8.68 (s, 1H).
    • EXAMPLE 391 Preparation of Compound 569 in Table 20
  • An analogous reaction to that described in example 383, but starting with N-(3-chlorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide (200 mg, 0.74 mmol) yielded title compound (130 mg, 30%).
  • MS ES+: 587.5, 589.5 (M+H)+
  • 1HNMR (DMSOd6): 0.97 (s, 6H); 2.63 (m, 2H); 3.19 (m, 2H); 3.90 (m, 3H); 3.98 (s, 3H); 4.10 (m, 1H); 4.18 (m, 1H); 4.55 (m, 1H); 5.03 (m, 1H); 7.13 (d, 1H); 7.29 (s, 1H); 7.37 (t, 1H); 7.39 (s, 1H); 7.48 (d, 1H); 7.86 (m, 1H); 8.13 (s, 1H); 8.68 (s, 1H).
    • EXAMPLE 392 Preparation of Compound 570 in Table 20
  • An analogous reaction to that described in example 381, but starting with N-(3-chlorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide (200 mg, 0.75 mmol) yielded title compound (211 mg, 48%).
  • MS ES+: 584.4 (M+H)+
  • 1HNMR (DMSOd6): 2.37 (m, 6H); 2.70 (m, 4H); 3.89 (s, 2H); 3.96 (s, 3H); 4.05 (m, 2H); 4.19 (m, 1H); 4.90 (m, 1H); 7.12 (d, 1H); 7.27 (s, 1H); 7.35 (t, 1H); 7.37 (s, 1H); 7.47 (d, 1H); 7.84 (m, 1H); 8.10 (s, 1H); 8.66 (s, 1H).
    • EXAMPLE 393 Preparation of Compound 571 in Table 20
  • An analogous reaction to that described in example 388, but starting with N′-(2-cyano-5-((2S)-2-hydroxy-3-methoxy)propoxy-4-methoxyphenyl)-N,N-dimethyl imidoformamide (252 mg, 0.82 mmol) yielded title compound (200 mg, 50%).
  • MS ES+: 530.4, 532.4 (M+H)+
  • 1HNMR (DMSOd6): 3.22 (s, 3H); 3.42 (m, 2H); 3.91 (s, 2H); 3.98 (s, 2H); 4.10 (m, 3H); 5.21 (d, 1H); 7.13 (d, 1H); 7.26 (s, 1H); 7.37 (t, 1H); 7.39 (s, 1H); 7.48 (d, 1H); 7.85 (m, 1H); 8.13 (m, 1H); 8.69 (s, 1H).
  • N′-(2-cyano-5-((2S)-2-hydroxy-3-methoxy)propoxy-4-methoxy-phenyl)-N,N-dimethylimidoformamide.
  • N′-(2-cyano-5-(2S)-oxiranylmethoxy-4-methoxyphenyl)-N,N-dimethylimidoformamide (1 g, 3.6 mmol) in methanol (80 ml) was treated with sodium methoxide (10 g, 218 mmol) at reflux in a microwave oven for 0.5 hour. The solvent was evaporated and the mixture purified by silica gel chromatography, Eluant CH2Cl2/MeOH 95/5 to give title compound (896 mg, 80 %).
  • 1HNMR (DMSOd6): 2.97 (s, 1H); 3.07 (s, 1H); 3.29 (s, 1H); 3.38 (m, 2H); 3.75 (s, 3H); 3.98 (m, 3H); 5.16 (d, 1H); 6.75 (s, 1H); 7.10 (s, 1H); 7.93 (s, 1H).
    • EXAMPLE 394 Preparation of Compound 572 in Table 20
  • An analogous reaction to that described in example 378, but starting with N-(3-chlorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide (200 mg, 0.75 mmol) yielded title compound (268 mg, 61%).
  • MS ES+: 583.5 (M+H)+
  • 1HNMR (DMSOd6): 1.38 (m, 2H); 1.50 (m, 4H); 2.43 (m, 6H); 3.91 (s, 2H); 3.98 (s, 3H); 4.05 (m, 2H); 4.21 (m, 1H); 4.88 (m, 1H); 7.14 (d, 1H); 7.29 (s, 1H); 7.37 (t, 1H); 7.39 (s, 1H); 7.48 (d, 1H); 7.85 (m, 1H); 8.12 (s, 1H)); 8.68 (s, 1H).
    • EXAMPLE 395 Preparation of Compound 573 in Table 20
  • An analogous reaction to that described in example 378, but starting with N-(3,5-difluorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide (200 mg, 0.74 mmol) yielded title compound (157-mg, 36%).
  • MS ES+: 585.5 (M+H)+
  • 1HNMR (DMSOd6): 1.37 (m, 2H); 1.50 (m, 4H); 2.40 (m, 6H); 3.90 (s, 2H); 3.96 (s, 3H); 4.05 (m, 2H); 4.19 (m, 1H); 4.88 (m, 1H); 6.92 (m, 1H); 7.28 (s, 1H); 7.34 (m, 2H); 7.38 (s, 1H); 8.11 (s, 1H); 8.67 (s, 1H).
  • N-(3,5-difluorophenyl)-2-(2-amino-1,3-thiazole-5-yl) acetamide
  • An analogous reaction to that described in example 378, but starting with N-(3,5-difluorophenyl)-2-(2-tritylamino-1,3-thiazole-5-yl)acetamide (11.4 g, 28.5 mmol) yielded title compound (4.75 g, 62%).
  • 1HNMR (DMSOd6: 3.64 (s, 2H); 6.74 (s, 1H); 6.76 (s, 2H); 6.89 (m, 1H); 7.29 (m, 2H).
  • N-(3,5-difluorophenyl)-2-(2-tritylamino-1,3-thiazole-5-yl)acetamide.
  • An analogous reaction to that described in example 378, but starting with 3,5-difluoroaniline (1.68 g, 13 mmol) yielded title compound (3.53 g, 69%).
  • 1HNMR (DMSOd6: 3.56 (s, 2H); 6.59 (s, 1H); 6.90 (m, 1H); 7.28 (m, 17H); 8.40 (s, 1H).
    • EXAMPLE 396 Preparation of Compound 574 in Table 20
  • An analogous reaction to that described in example 379 but starting with N-(3,5-difluorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide (200 mg, 0.74 mmol) yielded title compound (200 mg, 47%).
  • MS ES+: 571.5 (M+H)+
  • 1HNMR (DMSOd6: 1.65 (m, 4H); 2.50 (m, 5H); 2.65 (m, 1H); 3.91 (s, 1H); 3.96 (s, 3H); 4.04 (m, 2H); 4.20 (m, 1H); 4.95 (m, 1H); 6.92 (m, 1H); 7.26 (s, 1H); 7.34 (m, 2H); 7.38 (s, 1H); 8.11 (s, 1H); 8.66 (s, 1H).
    • EXAMPLE 397 Preparation of Compound 575 in Table 20
  • An analogous reaction to that described in example 383 but starting with N-(3,5-difluorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide (200 mg, 0.74 mmol) yielded title compound (177 mg, 40%).
  • MS ES+: 589.4 (M+H)+
  • 1HNMR (DMSOd6: 0.96 (s, 3H); 0.97 (s, 3H); 2.64 (m, 2H); 3.19 (dd, 2H); 3.92 (m, 3H); 3.98 (s, 3H); 4.09 (m, 1H); 4.20 (m, 1H); 4.56 (m, 1H); 5.05 (m, 1H); 6.94 (m, 1H); 7.29 (s, 1H); 7.35 (m, 2H); 7.39 (s, 1H); 8.12 (s, 1H); 8.68 (s, 1H).
    • EXAMPLE 398 Preparation of Compound 576 in Table 20
  • An analogous reaction to that described in example 381 but starting with N-(3,5-difluorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide (200 mg, 0.74 mmol) yielded title compound (40 mg, 9%).
  • MS ES+: 628.5 (M+H)+
  • 1HNMR (DMSOd6: 2.05 (s, 3H); 2.40 (m, 4H); 2.57 (m, 2H); 2.69 (m, 4H); 3.91 (s, 2H); 3.97 (s, 3H); 4.35 (m, 2H); 5.31 (m, 1H); 6.93 (m, 1H); 7.33 (s, 1H); 7.35 (m, 2H); 7.39 (s, 1H); 8.13 (s, 1H); 8.68 (s, 1H).
    • EXAMPLE 399 Preparation of Compound 577 in Table 20
  • An analogous reaction to that described in example 381 but starting with N-(3,5-difluorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide (200 mg, 0.74 mmol) yielded title compound (192 mg, 44%).
  • MS ES+: 586.5 (M+H)+
  • 1HNMR (DMSOd6: 2.42 (m, 6H); 2.74 (m, 4H); 3.92 (s, 2H); 3.98 (s, 3H); 4.09 (m, 2H); 4.20 (m, 1H); 4.92 (m 1H); 6.93 (m, 1H); 7.29 (s, 1H); 7.35 (m, 2H); 7.39 (s, 1H); 8.12 (s, 1H); 8.68 (s, 1H).
    • EXAMPLE 400 Preparation of Compound 578 in Table 20
  • An analogous reaction to that described in example 379 but starting with N-(3-fluorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide (200 mg, 0.8 mmol) yielded title compound (156 mg, 35%)
  • MS ES+: 553.5 (M+H)+
  • 1HNMR (DMSOd6: 1.70 (m, 4H); 2.5 (m, 5H); 2.67 (m, 1H); 3.90 (s, 2H); 3.98 (s, 3H); 4.06 (m, 2H); 4.20 (m, 1H); 4.97 (m, 1H); 6.92 (m, 1H); 7.28 (m, 1H); 7.35 (m, 2H); 7.39 (s, 1H); 7.63 (m, 1H); 8.12 (s, 1H); 8.68 (s, 1H).
  • N-(3-fluorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide
  • An analogous reaction to that described in example 378 but starting with N-(3-fluorophenyl)-2-(2-tritylamino-1,3-thiazole-5-yl)acetamide (14.6 g, 38.4 mmol) yielded title compound (6.21 g, 65%).
  • 1HNMR (DMSOd6: 3.65 (s, 2H); 6.76 (m, 3H); 6.89 (t, 1H); 7.35 (m, 2H); 7.59 (d, 1H).
  • N-(3-fluorophenyl)-2-(2-tritylamino-1,3-thiazole-5-yl)acetamide.
  • An analogous reaction to that described in example 378 but starting with 3-fluoroaniline yielded title compound (14.6 g, 79%).
  • 1HNMR (DMSOd6: 3.56 (s, 2H); 6.61 (s, 1H); 6.89 (t, 1H); 7.25 (m, 17H); 7.56 (d, 1H); 8.41 (s, 1H).
    • EXAMPLE 401 Preparation of Compound 579 in Table 20
  • An analogous reaction to that described in example 378 but starting with N-(3-fluorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide (200 mg, 0.8 mmol) yielded title compound (214 mg, 47%).
  • MS ES+: 567.6 (M+H)+
  • 1HNMR (DMSOd6): 1.38 (m, 2H); 1.52 (m, 4H) 2.42 (m, 6H); 3.91 (s, 2H); 3.98 (s, 3H); 4.04 (m, 2H); 4.20 (m, 1H); 4.89 (m, 1H); 6.91 (m, 1H); 7.29 (s, 1H); 7.37 (m, 2H); 7.39 (s, 1H); 7.63 (m, 1H); 8.13 (s, 1H); 8.68 (s, 1H).
    • EXAMPLE 402 Preparation of Compound 580 in Table 20
  • An analogous reaction to that described in example 381 but starting with N-(3-fluorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide (200 mg, 0.8 mmol) yielded title compound (210 mg, 46%).
  • MS ES+: 568.5 (M+H)+
  • 1HNMR (DMSOd6: 2.38 (m, 6H); 2.70 (m, 4H); 3.89 (s, 2H); 3.96 (s, 3H); 4.02 (m, 2H); 4.19 (m, 1H); 4.98 (m, 1H); 6.89 (m, 1H); 7.27 (s, 1H); 7.32 (m, 2H); 7.37 (s, 1H); 7.61 (m, 1H); 8.10 (s, 1H); 8.66(s, 1H).
    • EXAMPLE 403 Preparation of Compound 581 in Table 20
  • An analogous reaction to that described in example 381 but starting with N-(3-fluorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide (200 mg, 0.8 mmol) yielded title compound (35 mg, 7%).
  • MS ES+: 610.5 (M+H)+
  • 1HNMR (DMSOd6: 2.03 (s, 3H); 2.38 (m, 4H); 2.57 (m, 2H); 2.69 (m, 4H); 3.88 (s, 2H); 3.95 (s, 3H); 4.34 (m, 2H); 5.30 (m, 1H); 6.89 (m, 1H); 7.31 (s, 1H); 7.34 (m, 2H); 7.37 (s, 1H); 7.62 (m, 1H); 8.11 (s, 1H); 8.66 (s, 1H).
    • EXAMPLE 404 Preparation of Compound 582 in Table 20
  • An analogous reaction to that described in example 382 but starting with N-(3-fluorophenyl)-2-(2-amino-1,3-thiazole-5-yl)acetamide (200 mg, 0.8 mmol) yielded title compound (196 mg, 43%)
  • MS ES+: 567.5 (M+H)+
  • 1HNMR (DMSOd6): 1.30 (m, 2H); 1.47 (m, 2H); 1.61 (m, 2H); 1.73 (m, 3H); 2.62 (m, 1H); 2.71 (m, 1H); 3.0 (m, 1H); 3.89 (m, 1H); 3.97 (s, 3H); 4.07 (m, 1H); 4.13 (m, 1H); 5.03 (m, 1H); 6.90 (m, 1H); 7.25 (s, 1H); 7.35 (m, 2H); 7.37 (s, 1H); 7.62 (m, 1H); 8.10 (s, 1H); 8.66 (s, 1H).
    • EXAMPLE 405 Preparation of Compound 583 in Table 21
  • 4-((2-amino-1,3-thiazole-5-yl)acetic acid)-6,7-dimethoxyquinazoline (173 mg, 0.5 mmol) in NMP (2 ml) was reacted with 3,5-difluoroaniline (98 mg, 0.75 mmol) in the presence of 0-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (285 mg, 0.75 mmol) and DIEA (130 μL, 0.75 mmol) at 50° C. for 20 hours. The mixture was cooled, dimethylamine (2M MeOH, 2 ml) was added, and the resulting solution was stirred at room temperature for 15 hours, MeOH was evaporated, and water (20 ml) added to the mixture, the precipitate was recovered, washed with water, and purified by silicagel chromatography, eluant CH2Cl2/MeOH 50/40/10 to give title compound (22 mg, 10%).
  • 1HNMR (DMSOd6): 3.90 (s, 2H); 3.95 (s, 6H); 6.93 (t, 1H); 7.26 (s, 1H); 7.34 (d, 2H); 7.39 (s, 1H); 8.12 (s, 1H); 8.68 (s, 1H).
  • 4-((2-amino-1,3-thiazole-5-yl)acetic acid)-6,7-dimethoxyquinazoline
  • 4-(methyl(2-amino-1,3-thiazole-5-yl)acetate)-6,7-dimethoxyquinazoline (3.92 g, 10.9 mmol) in ethanol 50 ml was treated with sodium hydroxyde (2N, 27 ml, 54.5 mmol) for 45 minutes. The solvent was evaporated, the residue dissolved in CH2Cl2/MeOH triethylamine (3 eq.) was added the solid removed by filtration, the filtrate was evaporated and triturated with ethanol to give title compound as a solid (1.88 g, 50%).
  • 1HNMR (DMSOd6): 3.83 (s, 2H); 3.96 (s, 6H); 7.27 (s, 1H); 7.35 (s, 1H); 8.13 (s, 1H); 8.69 (s, 1H).
  • 4-(methyl(2-amino-1,3-thiazole-5-yl)acetate)-6,7-dimethoxyquinazoline
  • N′-(2-cyano-4,5-dimethoxyphenyl)-N,N-dimethylimidoformamide (3.5 g, 15 mmol) in acetic acid (35 ml) was reacted with methyl (2-amino-1,3-thiazole-5-yl)acetate (3.22 g, 18.7 mmol) at reflux for 4 hours. The solvent was evaporated and the residue purified by silicagel chromatography, Eluant CH2Cl2/MeOH 95/5 to give title compound (3.92 g, 73%).
  • 1HNMR (DMSOd6): 3.69 (s, 3H); 3.95 (s, 2H); 3.96 (s, 6H); 7.27 (s, 1H); 7.38 (s, 1H); 8.12 (s, 1H); 8.69 (s, 1H).
    • EXAMPLE 406 Preparation of Compound 584 in Table 21
  • An analogous reaction to that described in example 405 but starting with 3-chloroaniline (80 μl, 0.75 mmol) yielded title compound (81 mg, 26%).
  • MS ES+: 456.4, 458.4 (M+H)+
  • 1HNMR (DMSOd6): 3.91 (s, 2H); 3.96 (s, 6H); 7.14 (d, 1H); 7.28 (s, 1H); 7.37 (t, 1H); 7.48 (d, 1H); 7.85 (m, 1H); 8.13 (s, 1H); 8.69 (s, 1H).
    • EXAMPLE 407 Preparation of Compound 585 in Table 21
  • An analogous reaction to that described in example 405 but starting 3-chloro-4-fluoroaniline (110 mg, 0.75 mmol) yielded title compound (93.7 mg, 40%).
  • MS ES+: 474.4, 476.4 (M+H)+
  • 1HNMR: 3.90 (s, 2H); 3.97 (s, 3H); 7.28 (s, 1H); 7.40 (m, 1H); 7.40 (s, 1H); 7.50 (m, 1H); 7.96 (m, 1H); 8.14 (s, 1H); 8.70 (s, 1H).
    • EXAMPLE 408 Preparation of Compound 586 in Table 21
  • An analogous reaction to that described in example 405 but starting 3,4-difluoroaniline (75 mg, 0.75 mmol) yielded title compound (130 mg, 60%).
  • MS ES+: 458.5 (M+H)+
  • 1HNMR: 3.89 (s, 2H); 3.97 (s, 6H); 7.28 (s, 1H); 7.33 (m, 1H); 7.40 (s, 1H); 7.41 (m, 1H); 7.82 (m, 1H); 8.14 (s, 1H); 8.69 (s, 1H).
    • EXAMPLE 409 Preparation of Compound 587 in Table 22
  • 4-((2-amino-1,3-thiazole-5-yl)(hydroxy)acetic acid)-6-methoxy-7-(3-morpholinopropoxy)quinazoline (143 mg, 0.3 mmol) in DMF (4 ml) was reacted with aniline (36 mg, 0.39 mmol) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (63 mg, 0.33-mmol), 2-hydroxypyridine N-oxyde (33 mg, 0.3 mmol) and DIEA (36 mg, 0.3 mmol) at 90° C. for 1 hour. The mixture was cooled, diluted with CH2Cl2 (8 ml) and purified by silica gel chromatography, Eluant CH2Cl2/MeOH 90/10 to 85/15. The combined fractions containing product were evaporated, the residue was dissolved in MeOH, water was added and the precipitate recovered, dissolved in MeOH/CH2Cl2, dried, concentrated to give title compound (145 mg, 88%).
  • MS ES+: 551.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 3.15 (t, 2H); 3.34 (t, 2H); 3.55 (d, 2H); 3.71 (t, 2H); 3.98 (s, 3H); 4.03 (d, 2H); 4.31 (t, 2H); 5.47 (s, 1H); 7.11 (t, 1H); 7.31 (s, 1H); 7.33 (t, 2H); 7.70 (s, 1H); 7.73 (d, 2H); 7.92 (s, 1H); 9.12 (s, 1H).
  • 4-(2-amino-1,3-thiazole-5-yl)-6-methoxy-7-(3-morpholinopropoxy)quinazoline.
  • N′-(2-cyano-4-methoxy-5-(3-morpholinopropoxy)phenyl)-N,N-dimethylimidoformaride (692 mg, 2 mmol) was reacted with amino-1,3-thiazole (240 mg, 2.4 mmol) in acetic acid (6.9 ml) at reflux for 4 hours. The mixture was concentrated, the residue dissolved in AcOEt, washed with aqueous sodium bicarbonate, the organic phase was dried, concentrated, the residual oil triturated in ether to give a solid (560 mg, 70%).
  • MS ES+: 402.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.29 (t, 2H); 3.16 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 3.99 (s, 3H); 4.04 (d, 2H); 4.31 (t, 2H); 7.32 (s, 1H); 7.47 (d, 1H); 7.75((d, 1H); 7.95 (s, 1H); 9.11 (s, 1H).
  • 4-((2-amino-1,3-thiazole-5-yl)(hydroxy)acetic acid)-6-methoxy-7-(3-morpholinopropoxy)quinazoline.
  • 4-(2-amino-1,3-thiazole-5-yl)-6-methoxy-7-(3-morpholinopropoxy)quinazoline (1.6 g, 4 mmol) in water (16 ml), MeOH (16 ml), was reacted with glyoxylic acid (740 mg, 8 mmol) at pH 11.5 (NaOH 6N) and 45-50° C. for 6. hours. Methanol was evaporated, and the pH of the aqueous phase adjusted to 3 (HCl 6N), and the solution poured on a strong cation exchanger (isolute®) column, washed with water (120 ml), methanol (120 ml) and eluted with CH2Cl2/MeOH, NH3 (3N) 1/1 200 ml to give title compound (1.58 g, 83%).
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.68 (t, 2H); 3.98 (s, 3H); 4.03 (d, 2H); 4.30 (t, 2H); 5.38 (s, 1H); 7.32 (s, 1H); 7.68 (s, 1H); 7.91 (s, 1H); 9.12 (s, 1H).
    • EXAMPLE 410 Preparation of Compound 588 in Table 22
  • An analogous reaction to that described in example 409 but starting with 3,4(difluoroaniline (34 mg, 0.26 mmol) yielded title compound (30 mg, 26%).
  • MS ES+: 587.5 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 3.16 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.69 (t, 2H); 3.98 (s, 3H); 4.04 (d, 2H); 4.30 (t, 2H); 5.48 (s, 1H); 7.32 (s, 1H); 7.40 (q, 1H); 7.57 (m, 1H); 7.70 (s, 1H); 7.92 (m, 2H); 9.12 (s, 1H).
    • EXAMPLE 411 Preparation of Compound 589 in Table 22
  • N′-(2-cyano-4methoxy-5-(3-N-methylpiperazinylpropoxy)4-methoxyphenyl)-N,N-dimethylimidoformamide (144 mg, 0.4 mmol) was reacted with N-(3,4-difluorophenyl)-2-(2-amino-1,3-thiazole-5-yl)-2-hydroxyacetamide (137 mg, 0.4 mmol) in acetic acid (350 μl) at reflux for 40 minutes. The solvent was removed, and the residue purified by silica gel chromatography, Eluant CH2Cl2/MeOH/Et3N, 90.10.1 to give title compound (180 mg, 37%).
  • MS ES+: 600.5 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.30 (t, 2H); 2.94 (s, 3H); 3.14.1 (m, 8H); 3.44 (t, 2H); 3.99 (s, 3H); 4.30 (t, 2H); 5.48 (s, 1H); 7.32 (s, 1H); 7.40 (q, 1H); 7.57 (m, 1H); 7.70 (s, 1H); 7.92 (m, 2H); 9.12 (s, 1H).
  • Methyl(2-tert-butoxycarbonylamino-1,3-thiazole-5-yl)acetate
  • Methyl(2-amino-1,3-thiazol-5-yl)acetate (4.3 g, 25 mmol) was reacted with di-tert-butyl dicarbonate (10.9 g, 50 mmol) neat, at 100° C. for 2 hours. The cold mixture was triturated in ether to give title compound as a solid (4.3 g, 63%).
  • 1HNMR (DMSOd6): 1.48 (s, 9H); 3.66 (s, 3H); 3.86 (s, 2H); 7.17 (s, 1H).
  • Methyl(2-tert-butoxycarbonylamino-1,3-thiazole-5-yl)(oxo)acetate.
  • Methyl(2-tert-butoxycarbonylamino-1,3-thiazole-5-yl)acetate (4.08 g, 15 mmol) in dioxane (60 ml) was reacted with selenium dioxide (4 g, 36 mmol) at reflux for 45 minutes. The mixture was cooled, CH2Cl2/MeOH 8/2 (150 ml) was added, the insoluble material was filtered, the organic phase was washed with a saturated solution of sodium bicarbonate, and extracted with CH2Cl2, dried, purified by chromatography over alumina, eluant CH2Cl2/MeOH 9/1 to give title compound (1 g, 23%).
  • 1HNMR (DMSOd6): 1.57 (s, 9H); 3.94 (s, 3H); 8.48 (s, 1H).
  • (2-tert-butoxycarbonylamino-1,3-thiazole-5-yl)(oxo)acetic acid.
  • Methyl(2-tert-butoxycarbonylamino-1,3-thiazole-5-yl)(oxo)acetate (1.14 g, 4 mmol) in ethanol (10 ml) was treated with sodium hydroxyde (2N, 4 ml, 8 mmol) for 3M minutes at room temperature. Ethanol was removed, the aqueous solution was acidified (pH 3). The solid was recovered, dried to give title product (900 mg, 82%).
  • 1HNMR (DMSOd6): 1.53 (s, 9H); 8.41 (s, 1H).
  • N-(3,4-difluorophenyl)-2-(2-tert-butoxycarbonylamino-1,3-thiazole-5-yl)(oxo)acetamide 2-tert-butoxycarbonylamino-1,3-thiazole-5-yl)(oxo)acetic acid (136 mg, 0.5 mmol) in DMF (2 ml) was reacted with 3,4-difluoroaniline (77 mg, 0.6 mmol) in presence of 0-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (203 mg, 0.55 mmol) and DIEA (77 mg, 0.6 mmol) for 15 minutes. The mixture was diluted with water, the solid was filtered, washed with water, dried, to give title compound (162 mg, 84%).
  • 1HNMR (DMSOd6): 1.53 (s, 9H); 7.48 (q, 1H); 7.68 (m, 1H); 7.98 (m, 1H); 8.61 (s, 1H).
  • N-(3,4-difluorophenyl)-2-(2-tert-butoxycarbonylamino-1,3-thiazole-5-yl)-2-hydroxyacetamide.
  • N-(3,4-difluorophenyl)-2-(2-tert-butoxycarbonylamino-1,3-thiazole-5-yl)(oxo)acetamide (938 mg, 2.4 mmol) in THF (50 ml) and MeOH (10 ml) was treated with sodium borohydride (93 mg, 2.4 mmol) for 30 minutes. The mixture was evaporated, the residue dissolved in ethanol (3 ml) water (25 ml) was added, and the pH adjusted to 6, more water was added, a solid was recovered, dried, recristalized in ether/petroleum ether to give title compound (850 mg, 90%).
  • 1HNMR (DMSOd6): 1.48 (s, 9H); 5.34 (d, 1H); 6.78 (d, 1H); 7.33 (s, 1H); 7.40 (s, 1H); 7.56 (m, 1H); 7.90 (m, 1H).
  • N-(3,4-difluorophenyl)-2-(2-tert-butoxycarbonylamino-1,3-thiazole-5-yl)-2-hydroxyacetamide (847 mg, 2.2 mmol) in CH2Cl2 (12 ml) and TFA (4 ml) was stirred at room temperature for 3 hours. The solvent was evaporated, the residue dissolved in MeOH /H2O, the pH adjusted to 7 and the mixture was extracted with ethyl acetate. The organic layer was dried, evaporated, the residue was triturated in ether, the solid filtered to give title compound (515 mg, 82%).
  • 1HNMR (DMSOd6): 5.17 (d, 1H); 6.51 (d, 1H); 6.91 (m, 3H); 7.39 (s, 1H); 7.52 (m, 1H); 7.87 (m, 1H).
    • EXAMPLE 412 Preparation of Compound 590 in Table 22
  • N′-(2-cyano-4-methoxy-5-(3-piperidinylpropoxy)4methoxyphenyl)-N,N-dimethylimidoformamide (100 mg, 0.29 mmol) was reacted with N-(3-fluorophenyl)-2-(2-amino-1,3-thiazole-5-yl)-2-hydroxyacetamide (82 mg, 0.3 mmol) in acetic acid (260 mg) at 105° C. for 40 minutes. The mixture was evaporated and purified by silica gel chromatography, eluant CH2Cl2/MeOH (NH3 3N) 9/1 to give title compound (42 mg, 26%).
  • MS ES+: 567.5 (M+H)+
  • 1HNMR (DMSOd6): 1.4 (m, 2H); 1.51 (m, 4H); 1.95 (t, 2H); 2.40 (m, 6H); 3.95 (s, 3H); 4.19 (t, 2H); 5.41 (d, 1H); 6.78 (d, 1H); 6.91 'm, 1H); 7.25 (s, 1H); 7.35 (q, 1H); 7.50 (s, 1H); 7.55 (d, 1H); 7.71 (m, 1H); 8.10 (s, 1H); 8.68 (s, 1H).
  • N′-(2-cyano-4-methoxy-5-(3-piperidinylpropoxy)-4-methoxyphenyl)-N,N-dimethylimidoformamide.
  • N′-(2-cyano-4-methoxy-5-(3-chloropropoxy)-4-methoxyphenyl)-N,N-dimethylimidoformamide (3 g, 10 mmol) in acetonitrile (50 ml) was reacted with piperidine (10 ml, 100 mmol) in presence of KI (300 mg, 1.8 mmol) and K2CO3 (2.1 g, 0.015 mmol) at 75° C. under argon for 3 hours. The solvent was evaporated, and the residue purified by silica gel chromatography, Eluant CH2Cl2/MeOH, NH3 3N 95/5 to give title compound (3.48 g, 100%).
  • MS ES+: 345.6 (M+H)+
  • 1HNMR (DMSOd6): 1.4 (m, 2H); 1.50 (m, 4H); 1.88 (m, 2H); 2.35 (m, 6H); 2.95 (s, 3H); 3.05 (s, 3H); 3.72 (s, 3H); 4.05 (t, 2H); 6.72 (s, 1H); 7.07 (s, 1H); 7.89 (s, 1H).
  • N-(3-fluorophenyl)-2-(2-amino-1,3-thiazole-5-yl)-2-hydroxyacetamide.
  • An analogous reaction to that described in example 411, but starting with N-(3-fluorobenzyl)-2-(2-tert-butoxycarbonylamino-1,3-thiazole-5-yl)-2-hydroxyacetamide (2.55 g, 0.69 mmol) yielded title compound (1.37 g, 75%).
  • MS ES+: 268.5 (M+H)+
  • 1HNMR (DMSO6): 5.16 (d, 1H); 6.45 (d, 1H); 6.90 (m, 4H); 7.34 (q, 1H); 7.49 (d, 1H); 7.70 (m, 1H).
  • N-(3-fluorophenyl)-2-(2-tert-butoxycarbonylamino-1,3-thiazole-5-yl)-2-hydroxyacetamide.
  • An analogous reaction to that described in example 411, but starting with N-(3-fluorophenyl)-2-(2-tert-butoxycarbonylamino-1,3-thiazole-5-yl)(oxo)acetamide (2.92 g, 8 mmol) yielded title compound (2.59 g, 88%).
  • 1HNMR (DMSOd6): 1.48 (s, 9H); 5.34 (d, 1H); 6.74 (d, 1H); 6.90 (m, 1H); 7.33 (m, 2H); 7.54 (d, 1H); 7.70 (m, 1H).
  • N-(3-fluorophenyl)-2-(2-tert-butoxycarbonylamino-1,3-thiazole-5-yl)(oxo)acetamide.
  • An analogous reaction to that described in example 411, but starting with 3-fluoroaniline (1.6 g, 14.4 mmol) yielded title compound (4.06 g, 93%).
  • 1HNMR (DMSOd6): 1.54 (s, 9H); 7.01 (m, 1H); 7.42 (m, 1H); 7.69 (m, 1H); 7.80 (m, 1H); 8.6 (s, 1H).
    • EXAMPLE 413 Preparation of Compound 591 in Table 22
  • An analogous reaction to that described in example 412, but starting with N-(3-chlorophenyl)-2-(2-amino-1,3-thiazole-5-yl)-2-hydroxyacetamide (99 mg, 0.35 mmol) yielded title compound (47 mg, 23%).
  • MS ES+: 583.4 (M+H)+
  • 1HNMR (DMSOd6): 1.38 (m, 2H); 1.51 (m, 4H); 1.95 (m, 2H); 2.38 (m, 6H); 3.95 (s, 3H); 4.19 (t, 2H); 5.40 (d, 1H); 6.79 (d, 1H); 7.14 (d, 1H); 7.24 (s, 1H); 7.35 (t, 1H); 7.50 (s, 1H); 7.67 (d, 1H); 7.95 (s, 1H); 8.10 (s, 1H); 8.68 (s, 1H).
  • N-(3-chlorophenyl)-2-(2-amino-1,3-thiazole-5-yl)-2-hydroxyacetamide.
  • An analogous reaction to that described in example 412, but starting with N-(3-chlorophenyl)-2-(2-tert-butoxycarbonylamino-1,3-thiazole-5-yl)-2-hydroxyacetamide (2.13 g, 5.5 mmol) yielded title compound (1.02 g, 65%).
  • 1HNMR (DMSOd6): 5.15 (d, 1H); 6.45 (d, 1H); 6.90 (m, 3H); 7.12 (dd, 1H); 7.33 (t, 1H); 7.62 (d, 1H); 7.89 (m, 1H).
  • N-(3-chlorophenyl)-2-(2-tert-butoxycarbonylamino-1,3-thiazole-5-yl)-2-hydroxyacetamide.
  • An analogous reaction to that described in example 412, but starting with N-(3-chlorophenyl)-2-(2-tert-butoxycarbonylamino-1,3-thiazole-5-yl)(oxo)acetamide (2.5 g, 6.5 mmol) yielded title compound (2.23 g, 89%).
  • 1HNMR (DMSOd6): 1.48 (s, 9H); 5.34 (d, 1H); 6.74 (d, 1H); 7.14 (m, 1H); 7.34 (m, 2H); 7.65 (m, 1H); 7.92 (m, 1H).
  • N-(3-chlorophenyl)-2-(2-tert-butoxycarbonylamino-1,3-thiazole-5-yl)(oxo)acetamide.
  • An analogous reaction to that described in example 412, but starting with 3-chloroaniline (1.84 g, 14 mmol) yielded title compound (3.6 g, 79%).
  • 1HNMR (DMSOd6): 1.54 (s, 9H); 7.24 (d, 1H); 7.43 (t, 1H); 7.79 (d, 1H); 8.03 (s, 1H); 8.61 (s, 1H).
    • EXAMPLE 414 Preparation of Compound 592 in Table 22
  • N′-(2(cyano-4-methoxy-5-(N-methyl-3-piperazinylpropoxyphenyl)-N,N-dimethylimidoformamide (140 mg, 0.39 mmol) in acetic acid (0.5 ml) in presence of N-(3,4-difluorophenyl)-2-(2-amino-1,3-thiazole-5-yl)-2-(hydroxyimino)acetamide (116 mg, 0.39 mmol) was heated at 110° C. for 16 hours. The mixture was concentrated and purified by silica gel chromatography, Eluant CH2Cl2/MeOH HN3 3N 95/5 to 90/10, to give title compound (23 mg, 10%).
  • MS ES+: 613.5 (M+H)+
  • 1HNMR (DMSOd6): 2.0 (m, 2H); 2.22 (s, 3H); 2.47 (m, 10H); 4.0 (s, 3H); 4.22 (t, 2H); 7.29 (m, 1H); 7.47 (m, 1H); 7.57 (m, 1H); 7.97 (m, 1H); 8.2 (s, 1H); 8.38 (s, 1H); 8.80 (s, 1H).
  • N-(3,4-difluorophenyl)-2-(2-amino-1,3-thiazol-5-yl)-2-(hydroxyimino)acetamide.
  • N-(3,4-difluorophenyl)-2-(2-tert-butoxycarbonyl-amino-1,3-thiazol-5-yl)-2-(hydroxyimino)acetamide (600 mg, 1.5 mmol) in CH2Cl2 (12 ml) and TFA (4 ml) was stirred at room temperature for 2 hours. The mixture was evaporated, dissolved in methanol, the pH adjusted to 6 with sodium bicarbonate, water was added, the precipitate recovered, dried to give title compound (388 mg, 86%).
  • MS ES+: 299.4 (M+H)+
  • 1HNMR (DMSOd6) mixture of isomers 7.05, 7.8 (2s, 1H); 7.43 (m, 4H); 7.88 (m, 1H).
  • N-(3,4-difluorophenyl)-2-(2-tert-butoxycarbonyl-amino-1,3-thiazole-5-yl)-2-(hydroxyimino)acetamide.
  • N-(3,4-difluorophenyl)-2-(2-tert-butoxycarbonyl-amino-1,3-thiazole-5-yl)(oxo)acetamide (100 mg, 0.26 mmol) in pyridine (8 ml) was reacted with hydroxylamine hydrochloride (27 mg, 0.39 mmol) at 70° C. for 15 hours. The solvent was evaporated, water was added to the residue, the solid was filtered, washed with water, dried to give title compound (84 mg, 81%).
  • 1HNMR (DMSOd6) mixture of isomers 7.41, 8.18 (2s, 1H); 7.50 (m, 2H); 7.90 (m, 1H).
    • EXAMPLE 415 Preparation of Compound 593 in Table 23
  • 5-((6-methoxy-7-(3-morpholinopropoxy)quinazolin-4yl)amino)thiophene-2-carboxylic acid (80 mg, 0.18 mmol) in DMF (2 ml) was reacted with 2-aminopyridine (17 mg, 0.18 mmol) in presence of 0-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (70 mg, 0.18 mmol) and DIEA (80 μl, 0.46 mmol), at 50° C. for 6 hours. A saturated solution of sodium bicarbonate (2 ml) was added and the mixture stirred for 0.5 hour. A solid is recovered by filtration, washed with water, dried to give title compound (15 mg, 16%).
  • MS ES+: 521 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (m, 2H); 3.16 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 4.03 (d, 2H); 4.05 (s, 3H); 4.32 (t, 2H); 7.43 (m, 2H); 7.53 (t, 1H); 7.94 (d, 1H); 8.21 (m, 2H); 8.35 (t, 1H); 8.49,(d, 1H); 9.30 (s, 1H).
    • EXAMPLE 416 Preparation of Compound 594 in Table 23
  • An analogous reaction to that described in example 415, but starting with 4-methylaniline (19 mg, 0.18 mmol) yielded title compound (69 mg, 72%).
  • MS ES+: 535 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.34 (s, 3H); 2.40 (t, 2H); 3.11 (t, 2H); 3.38 (t, 2H); 3.60 (d, 2H); 3.90 (t, 2H); 4.03 (d, 2H); 4.05 (s, 3H); 4.35 (t, 2H); 7.15 (d, 2H); 7.27 (d, 1H); 7.52 (s, 1H); 7.62 (d, 2H); 7.85 (d, 1H); 8.15 (s, 1H); 8.87 (s, 1H).
    • EXAMPLE 417 Preparation of Compound 595 in Table 23
  • An analogous reaction to that described in example 415, but starting 2-methylaniline (19 mg, 0.18 mmol) yielded title compound (28 mg, 29%).
  • MS ES+: 535 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.28 (s, 3H); 2.32 (t, 2H); 3.18 (t, 2H); 3.37 (t, 2H); 3.56 (d, 2H); 3.70 (t, 2H); 4.05 (d, 2H); 4.07 (s, 3H); 7.30 (m, 4H); 7.35 (d, 1H); 7.41 (s, 1H); 7.96 (d, 1H); 8.22 (s, 1H); 9.26 (s, 1H).
    • EXAMPLE 418 Preparation of Compound 596 in Table 23
  • An analogous reaction to that described in example 415, but starting 3-methoxyaniline (22 mg, 0.18 mmol) yielded title compound (14 mg, 14%).
  • MS ES+: 550.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (t, 2H); 3.17 (t, 2H); 3.37 (t, 2H); 3.57 (d, 2H); 3.70 (t, 2H); 3.78 (s, 3H); 4.04 (d, 2H); 4.06 (s, 3H); 4.33 (t, 2H); 6.7 (d, 1H); 7.28 (s, 1H); 7.35 (s, 1H); 7.36 (d, 1H); 7.41 (s, 1H); 7.45 (s, 1H); 8.01 (d, 1H); 8.22 (s, 1H); 9.27 (s, 1H).
    • EXAMPLE 419 Preparation of Compound 597 in Table 23
  • An analogous reaction to that described in example 415, but starting 2-hydroxymethyl-aniline (22 mg, 0.18 mmol) yielded title compound (7 mg, 7%).
  • MS ES+: 550.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (m, 2H); 3.18 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 4.06 (m, 5H); 4.32 (t, 2H); 4.65 (s, 2H); 7.22 (t, 1H); 7.32 (t, 1H); 7.37 (d, 1H); 7.40 (s, 1H); 7.46 (d, 1H); 7.72 (d, 1H); 7.81 (d, 1H); 8.22 (s, 1H); 9.27 (s, 1H).
    • EXAMPLE 420 Preparation of Compound 598 in Table 23
  • An analogous reaction to that described in example 415, but starting 3-nitroaniline (25 mg, 0.18 mmol) yielded title compound (6 mg, 6%).
  • MS ES+: 565.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (t, 2H); 3.18 (t, 2H); 3.38 (t, 2H); 3.58 (d, 2H); 3.70 (t, 2H); 4.05 (d, 2H); 4.07 (s, 3H); 4.33 (t, 2H); 7.39 (d, 1H); 7.42 (s, 1H); 7.68 (t, 1H); 7.98 (d, 1H); 8.08 (d, 1H); 8.20 (m, 1H); 8.23 (s, 1H); 8.77 (s, 1H); 9.3 (s, 1H).
    • EXAMPLE 421 Preparation of Compound 599 in Table 23
  • An analogous reaction to that described in example 415, but starting 4-trifluoromethylaniline (29 mg, 0.18 mmol) yielded title compound (8 mg, 8%).
  • MS ES+: 588.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.33 (m, 2H); 3.19 (t, 2H); 3.41 (t, 2H); 3.61 (d, 2H); 3.75 (t, 2H); 4.05 (d, 2H); 4.08 (s, 1H); 4.37 (t, 2H); 7.39 (d, 1H); 7.43 (s, 1H); 7.72 (d, 2H); 8.03 (d, 2H); 8.10 (d, 1H); 8.23 (s, 1H); 9.29 (s, 1H).
    • EXAMPLE 422 Preparation of Compound 600 in Table 23
  • An analogous reaction to that described in example 415, but starting 3-chloroaniline (23 mg, 0.18 mmol) yielded title compound (21 mg, 21%).
  • 1HNMR (DMSOd6, TFA): 2.32 (m, 2H); 3.19 (t, 2H); 3.37 (t, 2H); 3.57 (d, 2H); 3.70 (t, 2H); 4.03 (d, 2H); 4.07 (s, 3H); 4.34 (t, 2H); 7.17 (d, 1H); 7.37 (t, 1H); 7.40 (m, 2H); 7.70 (d, 1H); 7.95 (m, 1H); 8.02 (d, 1H); 8.22 (s, 1H); 9.29 (s, 1H).
    • EXAMPLE 423 Preparation of Compound 601 in Table 23
  • An analogous reaction to that described in example 415, but starting 2-methoxyaniline (22 mg, 0.18 mmol) yielded title compound (32 mg, 32%).
  • 1HNMR (DMSOd6, TFA): 2.35 (t, 2H); 3.18 (t, 2H); 3.37 (t, 2H); 3.56.(d, 2H); 3.70 (t, 2H); 3.87 (s, 3H); 4.05 (d, 2H); 4.06 (s, 3H); 4.34 (t, 2H); 6.99 (t, 1H); 7.11 (d, 1H); 7.20 (s, 1H); 7.33 (d, 1H); 7.40 (s, 1H); 7.73 (dd, 1H); 7.97 (d, 1H); 8.22 (s, 1H); 9.27 (s, 1H).
    • EXAMPLE 424 Preparation of Compound 602 in Table 23
  • An analogous reaction to that described in example 415, but starting 3-(2-hydroxyethyl) aniline (25 mg, 0.18 mmol) yielded title compound (27 mg, 26%).
  • MS ES+: 564.7 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.37 (d, 3H); 2.32 (t, 2H); 3.19 (t, 2H); 3.38 (t, 2H); 3.58 (d, 2H); 3.62 (t, 2H); 4.06 (d, 2H); 4.08 (s, 3H); 4.36 (t, 2H); 4.76 (q, 1H); 7.08 (d, 1H); 7.29 (t, 1H); 7.35 (d, 1H); 7.42 (s, 1H); 7.70 (d, 1H); 7.76 (s, 1H); 8.05 (d, 1H); 8.23 (s, 1H); 9.28 (s, 1H).
    • EXAMPLE 425 Preparation of Compound 603 in Table 23
  • An analogous reaction to that described in example 415, but starting 3-fluoro-4-methoxyaniline (25 mg, 0.18 mmol) yielded title compound (14 mg, 14%).
  • MS ES+: 568.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (t, 2H); 3.19 (t, 2H); 3.38 (t, 2H); 3.57 (d, 2H); 3.72 (t, 2H); 3.85 (s, 3H); 4.04 (d, 2H); 4.07 (s, 3H); 4.35 (t, 2H); 7.17 (t, 1H); 7.36 (d, 1H); 7.42 (s, 1H); 7.47 (dd, 1H); 7.73 (dd, 1H); 7.98 (d, 1H); 8.24 (s, 1H); 9.27 (s, 1H).
    • EXAMPLE 426 Preparation of Compound 604 in Table 23
  • An analogous reaction to that described in example 415, but starting 2-methyl-4-fluoroaniline (23 mg, 0.18 mmol) yielded title compound (27 mg, 27%).
  • MS ES+: 552.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.28 (s, 3H); 2.31 (t, 2H); 3.18 (t, 2H); 3.38 (t, 2H); 3.57 (d, 2H); 3.71 (t, 2H); 4.05 (d, 2H); 4.07 (s, 3H); 7.07 (dt, 1H); 7.15 (dd, 1H); 7.35 (d, 1H); 7.36 (m, 1H); 7.41 (s, 1H); 7.95 (d, 1H); 8.23 (s, 1H); 9.26 (s, 1H).
    • EXAMPLE 427 Preparation of Compound 605 in Table 23
  • An analogous reaction to that described in example 415, but starting 2-fluoro-5-methylaniline (23 mg, 0.18 mmol) yielded title compound (9 mg, 9%).
  • MS ES+: 552.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.33 (m, 5H); 3.19 (t, 2H); 3.38 (t, 2H); 3.56 (d, 2H); 3.71 (t, 2H); 4.04 (d, 2H); 4.07 (s, 3H); 4.35 (t, 2H); 7.09 (m, 1H); 7.18 (m, 1H); 7.35 (d, 1H); 7.40 (s, 1H); 7.41 (m, 1H); 8.0 (d, 1H); 8.23 (s, 1H); 9.27 (s, 1H).
    • EXAMPLE 428 Preparation of Compound 606 in Table 23
  • An analogous reaction to that described in example 415, but starting 3-cyanoaniline (21 mg, 0.18 mmol) yielded title compound (9 mg, 9%).
  • MS ES+: 545.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.33 (t, 2H); 3.21 (t, 2H); 3.39 (t, 2H); 3.60 (d, 2H); 3.72 (t, 2H); 4.07 (d, 2H); 4.10 (s, 3H); 4.37 (t, 2H); 7.40 (d, 1H); 7.44 (s, 1H); 7.62 (s, 1H); 7.63 (m, 1H); 8.06 (m, 1H); 8.06 (d, 1H); 8.26 (s, 1H); 8.30 (s, 1H); 9.32 (s, 1H).
    • EXAMPLE 429 Preparation of Compound 607 in Table 23
  • An analogous reaction to that described in example 415, but starting isoamylamine (16 mg, 0.18 mmol) yielded title compound (15 mg, 17%).
  • MS ES+: 514.7 (M+H)+
  • 1HNMR (CDCl3): 0.96 (d, 6H); 1.77 (m, 5H); 2.11 (m, 2H); 2.5 (m, 4H); 2.56 (t, 2H); 3.73 (m, 4H); 4.03 (s, 3H); 4.22 (t, 2H); 6.05 (t, 1H); 6.88 (d, 1H); 7.24 (s, 1H); 7.39 (d, 1H); 7.58 (s, 1H); 8.70 (s, 1H).
    • EXAMPLE 430 Preparation of Compound 608 in Table 23
  • An analogous reaction to that described in example 415, but starting 2-chloroaniline (23 mg, 0.18 mmol) yielded title compound (5 mg, 5%).
  • MS ES+: 554.5, 556.5 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (t, 2H); 3.19 (t, 2H); 3.39 (t, 2H); 3.57 (d, 2H); 3.70 (t, 2H); 4.04 (d, 2H); 4.07 (s, 3H); 4.34 (t, 2H); 7.32 (t, 1H); 7.36 (d, 1H); 7.41 (s, 1H); 7.41 (t, 1H); 7.57 (d, 1H); 7.63 (d, 1H); 8.0 (d, 1H); 8.23 (s, 1H); 9.27 (s, 1H).
    • EXAMPLE 431 Preparation of Compound 609 in Table 24
  • An analogous reaction to that described in example 415, but starting with 5-((6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl)amino)thiophene-3-carboxylic acid (80 mg, 0.18 mmol) and aniline (20 μl, 0.22 mmol) yielded title compound (28 mg, 30%).
  • MS ES+: 520 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (t, 2H); 3.18 (t, 2H); 3.38 (t, 2H); 3.56 (d, 2H); 3.71 (t, 2H); 4.05 (d, 2H); 4.06 (s, 3H); 4.34 (t, 2H); 7.12 (t, 1H); 7.37 (t, 2H); 7.40 (s, 1H); 7.76 (d, 1H); 7.79 (d, 2H); 8.18 (s, 1H); 8.21 (d, 1H); 9.17 (s, 1H).
  • 5-((6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl)amino)thiophene-3-carboxylic acid.
  • Ethyl-5-((6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl)amino thiophene-3-carboxylate (1.05 g, 2.2 mmol) in methanol (10 ml) was treated with sodium hydroxyde (2N, 10 ml) at 75° C. for 1.5 hour. Methanol was evaporated, HCl (2N) was added (pH 3) the solid filtered, redissolved in CH2Cl2/MeOH 1/1, DIEA (1.5 ml, 8.8 mmol) was added the solid removed by filtration, the filtrate was concentrated, and the residue dissolved in ethanol, title material was obtained as a solid (0.7 g, 71%).
  • MS ES+: 445 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.36 (t, 2H); 3.17 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.79 (t, 2H); 4.03 (d, 2H); 4.08 (s, 3H); 4.35 (t, 2H); 7.45 (s, 1H); 7.81 (s, 1H); 8.03 (s, 1H); 8.50 (s, 1H); 9.15 (s, 1H).
  • Ethyl-5-((6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl)aminothiophene-3-carboxylate.
  • 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (1 g, 3 mmol) in isopropanol (25 ml) and isopropanol HCl (0.5 ml) was reacted with ethyl 5-aminothiophene-3-carboxylate (0.6 g, 3.3 mmol) at 110° C. for 1 hour. The mixture was cooled, diluted with EtOAc, filtered to give title compound (1.58 g, 99%).
  • MS ES+: 473 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.33 (t, 3H); 2.33 (t, 2H); 3.17 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.75 (t, 2H); 4.03 (d, 2H); 4.06 (s, 3H); 4.30 (q, 2H); 4.33 (t, 2H); 7.42 (s, 1H); 7.73 (s, 1H); 8.09 (s, 1H); 8.35 (s, 1H); 9.15 (s, 1H).
    • EXAMPLE 432 Preparation of Compound 610 in Table 24
  • An analogous reaction to that described in example 431, but starting with 4-fluoroaniline (24 mg, 0.18 mmol) yielded title compound (20 mg, 22%).
  • MS ES+: 538.5 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (t, 2H); 3.20 (t, 2H); 3.40 (t, 2H); 3.60 (d, 2H); 3.72 (t, 2H); 4.04 (d, 2H); 4.07 (s, 3H); 4.34 (t, 2H); 7.9 (s, 1H); 7.20 (m, 2H); 7.41 (s, 1H); 7.76 (d, 1H); 7.82 (m, 1H); 8.19 (s, 1H); 8.21 (d, 1H); 9.17 (s, 1H).
    • EXAMPLE 433 Preparation of Compound 611 in Table 24
  • An analogous reaction to that described in example 431, but starting with 3-hydroxyaniline (24 mg, 0.18 mmol) yielded title compound (15 mg, 17%).
  • MS ES+: 536.6 (M+H)+
    • EXAMPLE 434 Preparation of Compound 612 in Table 24
  • An analogous reaction to that described in example 431, but starting with 3-(methylthio)aniline (30 mg, 0.18 mmol) yielded title compound (23 mg, 24%).
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 3.17 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 4.04 (m, 5H); 4.33 (t, 2H); 7.24 (t, 1H); 7.32 (t, 1H); 7.41 (s, 1H); 7.43 (m, 2H); 7.72 (d, 2H); 8.16 (m, 2H); 9.17 (s, 1H).
    • EXAMPLE 435 Preparation of Compound 613 in Table 24
  • An analogous reaction to that described in example 431, but starting with 4-fluoro-3-chloroaniline (32 mg, 0.18 mmol) yielded title compound (21 mg, 21%).
  • MS ES+: 577 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (t, 2H); 3.19 (t, 2H); 3.37 (t, 2H); 3.57 (d, 2H); 3.71 (t, 2H); 4.06 (m, 5H); 4.34 (t, 2H); 7.41 (m, 2H); 7.75 (m, 2H); 8.11 (m, 1H); 8.18 (s, 1H); 8.21 B(s, 1H); 9.18 (s, 1H).
    • EXAMPLE 436 Preparation of Compound 614 in Table 24
  • An analogous reaction to that described in example 431, but starting with 2,4-difluorobenzylamine (31 mg, 0.18 mmol) yielded title compound (22 mg, 22%).
  • MS ES+: 570.5 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.34 (t, 2H); 3.19 (t, 2H); 3.39 (t, 2H); 3.58 (d, 2H); 3.72 (t, 2H); 4.06 (m, 5H); 4.34 (t, 2H); 4.51 (s, 2H); 7.06 (t, 1H); 7.15 (t, 1H); 7.40 (s, 1H); 7.48 (m, 1H); 7.69 (d, 1H); 8.03 (d, 1H); 8.17 (s, 1H); 9.14 (s, 1H).
    • EXAMPLE 437 Preparation of Compound 615 in Table 24
  • An analogous reaction to that described in example 431, but starting with 3-fluoroaniline (24 mg, 0.18 mmol) yielded title compound (27 mg, 29%).
  • MS ES+: 538.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.33 (t, 2H); 3.18 (t, 2H); 3.38 (t, 2H); 3.58 (d, 2H); 3.72 (d, 2H); 4.04 (d, 2H); 4.07 (s, 3H); 4.35 (t, 2H); 6.91 (m, 1H); 7.42 (m, 2H); 7.59 (d, 1H); 7.78 (d, 1H); 7.79 (m, 1H); 8.19 (s, 1H); 8.24 (d, 1H); 9.18 (s, 1H).
    • EXAMPLE 438 Preparation of Compound 616 in Table 25
  • 2-((6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl)amino)imidazole-5-carboxylic acid (200 mg, 0.47 mmol) in DMF (3 ml) was reacted with aniline (43 μl, 0.47 mmol) in presence of 0-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (178 mg, 0.47 mmol) and DIEA (120 μl, 0.7 mmol) at 40° C. for 3 hours. A solution of dimethylamine in methanol (2M, 1 ml) was added and stirring was carried on for 3 hours. The solvent was evaporated, and the mixture was purified by silica gel chromatography, Eluant CH2Cl2/MeOH NH3 (sat.) 95/5 to give title compound (80 mg, 34%).
  • MS ES+: 504.1 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.29 (t, 2H); 3.18 (t, 2H); 3.35 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 3.96 (s, 3H); 4.04 (d, 2H); 4.27 (t, 2H); 7.15 (t, 1H); 7.25 (s, 1H); 7.40 (t, 2H); 7.74 (d, 2H); 7.81 (s, 1H); 8.09 (s, 1H); 8.75 (s, 1H).
    • EXAMPLE 439 Preparation of Compound 617 in Table 25
  • An analogous reaction to that described in example 438, but starting with 4-fluoroaniline (60 μl, 0.58 mmol) yielded title compound (120 mg, 39%).
  • MS ES+: 522.1 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.29 (t, 2H); 3.17 (t, 2H); 3.36 (t, 2H); 3.55 (d, 1H); 3.69 (t, 2H); 3.96 (s, 3H); 4.04 (d, 2H); 4.27 (t, 2H); 7.22 (m, 3H); 7.74 (m, 2H); 7.82 (s, 1H); 8.07 (s, 1H); 8.76 (s, 1H).
    • EXAMPLE 440 Preparation of Compound 618 in Table 25
  • An analogous reaction to that described in example 438, but starting with alkylamine 50 μl, 0.7 mmol) yielded title compound (133 mg, 40%).
  • MS ES+: 468.1 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.28 (t, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.68 (t, 2H); 3.94 (m, 5H); 4.04 (d, 2H); 4.26 (t, 2H); 5.14 (dd, 1H); 5.23 (dd, 1H); 5.88 (m, 1H); 7.23 (s, 1H); 7.77 (s, 1H); 7.86 (s, 1H); 8.71 (s, 1H).
  • 2-((6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl)amino)imidazole-5-carboxylic acid.
  • ethyl-2((4-imino-6-methoxy-7-(3-morpholinopropoxy)quinazolin-3-(4H)-yl)imidazole-5-carboxylate (650 mg, 1.42 mmol) in methanol (14 ml) was treated with sodium hydroxyde (2N, 14 ml) at 80° C. for 1.5 hour. Methanol was evaporated, hydrochloric acid (6N) was added (pH 2.5), the precipitate was recovered by filtration, dried to give title compound (650 mg, 100%).
  • 1HNMR (DMSOd6, TFA): 2.35 (t, 2H); 3.13 (t, 2H); 3.32 (t, 2H); 3.5 (d, 2H); 3.95 (m, 7H); 4.28 (t, 2H); 7.42 (s, 1H); 7.8 (s, 1H); 7.86 (s, 1H); 8.72 (s, 1H).
    • EXAMPLE 441 Preparation of Compound 619 in Table 26
  • 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (265 mg, 0.79 mmol) in 2-propanol (14 ml) was reacted with 4-amino-N-phenylthiophene-3-carboxamide hydrochloride (210 mg, 0.82 mmol) at 100° C. for 2 hours. The solvent was evaporated and the residue purified by silica gel chromatography, eluent CH2Cl2/MeOH, NH3 sat. 95/5 to give title compound (330 mg, 81%).
  • MS ES+: 520.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.30 (t, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.68 (t, 2H); 4.03 (s, 3H); 4.04 (d, 2H); 4.32 (t, 2H); 7.13 (t, 1H); 7.35 (t, 2H); 7.39 (s, 1H); 7.69 (d, 2H); 7.79 (s, 1H); 8.13 (d, 1H); 8.58 (d, 1H); 8.95 (s, 1H).
  • 4-(tert-butoxycarbonylamino-N-phenylthiophene-3-carboxamide
  • 4-(tert-butoxycarbonylamino)thiophene-3-carboxylic acid obtained by a literature procedure, Tetrahedron Letters 1997, 2637, (385 mg, 1.58 mmol) in DMF (5 ml) was reacted with aniline (140 μl, 1.58 mmol) in presence of 0-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (602 mg, 1.58 mmol) at 40° C. for 7 hours. The solvent was evaporated, and the residue purified by silica gel chromatography, Eluant petroleum ether/AcOEt: 80/20 to give title compound (348 mg, 70%).
  • 1HNMR (CDCl3): 1.50 (s, 9H); 7.19 (t, 1H); 7.39 (t, 2H); 7.54 (d, 2H); 7.69 (s, 2H); 7.71 (s, 1H); 9.45 (s, 1H).
  • 4-amino-N-phenylthiophene-3-carboxamide
  • 4-(tert-butoxycarbonylamino)-N-phenylthiophene-3-carboxamide (300 mg, 0.94 mmol) in CH2Cl2 (3 ml) was treated with TFA (0.36 ml, 4.71 mmol) at room temperature for 2.5 hours. The solvent was evaporated, the residue was dissolved in methanol/HCl, ether was added to the solution, the precipitate was recovered to give title compound (210 mg, 87%) which was used as is in the next step.
    • EXAMPLE 442 Preparation of Compound 620 in Table 26
  • An analogous reaction to that described in example 441, but starting with 4-amino-N-alkylthiophene-3-carboxamide (218 mg, 1.06 mmol) yielded title compound (366 mg, 75%).
  • MS ES+: 484.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.28 (t, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.68 (t, 2H); 3.95 (d, 2H); 4.03 (m, 5H); 4.32 (t, 2H); 5.14 (dd, 1H); 5.24 (dd, 1H); 5.91 (m, 1H); 7.41 (s, 1H); 7.59 (s, 1H); 8.28 (d, 1H); 8.51 (d, 1H); 9.04 (s, 1H).
  • 4-tert-butoxycarbonylamino)-N-alkylthiophene-3-carboxamide
  • An analogous reaction to that described in example 319, but starting with alkylamine (150 μl, 2.06 mmol) yielded title compound (385 mg, 66%).
  • 1HNMR (CDCl3): 1.51 (s, 9H); 4.04 (m, 2H); 5.21 (dd, 1H); 5.29 (dd, 1H); 5.92 (m, 1H); 6.1 (m, 1H); 7.54 (d, 1H); 7.64 (m, 1H); 9.64 (s, 1H).
  • 4-amino-N-alkylthiophene-3-carboxamide
  • An analogous reaction to that described in example 441, but starting with 4-tert-butoxycarboxylamino-N-alkyl-thiophene-3-carboxamide (320 mg, 1.13 mmol) yielded title compound (218 mg, 94%) which was used as is in the next step.
    • EXAMPLE 443 Preparation of Compound 621 in Table 27
  • 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinzaoline (100 mg, 0.29 mmol) in isopropanol (5 ml) was reacted with methyl-4-amino-thiophene-4-carboxylate hydrochloride (63.6 mg, 0.33 mmol) at reflux for 1 hour. Ethyl acetate was added to the reaction mixture, the solid was recovered by filtration, dried, to give title compound (140 mg, 89%).
  • MS ES+: 459.1 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.39 (t, 2H); 3.19 (t, 2H); 3.40 (t, 2H); 3.58 (d, 2H); 3.77 (m, 5H); 4.06 (m, 5H); 4.37 (t, 2H); 7.42 (s, 1H); 7.95 (s, 1H); 8.01 (d, 1H); 8.49 (d, 1H); 8.93 (s, 1H).
    • EXAMPLE 444 Preparation of Compound 622 in Table 28
  • 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (110 mg, 0.3 mmol) in 2-pentanol (5 ml) and isopropanol/HCl (55 μl) was reacted with 2-amino-5-isopropylthiophene-3-carboxamide (60 mg, 0.33 mmol) at 100° C. for 1 hour, ether and ethylacetate was added to the mixture, the precipitate was filtered to give title compound (155 mg, 93%).
  • MS ES+: 486.6 (M+H)+
  • 1HNMR (DMSOd6, TFA); 1.38 (d, 6H); 2.38 (t, 2H); 3.20 (m, 3H); 3.38 (t, 2H); 3.57 (d, 2H); 3.82 (t, 2H); 4.05 (d, 2H); 4.08 (s, 3H); 4.39 (t, 2H); 7.40 (s, 1H); 7.47 (s, 1H); 7.52 (s, 1H); 9.23 (s, 1H).
    • EXAMPLE 445 Preparation of Compound 623 in Table 28
  • An analogous reaction to that described in example 444 but starting with alkyl-5-aminothiophene-2-carboxylate (67 mg, 0.33 mmol) at 100° C. for 2 hours yielded title compound (151 mg, 85%).
  • MS ES+: 485.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.38 (t, 2H); 3.18 (t, 2H); 3.38 (t, 2H); 3.57 (d, 2H); 3.80 (t, 2H); 4.06 (d, 2H); 4.12 (s, 3H); 4.38 (t, 2H); 4.84 (d, 2H); 5.33 (d, 1H); 5.45 (d, 1H); 6.10 (m, 1H); 7.48 (s, 1H); 7.65 (d, 1H); 7.84 (d, 1H); 8.64 (s, 1H); 9.30 (s, 1H).
    • EXAMPLE 446 Preparation of Compound 624 in Table 28
  • An analogous reaction to that described in example 444 but starting with 2-aminothiophene-3-carboxamide (46 mg, 0.33 mmol) yielded title compound (154 mg, 99%).
  • MS ES+: 444.6 (M+H)+ 1HNMR (DMSOd6, TFA): 2.34 (t, 2H); 3.15 (t, 2H); 3.36 (t, 2H); 3.54 (d, 2H); 3.76 (t, 2H); 4.02 (d, 2H); 4.05 (s, 3H); 4.36 (t, 2H); 7.32 (d, 1H); 7.41 (s, 1H); 7.48 (s, 1H); 7.66 (d, 1H); 9.23 (s, 1H).
    • EXAMPLE 447 Preparation of Compound 625 in Table 28
  • An analogous reaction to that described in example 444 but starting with 2-amino-5-ethylthiophene-3-carboxamide (55 mg, 0.33 mmol) yielded title compound (147 mg, 90%).
  • MS ES+: 472.5 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.34 (t, 3H); 2.38 (t, 2H); 2.86 (q, 2H); 3.18 (t, 2H); 3.38 (t, 2H); 3.57 (d, 2H); 3.80 (t, 2H); 4.05 (d, 2H); 4.07 (s, 3H); 4.38 (t, 2H); 7.40 (s, 1H); 7.43 (s, 1H); 7.52 (s, 1H); 9.21 (s, 1H).
    • EXAMPLE 448 Preparation of Compound 626 in Table 29
  • Methyl-2-cyano-4-methoxy-5-(3-morpholinopropoxy)phenylimidoformate (100 mg; 0.3 mmol) in DMF (1.5 ml) was reacted with 2-amino-4-phenyl-1,3-thiazole (58 mg; 0.33 mmol) in presence of sodium hydride (13.2 mg; 0.33 mmol) at 75° C. for 1.5 h. Acetic acid (1.5 eq.) was added and the solvent was evaporated to give 6-methoxy-7-(3-morpholinopropoxy)-3-(4-phenyl-1,3-thiazol-2-yl)quinazolin-4(3H)-imine as an intermediate which was redissolved in DMF (1.5 ml) and ammonium acetate (95 mg ; 0.9 mmol) added. The mixture was stirred at 75° C. for 1 h, the solvent was evaporated and the residue purified by silica gel chromatography, CH2Cl2/MeOH 95/5→90/10 to give title compound (44 mg, 31%).
  • 1HNMR (DMSOd6, TFA): 2.30 (t, 2H); 3.17 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.70 (t, 2H); 4.05 (m, 5H); 4.33 (t, 2H); 7.42 (m, 2H); 7.51 (t, 2H); 7.90 (s, 1H); 8.00 (d, 2H); 8.35 (s, 1H); 9.27 (s, 1H).
    • EXAMPLE 449 Preparation of Compound 627 in Table 29
  • An analogous reaction to that described in example 448 but starting with 2-amino-4-methyl-5-acetyl-1,3-thiazole (103 mg, 0.66 mmol), heating at 75° C. for 1 h in the first step, and stirring the intermediate in the above conditions at room temperature for 1 h, gave title compound (71 mg, 52%).
  • MS ES+: 458 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (t, 2H); 2.55 (s, 3H); 2.67 (s, 3H); 3.16 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 4.0 (s, 3H); 4.03 (d, 2H); 4.32 (t, 2H); 7.37 (s, 1H); 7.99 (s, 1H); 9.26 (s, 1H).
    • EXAMPLE 450 Preparation of Compound 628 in Table 29
  • An analogous reaction to that described in example 448 but starting with ethyl-2-amino-4-trifluoromethyl-1,3-thiazole-5-carboxylate (79 mg, 0.33 mmol) yielded title compound (81 mg, 50%).
  • MS ES+: 542 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.34 (t, 3H); 2.32 (t, 2H); 3.17 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 4.03 (s, 3H); 4.04 (d, 2H); 4.36 (m, 4H); 7.47 (s, 1H); 8.41 (s, 1H); 9.34 (s, 1H).
    • EXAMPLE 451 Preparation of Compound 629 in Table 29
  • An analogous reaction to that described in example 448 but starting with ethyl-2-amino-4-phenyl-1,3-thiazole-5-carboxylate (82 mg, 0.33 mmol) yielded title compound (133 mg, 81%).
  • MS ES+: 550 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.25 (t, 2H); 2.32 (t, 2H); 3.16 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 4.02 (s, 1H); 4.04 (d, 2H); 4.26 (q, 2H); 4.35 (t, 2H); 7.45 (s, 1H); 7.50 (m, 3H); 7.79 (m, 2H); 8.33 (s, 1H); 9.37 (s, 1H).
    • EXAMPLE 452 Preparation of Compound 630 in Table 29
  • An analogous reaction to that described in example 448 but starting with 4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine (51 mg, 0.33 mmol) yielded title compound (97 mg, 71%).
  • MS ES+: 456 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.83 (m, 4H); 2.29 (t, 2H); 2.61 (m, 2H); 2.67 (m, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.68 (t, 2H); 3.97 (s, 3H); 4.04 (d, 2H); 4.29 (t, 2H); 7.28 (s, 1H); 7.84 (s, 1H); 9.0 (s, 1H).
    • EXAMPLE 453 Preparation of Compound 631 in Table 29
  • An analogous reaction to that described in example 448 but starting with N-(4-(2-amino-1,3-30 thiazol-4-yl)phenyl)acetamide (77 mg, 0.33 mmol) yielded title compound (58 mg, 36%).
  • MS ES+: 535 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.09 (s, 3H); 2.32 (t, 2H); 3.17 (t, 2H); 3.37 (t, 2H); 3.56 (d, 2H); 3.70 (t, 2H); 4.05 (s, 3H); 4.06 (d, 2H); 4.35 (t, 2H); 7.40 (s, 1H); 7.72 (d, 2H); 7.77 (s, 1H); 7.92 (d, 2H); 8.33 (s, 1H); 9.25 (s, 1H).
    • EXAMPLE 454 Preparation of Compound 632 in Table 29
  • An analogous reaction to that described in example 448 but starting with 5-phenyl-4-(trifluoromethyl)-1,3-thiazole-2-amine (81 mg, 0.33 mmol) yielded title compound (144 mg, 88%).
  • MS ES+: 546 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (t, 2H); 3.16 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 4.04 (d, 2H); 4.05 (s, 3H); 4.36 (t, 2H); 7.49 (s, 1H); 7.54 (s, 5H); 8.46 (s, 1H); 9.30 (s, 1H).
    • EXAMPLE 455 Preparation of Compound 633 in Table 29
  • An analogous reaction to that described in example 448 but starting with 4-(trifluoromethyl)-1,3-thiazole-2-amine (55 mg, 0.33 mmol) yielded title compound (62 mg, 44%).
  • MS ES+: 470 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (t, 2H); 3.17 (t, 2H); 3.37 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 4.04 (s, 3H); 4.05 (d, 2H); 4.36 (t, 2H); 7.49 (s, 1H); 8.23 (s, 1H); 8.44 (s, 1H); 9.34 (s, 1H).
    • EXAMPLE 456 Preparation of Compound 634 in Table 29
  • An analogous reaction to that described in example 448 but starting with 4-tert-butyl-1,3-thiazole-2-amine (52 mg, 0.33 mmol) yielded title compound (90 mg, 65%).
  • MS ES+: 458 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.46 (s, 9H); 2.32 (t, 2H); 3.16 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 4.00 (s, 3H); 4.03 (d, 2H); 4.32 (d, 2H); 7.38 (s, 1H); 7.95 (s, 1H); 9.18 (s, 1H).
    • EXAMPLE 457 Preparation of Compound 635 in Table 29
  • An analogous reaction to that described in example 448 but starting with 4,5-dimethyl-1,3-thiazole-2-amine (42 mg, 0.33 mmol) yielded title compound (61 mg, 47%).
  • MS ES+: 430 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.25 (s, 3H); 2.30 (m, 5H); 3.15 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.68 (t, 2H); 3.96 (s, 3H); 4.04 (d, 2H); 4.28 (t, 1H); 7.28 (s, 1H); 7.82 (s, 1H); 8.98 (s, 1H).
    • EXAMPLE 458 Preparation of Compound 636 in Table 29
  • An analogous reaction to that described in example 448 but starting with 4-methyl-1,3-thiazole-2-amine (38 mg, 0.33 mmol) yielded title compound (40 mg, 32%).
  • MS ES+: 415 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 2.34 (s, 3H); 3.15 (t, 2H); 3.37 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 3.99 (s, 3H); 4.04 (d, 2H); 4.29 (t, 2H); 7.03 (s, 1H); 7.29 (s, 1H); 7.87 (s, 1H); 9.05 (s, 1H).
    • EXAMPLE 459 Preparation of Compound 637 in Table 29
  • 1-(2-((6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl)amino)4-methyl-1,3-thiazole-5-yl)ethanone (50 mg, 0.11 mmol) in ethanol (4 ml) and pyridine (1 ml) was reacted with hydroxylamine hydrochloride (19.5 mg, 0.27 mmol) at reflux for 3 h. The solvent was evaporated, water was added to the residue and a solid was recovered, washed with water to give title compound (14 mg, 27%)
  • MS ES+: 473 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.25 (s, 3H); 2.30 (t, 2H); 2.53 (s, 3H); 3.17 (t, 2H); 3.38 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 3.99 (s, 3H); 4.05 (d, 2H); 4.32 (t, 2H); 7.32 (s, 1H); 7.88 (s, 1H); 9.12 (s, 1H).
    • EXAMPLE 460 Preparation of Compound 638 in Table 29
  • 2-((6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl)amino)-1,3-thiazole-5-carboxylic acid (89 mg, 0.2 mmol) in DMF (1.5 ml) was treated with diphenylphosporyl azide (66 mg, 0.24 mmol) and triethylamine (26 mg, 0.26 mmol). The solution was stirred at room temperature for 1 h and at 45° C. for 1 h. Tert-butanol (1 ml) was added, and the mixture heated at 90° C. for 2 h. The mixture was diluted with ethylacetate, aqueous sodium bicarbonate, the organic phase was recovered, dried over MgSO4, filtered, concentrated and purified by silica gel chromatography, eluent CH2Cl2/MeOH 95/5 to 85/15 to give title compound as a yellow solid (25 mg, 24%).
  • MS ES+: 517 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.50 (s, 9H); 2.31 (t, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 3.97 (s, 3H); 4.04 (d, 2H); 4.29 (t, 2H); 7.13 (s, 1H); 7.26 (s, 1H); 7.94 (s, 1H); 9.11 (s, 1H).
    • EXAMPLE 461 Preparation of Compound 639 in Table 29
  • An analogous reaction to that described in example 459 but starting with O-methylhydroxylamine hydrochloride (18 mg, 0.22 mmol) and heating at reflux for 72 h yielded title compound (39 mg, 63%).
  • MS ES+: 487 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.26 (s, 3H); 2.31 (t, 2H); 3.53 (s, 3H); 3.16 (t, 2H); 3.35 (t, 2H); 3.54 (d, 2H); 3.76 (s, 2H); 3.94 (s, 3H); 3.99 (s, 3H); 4.02 (d, 2H); 4.33 (t, 2H); 7.35 (s, 1H); 7.89 (s, 1H); 9.11 (s, 1H).
    • EXAMPLE 462 Preparation of Compound 640 in Table 29
  • An analogous reaction to that described in example 459 but starting with O-phenylhydroxylamine hydrochloride (32 mg, 0.22 mmol) yielded title compound (8 mg, 12
  • MS ES+: 549 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.28 (t, 2H); 3.12 (t, 2H); 3.32 (t, 2H); 3.52 (d, 2H); 3.65 (t, 2H); 3.96 (s, 3H); 4.0 (d, 2H); 4.27 (t, 2H); 7.06 (t, 1H); 7.20 (d, 2H); 7.28 (s, 1H); 7.34 (t, 2H); 7.91 (s, 1H); 9.17 (s, 1H).
    • EXAMPLE 463 Preparation of Compound 641 in Table 29
  • An analogous reaction to that described in example 448 but starting with 2-amino-5-(4-methoxyphenyl)-1,3-thiazole, HBr (86 mg, 0.33 mmol) yielded title compound (105 mg, 77%).
  • MS ES+: 508.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.33 (t, 2H); 3.20 (t, 2H); 3.40 (t, 2H); 3.60 (d, 2H); 3.73 (t, 2H); 3.86 (s, 3H); 4.08 (s, 3H); 4.09 (d, 2H); 4.36 (t, 2H); 7.10 (d, 2H); 7.44 (s, 1H); 7.76 (s, 1H); 7.96 (d, 2H); 8.33 (s, 1H); 9.26 (s, 1H).
    • EXAMPLE 464 Preparation of Compound 642 in Table 29
  • An analogous reaction to that described in example 448 but starting with 2-amino-5-phenyl)-1,3-thiazole (58 mg, 0.33 mmol) yielded title compound (120 mg, 84%).
  • MS ES+: 478.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 3.17 (t, 2H); 3.37 (t, 2H); 3.56 (d, 2H); 3.70 (t, 2H); 4.01 (s, 3H); 4.05 (d, 2H); 4.32 (t, 2H); 7.34 (s, 1H); 7.41 (t, 1H); 7.51 (t, 2H); 7.72 (d, 2H); 7.97 (s, 1H); 8.24 (s, 1H); 9.16 (s, 1H).
    • EXAMPLE 465 Preparation of Compound 643 in Table 29
  • Methyl-2-cyano-4-methoxy-5-(3-morpholinopropoxy)phenyl-imidoformate (300 mg, 0.9 mmol) in DMF (4.5 ml) was reacted with 2-amino-5-ethyl-1,3-thiazole (127 mg, 0.99 mmol) in presence of sodium hydride (39.6 mg, 0.99 mmol) at 75° C. for 2 h. Acetic acid (77 μl, 1.35 mmol) was added to the mixture at room temperature, followed by MeOH/Me2NH (2M) (90 μl, 0.18 mmol) and the mixture was stirred at 75° C. for 1 h. The solvent was evaporated and the mixture was purified by silica gel chromatography, eluent CH2Cl2/MeOH 95/5→90/10 to give title compound (193 mg, 50%).
  • MS ES+: 430.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.29 (t, 3H); 2.32 (t, 2H); 2.81 (q, 2H); 3.16 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 3.98 (s, 3H); 4.05 (d, 2H); 4.30 (t, 2H); 7.30 (s, 1H); 7.50 (s, 1H); 7.87 (s, 1H); 9.04 (s, 1H).
    • EXAMPLE 466 Preparation of Compound 644 in Table 29
  • An analogous reaction to that described in example 465 but starting with 2-amino-5-isopropyl)-1,3-thiazole (141 mg, 0.99 mmol) yielded title compound (107 mg, 26%).
  • MS ES+: 444.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.33 (d, 6H); 2.32 (t, 2H); 3.17 (t, 2H); 3.36 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 3.98 (s, 3H); 4.04 (d, 2H); 4.30 (t, 2H); 7.29 (s, 1H); 7.49 (s, 1H); 7.87 (s, 1H); 9.05 (s, 1H).
    • EXAMPLE 467 Preparation of Compound 645 in Table 29
  • An analogous reaction to that described in example 465 but starting with 2-amino-5-benzyl)-1,3-thiazole (188 mg, 0.99 mmol) yielded title compound (370 mg, 84%).
  • MS ES+: 492.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 3.16 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 3.98 (s, 3H); 4.04 (d, 2H); 4.18 (s, 2H); 4.29 (t, 2H); 7.27 (s, 1H); 7.28 (m, 1H); 7.35 (m, 4H); 7.61 (s, 1H); 7.88 (s, 1H); 9.02 (s, 1H).
    • EXAMPLE 468 Preparation of Compound 646 in Table 29
  • An analogous reaction to that described in example 465 but starting with 2-amino-5-methyl)-1,3-thiazole (113 mg, 0.99 mmol) yielded title compound (300 mg, 80%).
  • MS ES+: 416.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 2.42 (s, 3H); 3.16 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.68 (t, 2H); 3.97 (s, 3H); 4.04 (d, 2H); 4.29 (t, 2H); 7.30 (s, 1H); 7.48 (s, 1H); 7.86 (s, 1H); 9.03 (s, 1H).
    • EXAMPLE 469 Preparation of Compound 647 in Table 29
  • An analogous reaction to that described in example 465 but starting with 2-amino-5-butyl)-1,3-thiazole (155 mg, 0.99 mmol) yielded title compound (385 mg, 93%).
  • MS ES+: 458.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 0.93 (t, 3H); 1.36 (m, 2H); 1.64 (m, 2H); 2.29 (t, 2H); 2.79 (t, 2H); 3.16 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.68 (t, 2H); 3.97 (s, 3H); 4.04 (d, 2H); 4.29 (t, 2H); 7.29 (s, 1H); 7.51 (s, 1H); 7.86 (s, 1H); 9.03 (s, 1H).
    • EXAMPLE 470 Preparation of Compound 648 in Table 29
  • An analogous reaction to that described in example 465 but starting with 2-amino-5-formyl-1,3-thiazole (499.4 mg, 3.9 mmol) yielded title compound (244 mg, 39%).
  • MS ES+: 430.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (t, 2H); 3.17 (t, 2H); 3.37 (t, 2H); 3.57 (d, 2H); 3.70 (t, 2H); 4.03 (s, 3H); 4.06 (d, 2H); 4.35 (t, 2H); 7.45 (s, 1H); 8.12 (s, 1H); 8.71 (s, 1H); 9.32 (s, 1H).
    • EXAMPLE 471 Preparation of Compound 649 in Table 29
  • An analogous reaction to that described in example 459 but starting with 2-((6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl)amino-1,3-thiazol-5-carbaldehyde (100 mg, 0.23 mmol) and heating at 80° C. for 4 h, yielded title compound (21 mg, 20%).
  • MS ES+: 445.6 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.31 (t, 2H); 3.17 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.70 (t, 2H); 4.00 (s, 3H); 4.05 (d, 2H); 4.32 (t, 2H); 7.36 (s, 1H); 7.92 (s, 1H); 7.98 (s, 1H); 8.33 (s, 1H); 9.20 (s, 1H).
    • EXAMPLE 472 Preparation of Compound 650 in Table 30
  • An analogous reaction to that described in example 448, but starting with 2-amino-5-tert-butyl-1,3,4-thiadiazol (52 mg, 0.33 mmol) yielded title compound (80 mg, 58%).
  • MS ES+: 458 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.45 (s, 9H); 2.32 (t, 2H); 3.16 (t, 2H); 3.36 (t, 2H); 3.56 (d, 2H); 3.69 (t, 2H); 4.00 (s, 3H); 4.03 (d, 2H); 4.32 (t, 2H); 7.38 (s, 1H); 7.95 (s, 1H); 9.18 (s, 1H).
    • EXAMPLE 473 Preparation of Compound 651 in Table 30
  • An analogous reaction to that described in example 448, but starting with 2-amino-5-cyclopropyl-1,3,4-thiadiazol (47 mg, 0.33 mmol) yielded title compound (105 mg, 83%).
  • MS ES+: 443 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.08 (m, 2H); 1.23 (m, 3H); 2.32 (t, 2H); 3.15 (t, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.68 (t, 2H); 3.99 (s, 3H); 4.04 (d, 2H); 4.32 (t, 2H); 7.38 (s, 1H); 7.93 (s, 1H); 9.14 (s, 1H).
    • EXAMPLE 474 Preparation of Compound 652 in Table 30
  • An analogous reaction to that described in example 448, but starting with 2-amino-5-ethylthio-1,3,4-thiadiazol (53 mg, 0.33 mmol) yielded title compound (103 mg, 75%).
  • MS ES+: 463 (M+H)+
  • 1HNMR (DMSOd6, TFA): 1.41 (t, 3H); 2.31 (t, 2H); 3.15 (t, 2H); 3.31 (q, 2H); 3.35 (t, 2H); 3.55 (d, 2H); 3.69 (t, 2H); 4.00 (s, 3H); 4.04 (d, 2H); 4.33 (t, 2H); 7.41 (s, 1H); 8.08 (s, 1H); 9.19 (s, 1H).
    • EXAMPLE 475 Preparation of Compound 653 in Table 30
  • An analogous reaction to that described in example 448, but starting with 2-amino-5-phenyl-1,3,4-thiadiazol (91 mg, 0.33 mmol) yielded title compound (110 mg, 76%).
  • MS ES+: 479 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (t, 2H); 3.16 (t, 2H); 3.37 (t, 2H); 3.57 (d, 2H); 3.69 (t, 2H); 4.03 (s, 3H); 4.05 (d, 2H); 4.34 (t, 2H); 7.42 (s, 1H); 7.61 (m, 3H); 7.99 (m, 2H); 8.06 (s, 1H); 9.25 (s, 1H).
    • EXAMPLE 476 Preparation of Compound 654 in Table 30
  • An analogous reaction to that described in example 448, but starting with N-phenyl-4H-1,2,4-triazole-3,5-diamine (58 mg, 0.33 mmol) yielded title compound (70 mg, 49%).
  • MS ES+: 477 (M+H)+
  • 1HNMR (DMSOd6, TFA): 2.32 (t, 2H); 3.16 (t, 2H); 3.37 (t, 2H); 3.57 (d, 2H); 3.70 (t, 2H); 4.02 (s, 3H); 4.05 (d, 2H); 4.34 (t, 2H); 6.92 (t, 1H); 7.30 (t, 1H); 7.42 (s, 1H); 7.58 (d, 2H); 8.19 (s, 1H); 8.95 (s, 1H).
  • Biological Data
  • The compounds of the invention inhibit the serine/threonine kinase activity of the aurora 2 kinase and thus inhibit the cell cycle and cell proliferation. These properties may be assessed, for example, using one or more of the procedures set out below:
  • (a) In Vitro Aurora 2 Kinase Inhibition Test
  • This assay determines the ability of a test compound to inhibit serine/threonine kinase activity. DNA encoding aurora 2 may be obtained by total gene synthesis or by cloning. This DNA may then be expressed in a suitable expression system to obtain polypeptide with serine/threonine kinase activity. In the case of aurora 2, the coding sequence was isolated from cDNA by polymerase chain reaction (PCR) and cloned into the BamH1 and Not1 restriction endonuclease sites of the baculovirus expression vector pFastBac HTc (GibcoBRL/Life technologies). The 5′ PCR primer contained a recognition sequence for the restriction endonuclease BamH1 5′ to the aurora 2 coding sequence. This allowed the insertion of the aurora 2 gene in frame with the 6 histidine residues, spacer region and rTEV protease cleavage site encoded by the pFastBac HTc vector. The 3′ PCR primer replaced the aurora 2 stop codon with additional coding sequence followed by a stop codon and a recognition sequence for the restriction endonuclease Not1. This additional coding sequence (5′ TAC CCA TAC GAT GTT CCA GAT TAC GCT TCT TAA 3′) encoded for the polypeptide sequence YPYDVPDYAS. This sequence, derived from the influenza hemagglutin protein, is frequently used as a tag epitope sequence that can be identified using specific monoclonal antibodies. The recombinant pFastBac vector therefore encoded for an N-terminally 6 his tagged, C terminally influenza hemagglutin epitope tagged aurora 2 protein. Details of the methods for the assembly of recombinant DNA molecules can be found in standard texts, for example Sambrook et al. 1989, Molecular Cloning—A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press and Ausubel et al. 1999, Current Protocols in Molecular Biology, John Wiley and Sons Inc.
  • Production of recombinant virus can be performed following manufacturer's protocol from GibcoBRL. Briefly, the pFastBac-1 vector carrying the aurora 2 gene was transformed into E. coil DH10Bac cells containing the baculovirus genome (bacmid DNA) and via a transposition event in the cells, a region of the pFastBac vector containing gentamycin resistance gene and the aurora 2 gene including the baculovirus polyhedrin promoter was transposed directly into the bacmid DNA. By selection on gentamycin, kanamycin, tetracycline and X-gal, resultant white colonies should contain recombinant bacmid DNA encoding aurora 2. Bacmid DNA was extracted from a small scale culture of several BH10Bac white colonies and transfected into Spodoptera frugiperda Sf21 cells grown in TC100 medium (GibcoBRL) containing 10% serum using CellFECTIN reagent (GibcoBRL) following manufacturer's instructions. Virus particles were harvested by collecting cell culture medium 72 hrs post transfection. 0.5 mls of medium was used to infect 100 ml suspension culture of Sf21s containing 1×107 cells/ml. Cell culture medium was harvested 48 hrs post infection and virus titre determined using a standard plaque assay procedure. Virus stocks were used to infect Sf9 and “High 5” cells at a multiplicity of infection MOI) of 3 to ascertain expression of recombinant aurora 2 protein. For the large scale expression of aurora 2 kinase activity, Sf21 insect cells were grown at 28° C. in TC100 medium supplemented with 10% foetal calf serum (Viralex) and 0.2% F68 Pluronic (Sigma) on a Wheaton roller rig at 3 r.p.m. When the cell density reached 1.2×106 cells ml−1 they were infected with plaque-pure aurora 2 recombinant virus at a multiplicity of infection of 1 and harvested 48 hours later. All subsequent purification steps were performed at 4° C. Frozen insect cell pellets containing a total of 2.0×108 cells were thawed and diluted with lysis buffer (25 mM HEPES (N-[2-hydroxyethyl]piperazine-N′-[2-ethanesulphonic acid]) pH 7.4 at 4° C., 100 mM KCl, 25 M NaF, 1 mM Na3VO4, 1 M PMSF (phenylmethylsulphonyl fluoride), 2 mM 2-mercaptoethanol, 2 mM imidazole, 1 μg/ml aprotinin, 1 μg/ml pepstatin, 1 μg/ml leupeptin), using 1.0 ml per 3×107 cells. Lysis was achieved using a dounce homogeniser, following which the lysate was centrifuged at 41,000 g for 35 minutes. Aspirated supernatant was pumped onto a 5 mm diameter chromatography column containing 500 μl Ni NTA (rutrilo-tri-acetic acid) agarose (Qiagen, product no. 30250) which had been equilibrated in lysis buffer. A baseline level of UV absorbance for the eluent was reached after washing the column with 12 ml of lysis buffer followed by 7 ml of wash buffer (25 mM HEPES pH7.4 at 4° C., 100 mM KCl, 20 mM imidazole, 2 mM 2-mercaptoethanol). Bound aurora 2 protein was eluted from the column using elution buffer (25 mM HEPES pH7.4 at 4° C., 100 mM KCl, 400 mM imidazole, 2 mM 2-mercaptoethanol). An elution fraction (2.5 ml) corresponding to the peak in UV absorbance was collected. The elution fraction, containing active aurora 2 kinase, was dialysed exhaustively against dialysis buffer (25 mM HEPES pH7.4 at 4° C., 45% glycerol (v/v), 100 mM KCl, 0.25% Nonidet P40 (v/v), 1 mM dithiothreitol).
  • Each new batch of aurora 2 enzyme was titrated in the assay by dilution with enzyme diluent (25 mM Tris-HCl pH7.5, 12.5 mM KCl, 0.6mM DTM). For a typical batch, stock enzyme is diluted 1 in 666 with enzyme diluent & 20 μl of dilute enzyme is used for each assay well. Test compounds (at 10 mM in dimethylsulphoxide (DMSO)) were diluted with water & 10 μl of diluted compound was transferred to wells in the assay plates. “Total” & “blank” control wells contained 2.5% DMSO instead of compound. Twenty microlitres of freshly diluted enzyme was added to all wells, apart from “blank” wells. Twenty microlitres of enzyme diluent was added to “blank” wells. Twenty microlitres of reaction mix (25 mM Tris-HCl, 78.4 mM KCl, 2.5 mM NaF, 0.6 mM dithiothreitol, 6.25 mM MnCl2, 6.25 mM ATP, 7.5 μM peptide substrate [biotin-LRRWSLGLRRWSLGLRRWSLGLRRWSLG]) containing 0.2 μCi [γ33P]ATP (Amersham Pharmacia, specific activity≧2500 Ci/mmol) was then added to all test wells to start the reaction. The plates were incubated at room temperature for 60 minutes. To stop the reaction 100 μl 20% v/v orthophosphoric acid was added to all wells. The peptide substrate was captured on positively-charged nitrocellulose P30 filtermat (Whatman) using a 96-well plate harvester (TomTek) & then assayed for incorporation of 33P with a Beta plate counter. “Blanks” (no enzyme) and “total” (no compound) control values were used to determine the dilution range of test compound which gave 50% inhibition of enzyme activity. In this test, compound 52 in Table 2 gave 50% inhibition of enzyme activity at a concentration of 0.167 μM, and Compound 253 in Table 21 gave 50% inhibition of enzyme activity at 0.089 μm.
  • (a) In Vitro Cell Proliferation Assay
  • This assay determines the ability of a test compound to inhibit the growth of adherent mammalian cell lines, for example the human tumour cell line MCF7. MCF-7 (ATCC HTB-22) or other adherent cells were typically seeded at 1×103 cells per well (excluding the peripheral wells) in DMEM (Sigma Aldrich) without phenol red, plus 10% foetal calf serum, 1% L-glutamine and 1% penicillin/streptomycin in 96 well tissue culture treated clear plates (Costar). The following day (day 1), the media was removed from a no treatment control plate and the plate stored at −80° C. The remaining plates were dosed with compound (diluted from 10 mM stock in DMSO using DMEM (without phenol red, 10% FCS, 1% L-glutamine, 1% penicillin/streptomycin). Untreated control wells were included on each plate. After 3 days in the presence/absence of compound (day 4) the media was removed and the plates stored at −80° C. Twenty four hours later the plates were thawed at room temperature and cell density determined using the CyQUANT cell proliferation assay kit (c-7026/c-7027 Molecular Probes Inc.) according to manufacturers directions. Briefly, 200 μl of a cell lysis/dye mixture (10 μl of 20× cell lysis buffer B, 190 μl of sterile water, 0.251 μl of CYQUANT GR dye) was added to each well and the plates incubated at room temperature for 5 minutes in the dark. The fluorescence of the wells was then measured using a fluorescence microplate reader (gain 70, 2 reads per well, 1 cycle with excitation 485 nm and emission 530 nm using a CytoFluor plate reader (PerSeptive Biosystems Inc.)). The values from day 1 and day 4 (compound treated) together with the values from the untreated cells were used to determine the dilution range of a test compound that gave 50% inhibition of cell proliferation. Compound 52 in Table 2 was effective in this test at 0.616 μm and Compound 253 in Table 20 was effective at 5.91 μM.
  • These values could also be used to calculate the dilution range of a test compound at which the cell density dropped below the day 1 control value. This indicates the cytotoxicity of the compound.
  • (a) In Vitro Cell Cycle Analysis Assay
  • This assay determines the ability of a test compound to arrest cells in specific phases of the cell cycle. Many different mammalian cell lines could be used in this assay and MCF7 cells are included here as an example. MCF-7 cells were seeded at 3×105 cells per T25 flask (Costar) in 5 ml DMEM (no phenol red 10% FCS, 1% L-glutamine 1% penicillin/streptomycin). Flasks were then incubated overnight in a humidified 37° C. incubator with 5% CO2. The following day 1 ml of DMEM (no phenol red 10% FCS, 1% L-glutamine 1% penicillin/streptomycin) carrying the appropriate concentration of test compound solubilised in DMSO was added to the flask. A no compound control treatments was also included (0.5% DMSO). The cells were then incubated for a defined time (usually 24 hours) with compound. After this time the media was aspirated from the cells and they were washed with 5 ml of prewarmed (37° C.) sterile PBSA, then detached from the flask by brief incubation with trypsin and followed by resuspension in 10 ml of 1% Bovine Serum Albumin (BSA, Sigma-Aldrich Co.) in sterile PBSA. The samples were then centrifuged at 2200 rpm for 10 min. The supernatant was aspirated and the cell pellet was resuspended in 200 μl of 0.1% (w/v) Tris sodium citrate, 0.0564% (w/v) NaCl, 0.03% (v/v) Nonidet NP40, [pH 7.6]. Propridium Iodide (Sigma Aldrich Co.) was added to 40 μg/ml and RNAase A (Sigma Aldrich Co.) to 100 μg/ml. The cells were then incubated at 37° C. for 30 minutes. The samples were centrifuged at 2200 rpm for 10 min, the supernatant removed and the remaining pellet (nuclei) resuspended in 200 μl of sterile PBSA. Each sample was then syringed 10 times using 21 gauge needle. The samples were then transferred to LPS tubes and DNA content per cell analysed by Fluorescence activated cell sorting (FACS) using a FACScan flow cytometer (Becton Dickinson). Typically 25000 events were counted and recorded using CellQuest v1.1 software (Verity Software). Cell cycle distribution of the population was calculated using Modfit software (Verity Software) and expressed as percentage of cells in G0/G1, S and G2/M phases of the cell cycle.
  • Treating MCF7 cells with 1 μM Compound 52 in Table 2 for 24 hours produced the following changes in cell cycle distribution:
    Treatment % Cells in G2/M
    DMSO (control) 9.27%
    10 μM Compound 52  >50%

Claims (16)

1. A compound of formula (I)
Figure US20060046987A1-20060302-C00160
or a salt, ester or amide thereof;
where X is O, or S, S(O) or S(O)2, or NR6 where R6 is hydrogen or C1-6alkyl;
R5 is pyrrole, pyrazole, pyrazolone, imidazole, oxazole, furan, tetrazole or triazole, any of which may be optionally substituted,
R1, R2, R3, R4 are independently selected from, halo, cyano, nitro, trifluoromethyl, C1-3alkyl, —NR7R8 (wherein R7 and R8, which may be the same or different, each represents hydrogen or C1-3alkyl), or —X1R9 (wherein X1 represents a direct bond, —O—, —CH2—, —OCO—, carbonyl, —S—, —SO—, —SO2—, —NR10CO—, —CONR11—, —SO2NR12—, —NR13SO2— or —NR14— (wherein R10, R11, R12, R13 and R14 each independently represents hydrogen, C1-3alkyl or C2-3alkoxyC2-3alkyl), and R9 is selected from one of the following groups:
1) hydrogen or C1-5alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro or amino,
2) C1-5alkylX2COR15 (wherein X2 represents —O— or —NR16— (in which R15 represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R16 represents C1-3alkyl, —NR17R18 or —OR19 (wherein R17, R18 and R19 which may be the same or different each represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl));
3) C1-5alkylX3R20 (wherein X3 represents —O—, —S—, —SO—, —SO2—, —OCO—, —NR21CO—, —CONR22—, —SO2NR23—, —NR24SO2— or —NR25— (wherein R21, R22, R23, R24 and R25 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R20 represents hydrogen, C1-3alkyl, cyclopentyl, cyclohexyl or a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C1-3alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C1-4alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy);
4) C1-5alkylX4C1-5alkylX5R26 (wherein X4 and X5 which may be the same or different are each —O—, —S—, —SO—, —SO2—, —NR27CO—, —CONR28—, —SO2NR29—, —NR30SO2— or —NR31— (wherein R27, R28, R29, R30 and R31 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R26 represents hydrogen or C1-3alkyl);
5) R32 (wherein R32 is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl, C1-4alkoxy, C1-4alkoxyC1-4alkyl and C1-4alkylsulphonylC1-4alkyl);
6) C1-5alkylR32 (wherein R32 is as defined hereinbefore);
7) C2-5alkenylR32 (wherein R32 is as defined hereinbefore);
8) C2-5alkynylR32 (wherein R32 is as defined hereinbefore);
9) R33 (wherein R33 represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents on an available carbon atom selected from hydroxy, halogeno, amino, C1-4alkyl, C1-4alkoxy, C1-4hydroxyalkyl, C1-4aminoalkyl, C1-4alkylamino, C1-4hydroxyalkoxy, carboxy, trifluoromethyl, cyano, —CONR34R35 and —NR36COR37 (wherein R34, R35, R36 and R37, which may be the same or different, each represents hydrogen, C1-4alkyl or C1-3alkoxyC2-3alkyl));
10) C1-5alkylR33 (wherein R33 is as defined hereinbefore);
11) C2-5alkenylR33 (wherein R33 is as defined hereinbefore);
12) C2-5alkynylR33 (wherein R33 is as defined hereinbefore);
13) C1-5alkylX6R33 (wherein X6 represents —O—, —S—, —SO—, —SO2—, —NR38CO—, —CONR39—, —SO2NR40—, —NR41SO2— or —NR42— (wherein R38, R39, R40, R41 and R42 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R33 is as defined hereinbefore);
14) C2-5alkenylX7R33 (wherein X7 represents —O—, —S—, —SO—, —SO2—, —NR43CO—, —CONR44—, —SO2NR45—, —NR46SO2— or —NR47— (wherein R43, R44, R45, R46 and R47 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R33 is as defined hereinbefore);
15) C2-5alkynylX8R33 (wherein X8 represents —O—, —S—, —SO—, —SO2—, —NR48CO—, —CONR49—, —SO2NR50—, —NR51SO2— or —NR52— (wherein R48, R49, R50, R51 and R52 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R33 is as defined hereinbefore);
16) C1-3alkylX9C1-3alkylR33 (wherein X9 represents —O—, —S—, —SO—, —SO2—, —NR53CO—CONR54—, —SO2NR55—, —NR56SO2— or —NR57— (wherein R53 , R54, R55, R56 and R57 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R33 is as defined hereinbefore); and
17) C1-3alkylX9C1-3alkylR32 (wherein X9 and R28 are as defined hereinbefore).
2. A method for inhibiting aurora 2 kinase in a warm blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt, or an in vivo hydrolysable ester thereof.
3. A compound according to claim 1 having a structure of formula (IA)
Figure US20060046987A1-20060302-C00161
or a salt, ester or amide thereof;
where X is as defined in relation to formula (I);
R1, R2, R3, R4 are equivalent to R1, R2, R3, R4 as defined in relation to formula (I) and R5a is pyrrole, pyrazole, pyrazolone, imidazole, oxazole, furan, tetrazole or triazole, any of which may be optionally substituted , subject to the following provisos:
(i) that where R5a is a pyrazole group, it carries a substituent of formula (k),
Figure US20060046987A1-20060302-C00162

—B1—(CH2)p-A1  (IV)
(ii) that where X is NH and R5a is a substituted pyrazolone or tetrazolyl group, at least one of R1′, R2′, R3′ and R4′ is other than hydrogen; or
(iii) that where X is O and R5a is 1-methyl-4-nitro-1H-imidazol-5-yl, at least one of R1′, R2′, R3′ and R4′ is other than hydrogen;
or a pharmaceutically acceptable salt, or an in vivo hydrolysable ester thereof.
4. A method for inhibiting aurora 2 kinase in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of claim 3 or a pharmaceutically acceptable salt, or an in vivo hydrolysable ester thereof.
5. A method according to claim 2 or 4, wherein the animal is a human.
6. A pharmaceutical composition comprising a compound according to claim 1 or 3, in combination with a pharmaceutically acceptable carrier.
7. The compound as recited in claim 3, wherein R5a is selected from the group consisting of:
Figure US20060046987A1-20060302-C00163
wherein where R60, R61 and R62 are independently selected from hydrogen or a substituent group and * indicates the point of attachment to the group X in formula (IA).
8. The composition as recited in claim 7, wherein R60, R61 or R62 is a group of sub-formula (k):
Figure US20060046987A1-20060302-C00164
wherein p and q are independently 0 or 1 and R1′ and R1″ are independently hydrogen, hydroxy, optionally substituted alkyl, optionally substituted cycloalkyl, halogen, cyano, optionally substituted alkyl, or optionally substituted alkyenyl, wherein R1′ can form with R1″ a 3 to 6 membered ring; wherein T is C═O, SOn, C(═NOR)CO, C(O)C(O), C═NCN, or CV═NO or wherein n=0, 1 or 2 and V is independently R63 or N(R63)R64 wherein R63 and R64 are independently selected from hydrogen, optionally substituted hydrocarbyl or optionally substituted heterocyclyl, or R63 and R64 together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring.
9. The composition as recited in claim 7, wherein R60, R61 or R62 is a group of sub-formula:
Figure US20060046987A1-20060302-C00165
wherein p and q are independently 0 or 1, and r is 0, 1, 2, 3 or 4 and wherein R and R′ are independently hydrogen, hydroxy, optionally substituted alkyl, optionally substituted cycloalkyl, halogen, cyano, optionally substituted alkyl, optionally substituted alkyenyl, wherein R can form with R′ a 3 to 6 membered ring; wherein T is C═O, SOn, C(═NOR)CO, C(O)C(O), C═NCN, or CV═NO or wherein n=0, 1 or 2 and V is independently R63 or N(R63)R64 wherein R63 and R64 are independently selected from hydrogen, optionally substituted hydrocarbyl or optionally substituted heterocyclyl, or R63 and R64 together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring; wherein R70 is hydrogen, hydroxy (other than where q is 0), C1-6alkyl, C1-6alkoxy, amino, N-C1-6alkylamino, N,N—(C1-6alkyl)2amino, hydroxyC2-6alkoxy, C1-6alkoxyC2-6alkoxy, aminoC2-6alkoxy, N—C1-6alkylaminoC2-6alkoxy, N,N—(C1-6-alkyl)2aminoC2-6alkoxy or C3-7cycloalkyl, or R70 is of the Formula (III):

-K-J  (III)
wherein J is aryl, heteroaryl or heterocyclyl and K is a bond, oxy, imino, N—(C1-6alkyl)imino, oxyC1-6alkylene, iminoC1-6alkylene, N—(C1-6alkyl)iminoC1-6alkylene, —NHC(O)—, —SO2NH—, —NHSO2— or —NHC(O)—C1-6alkylene.
10. The compound as recited in claim 3, wherein R5a is pyrrole, pyrazole, imidazole or triazole and wherein R60 is halogen, CN, or CONR63 R64, and wherein R61 is sub-formula (k):
Figure US20060046987A1-20060302-C00166
wherein p and q are independently 0 or 1 and R1′ and R1″ are independently hydrogen, hydroxy, optionally substituted alkyl, optionally substituted cycloalkyl, halogen, cyano, optionally substituted alkyl, optionally substituted alkyenyl, R1′ can form with R1″ a 3 to 6 membered ring; wherein T is C═O, SOn, C(═NOR)CO, C(O)C(O)), C═NCN, or V═NO or wherein n=0, 1 or 2 and V is independently R63 or N(R63)R64 wherein R63 and R64 are independently selected from hydrogen, optionally substituted hydrocarbyl or optionally substituted heterocyclyl, or R63 and R64 together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring.
11. The compound as recited in claim 3, wherein R 5a is pyrrole, pyrazole, imidazole or triazole, and wherein R60 is halogen, CN, or CONR63 R64, and wherein R61 is sub-formula (k):
Figure US20060046987A1-20060302-C00167
wherein p and q are independently 0 or 1, r is 0, 1, 2, 3 or 4 and R and R′ are independently hydrogen, hydroxy, optionally substituted alkyl, optionally substituted cycloalkyl, halogen, cyano, optionally substituted alkyl, optionally substituted alkyenyl, R can form with the other R group a 3 to 6 membered ring; wherein T is C═O, SOn, C(═NOR)CO, C(O)C(O)), C═NCN, or V═NO or wherein n=0, 1 or 2 and V is independently R63 or N(R63)R64 wherein R63 and R64 are independently selected from hydrogen, optionally substituted hydrocarbyl or optionally substituted heterocyclyl, or R63 and R64 together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring; wherein R70 is hydrogen, hydroxy (other than where q is 0), C1-6alkyl, C1-6alkoxy, amino, N—C1-6alkylamino, N,N—(C1-6alkyl)2amino, hydroxyC2-6alkoxy, C1-6alkoxyC2-6alkoxy, aminoC2-6alkoxy, N—C1-6alkylaminoC2-6alkoxy, N,N—(C1-6alkyl)2aminoC2-6alkoxy or C3-7cycloalkyl.
12. The compound as recited in claim 3, wherein R5a is pyrrole, pyrazole, imidazole or triazole and wherein R60 is halogen, CN, or CONR63R64, and wherein R61 is sub-formula (k):
Figure US20060046987A1-20060302-C00168
wherein p and q are independently 0 or 1, r is 0, 1, 2, 3 or 4 and R and R′ are independently hydrogen, hydroxy, optionally substituted alkyl, optionally substituted cycloalkyl, halogen, cyano, optionally substituted alkyl, optionally substituted alkyenyl, R can form with the other R group a 3 to 6 membered ring; wherein T is C═O, SOn, C(═NOR)CO, C(O)C(O)), C═NCN, or V═NO or wherein n=0, 1 or 2 and V is independently R63 or N(R63)R64 wherein R63 and R64 are independently selected from hydrogen, optionally substituted hydrocarbyl or optionally substituted heterocyclyl, or R63 and R64 together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring; wherein R70 is of the Formula (III):

-K-J  (III)
wherein J is aryl, heteroaryl or heterocyclyl and K is a bond, oxy, imino, N—(C1-6alkyl)imino, oxyC1-6alkylene, iminoC1-6alkylene, N—(C1-6-alkyl)iminoC1-6alkylene, —NHC(O)—, —SO2NH—, —NHSO2— or —NHC(O)—C1-6alkylene-, and any aryl, heteroaryl or heterocyclyl group in a R70 group may be optionally substituted by one or more groups selected from hydroxy, halo, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl, formyl, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, —O—(C1-3alkyl)-O—, C1-6alkylS(O)n— (wherein n is 0-2), N—C1-6alkylamino, N,N—(C1-6alkyl)2amino, C1-6alkoxycarbonyl, N—C1-6alkylcarbamoyl, N,N—(C1-6alkyl)2carbamoyl, C2-6alkanoyl, C1-6alkanoyloxy, C1-6alkanoylamino, N—C1-6alkylsulphamoyl, N,N—(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino and C1-6alkylsulphonyl-N—(C1-6alkyl)amino, or any aryl, heteroaryl or heterocyclyl group in a R70 group may be optionally substituted with one or more groups of the Formula (IV):

—B1—(CH2)p-A1  (IV)
wherein A1 is halo, hydroxy, C1-6alkoxy, cyano, amino, N—C1-6alkylamino, N,N—(C1-6alkyl)2amino, carboxy, C1-6alkoxycarbonyl, carbamoyl, N—C1-6alkylcarbamoyl or N,N—(C1-6alkyl)2carbamoyl, p is 1-6, and B1 is a bond, oxy, imino, N—(C1-6alkyl)imino or —NHC(O)—, with the proviso that p is 2 or more unless B1 is a bond or —NHC(O)—;
or any aryl, heteroaryl or heterocyclyl group in a R70 group may be optionally substituted with one or more groups of the Formula (V):

-E1-D1  (V)
wherein D1 is aryl, heteroaryl or heterocyclyl and E1 is a bond, C1-6alkylene, oxyC1-6alkylene, oxy, imino, N—(C1-6alkyl)imino, iminoC1-6alkylene, N—(C1-6alkyl)-iminoC1-6alkylene, C1-6alkylene-oxyC1-6alkylene, C1-6alkylene-iminoC1-6alkylene, C1-6alkylene-N—(C1-6alkyl)-iminoC1-6alkylene, —NHC(O)—, —NHSO2—, —SO2NH— or —NHC(O)—C1-6-alkylene-, and any aryl, heteroaryl or heterocyclyl group in a substituent on D1 may be optionally substituted with one or more groups selected from hydroxy, halo, C1-6alkyl, C1-6alkoxy, carboxy, C1-6alkoxycarbonyl, carbamoyl, N—C1-6alkylcarbamoyl, N—(C1-6alkyl)2carbamoyl, C2-6alkanoyl, amino, N—C1-6alkylamino and N,N—(C1-6alkyl)2amino, and any C3-7cycloalkyl or heterocyclyl group in a R70 group may be optionally substituted with one or two oxo or thioxo substituents, and any of the R70 groups defined hereinbefore which comprises a CH2 group which is attached to 2 carbon atoms or a CH3 group which is attached to a carbon atom may optionally bear on each said CH2 or CH3 group a substituent selected from hydroxy, amino, C1-6alkoxy, N—C1-6alkylamino, N,N—(C1-6alkyl)2amino and heterocyclyl.
13. A method for inhibiting aurora 2 kinase in a warm blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of any one of claims 7-12, or a pharmaceutically acceptable salt, or an in vivo hydrolysable ester thereof.
14. (canceled)
15. A pharmaceutical composition comprising a compound according to any one of claims 7-12 in combination with a pharmaceutically acceptable carrier.
16. (canceled)
US11/070,057 2000-06-28 2005-03-02 Substituted quinazoline derivatives and their use as inhibitors Abandoned US20060046987A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/070,057 US20060046987A1 (en) 2000-06-28 2005-03-02 Substituted quinazoline derivatives and their use as inhibitors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00401842.0 2000-06-28
EP00401842 2000-06-28
US10/311,916 US6919338B2 (en) 2000-06-28 2001-06-21 Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase
PCT/SE2001/001450 WO2002000649A1 (en) 2000-06-28 2001-06-21 Substituted quinazoline derivatives and their use as inhibitors
US11/070,057 US20060046987A1 (en) 2000-06-28 2005-03-02 Substituted quinazoline derivatives and their use as inhibitors

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/SE2001/001450 Continuation WO2002000649A1 (en) 2000-06-28 2001-06-21 Substituted quinazoline derivatives and their use as inhibitors
US10/311,916 Continuation US6919338B2 (en) 2000-06-28 2001-06-21 Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase

Publications (1)

Publication Number Publication Date
US20060046987A1 true US20060046987A1 (en) 2006-03-02

Family

ID=8173742

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/311,916 Expired - Fee Related US6919338B2 (en) 2000-06-28 2001-06-21 Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase
US11/070,057 Abandoned US20060046987A1 (en) 2000-06-28 2005-03-02 Substituted quinazoline derivatives and their use as inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/311,916 Expired - Fee Related US6919338B2 (en) 2000-06-28 2001-06-21 Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase

Country Status (27)

Country Link
US (2) US6919338B2 (en)
EP (1) EP1299381B1 (en)
JP (1) JP2004501914A (en)
KR (1) KR20030014411A (en)
CN (1) CN1267431C (en)
AR (1) AR030432A1 (en)
AT (1) ATE394102T1 (en)
AU (1) AU2001266505A1 (en)
BG (1) BG107376A (en)
BR (1) BR0111754A (en)
CA (1) CA2412592A1 (en)
CZ (1) CZ20024120A3 (en)
DE (1) DE60133897D1 (en)
EE (1) EE200200715A (en)
ES (1) ES2305081T3 (en)
HK (1) HK1053124A1 (en)
HU (1) HUP0301236A2 (en)
IL (1) IL153246A0 (en)
IS (1) IS6656A (en)
MX (1) MXPA02011974A (en)
NO (1) NO20026010L (en)
NZ (1) NZ522696A (en)
PL (1) PL360439A1 (en)
RU (1) RU2283311C2 (en)
SK (1) SK18102002A3 (en)
WO (1) WO2002000649A1 (en)
ZA (1) ZA200209412B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090215770A1 (en) * 2001-12-24 2009-08-27 Astrazeneca Ab Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases
US8592396B2 (en) 2010-04-14 2013-11-26 Bristol-Myers Squibb Company Glucokinase activators and methods of using same

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0302172A2 (en) 2000-09-15 2003-09-29 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
KR100909665B1 (en) * 2000-12-21 2009-07-29 버텍스 파마슈티칼스 인코포레이티드 Pyrazole Compounds Useful as Protein Kinase Inhibitors and Pharmaceutical Compositions Comprising the Same
RU2004126671A (en) * 2002-02-06 2005-04-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) HETEROARYL COMPOUNDS USEFUL AS GSK-3 INHIBITORS
WO2003075921A2 (en) * 2002-03-05 2003-09-18 Transtech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
AU2003218215A1 (en) * 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
ATE489384T1 (en) * 2002-05-06 2010-12-15 Vertex Pharma THIADIAZOLES OR OXADIAZOLES AND THEIR USE AS JAK PROTEIN KINASE INHIBITORS
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
ES2400339T3 (en) 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compounds, pharmaceutical compositions thereof and their use in the treatment of cancer
EP1532145B1 (en) 2002-08-02 2006-09-13 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of gsk-3
GB0221245D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Chemical process
WO2004058781A1 (en) 2002-12-24 2004-07-15 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
CN101074227B (en) * 2002-12-24 2010-09-29 阿斯利康(瑞典)有限公司 Phosphine acyloxy quinazoline derivatives and their medicine uses
EP1575946A1 (en) * 2002-12-24 2005-09-21 AstraZeneca AB Quinazoline compounds
US7601718B2 (en) * 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
EP1613619B1 (en) * 2003-04-16 2008-03-26 AstraZeneca AB Quinazoline derivatives for treatment of cancer
EP1635823A1 (en) * 2003-05-20 2006-03-22 TransTech Pharma Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
WO2004105764A1 (en) * 2003-06-02 2004-12-09 Astrazeneca Ab (3- ((quinazolin-4-yl) amino )-1h-pyrazol-1-yl) acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
GB0320793D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Chemical process
SI2213661T1 (en) 2003-09-26 2011-11-30 Exelixis Inc c-Met Modulators and Methods of Use
US20080051414A1 (en) * 2003-10-14 2008-02-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US20090143399A1 (en) * 2003-10-14 2009-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US20090099165A1 (en) * 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
DE602004022318D1 (en) * 2003-10-14 2009-09-10 Supergen Inc PROTEIN KINASE INHIBITORS
EP1678149A2 (en) * 2003-10-31 2006-07-12 Neurogen Corporation 4-amino(aza)quinoline derivatives as capsaicin receptor agonists
CN1902193B (en) * 2003-12-04 2011-07-13 沃泰克斯药物股份有限公司 Quinoxalines useful as inhibitors of protein kinases
WO2005061519A1 (en) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
US8119684B2 (en) * 2003-12-30 2012-02-21 Dana-Farber Cancer Institute, Inc. Thiophene derivatives for up-regulating HLA-DM activity
US7687502B2 (en) * 2004-03-23 2010-03-30 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
JP2007533753A (en) * 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド Indole derivatives and their use as kinase inhibitors
WO2006023931A2 (en) * 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
WO2006040520A1 (en) 2004-10-12 2006-04-20 Astrazeneca Ab Quinazoline derivatives
US20090036485A1 (en) * 2004-10-12 2009-02-05 Frederic Henri Jung Quinoline derivatives
ATE479687T1 (en) 2004-10-15 2010-09-15 Takeda Pharmaceutical KINASE INHIBITORS
CN1854130B (en) * 2005-04-15 2011-04-20 中国医学科学院药物研究所 Chinazoline derivative, its production, medicinal composition and use
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
GB0510963D0 (en) * 2005-05-28 2005-07-06 Astrazeneca Ab Chemical compounds
JP2009504771A (en) * 2005-08-18 2009-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrazine kinase inhibitor
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2006311830B2 (en) * 2005-11-03 2013-03-14 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
EP1785420A1 (en) * 2005-11-14 2007-05-16 4Sc Ag Thiazole analogues and uses thereof
AU2007208351C1 (en) 2006-01-23 2011-07-07 Amgen Inc. Aurora kinase modulators and method of use
US7560551B2 (en) * 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
US7868177B2 (en) * 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
WO2007099323A2 (en) * 2006-03-02 2007-09-07 Astrazeneca Ab Quinoline derivatives
UY30183A1 (en) 2006-03-02 2007-10-31 Astrazeneca Ab QUINOLINE DERIVATIVES
WO2007113005A2 (en) * 2006-04-03 2007-10-11 European Molecular Biology Laboratory (Embl) 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors
MX2009003793A (en) 2006-10-09 2009-12-14 Takeda Pharmaceutical Kinase inhibitors.
JP5528806B2 (en) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド Compound drug
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
US8236823B2 (en) * 2006-10-27 2012-08-07 Amgen Inc. Multi-cyclic compounds and methods of use
US20080207632A1 (en) * 2006-10-31 2008-08-28 Supergen, Inc. Protein kinase inhibitors
CA2668429A1 (en) * 2006-11-02 2008-05-15 Vertex Pharmaceuticals Incorporated Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
WO2008077086A1 (en) * 2006-12-19 2008-06-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
CA2680029A1 (en) * 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
CA2679701A1 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
CA2679884A1 (en) * 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
MX2009010517A (en) 2007-04-05 2009-10-19 Amgen Inc Aurora kinase modulators and method of use.
WO2008128009A2 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
JP5572087B2 (en) * 2007-05-02 2014-08-13 バーテックス ファーマシューティカルズ インコーポレイテッド Aminopyrimidines useful as kinase inhibitors
JP5389786B2 (en) * 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド Aminopyrimidines useful as kinase inhibitors
WO2008137619A2 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
AU2008257044A1 (en) * 2007-05-24 2008-12-04 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
ES2395581T3 (en) * 2007-06-20 2013-02-13 Merck Sharp & Dohme Corp. Janus kinase inhibitors
EP2170842A1 (en) * 2007-06-21 2010-04-07 Irm, Llc Protein kinase inhibitors and methods for using thereof
EP2176261B1 (en) * 2007-07-31 2012-12-19 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
DE102008015032A1 (en) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituted pyrazolamides and their use
DE102008015033A1 (en) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituted (pyrazolyl-carbonyl) imidazolidinones and their use
US8404694B2 (en) * 2008-03-20 2013-03-26 Amgen Inc. Aurora kinase modulators and method of use
WO2010019473A1 (en) 2008-08-14 2010-02-18 Amgen Inc. Aurora kinase modulators and methods of use
EP2323622A1 (en) * 2008-09-03 2011-05-25 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
ES2489040T3 (en) 2008-12-03 2014-09-01 The Scripps Research Institute Stem cell cultures
DE102008062878A1 (en) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituted furancarboxamides and their use
DE102008062863A1 (en) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituted (thiophenyl-carbonyl) imidazolidinones and their use
AU2010204619B2 (en) 2009-01-16 2016-08-11 Exelixis, Inc. Malate salt of N-(4-{ [ 6, 7-bis (methyloxy)-quinolin-4-yl] oxy}phenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
BRPI1008325A2 (en) * 2009-02-11 2020-08-25 Merck Patent Gmbh amino azaeterocyclic carboxamides
UA108618C2 (en) 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
ES2467923T3 (en) 2009-09-30 2014-06-13 Transtech Pharma, Llc Substituted imidazole derivatives for the treatment of Alzheimer's disease
US9090633B2 (en) 2010-11-18 2015-07-28 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
WO2012066578A2 (en) * 2010-11-18 2012-05-24 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
US8785459B2 (en) * 2011-12-27 2014-07-22 Development Center For Biotechnology Quinazoline compounds as kinase inhibitors
GB201202027D0 (en) 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
PL2634185T3 (en) 2012-03-02 2016-06-30 Sareum Ltd TYK2 kinase inhibitors
CN103788085B (en) * 2012-10-31 2016-09-07 复旦大学 2-(quinazoline-4-amino)-5-thiazole carboxamides analog derivative and bio-pharmaceutical purposes thereof
CN104098551B (en) * 2013-04-03 2019-03-22 广东东阳光药业有限公司 Substituted quinazoline analog derivative as Ou Ruola kinase inhibitor
CN105555315B (en) 2013-09-16 2019-05-07 阿斯利康(瑞典)有限公司 Therapeutic polymer nano granules and its preparation and application
CN108473435A (en) 2015-10-05 2018-08-31 纽约市哥伦比亚大学理事会 The treatment of the removing and protein sickness of the activator of autophagy tide and phospholipase D and the protein masses including TAU
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
AR112027A1 (en) * 2017-06-15 2019-09-11 Biocryst Pharm Inc ALK 2 KINASE INHIBITORS CONTAINING IMIDAZOLE
EP4025565A1 (en) * 2019-09-06 2022-07-13 Inflazome Limited Nlrp3 inhibitors
CN110746398A (en) * 2019-10-18 2020-02-04 刘沛友 4-heterocyclic substituted quinazoline derivative and preparation method and application thereof
CN111574473A (en) * 2020-06-04 2020-08-25 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） Method for synthesizing aminothiazole compound
CN113311166B (en) * 2021-04-28 2022-10-28 新疆农垦科学院 Protein biomarker for diagnosing early pregnancy of sheep and method for detecting early pregnancy of sheep
CN115557601B (en) * 2022-11-08 2024-11-08 成都理工大学 Biomass microsphere, preparation method and application thereof, bioreactor and underground well
WO2024184550A1 (en) * 2023-03-09 2024-09-12 Cancer Research Technology Limited Biarylamide derivatives and their use as pkmyt1 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870725A (en) * 1971-03-30 1975-03-11 Lilly Industries Ltd Nitrothiazole derivatives
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
IL117620A0 (en) * 1995-03-27 1996-07-23 Fujisawa Pharmaceutical Co Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
TW436485B (en) * 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
ES2241324T3 (en) * 1998-10-08 2005-10-16 Astrazeneca Ab DERIVATIVES OF QUINAZOLINA.
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090215770A1 (en) * 2001-12-24 2009-08-27 Astrazeneca Ab Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases
US8592396B2 (en) 2010-04-14 2013-11-26 Bristol-Myers Squibb Company Glucokinase activators and methods of using same

Also Published As

Publication number Publication date
ZA200209412B (en) 2004-02-19
CA2412592A1 (en) 2002-01-03
KR20030014411A (en) 2003-02-17
CN1267431C (en) 2006-08-02
HK1053124A1 (en) 2003-10-10
PL360439A1 (en) 2004-09-06
RU2283311C2 (en) 2006-09-10
CZ20024120A3 (en) 2003-03-12
BR0111754A (en) 2003-04-29
NO20026010D0 (en) 2002-12-13
MXPA02011974A (en) 2004-09-06
EP1299381A1 (en) 2003-04-09
BG107376A (en) 2003-09-30
ES2305081T3 (en) 2008-11-01
WO2002000649A9 (en) 2007-09-20
IS6656A (en) 2002-12-17
NO20026010L (en) 2002-12-13
ATE394102T1 (en) 2008-05-15
EP1299381B1 (en) 2008-05-07
SK18102002A3 (en) 2003-07-01
AR030432A1 (en) 2003-08-20
DE60133897D1 (en) 2008-06-19
AU2001266505A1 (en) 2002-01-08
IL153246A0 (en) 2003-07-06
CN1496364A (en) 2004-05-12
WO2002000649A1 (en) 2002-01-03
JP2004501914A (en) 2004-01-22
EE200200715A (en) 2004-08-16
HUP0301236A2 (en) 2003-10-28
NZ522696A (en) 2004-08-27
US6919338B2 (en) 2005-07-19
US20030187002A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
US6919338B2 (en) Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase
US7105669B1 (en) Quinazoline derivatives
US7081461B1 (en) Quinazoline compounds and pharmaceutical compositions containing them
US7235559B1 (en) Therapeutic quinazoline derivatives
US7709479B1 (en) Quinazoline derivatives and their use as pharmaceuticals
US7402585B2 (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
US6977259B2 (en) Quinoline derivatives and their use as aurora 2 kinase inhibitors
US7125995B2 (en) Substituted amidoalkyl uracils and their use as inhibitors of the poly(adp-ribose) synthetase (PARS)

Legal Events

Date Code Title Description
AS Assignment

Owner name: ASTRAZENECA AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MORTLOCK, ANDREW;JUNG, FREDERIC HENRI;REEL/FRAME:016355/0121;SIGNING DATES FROM 20021107 TO 20021118

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION